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FOREWORD 
 
 Maintaining normal glycaemia is a finely tuned, crucial physiological function. 
Indeed, most mammals, including humans, are incapable of tolerating hypoglycemia for 
more than a few minutes. Glucose obtained from the digestion of food is partially used 
right away in order to maintain glycaemia, and the rest is rapidly stored in the form of 
glycogen (in the liver and muscles) and lipids, in order to prevent abnormal glucose 
concentrations in the blood stream. Furthermore, during fasting periods, the organism 
maintains a plasmatic glycemic concentration of around 5 mM (=100 mg/dL) via the 
endogenous glucose production (EGP). EGP starts off by glucose production via 
glycogenolysis, by degrading hepatic glycogen stores. The second pathway of EGP is 
gluconeogenesis, which is  generally activated in prolonged fasting periods, assuring 
the synthesis of glucose form non-carbohydrate substrates? in the liver, kidneys and 
intestine (Mithieux et al., 2017). 
 The last common reaction for glycogenolysis and gluconeogenesis is the 
hydrolysis of glucose-6 phosphate (G6P) into free glucose and inorganic phosphate by 
glucose-6 phosphatase (G6Pase). The expression of G6Pase is restricted to the liver, 
kidneys and intestine, conferring to these organs the capacity to produce glucose. 
G6Pase is composed of two subunits, which are the G6Pase catalytic subunit (G6PC) 
and the G6Pase transport subunit (G6PT). Alterations affecting the activity of this 
enzyme are responsible for the development of different metabolic pathologies, such as 
type 2 diabetes, characterized by glucose overproduction leading to hyperglycemia, and 
glycogen storage disease type I (GSDI), characterized by the absence of EGP and 
hypoglycemia. 
 GSDI is a rare genetic disease (1/100,000 births), caused by G6Pase deficiency. 
There are two types of GSDI, which are GSDI type a, caused by mutations in G6PC, 
and GSDI type b, caused by mutations in SLC37A encoding G6PT. To date, there are 
12 known glycogen storage diseases, all caused by mutations affecting different 
enzymes involved in glycogen synthesis or degradation ??????? ?????. They are 
qualified as hepatic, muscular or both, depending on the tissue-specificity of the enzyme 
which is deficient. For example, GSDII (Pompe disease) ???????????????????????????-1,4-
???
?
glucosidase, GSDIII  ???????? ????????? ??? ???? ??? ?? ??????????? ??? glycogen debranching 
enzyme and GSD?? ??????????? ????????? ??? ???? ??? ?? deficiency in glycogen 
phosphorylase. As hepatic glycogen is degraded into glucose to maintain blood 
glucose, hepatic GSDs are characterized by hypoglycemia during short fasting. On the 
other hand, as glycogen accumulated in the muscles is used to produce energy during a 
physical effort, muscular GSDs are classified as myopathies. 
In GSDI, the loss of G6Pase activity leads to the absence of EGP and the 
accumulation of G6P that deeply modifies the hepatic, renal and intestinal metabolisms. 
GSDI is characterized by abnormal accumulation of glycogen in the liver and kidneys, 
resulting in hepatomegaly and nephromegaly, respectively (Kishnani et al., 2014; Rake 
et al., 2002a). In addition to severe hypoglycemic episodes, GSDI patients exhibit 
metabolic parameter alterations, such as hypercholesterolemia, hypertriglyceridemia, 
lactic acidosis and hyperuricemia. Unfortunately, GSDI is further characterized by 
hepatic and renal complications, which occur generally in adulthood. Most adult patients 
develop hepatocellular adenoma / carcinoma (HCA / HCC) and / or nephropathy, firstly 
characterized by microalbuminuria and leading to renal failure in some cases. 
The only treatment available for GSDI so far is a controlled dietary regimen, 
consisting in regular consumption of raw cornstarch (every 3h-4h), which helps to 
maintain normal glycaemia and avoid lactatemia (Kishnani et al., 2014; Rake et al., 
2002a, 2002b). This regimen, which was installed in the 1980s, is very effective and it 
significantly reduces mortality in GSDI patients. However, it does not allow the complete 
prevention of long-term pathology development.  
Many aspects of the hepatic carcinogenesis, as well as chronic kidney disease 
(CKD) development remain unknown in the case of GSDI. Before the dietary regimen 
was recommended, the main complication that led to mortality in GSDI patients was 
hypoglycemia, and hepatic and renal pathologies were not followed appropriately. In 
order to understand the mechanisms behind these long-term complications, our 
laboratory developed mouse models in which G6Pase was deficient specifically in the 
liver or in the kidney. These mouse models were developed since total knock-out animal 
models present severe hypoglycemia and do not survive weaning periods in the 
???
?
absence of frequent glucose injections. Interestingly, L.G6pc-/- mice, which present a 
deletion of G6pc in the liver, exhibit all of the hepatic hallmarks of GSDI, including 
hepatocellular tumor development (Mutel et al., 2011a). On the other hand, K.G6pc-/- 
mice, with a specific deletion of G6pc in the kidneys, develop progressive nephropathy 
over time, as observed in GSDI patients (Clar et al., 2014). In this work, these two 
models were used not only to understand the pathways leading to GSDI long-term 
complications, but also to test different approaches for a treatment strategy.  
The first part of the literature data consists in the description of the EGP and the 
metabolic pathways altered by G6Pase deficiency. The following chapters highlight the 
hepatic and renal pathophysiology of GSDI. Finally, in the last chapter, the animal 
models developed to study GSDI are described, along with the gene therapy assays 
performed so far, aiming to develop a curative strategy for this rare disease. 
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?????????????????????????????????????????????????????????????????????????????????????????
In order to detect ingested ????????? ?? ?????? in the pancreas express a specific glucose transporter 
(GLUT2), which transfers glucose into the cells proportionally to the plasmatic glucose concentrations. 
When blood glucose is high?????????????????????????????????????????????reasing the ATP / ADP ratio in the 
cytoplasm. Increased ATP / ADP ratio signalizes an increase in energy levels, resulting in the inhibition of 
?????????? ????????? ?????????? ??? ????? ??????????? ??????????????? ??? ????????????? ??? ?? ??????? ???? ???
induction of the exocytosis of vesicles containing insulin. 
???
?
I) How does the body maintain normal glycaemia? 
Glucose is a simple carbohydrate, containing 6 carbon atoms (Figure 1). It is 
??????????? ??? ?????????????????? ?? ???????? ???????? ??? ??? ???????? ???? ????? ??????????
???????? ????? ???? ?????? ?????????? ???????? ????????? ???????? ??? ????? ??? ??? ????gy 
source in almost all living organisms, from the lowest life-forms, such as bacteria, to the 
more complex ones, including humans. Plants synthetize this sugar by using carbon 
dioxide and sunlight via a well-known process called photosynthesis. 
In mammals, glucose is maintained around 5 mM in the bloodstream at all times. 
While some organs can adapt and switch to other energy sources when glucose is 
scarce, such as ketone bodies, for others glucose represents more than half of the 
energy supplies used to function properly. Furthermore, ?energy source? has always 
been the main function attributed to glucose, and while this may be true in some 
situations, the other essential roles of glucose in the cell, such as providing carbon 
skeletons on which all other specialized biochemical pathways ultimately depend, tend 
to be put aside (Soty et al., 2017). Interestingly, glucose can be a limiting factor in cell 
proliferation not only by its energetic role, but above all by providing carbons for 
nucleotide synthesis via the pentose shunt, required for DNA replication. Thus the many 
roles of glucose, including maintaining blood glucose levels in a very narrow range 
between 4 to 8 mM, are crucial for normal functioning of the organism. Glucose levels 
during fasting periods are assured first by the degradation of hepatic glycogen, and 
further on, when glycogen stores are depleted, by the gluconeogenesis (GNG) pathway, 
which is the synthesis of glucose from non-carbohydrate substrates.  
I.1) What happens right after a meal (post-prandial period)? 
After a meal, a portion of the glucose that has been ingested is immediately used 
in order to produce energy. Glucose is taken up from the blood into various organs via 
specific transporter systems, followed by a phosphorylation by hexokinases leading to 
glycolysis and pyruvate production. The inhibition of hexokinases activity in the muscle 
and adipose tissue by its product, i.e. G6P, ensures a controlled uptake of glucose in 
peripheral tissue.  
 ?????????????????????????????
The linear chains of glucose in glycogen are linked with ??????????????????????????????????????? ???????
?????????????????. 
 
 
??????????????????????????????????????????????????
Glucose is converted to G6P by glucokinase. G6P is further converted to G1P by phosphoglucomutase. 
An UDP residue is then transferred by the UDP - glucose pyrophosphorylase, leading to the formation of 
UDP-glucose. UDP-glucose is then attached to the glycogen polymer via the glycogen synthase, 
releasing uridine and thus elongating the linear chain of glycogen. 
???
?
The rise of glucose levels in the blood stream stimulates the secretion of insulin, 
??????????????????? ??? ??????????????? ???????????? (Henquin, 2000). The activation of 
insulin secretion by glucose is a complex process summarized in Figure 2. Once insulin 
is secreted, it targets the liver, muscle and adipose tissue, all of which express the 
insulin receptor (Van Obberghen et al., 2001). This increases the up-take of glucose in 
these organs and induces the storage of glucose in the form of glycogen and / or lipids, 
thus restoring normal blood glucose levels. The hypoglycemic effect of insulin is also 
mediated by inhibiting EGP during post-absorptive periods (Girard, 2006). Besides 
glycogen and lipids, glucose increase and the subsequent insulin release also lead to 
protein synthesis activation (Proud, 2006). Thus this hormone activates many anabolic 
pathways (i.e. glycogen, lipid and protein synthesis) in order to decrease blood glucose 
levels after a meal. 
I.1.1) Glycogen synthesis is activated in the liver and muscles 
As mentioned, right after a meal, the excess glucose which is not used right 
away is rapidly stored in the form of glycogen and lipids. Therefore, during postprandial 
periods, around 30% of alimentary glucose is stored in the form of glycogen.  
Glycogen is a polymer of glucose, stored mainly in the liver and muscles (Figure 
3). This polymer is composed of glucose molecules forming long linear chains linked by 
???-??????????????????????????????????????????????????????-6) branching bonds (Roach 
et al., 2012). Hepatic glycogen represents around 5% of the weight of the liver in normal 
conditions.  
The first stage of glycogen synthesis is the conversion of glucose to glucose-6 
phosphate (G6P). In the liver, this conversion is done by the glucokinase (GK) enzyme. 
GK has a low affinity for glucose and it is therefore activated only when glucose is 
present in abundance (Figure 4). G6P is then converted to glucose-1 phosphate (G1P) 
and further to uridine diphosphate glucose (UDP-glucose), which is the substrate of 
glycogen synthase, the key enzyme responsible for glycogen synthesis (Adeva-Andany 
et al., 2016). Insulin stimulates the dephosphorylation of this enzyme by activating the 
protein phosphatase 1 (PP1) and by inhibiting glycogen synthase kinase 3 (GSK3). 
?????????? ?????????
????????????????????????
??????????????????????????????
??????????
Increased glucose levels induce  
(i) glucokinase (GK) and L-PK 
for glycolysis; (ii) ATP citrate 
lyase, ACC, and FAS for 
lipogenesis; (iii) ELOVL6 and 
SCD1 for fatty acid elongation 
and desaturation steps; and 
finally (iv) GPAT and DGAT for 
TG synthesis. Elevation in 
malonyl-CoA concentrations 
inhibits CPT I, the rate-limiting 
??????? ??? ?-oxidation (v), 
which regulates the transfer of 
long-chain acyl-CoAs from the cytosol into the mitochondria, thus resulting in a shift from an oxidative 
(production of ketone bodies) to an esterification pathway (TG synthesis). F6P, fructose 6-phosphate; F1, 
6P2, fructose 1,6 diphosphate; G3P, glycerol 3-phosphate; G6P, glucose 6-phosphatase; PEP, 
phosphoenol pyruvate; LCFA, long-chain fatty acids; CPT II, carnitine palmitoyltransferase II. (Postic and 
Girard, J Clin Invest., 2008) 
 
?????????????????????? ???????????
???????????????????????????????
ChREBP is located in the cytoplasm under low 
plasma glucose concentration due to its 
phosphorylation on Ser196. As the plasma 
glucose level rises, glucose enters hepatocytes 
and is rapidly equilibrated due to the low-
Km glucose transporter GLUT2. Glucose 
phosphorylation is then initiated by GK, leading 
to the formation of xyulose-5-phosphate (X-5-P) 
by the hexose monophosphate shunt pathway. 
Increased xyulose-5-phosphate in turn appears 
to cause dephosphorylation of Ser196 on 
ChREBP (probably through activation of 
PP2A), thereby allowing ChREBP to enter the 
nucleus and affect gene expression. Insulin appears to affect hepatic lipogenesis principally by increasing 
transcription of both ChREBP and SREBP-1c genes. Furthermore, SREBP-1c function is also activated 
by insulin at the post-translational level. Activated SREBP-1c binds to SRE (Sterol Regulatory Element) 
sequences found on the promoters of its target genes. LXR is transcription factor that can also upregulate 
ChREBP and SREBP-1c gene expressions. In order to activate lipogenic gene transcription, LXR needs 
to dimerize with RXR. (Shiota et al., 2008) 
???
?
Therefore, the dephosphorylated form of glycogen synthase is the active form. In 
parallel, PP1 and G6P stimulate the inhibition of glycogen degradation (Newgard et al., 
2000). G6P is also a strong agonist of glycogen synthase. Indeed, this metabolite 
activates the enzyme allosterically and stimulates its dephosphorylation (Villar-???????
and Guinovart, 1997). 
I.1.2) De novo lipid synthesis in the liver is induced by excess of glucose 
When the storage capacity of glucose in the form of glycogen in the liver is 
exceeded, glucose is stored under the form of lipids. Indeed, high glucose 
concentrations activate the glycolysis pathway, leading to the production of pyruvate 
(Figure 5). Pyruvate is then transported in the mitochondria, where it is converted into 
acetyl-CoA, a precursor for the synthesis of fatty acids and cholesterol. Fatty acid 
synthesis is initiated by the conversion of acetyl-CoA into malonyl-CoA via acetyl-CoA 
carboxylase (ACC). Furthermore, malonyl-CoA is transformed into palmitate via fatty 
acid synthase (FAS). Fatty acids can then be elongated, desaturated, esterified and 
used to synthesize triglycerides (TG). TG are stored in lipid vesicles, which can either 
stay in the cytosol or be transported to the adipose tissue via the export of very low 
density lipoproteins (VLDL) (Postic and Girard, 2008). 
The key enzymes involved in TG synthesis i.e. ACC and FAS are activated by 
insulin (Girard et al., 1994). This activation is mediated via sterol regulatory element 
binding protein 1 (SREBP1). Indeed, when activated by insulin, SREBP1 binds to the 
promoters of FASN, ACACA and GCK, and therefore activates not only lipogenesis, but 
also glycolysis needed for the production of pyruvate ?????????? ???? ??????? ?????. 
SREBP1 is not the only actor involved in this broad regulation. During postprandial 
periods, carbohydrate responsive element binding protein ? (ChREBP-?) is also 
activated by glucose metabolism (Figure 6).  This transcription factor senses glucose 
levels in the cells and can also induce lipid synthesis, making it an important bridge 
between glucose and lipid metabolisms (Abdul-Wahed et al., 2017). Recently, a new 
glucose-insensitive isoform of ChREBP, called ChREBP-?? ???? ????? ????????????
Interestingly, a feed-forward mechanism has been suggested placing ChREBP-????????
the transcriptional control of ChREBP-?. In this scenario, ChREBP-? is first activated by 
??????????? ??????????????????????????????????????????????????????????????????????????
Increased adipocyte lipolysis can lead to an increase in NEFA production, which can enter the liver and 
increase the pool of FA. Increased glucose levels and deregulated insulin signaling can subsequently 
activate lipogenesis, again increasing the pool of hepatic FA. Furthermore, by-products of the lipogenesis 
pathway can inhibit lipid oxidation which results in accumulation of lipids. Finally, a decrease in VLDL 
export from the liver can also contribute to hepatic steatosis. Hepatic steatosis is tightly associated to 
insulin resistance development. 
TG ? triglycerides, NEFA ? non-esterified fatty acids, FA ? fatty acids, VLDL ? very low density 
lipoproteins 
(Postic and Girard,. 2008) 
 
?????????? ??????????????????????????????????????????????????????????????????????????????
These data were obtained in rats at 6h (left) of fasting and at 48h of fasting (right). 
(Mithieux et al., 2017) 
???
?
glucose metabolism and, in turn, stimulates Chrebp-? expression, amplifying the 
response to glucose (Abdul-Wahed et al., 2017). The main activator of ChREBP-? is 
xylulose-5-phosphate produced in the pentose phosphate pathway (PPP), which 
activates protein phosphatase 2A (PP2A), dephosphorylating ChREBP-?. ChREBP-? 
can then be translocated into the nucleus and induce the transcription of its target 
genes, such as FASN, ACACA and the liver pyruvate kinase (L-PK). Recent studies 
showed that G6P can also induce ChREBP-???? ???????????????? ???????? (Dentin et al., 
2012), rendering this transcription factor even more complex, joining glucose and lipid 
metabolisms.  
While hepatic lipid synthesis is a normal physiological process, excessive 
storage of lipids in the liver represents a pathological state. Indeed, increased amount of 
lipid droplets in the liver leads to the development of steatosis. The degree of steatosis 
in the liver can vary greatly, according to the molecular origin of this event. Hepatic 
steatosis is the major hallmark of all of the non-alcoholic fatty liver diseases (NAFLD). 
Indeed, NAFLD are an array of metabolic diseases all characterized by hepatic lipid 
accumulation, which can be induced by viral, environmental or genetic factors. On a 
molecular level, lipid accumulation in NAFLD can be due to an excessive lipid synthesis 
or import of fatty acids, a decrease in lipid degradation or problems in the export of 
lipids out of the liver (Figure 7) (Postic and Girard, 2008). Histologically, NAFLD occurs 
as a spectrum from mild hepatic steatosis only, to non-alcoholic steatohepatitis (NASH), 
characterized by hepatocellular injury and inflammation, up to cirrhosis linked to marked 
fibrosis. The pathogenesis of NAFLD is frequently related to insulin resistance and, it is 
generally found in individuals who have central obesity or diabetes (Smith and Adams, 
2011). Furthermore, NAFLD predisposes the liver to hepatic cancer development and a 
correlation between the two has been proven many times (Font-Burgada et al., 2016; 
Michelotti et al., 2013).  
I.2) What happens during fasting periods? 
During fasting periods, the decrease in blood glucose levels, due to the utilization 
of glucose as an energy source, is compensated by the induction of EGP. 
Glycogenolysis is the first pathway that is activated at the end of post-prandial periods, 
?????????? ???????????????????????????????
???????? ??????????
Secreted glucagon binds to the glucagon 
receptor, leading to subsequent activation of the 
coupled G proteins. The G proteins lead to the 
activation of adenylate cyclase, increase in 
intracellular cAMP levels, and subsequent 
activation of protein kinase A (PKA). They also 
lead to the activation of phospholipase C, 
production of inositol 1,4,5-triphosphate, and 
subsequent release of intracellular calcium.  
These molecular events translate in the 
modulation of glycogenolysis, glycogenesis, 
gluconeogenesis, and glycolysis, in order to 
enhance glucose production. 
 
(Jiang and Zang, 2003) 
 
 
 
 
 
 
????????????????????
????????????????????
Degradation of glycogen is done 
by glycogen phosphorylase and 
glycogen debranching enzyme 
(GDE) to produce glucose-1 
phosphate, which is immediately 
converted mainly into glucose-6 
phosphate. 
 
 
 
 
 
???
?
while gluconeogenesis (GNG) progressively takes place as fasting continues (Mithieux 
et al., 2017). Indeed, at the beginning of a post-absorptive period, a time where liver 
glycogen stores are still present and are being mobilized, the liver accounts for at least 
80% of EGP (Figure 8). Renal GNG at this time accounts for about 15-20% and 
intestinal GNG is low, estimated between 5 and 10% of EGP (Croset et al., 2001; 
Mithieux et al., 2006). On the other hand, the repartition is different after 24h of fasting, 
a time at which glycogenolysis has ended in rodents because of glycogen store 
depletion. Indeed, renal and intestinal GNG are progressively activated at this time 
point. If the fast is further prolonged, in the next 48h-72h, renal and intestinal EGP can 
then contribute up to 50% and 20%, respectively (Croset et al., 2001; Mithieux et al., 
2004a).  
The decrease in blood glucose levels during fasting periods stimulates the 
secretion of glucagon by ? cells of the pancreas, and thereby the ratio glucagon / insulin 
is increased. To increase blood glucose, glucagon acts rapidly and promotes hepatic 
glucose output by increasing glycogenolysis and GNG and by decreasing glycogen 
synthesis and glycolysis in a concerted fashion via multiple mechanisms summarized in 
Figure 9 (Jiang and Zhang, 2003). While glucagon is mainly known to modulate hepatic 
EGP, it has recently been shown to modulate the transcription of G6PC in the kidneys 
and intestine, thus modulating renal and intestinal glucose production (Mutel et al., 
2011b). 
I.2.1) Normal glycaemia is maintained via glycogenolysis in post-absorptive state 
Hepatic glycogen degradation is the first catabolic pathway activated as 
response to glucose decrease. One of the main enzymes involved in glycogen 
degradation is glycogen phosphorylase, which releases G1P units from the linear 
??????? ??? ?????????? ??? ????????? ???-4) bonds (Figure 10). Once there are only 4 
residues of glucose left in the linear chain, glycogen debranching enzyme (GDE) 
transfers 3 of the 4 residues left on another linear chain with its transferase subunit. 
Then the ???-6)-glucosidase subunit of GDE hydrolyzes ???? ???-6) bond of the last 
residue, thus releasing another glucose molecule and completing the degradation of the 
chain (Figure 10). Furthermore, G1P molecules previously released are isomerized into 
 ?????????????????????????????????????????????????????????????????????????? ?????????????
?????????????????????
Insulin stimulates glycogen synthesis via the activating phosphorylation of PP1, which dephosphorylates 
both glycogen synthase (activation) and glycogen phosphorylase (inhibition). PP1 is also stimulated by 
glucose and glucose-6 P. Glucose-6 P also stimulates glycogen synthase allosterically. Furthermore, 
insulin inhibits the phosphorylation of the glycogen synthase, by inhibiting GSK3 and PKA. During fasting 
periods, glucagon inhibits the synthesis of glycogen and increases its degradation by increasing the 
phosphorylation of the glycogen synthase (inhibition) via PKA and glycogen phosphorylase (activation) 
via PK. (green arrows ? activation; red ? inhibition) 
UDP glucose - uridine diphosphate glucose; GSK3 - glycogen synthase kinase 3; PP1 - protein 
phosphatase 1; PKA - protein kinase A; PK - phosphorylase kinase; IR ? insulin receptor; GR ? glucagon 
receptor.  
 
?????????????????????????????? ???????????
????????????????????????????????
Gluconeogenesis is not a linear process. 
Indeed, different metabolites (Acetyl-CoA, 
amino acids, glycerol etc.) issued from various 
metabolic pathways can contribute to this 
anabolic process. Pathways which are 
positively regulated by glucagon are marked 
in green, negatively regulated pathways are 
marked in red.  
(Veerendra, 2014) 
???
?
G6P via phosphoglucomutase. The last stage is the hydrolysis of G6P into glucose and 
inorganic phosphate, which is performed by glucose-6 phosphatase (G6Pase). This 
enzyme is expressed in the liver, kidneys and intestine, but not in the muscles. 
Therefore, G6P is not converted into glucose in the muscles nor it is released in the 
bloodstream for glucose maintenance, but it is used only in glycolysis, producing energy 
for muscle contraction. 
Glycogen phosphorylase is a main switch responsible for the regulation of 
glycogenolysis. The inactive form b of this enzyme is activated by phosphorylation via 
phosphorylase kinase (PK), turning glycogen phosphorylase into its active form, called 
form a. Furthermore, glucose molecules can bind to the active site of the glycogen 
phosphorylase, inhibiting the enzyme by competing with its substrate and rendering it 
more sensitive to its inhibitor, the phosphorylase phosphatase (PP1) (Bollen et al., 
1998). G6P is also involved in glycogenolysis inhibition, by inducing PP1 and by 
inhibiting PK (Aiston et al., 2003). Glycogen stores are considered to contribute to EGP 
for about 10-12 hours in rodents and 20h in human subjects (Mithieux et al., 2017; 
Mutel et al., 2011b). 
To conclude, glycogen metabolism is a highly complex process, finely tuned by 
insulin and glucagon, in order to maintain normal blood glucose (Figure 11). 
Nevertheless, these hormones are not the only regulators of glycogen metabolism. The 
nervous system has been long-known to modulate glycogen metabolism independently. 
For example, stimulation of the splanchnic nerve system causes glycogenolysis in the 
liver by activation of glycogen phosphorylase, whereas stimulation of the vagus nerve 
system promotes glycogenesis in the liver by activation of glycogen synthase (Shimazu, 
1981; Shimazu and Fujimoto, 1971). These stimuli are in dependence of the glucose 
levels detected by the brain via the glucose sensors, such as the portal vein. Thus the 
regulation of EGP in the liver is tightly regulated by the central nervous system (Yi et al., 
2010). 
  
 
????????????????????????????????????????????????????????????????????????????????????????
 
 
???
?
I.2.2) Normal glycaemia is maintained by gluconeogenesis during long-term 
fasting 
GNG is the de novo synthesis of glucose from non-carbohydrate substrates. 
GNG consists of a maximum of 11 reactions (depending of the point of entry of the 
given metabolite), representing a crosstalk between the carbohydrate, lipid and protein 
metabolisms (Figure 12). Most of the reactions in GNG are the reverse steps of 
glycolysis (Figure 13). The only three reactions which are irreversible are: the 
transformation of pyruvate to phosphoenolpyruvate (PEP) via pyruvate carboxylase and 
phosphoenolpyruvate carboxykinase (PEPCK); the transformation of fructose?1,6 
bisphosphate into fructose?6?phosphate by fructose-1,6-biphosphatase and the 
hydrolysis of G6P into glucose and inorganic phosphate by G6Pase. Thus the last 
reaction of the GNG pathway is common with glycogenolysis.  
Pyruvate, lactate, amino acids and glycerol are the main substrates used in GNG 
(Figure 12). While alanine and lactate are mainly used in hepatic GNG, glutamine which 
is released by muscles during proteolysis, is mainly used in the kidneys and intestine to 
produce glucose (Mithieux et al., 2017). Glutamine cannot be used by the liver due to 
the kinetic properties of the liver glutaminase (Watford, 1993). Nevertheless, the 
degradation of glutamine in the gut leads to the production of alanine and pyruvate, 
captured by the liver and subsequently used for GNG, leading to the conclusion that 
intestinal GNG can also supply hepatic GNG (Croset et al., 2001). Interestingly, 
intestinal GNG can also use propionate produced by microbiota as substrate 
(De Vadder et al., 2014). Finally, adipose lipolysis can contribute by providing glycerol, 
a substrate used for GNG in all three gluconeogenic organs. 
 
 
 
 
 ??????????? ??????????????????????? ?????????
The abdomen is enlarged due to the hepatomegaly induced by strong glycogen accumulation in the liver. 
 
 
 
??????????????????????????????????????????????????
G6Pase is expressed in the liver, kidneys and intestine. Glucose-6-phosphate is transferred from the 
cytosol into the endoplasmic reticulum (ER) by the transport subunit (G6PT) of the enzyme, while the 
catalytic subunit (G6PC) converts glucose-6-phosphate into free glucose and inorganic phosphate. 
 
???
?
II) Molecular basis of glycogen storage disease type I 
 Glycogen storage disease type I (GSDI) is a rare genetic autosomal recessive 
disease, with an incidence rate of 1/100,000 births, due to a deficiency of G6Pase. 
Consequently, patients with GSDI cannot produce glucose during short fasts and suffer 
from severe hypoglycemia. 
 ????????????????????????????????????????????????????????????Edgar von GIerke, 
who was a German pediatrician that first described the disease in 1929. Indeed, his 
autopsy reports described 2 children with large livers (hepatomegaly) containing 
excessive amount of glycogen (Figure 14). This hepatomegaly was due to the inability 
of the G6Pase-deficient hepatocytes to degrade glycogen. He also reported similar 
findings in the kidneys (nephromegaly). Later on, in 1952, Cori and Cori reported 6 
similar patients (Cori and Cori, 1952). Interestingly, two of the patients had almost total 
deficiency of hepatic G6Pase activity, whereas the other 4 patients had normal enzyme 
activity determined in membrane-denatured conditions. These data were explained 
later, in the 1980s, when it was discovered that G6Pase was composed of two subunits 
(catalytic subunit G6PC and transport subunit G6PT) and that the loss of either one 
leads to the same pathological condition, which is GSDI (Narisawa et al., 1982). Thus 
the 4 patients analyzed by Cori and Cori, which had normal G6Pase activity in 
denatured conditions, actually had a loss of G6PT, and normal G6PC. This led to the 
conclusion that G6Pase activity assays need to be performed in non-denatured samples 
in order to detect a deficiency in G6PT. More importantly, this study highlighted the 
importance of the integrity of the membrane for the normal functioning of the G6Pase 
complex. 
II.1) Glucose-6 phosphatase complex & mutations 
 G6Pase is an enzyme that has the important role to convert G6P into glucose 
and to assure the maintenance of normal blood glucose levels. Thus G6Pase completes 
the last reaction of both glycogenolysis and GNG (Figure 15). As mentioned, this 
enzyme is composed of a catalytic subunit G6PC, encoded by G6PC and a transport 
subunit G6PT, encoded by SLC37A4. In the genome, G6PC is located at 17q21.31, and 
 ??????????? ????????????????????????????????????????
The amino acids coded by each exon are represented in 5 different colors. Amino acids represented in 
black are the ones which were described as mutated in GSDI. Amino acids in grey are a part of the 
catalytic site. 
(Adapted from Pan et al., 1998) 
 
 
??????????? ????????????????????????????????????????
Amino acids represented in black are the ones which were described as mutated in GSDI.  
(Adapted from Pan et al., 1998) 
 
???
?
SLC37A4 is located at 11q23.3. G6pc / G6PC was first isolated in mice and humans in 
1993 (Lei et al., 1993; Shelly et al., 1993). It is composed of 5 exons, coding for a 
protein of 357 amino acids, with a molecular mass of 37 kDa (Lei et al., 1993, 1994; 
Mithieux et al., 1995) (Figure 16). Interestingly, G6PC is anchored at the membrane of 
the endoplasmic reticulum (ER) by 9 transmembrane domains and its catalytic site is 
located in the ER lumen, composed of 5 highly conserved amino acids (Ghosh et al., 
2002). Other isoforms of G6PC have been identified, such as G6PC2 or IGRP (islet-
specific G6Pase related protein) and G6PC3 or UGRP (ubiquitously expressed G6Pase 
catalytic subunit related protein). These isoforms have a moderate sequence homology 
with G6PC, but the catalytic structures are very similar ???????? ???? ????????? ?????. 
G6PC2 is expressed in the pancreatic islets, yet several studies failed to report a 
G6Pase activity of this isoform (Arden et al., 1999; Martin et al., 2001). On the other 
hand, G6PC3 is expressed ubiquitously (Martin et al., 2002). This isoform does not 
seem to be involved in glucose metabolism regulation, since G6PC3 knock-out mice do 
not present hypoglycemia, but it rather translates to severe congenital neutropenia 
(Banka and Newman, 2013; Boztug et al., 2009).   
 SLC37A4 coding for G6PT was isolated in 1997 in humans (Gerin et al., 1997). 
This gene contains 9 exons and codes for a protein composed of 429 amino acids, with 
a molecular weight of 46 kDa, represented in Figure 17 (Annabi et al., 1998; Gerin et 
al., 1997). G6PT is responsible for the import of G6P from the cytoplasm to the ER 
lumen, where it is hydrolyzed by G6PC (van Schaftingen and Gerin, 2002). G6PT is a 
transporter which is expressed ubiquitously, whereas G6PC is present only in the liver, 
kidneys and intestine (Minassian et al., 1996; Mithieux et al., 2004b; Rajas et al., 1999). 
To be more precise, the G6Pase complex was detected in hepatocytes, in proximal 
tubules of the kidney cortex and at the top of the villi of the small intestine, co-expressed 
with PEPCK-c, another key enzyme in GNG. The restriction of the expression of G6PC 
to these organs is mediated by transcription factors such as HNF1 (hepatic nuclear 
factor 1), C/EBP (CAAT / enhancer binding protein) and CDX (caudal-related 
transcription factor) (Gautier-Stein et al., 2005; Xu et al., 2007). Furthermore, 
intrahepatic bile ducts, collecting tubes of the nephron, urinary epithelium in the calices 
of the kidney, and the crypts of the small intestine also express G6Pase, while PEPCK 
  
 
???????????????????? ??????????????????????????????????????????????? ???????????????
Glucose transported into the cytoplasm via GLUT1 is metabolized by hexokinase (HK) to G6P, which 
participates in three major pathways: glycolysis, the hexose monophosphate shunt (HMS), and 
endoplasmic reticulum (ER) cycling. In cycling, G6P enters the ER via G6PT, where it can accumulate 
until it is hydrolyzed to glucose by G6Pase-? (G6PC3) and transported back into the cytoplasm. By 
limiting cytoplasmic glucose/G6P availability, cycling regulates the other two cytoplasmic pathways for 
G6P metabolism. Disruption of ER cycling in G6PT?deficient neutrophils results in reduced glucose 
uptake and impaired energy homeostasis and thus functionality. The underlying cause of neutropenia in 
G6PT-deficiency is enhanced neutrophil ER stress and oxidative stress. The increases in Hsp90 and 
reactive oxygen species (ROS) in G6PT?deficient neutrophils stabilize HIF-???????????-inducible factor-
????? ??? ????????? ?????????? ??? ????-?? ???????????? ???????????????????????? ????????-???The increase in 
PPAR-????????????????????????????????????????????????????????????????????m mobilization activities. Thick 
arrows indicate the changes caused by a defect in G6PT activity. 
(Jun et al., 2014) 
 
 
???
?
is not co-expressed here. Thus this expression was suggested to be related to the 
transepithelial transport of glucose characteristic of these tissues, rather than to the 
neoformation of glucose (Rajas et al., 2007). 
 As mentioned, G6PT protein is expressed ubiquitously. In addition to its role in 
G6Pase activity, G6PT plays a crucial role in neutrophils (Jun et al., 2014). Thus G6PT 
deficiency results in enhanced apoptosis of neutrophils and therefore causes 
neutropenia (Figure 18). As pointed out above, neutropenia is also observed  in G6PC3-
deficient mice and patients (Jun et al., 2012). Thus deficiency in either G6PT or G6PC3 
was suggested to entail a loss of the G6PC3-G6PT complex, resulting in energy 
impairment and enhanced apoptosis in neutrophils (Jun et al., 2010, 2014). 
Interestingly, a variant of G6PT (vG6PT) with additional 66 bp in exon 7 is 
expressed in the brain, heart and muscles, but not in the liver, kidneys and neutrophils 
(Lin et al., 2000). vG6PT has been shown to have a transport role as G6PT, yet its 
implication in pathological conditions remains unknown. Therefore this exon could have 
an important role in the transport function of G6PT and it could be involved in the 
substrate specificity of this transporter. 
 Depending on which subunit of the G6Pase is mutated, GSDI can be further 
classified as GSD type Ia (80% of GSDI cases) or type Ib (20% of GSDI cases). GSD 
type Ia is due to mutations in G6PC and GSDI type Ib is due to mutations in SLC37A4. 
There are at least 85 known mutations of the G6PC gene (Bruni et al., 1999; Chou and 
Mansfield, 2008), including missense, nonsense, insertion / deletion, and splicing 
mutations that can affect the catalytic site, transmembrane domains or the ER lumen 
domains (Figure 16). Nowadays, it is known that the degree to which this deficiency 
translates into a pathological state is in relation to the type of mutation leading to a 
partial or total loss of G6Pase activity (Chou and Mansfield, 2008; Matern et al., 2002; 
Peeks et al., 2017). Moreover, G6PT transport capacity can also be either completely 
absent or partially functional, depending on how the mutation affects the integrity of the 
G6PT protein (Chou and Mansfield, 2008).  
 ??????????? ???????????????????????????????????????????????????
Increased levels of G6P activate the glycolysis pathway, glycogen synthesis, lipogenesis and the pentose 
phosphate pathway. 
(Postic et al., 2007) 
?
??????????? ??????????????????????????????????????????????????????????????
In the cytoplasm, glucose is converted to glycogen as a way to store energy. When energy is needed, 
glycogen is again degraded to glucose. Some of the glycogen in the cytoplasm is captured in a 
membrane and transported to the lysosomes in a process called 'autophagy'. In the lysosomes, this 
glycogen is de????????????????-glucosidase, releasing free glucose. 
(Pompe Center, 2007) 
???
?
II.2) Metabolic consequences of glucose-6 phosphatase deficiency 
 In addition to the absence of glucose production, the loss of G6Pase activity 
translates to an increase of intracellular G6P in hepatocytes and renal tubular cells. 
G6P accumulation is responsible for the induction of glycogen synthesis, de novo 
lipogenesis, glycolysis and PPP (Figure 19). 
II.2.1) Glycogen synthesis activation 
 As described earlier, glycogen synthesis is a process highly induced by G6P 
availability. Thus glycogen is stored in excessive amounts in the liver and kidneys in 
GSDI, resulting in hepatomegaly and nephromegaly. It is noteworthy that while the 
normal liver has the capacity to store glycogen, kidneys do not store glycogen in normal 
physiological conditions. 
For a long time, it was an enigma how GSDI patients retain a limited capacity for 
EGP despite the loss of G6Pase activity. Thus scientists have been investigating 
alternative residual glucose production pathways that could ensure limited glucose 
production. Interestingly, it has recently been discovered by our team (in collaboration 
with Dr. M. Oosterveer, Netherlands) that the metabolic flux through glycogen 
phosphorylase is increased in L.G6pc-/- livers, coupled to the release of free glucose 
via GDE and lysosomal glycogen breakdown (Figure 20) (Hijmans et al., 2017). Thus an 
important turnover of glycogen synthesis and degradation was highlighted in the liver of 
these mice, which could explain the limited glucose production in GSDI. Finally, the 
same study indicated that GK activity is 95% reduced, due to a metabolic adaptation of 
GSDI hepatocytes, in order to reduce G6P production in the liver as much as possible. 
II.2.2) Glycolysis activation  
 Glycolysis is a pathway which is not very efficient in energy production (2 ATP/ 
glucose), but it leads to the creation of 2 pyruvate molecules. Pyruvate is further used 
as a substrate for Krebs cycle and mitochondrial oxidative phosphorylation (OXPHOS) 
(import of pyruvate from the cytoplasm to the mitochondria and conversion to acetyl 
CoA), or diverted toward the production of lactate. 
 ??????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????
In the presence of oxygen, non-proliferating tissues first metabolize glucose to pyruvate via glycolysis and 
then completely oxidize most of that pyruvate in the mitochondria to CO2 via oxidative phosphorylation 
(OXPHOS). Because oxygen is required as the final electron acceptor to completely oxidize the glucose, 
oxygen is essential for this process. When oxygen is limiting, cells can redirect the pyruvate generated by 
glycolysis away from OXPHOS by generating lactate (anaerobic glycolysis). This generation of lactate 
during anaerobic glycolysis allows glycolysis to continue (by cycling NADH back to NAD+), but results in 
minimal ATP production when compared with OXPHOS. Warburg observed that cancer cells tend to 
convert most glucose to lactate regardless of whether oxygen is present (aerobic glycolysis). This 
property is shared by normal proliferative tissues. Nevertheless, aerobic glycolysis is less efficient than 
OXPHOS for generating ATP. In proliferating cells, ~10% of the glucose is diverted into biosynthetic 
pathways upstream of pyruvate production. (Vander Heiden et al., 2009) 
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Red arrows indicate significantly 
increased metabolic flows in GSDI 
patients, compared to normal 
subjects. 
(Jones et al., 2009) 
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Increased G6P levels in GSDI induce hyper-activation of glycolysis (Hijmans et 
al., 2017; Sun et al., 2009). Interestingly, glycolysis is frequently up-regulated in cancer 
cells by preferential expression of transporters and enzyme isoforms that drive glucose 
flux forward, in order  to adapt to the anabolic demands of cancer cells (Hay, 2016). 
This phenomenon of increased glycolysis, often accompanied by a decrease in 
OXPHOS, even in the presence of oxygen, is known as the Warburg effect (Figure 21). 
Therefore, a ?Warburg-like? phenotype has been demonstrated in several studies in the 
hepatocytes of GSDI patients and animal models (Hijmans et al., 2017; Sun et al., 
2009). This hyper-activation of glycolysis leads to the increase in pyruvate and a 
subsequent lactate production, confirmed by lactic acidosis (an increase in plasmatic 
lactate) in patients and animal models (Kishnani et al., 2014; Mutel et al., 2011a). As 
mentioned, down-regulation of GK has been confirmed in GSDI livers, an event 
frequently observed in glycolytic hepatocellular carcinomas (Guzman et al., 2015). The 
origin of GK downregulation in GSDI hepatocytes was assumed to be due to their 
attempt to limit glucose to G6P conversion (Hijmans et al., 2017). Nevertheless, G6P 
still remains elevated, since it cannot be converted back to glucose; it is blocked in the 
form of G6P and has to be metabolized through glycolysis. Therefore, G6P exerts a 
substrate pressure forcing the activation of this pathway, and the subsequent activation 
of lactate production. 
 Besides G6P production, another step which assures the commitment of glucose 
to glycolysis is the conversion of phosphoenolpyruvate into pyruvate by the liver 
pyruvate kinase (L-PK), resulting in the production of ATP. In GSDI, an increase in the 
expression of L-PK has been reported (Grefhorst et al., 2010; Jones et al., 2009). 
Interestingly, since GNG is blocked in GSDI, pyruvate recycling is significantly 
increased, as highlighted by the increase in pyruvate ? acetyl CoA, pyruvate ? 
oxaloacetate (OAA), OAA ? PEP and PEP ? pyruvate conversions (Jones et al., 
2009) (Figure 22). This could further contribute to lactate production in GSDI patients, 
accounting for lactic acidosis in the plasma. 
 To summarize, even though different molecular mechanisms are involved in the 
reprogramming of cancer cells and GSDI hepatocytes, these cells reflect similar 
??????????????????????????????
????????????????????????????????
Glycolysis (marked in yellow) and 
Krebs cycle (marked in green) 
provide the precursors needed to 
synthesize many important 
biological molecules, i.e. lipids, 
nucleotides, amino acids, sugars 
etc.  
Each black arrow in this diagram 
denotes a single enzyme-
catalyzed reaction; the red arrows 
generally represent pathways with 
many steps that are required to 
produce the indicated products. 
(Essential cell biology, 2/e., 2004 
Garland Science) 
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Glutamine enters the cells through 
glutamine transporter. After entering the 
mitochondria, glutamine is broken down 
into glutamate by glutaminase. 
Glutamate can be transported out to 
cytoplasm and be converted into 
glutathione, while in the mitochondria, 
?????????? ??? ?????????? ????? ?-
ketoglutarate and enters the 
tricarboxylic acid cycle (TCA). Malate 
formed in TCA cycle is transported out 
to the cytoplasm and finally converted 
into lactate in aerobic glycolysis for 
energy release. Malate can also be 
converted into oxaloacetate in 
mitochondria, which in turn be converted into aspartate or citrate. Aspartate is transported out to the 
cytoplasm for nucleotide synthesis. Citrate formed from malate is transported out to the cytoplasm for 
amino acid and lipid synthesis. 
(Fung and Chan et al., 2017) 
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metabolic phenotypes characterized by an increase in G6P, pyruvate and lactate levels, 
mediated by a hyper-activation of glycolysis, all contributing to a ?Warburg-like? 
phenotype of GSDI hepatocytes.  
II.2.3) Krebs cycle alteration and amino acid imbalance 
The activation of glycolysis in GSDI was suspected to have a subsequent impact 
on Krebs cycle, since these pathways are tightly linked (Figure 23). In GSDIa mice (total 
knock-out of G6pc), an increase in citrate, lactate, and pyruvate was reported, with a 
?????????????????????????????????????????????????????-ketoglutarate (Farah et al., 2017). 
???????? ??????? ?-ketoglutarate in the cycle were present at similar levels as those 
found in wild-type mice, suggesting a partial blockage of the cycle in GSDI mice. 
Furthermore, the same study suggested that this blockade after citrate could be 
responsible for the alteration of amino acid metabolism, since the authors observed a 
relative increase in the levels of histidine, proline, and arginine in the livers of GSDI 
mice, with a relative decrease in glycine, phenylalanine, serine, tryptophan, and tyrosine 
levels. In another study glutamine was reported to be elevated in GSDI, along with 
alanine and proline (Slonim et al., 1979). These results on amino acid imbalance 
contribute to a cancerous-like metabolic reprogramming in GSDI hepatocytes. Indeed, 
with the increased metabolic rate and proliferation, cancer tissues have a much higher 
amino acid demand compared to normal tissues. As adaptation to fulfill the increased 
demand, these cells upregulate amino acid transporters, but also reprogram their 
metabolism in order to synthesize more amino acids (Fung and Chan, 2017). In 
particular, cancer cells are known to have enhanced glutaminolysis (conversion of 
glutamine into glutamate), (Fung and Chan, 2017) (Figure 24). As mentioned above, 
this amino acid is increased in GSDI along with alanine and proline, which can both be 
converted to glutamate and subsequently to glutamine (Phang et al., 2015). Thus amino 
acid imbalance in GSDI livers could be particularly favorable for increased cell 
proliferation rates. 
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G6PC was knocked-down in AML-12 
?????? ???? ????????? then mitochondrial 
oximetry analysis was performed. Basal 
respiration, ATP turnover, maximal 
respiration, and spare mitochondrial 
capacity were determined. Oxygen 
consumption was normalized to total 
cellular protein content.  
(Farah et al., 2017) 
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Mitochondria were distended and swollen, 
with effacement of the cristae, disruption of 
the mitochondrial membranes, and influx of 
cytoplasmic contents into the mitochondria 
in G6pc-/- hepatocytes, compared to WT 
hepatocytes. 
(Farah et al., 2017) 
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II.2.4) Down-regulation of mitochondrial oxidative phosphorylation  
Metabolic alterations in GSDI livers, such as up-regulated glycolysis and 
unbalanced Krebs cycle can affect mitochondrial oxidative phosphorylation (OXPHOS) 
rates. This process was investigated in G6pc-/- hepatocytes (Farah et al., 2017). The 
team found a striking decrease in basal respiration, ATP turnover, maximal respiration, 
and spare mitochondrial capacity, implying a loss of mitochondrial function in GSDI 
(Figure 25). Furthermore, they observed distended and swollen mitochondria with outer 
membrane ruptures, effacement of the cristae, as well as an influx of cytoplasmic 
material into the mitochondria, further contributing to the down-regulation of OXPHOS 
(Figure 26). GSDI hepatocytes exhibited a decrease in mitochondrial number as well, 
possibly due to decreased mitochondrial biogenesis. 
Furthermore, the abnormal morphology of the mitochondria might not be the only 
reason why OXPHOS is decreased in GSDI livers. Indeed, OXPHOS can be altered by 
impairment in ??oxidation of lipids, since this pathway contributes to OXPHOS by 
providing substrates for oxidation. One study by our laboratory indicated that lipid 
degradation in GSDI livers is down-regulated, since the main activator of this catabolic 
process, the peroxisome proliferator-???????????????????????????????????????????????
targeted genes, were found to be down-regulated in L.G6pc-/- mouse livers (Abdul-
Wahed et al., 2014). 
Interestingly, in other metabolic diseases affecting the liver, such as the ones 
characterized as NAFLD, OXPHOS down-regulation is often observed, usually resulting 
from the decrease in pyruvate import in the mitochondria (McCommis and Finck, 2015). 
Therefore, mitochondrial pyruvate transport should be analyzed in the case of GSDI. 
Finally, down-regulation of OXPHOS is frequently observed in glycolytic cancers. 
Indeed, this phenomenon is observed concomitantly to glycolysis elevation, as another 
component of the Warburg effect. Thus OXPHOS down-regulation in GSDI livers 
strongly confirms that these livers exhibit cancer-like metabolic behavior. 
  
 
???????????????????????????????????? ?????????????????????????????????????????????
Livers of L-G6pc-/- mice were enlarged and pale and accounted for about 8% of total body mass, versus 
only 4% in control mice. 
(Mutel et al., 2011) 
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Histological analysis of Sudan red staining from WT (a) and K.G6pc-/- kidneys (b?c). 
(Clar et al., 2014) 
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II.2.5) De novo lipogenesis activation and decrease in lipid oxidation lead to 
steatosis 
 Since in GSDI the capacity of G6P storage in the form of glycogen is chronically 
exceeded, G6P activates de novo lipogenesis and leads to hepatic steatosis (Figure 
27). This was confirmed in GSDI mouse models and in GSDI patients (Bandsma et al., 
2008, 2014; Mutel et al., 2011a). Indeed, in GSDI human livers, de novo lipogenesis 
and cholesterol synthesis were found to be increased 40-fold and 7-fold, respectively 
(Bandsma et al., 2008). Production of VLDL was unchanged compared to control 
values, but conversion of VLDL into intermediate density lipoproteins was relatively 
delayed in GSDI patients. Lipid vesicles are present in abundance in GSDI livers, 
mainly in the periportal zone, which corresponds to the location of the expression of 
G6Pase in the liver (Rajas et al., 2007). Associated to glycogen accumulation, lipids 
contribute further to the development of hepatomegaly. 
In GSDI, lipid synthesis is activated via ChREBP, but independently of liver X 
receptor (LXR) and SREBP1c (Grefhorst et al., 2010). Besides lipogenesis, ChREBP is 
known to potentiate glycolysis and nucleotide biosynthesis, and it can have an inhibitory 
role on OXPHOS (Tong et al., 2009). Thus ChREBP could be a metabolic switch 
orchestrating the reprogramming in GSDI cells. Lack of SREBP1c activation could be 
due to low insulin signaling in GSDI (Rake et al., 2002a). As mentioned, this important 
increase in lipid synthesis translates to hepatic steatosis. In addition, it was suggested 
that accelerated glycolysis could supply acetyl-CoA molecules required for lipogenesis 
and thus potentiate this process.  
Moreover, increased lipid synthesis was confirmed not only in GSDI livers, but 
also in GSDI kidneys. Thus lipid accumulation was reported in the proximal tubules of 
K.G6pc-/-  kidneys, where G6Pase is normally expressed (Clar et al., 2014) (Figure 28). 
As observed in GSDI livers, de novo lipogenesis was suggested to be mediated by 
ChREBP (Clar et al., 2014). 
Hepatic steatosis in GSDI is not only due to an increase in lipid synthesis, but 
also to a decrease in lipid ??oxidation. This catabolic pathway was shown to be down-
? 
??????????????? ??????????????????????????????????????????????????????????????????????
Hepatic G6Pase deficiency leads to metabolic alterations including G6P accumulation and suppressed 
expression of PPAR-??? ?? ??????? ?????????? ??? ?????? ????? ?-oxidation. The G6P-mediated activation of 
ChREBP signaling induces lipogenesis, leading to hepatic steatosis which increases the expression of 
PPAR-??? ???????? ?????????? ??????? Moreover, aberrant PPAR-?? ??????????????? ?????????? hepatic 
steatosis. The net outcome is down-regulation of hepatic SIRT1 signaling. Impaired SIRT1 signaling 
increases ATG acetylation and decreases ATG12-ATG5 conjugation along with downregulation of FoxO 
signaling that induces autophagy genes. Accordingly, hepatic G6Pase deficiency-mediated autophagy 
impairment is characterized by decreased expression of ATG proteins, defective autophagic vesicle 
elongation, impaired autophagosome formation, marked p62 accumulation and attenuated autophagic 
flux. 
(Cho et al., 2017) 
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regulated in the liver of L.G6pc-/- mice (Abdul-Wahed et al., 2014), with a concomitant 
down-??????????? ??? ????????? ?????????? ??? ????????????? ?????. It has been suggested 
that the production of malonyl CoA by ACC during lipogenesis could further contribute 
to the decrease in ??oxidation in GSDI livers (Derks and van Rijn, 2015). Finally, a 
decreased activity of AMP-activated protein kinase (AMPK) in GSDI hepatocytes might 
also contribute to impaired fatty acid oxidation and increased fatty acid and cholesterol 
synthesis (Farah et al., 2016; Viollet et al., 2006). AMPK regulates these processes by 
decreasing malonyl CoA production via ACC inhibition and by controlling SREBP1 and 
ChREBP activities (Kawaguchi et al., 2002; Zhou et al., 2001). 
To conclude, lipid metabolism alterations have an important impact on the 
development of GSDI pathology. Increased lipid consumption is associated with a 
striking negative impact on GSDI liver (Rajas et al., 2015) and on GSDI kidneys 
(Gjorgjieva et al., 2015). Interestingly, this enhanced lipid synthesis is yet another 
hallmark of cancer cells observed in GSDI cells. Cancer cells are known to induce de 
novo lipogenesis in order to obtain an increased amount of lipids needed for rapid 
proliferation. They can also uptake free fatty acids (FFA) from the adjacent non-tumoral 
cells (Baenke et al., 2013). The importance of lipids and de novo lipogenesis activation 
needed for the progression of tumors has been proven in many studies from the specific 
inhibition of different enzymes involved in this pathway, such as FAS (Menendez and 
Lupu, 2007; Murata et al., 2010; Zaytseva et al., 2012).  
II.2.6) Link between altered lipid metabolism and autophagy 
Lipid metabolism is also connected to autophagy, a mechanism of self-
degradation that is required for the removal of defective proteins and organelles, 
induced mainly under nutrient limitation. Lipids are components of the autophagic 
process and can alter it at different levels ?????? ???? ??? ????? ?????. Interestingly, the 
release of lipids from lipid droplets in response to nutrient deprivation requires 
components of the autophagic machinery, including ATG5, and inhibition of autophagy 
results in lipid droplet accumulation (Singh et al., 2009). A recent study demonstrated 
that a decrease in autophagy levels in GSDI hepatocytes resulted in an aberrant 
accumulation of lipid vesicles (Farah et al., 2016). Consequently, an induction of 
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The pentose phosphate pathway generates NADPH (used for the biosynthesis of fatty acids, cholesterol 
and the production of reduced glutathione) and ribose 5-phosphate (precursor for the synthesis of 
nucleotides). There are two distinct phases in the pathway. The first is the oxidative phase (marked in 
red), in which NADPH is generated, and the second is the non-oxidative synthesis of 5-carbon sugars 
(marked in green). 
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autophagy in these cells resulted in an increase in lipid degradation, associated with an 
improved histology. While this study suggested that an activation of the mTOR pathway 
(generally considered as the canonical autophagy-regulation pathway) and down-
regulation of AMPK were the main processes that were responsible for the inhibition of 
autophagy in GSDI, another study suggested that autophagy in GSDI is regulated via 
the SIRT / FOXO signaling axis (Cho et al., 2017) (Figure 29). Indeed, SIRT1 signaling 
is known to induce autophagy via deacetylation of autophagy-related (ATG) proteins 
and FoxO transcriptional factors, known to transactivate autophagy genes. Consistently, 
defective autophagy in GSDI liver is characterized by attenuated expressions of 
autophagy components, increased acetylation of ATG5 and ATG7, decreased 
conjugation of ATG5 and ATG12 and reduced autophagic flux, leading to p62 
accumulation, but more importantly to lipid accumulation. Since SIRT1 is down-
regulated during lipogenesis, this study highlighted a vicious circle between lipid 
accumulation and autophagy in GSDI. Indeed, SIRT1 is blocked due to lipid synthesis, 
which subsequently blocks autophagy and leads to further lipid accumulation (Cho et 
al., 2017). 
II.2.7) Pentose phosphate pathway activation 
 Pentose phosphate pathway has been suggested to be activated in GSDI, due to 
the abundance of G6P, which is a precursor for this pathway, but this hypothesis has 
never been confirmed. Indeed, G6P can enter PPP, where it is oxidized by G6P-
dehydrogenase and NADPH+ H+ is formed (Figure 30). NADPH is used for the 
biosynthesis of fatty acid, cholesterol and the production of reduced glutathione. PPP is 
also responsible for the production of ribose-5-phosphate, a precursor of nucleotide 
synthesis. Moreover, the final product of purine nucleotide degradation is uric acid 
(Figure 31). 
 Uric acid is accumulated in plasma of GSDI patients, as well as in mouse models 
of GSDI (Kishnani et al., 2014; Mutel et al., 2011a), translating into hyperuricemia. 
Indeed, the accumulation of metabolites implicated in glycolysis in the case of GSDI 
provokes a decrease in hepatic ATP concentration and inorganic phosphate, which 
stimulates the catabolism of purine nucleotides into uric acid (Cohen et al., 1985; 
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Shortened representation of the link between the pentose phosphate pathway, purine synthesis and uric 
acid production. Xanthine oxidase converts hypoxanthine to xanthine and xanthine to uric acid. In order to 
prevent hyperuricemia, patients are often treated with Allupurinol, an inhibitor of xanthine oxidase. 
PRPP - phosphoribosyl pyrophosphate, GMP ? guanosine monophosphate, IMP ? inosine 
monophosphate, AMP ? adenosine monophosphate. 
(Adapted from Johnson and Patel, 1996) 
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Oberhaensli et al., 1988). Even though increase in nucleotide synthesis has never been 
clearly demonstrated in GSDI, several authors suggest that the increase in intracellular 
G6P could induce PPP and subsequently nucleotide synthesis and uric acid production 
(Schmitz et al., 1993).  The production of NADPH by PPP could also be increased in 
order to compensate for the great usage of NADPH in lipid and cholesterol synthesis in 
GSDI. 
 In conclusion, G6Pase deficiency in GSDI reshapes the metabolic landscape in 
the liver and kidneys. Indeed, glycogen synthesis, glycolysis, lipogenesis and PPP are 
chronically increased, concomitantly with a decrease in OXPHOS and lipid oxidation. 
This particular metabolic reprogramming in GSDI presents striking similarities with 
glycolytic cancerous cells, conferring a ?Warburg-like? phenotype, as well as a possible 
pre-neoplastic status to the cells in GSDI liver and kidneys. 
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III) GSDI symptoms, long-term complications and treatments 
III.1) Clinical manifestations and diagnosis 
 Patients with GSDI are usually diagnosed very early, soon after birth. Indeed, 
some infants with GSDI exhibit hypoglycemic episodes and lactic acidosis during the 
neonatal period. This is due to the fact that breast milk and formula feeding are not 
administered often enough to avoid hypoglycemia in infants with GSDI. Nevertheless, 
these symptoms are more commonly present between 3 to 6 months of age, sometimes 
accompanied with seizures. Interestingly, some adult patients can tolerate low glucose 
levels by using lactate as an energy fuel for the brain (Froissart et al., 2011). Other 
clinical characteristics include doll-like facies, short stature, and an enlarged abdomen 
due to pronounced hepatomegaly (Figure 14) and nephromegaly. Hepatic steatosis 
confers a NAFLD-like aspect to GSDI, which is in accordance with the hyperlipidemia.  
Cognitive development is usually normal, unless the patient has cerebral damage from 
recurrent hypoglycemic episodes. Besides hypoglycemia, biochemical manifestations 
include hyperlipidemia, hypertriglyceridemia, hyperlactatemia, and hyperuricemia (Chou 
et al., 2010a; Froissart et al., 2011; Rake et al., 2002a). Furthermore, other occasional 
complications include anemia, osteoporosis, pulmonary hypertension, impaired platelet 
function, vitamin D deficiency, polycystic ovaries, atherosclerosis and acute pancreatitis 
(Kishnani et al., 2014; Rake et al., 2002a).  
While all of these symptoms are common for both types of GSDI, patients with 
type Ib also exhibit neutropenia, impaired neutrophil function and enterocolitis, resulting 
in recurrent bacterial infections and oral and intestinal mucosa ulceration (Chou et al., 
2010b; Rake et al., 2002a, 2002b). As described earlier (Figure 18), generation of mice 
lacking either G6PT or G6PC3 have shown that neutrophils express G6PT/G6PC3 
complex capable of hydrolyzing G6P (Chou et al., 2010a; Jun et al., 2014; Shieh et al., 
2003). Loss of G6PT activity leads to enhanced ER stress, oxidative stress, and 
apoptosis that underlie neutropenia and neutrophil dysfunction in GSDIb (Chou et al., 
2010b). Neutrophil trafficking is also altered (Chen et al., 2003). These findings showed 
that G6PT is not just a G6P transport protein needed for G6Pase activity, but also an 
???
?
important immunomodulatory protein, the activities of which need to be addressed in 
treating the complications in GSDIb patients. 
 Despite marked steatosis, moderate aspartate transaminase (AST) and alanine 
transaminase (ALT) are observed in plasma of GSDI patients, indicating hepatic 
injuries. Interestingly, when GSDI patients are metabolically controlled by an 
appropriate diet, these liver injury markers are usually normalized, as opposed to other 
GSD types, such as GSDIII, where these markers are never completely decreased 
(Kishnani et al., 2014). Furthermore, GSDI patients do not present an increase in 
ketone bodies in the blood, as opposed to GSD 0, III, VI and IX. These plasmatic 
differences are helpful during diagnosis in order to distinguish between GSDs. 
 Nevertheless, since the identification of G6PC and SLC37A4, sequencing 
analyses of these 2 genes are the most determining evidence in diagnosis of GSDI. 
More importantly, it avoids liver biopsy procedure, which can be risky and painful,?since 
DNA is now purified from blood or saliva. In rare cases where no mutation is detected, 
yet the patient presents GSDI symptoms, the activity of G6Pase could be determined in 
order to diagnose the disease. Histology of the liver, requiring liver biopsy, can also 
distinguish GSDI from other GSDs. Indeed, even though all hepatic GSDs present 
glycogen accumulations in the hepatocytes, GSDI also presents lipid vesicle 
accumulation, that is far more important than in other GSDs.  
III.2) Long-term hepatic complications  
III.2.1) Hepatocellular adenoma 
Hepatocellular adenomas (HCA) are rare monoclonal benign liver tumors of 
presumable epithelial origin that usually develop in healthy liver. It constitutes 2% of all 
liver neoplasms in the general population (Vijay et al., 2015). These tumors are usually 
solitary and can range from 1 ? 30cm in diameter. Increased HCA incidence was 
detected in women who take oral contraception (Nault et al., 2017; Rooks et al., 1979; 
Zucman-Rossi et al., 2006). The role of estrogen in the development of these lesions 
has been established through multiple studies and withdrawal of this hormone was 
found to lead to tumor regression (Zucman-Rossi et al., 2006). Besides estrogen, 
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(A) Graphic representation of adenoma incidence in relation to the age of the patient, published in the 
European study of GSDI (Rake et al., 2002). 
(B) Kaplan-Meier survival curve of adenoma-free progression in GSD types Ia and Ib; The number of 
patients analyzed at different ages is indicated below the graph (Wang et al., 2011). 
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anabolic steroids also lead to increased incidence of HCA. Furthermore, obesity, 
metabolic syndrome manifestations such as type 2 diabetes, insulin resistance, 
dyslipidemia and high blood pressure are increasingly postulated as risk factors for 
development and progression of HCA (Bioulac-Sage et al., 2012). Finally, GSDI and 
GSDIII are also characterized by HCA development (Calderaro et al., 2013; Kudo, 
2001).  
Incidence in GSDI 
HCA is a major complication in GSDI (Figure 32) (Rake et al., 2002a, 2002b; 
Wang et al., 2011). Even though this disease was first described in 1929, the first 
tumors observed in GSDI were reported in 1955 (Mason and Andersen, 1955). This is 
mainly due to the fact that most patients at this time died very early (before 20 years of 
age) from hypoglycemia, which is too early to observe tumor development. Since the 
19????????????????????????????????have been tightly controlled thanks to a strict diet (see 
below), allowing an improvement in life expectancy of GSDI patients. As a 
consequence, the number of hepatic tumors described in GSDI patients has 
subsequently increased these last ten years. The results of the European study on 
GSDI reported that, on average, HCA are detected for the first time at around 15 years 
of age (ranging 2 ? 30 years), and at this point more than 60% of GSDI patients present 
multiple adenomas (Rake et al., 2002a) (Figure 32). The same study showed that 70-
80% of patients above 25 years bare at least one HCA. Early studies suggested that 
there is a higher HCA incidence in male GSDI patients than in female patients (Bianchi, 
1993), but the European study failed to confirm this observation. 
Histology of HCA 
HCA in GSDI livers resemble greatly to HCA developed in non-GSDI patients 
(Bianchi, 1993; Calderaro et al., 2013). They share many epidemiological features of 
estrogen-dependent tumors and yet do not necessarily behave in an estrogen-
dependent manner (Lee, 2002). Nodules, ranging from 0.3 cm to several cm in size, are 
partially, and in some cases entirely surrounded by a fibrotic capsule (Figure 33). 
Hepatocytes in HCA present pale, swollen cytoplasm (Figure 34-35). HCA can be well 
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Intensely enhancing lesions on arterial phase CT scan (black arrow). A smaller HCA with similar 
radiological features is also observed (white arrow). 
(Husainy et al., 2017) 
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(A) Hepatocellular adenoma in GSDI with sinusoidal dilation, steatosis, and inflammatory infiltrates.  
(B) GSDI non-tumor liver with hepatocyte clarification and steatosis. 
(Calderaro et al., 2013) 
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developed, and in some cases of peliosis, bleeding and compression of HCA can occur. 
Kupffer cells can be observed inside HCA, yet their number varies greatly (Bianchi, 
1993). One specific characteristics of GSDI HCA is the presence of Mallory bodies 
(damaged intermediate filaments) (Bianchi, 1993). This finding is important and needs 
to be studied further, since Mallory body presence is a trait generally characteristic for 
hepatocellular carcinoma (HCC), and not HCA. Thus Mallory body formation in HCA 
was speculated to be a risk factor for malignant transformation. 
Molecular characterization of HCA 
Several teams have analyzed the molecular background of HCA in GSDI. 
Analysis of 25 HCA samples from a French cohort of GSDI patients reported 3 different 
groups of classification based on the mutations present in HCA samples: inflammatory 
????????????-catenin-mutated HCA (28%) and unclassified HCA (20%) (Calderaro et 
al., 2013). Most inflammatory HCA presented mutations in the gene coding for the 
interleukin-6 signal transducer (IL6ST), whereas one had a mutation in the gene coding 
for guanine nucleotide binding protein (GNAS). Consequently, all analyzed samples 
with either IL6ST or GNAS mutations had high C reactive protein (CRP) and/or serum 
amyloid A (SAA) expression, in accordance with the inflammatory phenotype. 
??????????????? ??? ?-catenin-mutated HCA, 4 mutations we??? ???????????? ???????? ??? ?-
catenin exon 3, whereas 3 were unusual and located in exon 7, as rarely described in 
HCC samples (associated with poor prognosis) (Guichard et al., 2012). Thus the 
elevated number of HCA that ??????-catenin-mutated, as well as the type of mutations, 
suggest that these HCA have a strong predisposition to transform into HCC. In 
????????????????????????????-catenin ? mutated HCA showed high expression of leucine 
rich repeat containing G protein-coupled receptor 5 (LGR5) and/or glutamine synthetase 
????????????????????????????????????????????-catenin. This study confirmed that in GSDI 
there is a linear pattern of tumorigenesis, meaning that patients develop HCA, which 
can later be transformed in HCC, while HCC do not develop de novo in the liver 
(Calderaro et al., 2013). It is also noteworthy that HCAs issued from the same patient 
presented different mutations, indicating that when multiple adenomas are observed in 
???
??????????? ???????????????????????????????????????
Low-power (A) and higher magnification (B) and (C) images showing the interface between the adenoma 
and surrounding liver tissue. Note the glycogen in the pale swollen hepatocytes in the adjacent liver is 
sensitive to PAS-??? ???????????? ?????????????????????????????????????????????????? ?????????????????????
PAS-D, periodic acid-schiff diastase. 
(Schady et al., 2015) 
?
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?????????????????? ???????????????????????? ??????? ??????? ??????? ??????????
Schematic representation of (A) gluconeogenesis and glycolysis pathways, and (B) fatty acid synthesis 
????????? ?????????????? ??????????????? ?????? ??? ??? ?? ??????? ???????????? ????????? - mutated HCA 
and GSD non-tumoral liver are in solid boxes (red = up-regulation; green = down-regulation). 
(Calderaro et al., 2013) 
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a patient, they are not necessarily developed from the same clone (Calderaro et al., 
2013). 
This same classification system is used for non-GSDI HCA, and generally it 
includes an additional 4th ????????????-mutated HCA). Interestingly, ???????????????
has never been reported in HCA in GSDI, but HNF1a mRNA expression has been 
reported to be decreased, not only in all GSDI HCA, but also in GSDI livers (Calderaro 
et al., 2013; Kishnani et al., 2009). Astonishingly, non-GSDI HCAs with a mutation in 
HNF1? have a metabolism resembling that of GSDI livers, characterized by a decrease 
in GNG and an increase in glycolysis (Figure 36) (Calderaro et al., 2013).  
 Furthermore, another study reported that HCA in GSDI present a recurrent 
chromosomal alteration on chromosome 6, with simultaneous gain of 6p and a loss of 
6q (Kishnani et al., 2009). The size of HCA with these chromosome 6 alterations was 
significantly larger than HCA without these alterations. Interestingly, a gain of 6p and a 
loss of 6q is an event frequently observed in HCC in the general population of patients, 
but not in HCA. The expressions of Insulin-like growth factor 2 receptor (IGF2R) and 
large tumor suppressor kinase 1 (LATS1), tumor suppressor genes on chromosome 6, 
were reduced by 50%, which could potentially contribute to tumorigenesis. This 
phenomenon has been suggested to be a distinctive trigger of GSDI HCA, in 
accordance with their high potential of transformation into HCC. 
III.2.2) Hepatocellular carcinoma 
Incidence rates and detection 
GSDI patients with HCA present about 10% rate of transformation of HCA in 
HCC (Calderaro et al., 2013; Franco et al., 2005; Kishnani et al., 2014; Lee, 2002). 
Interestingly, this HCA-to-HCC transformation seems to be characteristic for GSDI 
carcinogenesis. Furthermore, similar HCA-to-HCC formation has also been reported in 
obese patients (Bioulac-Sage et al., 2012; Bunchorntavakul et al., 2011). However, the 
incidence of transformation in GSDI is significantly higher than in non-GSDI HCA (Lee, 
2002; Manzia et al., 2011). One study including 8 GSDI patients (6 male / 2 female) 
bearing HCC demonstrated that first detection of HCC ranged from 13-45 years (mean 
????????????????????? ????????
???????????? ??? ??????????
Index images of two hepatic 
lesions with an interval of 6 
months. Fat-suppressed T1W fat 
post-contrast image acquired in 
May 2014 and in Nov 2014. The 
anterior lesion (single arrow) 
shows interval decrease in size on 
follow-up imaging, whereas the 
posterior lesion (double arrows) is 
slightly increased in size, later on 
diagnosed as HCC. 
(Baheti et al., 2015) 
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????????? ??? ??????????
There is lack of portal tracts in all 
fragments.  
(a) In low-power magnification (H&E 
stain), there is moderate steatosis 
(thin arrows) with many ballooned 
cells (thick arrow), some containing 
Mallory-Denk bodies (blue arrow).  
(b) In low-power magnification (H&E 
stain), there are increased unpaired 
arteries (arrows).  
(c) In low-power magnification, there 
is focal Glypican-3 staining of the 
tumor cells.  
(d) In higher magnification, a reticulin stain shows focal loss of the reticulin framework (arrow). 
(Baheti et al., 2015) 
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28 years) (Franco et al., 2005). Alpha-fetoprotein (AFP), which is considered as a 
plasmatic marker for HCC, was normal in 6 out of 8 patients. Carcinoembryogenic 
antigen (CEA), another HCC marker, was normal in 5 patients out of 8 patients, 
highlighting that HCC markers, which are used in general, are not adapted for HCC 
diagnosis in GSDI. Therefore, regular abdominal MRI or CT scan is a better solution to 
follow up tumor development in GSDI patients (Figure 37). Of course, the potential risks 
associated with excessive radiation exposure in patients receiving multiple CT scans 
need to be taken into consideration. 
There are several challenges concerning the diagnosis of HCC in GSDI. 
Because of the abundance of HCA, biopsy is often not a good option. Not only is biopsy 
painful for patients, but it represents risks of tumor bleeding and dissemination of cancer 
cells. Indeed, in 9 cases of biopsy sampling in GSDI, cancer cells were disseminated 
along the biopsy tract (Kelly and Poon, 2001). One of the markers used to distinguish 
HCA from HCC at a histologic level is glypican 3 (Figure 38). Even though MRI and CT 
imaging are good tools for the detection of HCC, the distinction between HCC and well 
developed HCA is often difficult, especially if the tumor is in an intermediate stage of 
early malignancy. Thus high contrast imaging is recommended, in order to look for 
increase in lesion size, poorly defined / disrupted margins and / or spontaneous 
hemorrhage (Kishnani et al., 2014).  
Characteristics of HCC in GSDI 
Unfortunately, HCC in GSDI are not very well characterized at a molecular level. 
Most data arose from case study reports of GSDI patients with HCC. Patients usually 
presented several nodules in the liver that were stable and did not change until the 
onset of HCC. Lesions of HCC can have a fibrotic capsule delimitating tumor tissue, 
while in some cases they have been described as completely surrounded by HCA 
tissue, and the boundaries between normal hepatic tissue, HCA and HCC were not 
always clear (Kudo, 2001; Limmer et al., 1988). These complex cancerous structures 
can often lead to misdiagnosis. Unfortunately, several patients have been reported to 
present metastatic disease (Franco et al., 2005; Kelly and Poon, 2001). HCC 
metastases have been detected in the bone, lungs, spinal cord, portal vein and para-
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????????????????? ????????? ????
Kidneys of (a) WT mice and (b) mice with specific renal deletion of G6pc (K.G6pc -/-).  
(Clar et al., 2014) 
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Kidneys of (a) WT mice and (b?c) mice with specific renal deletion of G6pc (K.G6pc -/-).  
(Clar et al., 2014) 
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aortic lymph nodes in several patients. These findings are important in the case of 
GSDI, since the prognosis for HCC is poorly evaluated, due to the limited number of 
patients.  
In the general human population, HCC occur in fibrotic / cirrhotic livers, 
sometimes associated with alcoholic liver disease or viral hepatitis infection. On the 
contrary, GSDI patients do not exhibit hepatic fibrosis / cirrhosis, and HCC are formed 
from preexisting HCA. This is a major difference between non-GSDI and GSDI 
associated HCC that needs to be taken into consideration when analyzing the potential 
triggers of carcinogenesis in GSDI livers. 
HCA and HCC are not the only hepatic lesions observed in GSDI. Indeed, there 
have been reports of hepatoblastoma, focal fatty infiltration, focal fatty sparing, focal 
nodular hyperplasia and peliosis hepatitis (Lee, 2002). All of these render diagnostics in 
GSDI difficult, since often one complication can be mistaken for another. 
III.3) Long-term renal complications 
III.3.1) Chronic kidney disease 
Chronic kidney disease (CKD) is a recent complication described in GSDI, since 
life expectancy has been increased after diet management introduction. As early as 
1929, in the autopsy reports of two children with GSDI, Dr. von Gierke highlighted the 
presence of nephromegaly, due to strong glycogen accumulation in the kidneys. 
Nevertheless, hypoglycemia and metabolic perturbations were considered far more 
important than renal complications, due to their implication in mortality. CKD was 
acknowledged as a complication in GSDI ????????????????????????????????????????????????
GSDI patients revealed glomerulosclerosis, interstitial fibrosis and tubular atrophy 
(Baker et al., 1989; Chen, 1991; Reitsma-Bierens et al., 1992).  
G6Pase deficiency results in glycogen and lipid accumulation in renal proximal 
tubules of the kidney cortex (Figures 39 and 40). The first sign of CKD is progressive 
development of glomerular hyperperfusion and hyperfiltration (Chen, 1991). Glomerular 
filtration rates (GFR) are regularly measured in GSDI patients as an indicator of renal 
 ??????????? ???????????????????????????????????????????????????????????????????
(Martens et al., 2009) 
 
 
 
??????????? ?????????????????????????????????????????????????????????????
? ????????????????????????????????????????
(Rake et al., 2002) 
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function and a biphasic pattern in relation to age has been reported (Figure 41). This 
means that earlier in life, GSDI patients exhibit increased GFR, which reaches a peak 
on average at 15 years of age, and then starts declining, while albuminuria and 
proteinuria progress (Martens et al., 2009). Indeed, it has been reported that most adult 
GSDI patients over 25 years of age develop microalbuminuria and around 50% of them 
develop proteinuria (Kishnani et al., 2014; Rake et al., 2002b) (Figure 42). Another 
study reported similar results, stating that after 18 years, 67% of patients exhibit 
albuminuria and 42% present proteinuria (Martens et al., 2009). Many patients have 
nephrocalcinosis, due to hypercalciuria and hypocitraturia that enhance the likelihood of 
urine calcium precipitation. Because of hyperuricemia, uric acid nephrolithiasis and gout 
nephropathy can develop. Unfortunately, renal function loss, glomerulosclerosis and 
interstitial fibrosis can occur and these events can lead to renal failure at later stages. 
III.3.2) Molecular pathways involved in CKD development 
The molecular mechanism leading to CKD in GSDI patients has been proposed 
to be similar to the one observed in diabetic patients (Mundy and Lee, 2002; Rajas et 
al., 2013; Yiu et al., 2008a). Indeed, even though these two pathologies are highly 
different and even opposite in some aspects, the one point that they have in common is 
the increased metabolism of G6P. Also in line with this idea, the activation of Renin / 
Angiotensin system (RAS) is associated with both diabetic and GSDI CKD (Mundy and 
Lee, 2002; Yiu et al., 2008a).  
High G6P levels in GSDI patients activate glycolysis and PPP, resulting in an 
increased pool of triose phosphate molecules, such as glycerol-3 phosphate and 
dihydroxyacetone phosphate (Yiu et al., 2008a, 2008b). These are precursors for the de 
novo synthesis of glycerolipids, including diacylglycerol (DAG). DAG is a potent 
activator of protein kinase C (PKC) and acts by binding to a specific domain on the 
regulatory subunit of the enzyme. This activation of PKC leads to the activation of the 
RAS (Figure 43). In RAS, angiotensinogen (Agt) is the precursor of the Ang II, which is 
produced from two sequential enzymatic reactions - the conversion of Agt to Ang I by 
renin and the conversion of Ang I to Ang II by the Ang converting enzyme (ACE). Ang II 
stimulates the proliferation of mesangial cells, glomerular endothelial cells, and 
 ???????????????????????????????????????????????????????????????????????????????????????
?????????????????
Glucose-6 phosphate accumulation in GSDI kidneys leads to an increase in DAG synthesis. Increased 
DAG levels activate PKC, which in turn leads to the activation of the RAS / TGF-?1 signalization axis. The 
RAS / TGF-?1 activation consists in the conversion of Angiotensinogen to Angiotensin I via renin, which is 
subsequently converted to Angiotensin II via ACE, finally leading to an increase in TGF-?1 levels. TGF-?1 
is a profibrogenic factor capable of activating the epithelial ? mesenchymal transition process, eventually 
leading to kidney fibrosis development.     
DAG ? diacylglycerol, PKC ? protein kinase C, RAS ? Renin Angiotensin system, TGF-?1 ? transforming 
growth factor ?1, ACE ? Angiotensin converting enzyme. 
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fibroblasts, and acts as a profibrogenic factor.  Many profibrotic effects of RAS are 
mediated by transforming growth factor-??? ????-???. Indeed, renal fibrosis 
development is induced by TGF-??, which activates the expression of the extracellular 
matrix genes (Lan, 2011; Meng et al., 2015). In addition, TGF-?????????????? inducer of 
epithelial-to-mesenchymal transition (EMT) that characterizes the phenotype of renal 
interstitial fibrosis (Fragiadaki and Mason, 2011). 
Even though several treatments inhibiting the RAS / TGF? ?????????????????????
inhibitors, are being tested in GSDI patients, at the moment it is unclear whether they 
have an actual impact on the development of CKD. Indeed, while ACE inhibitors can 
decrease GFR and delay microalbuminuria, these drugs have no effect in patients with 
preexisting microalbuminuria / proteinuria (Martens et al., 2009).  
III.4) Intestinal complications 
 ??????????????????????????? intestinal G6Pase activity associated with an intestinal 
accumulation of glycogen has been reported in two patients with GSDI (Field et al., 
1965). Nevertheless, G6Pase expression was believed to be restricted to the liver and 
the kidneys at the time being. It was not until 1999 that the existence of intestinal 
G6Pase was confirmed by our laboratory in rat and human intestine (Rajas et al., 1999), 
more precisely in the mucosa of intestinal villi (Rajas et al., 2007).  
 The intestinal pathology of GSDI has not been studied as much as the hepatic 
and renal pathologies. Since it is considered that this complication is not involved in 
morbidity and mortality of GSDI patients, not many studies have been conducted in 
order to understand the molecular basis and its impact. It has been reported several 
times that patients with GSDIa as well as patients with GSDlb suffer from intermittent 
diarrhea, which seems to worsen with age (Visser et al., 2002). No common cause for 
diarrhea in GSDIa was found, while in GSDlb a loss of mucosal barrier function due to 
inflammation, documented by increased faecal ?1-antitrypsin excretion and 
inflammation in the colonic biopsies, seems to be the main cause (Visser et al., 2002). 
The inflammation is most likely related to disturbed neutrophil function, which is often 
found in GSDIb. Indeed, in the European study of GSDI, it has been reported that up to 
???
?
55% of GSDIb patients suffer from diarrhea (Rake et al., 2002b). This intestinal 
pathology is highly similar to Crohn?? disease. Furthermore, the diet of GSDI patients, 
consisting mainly of slow-release carbohydrates, could contribute to these intestinal 
manifestations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ??????????? ??????????????????????????????????????????????????????????????????????
FM ? frequent meals; UCCS ? uncooked corn starch; CNGDF ? continuous nocturnal gastric drip feeding. 
European study of GSDI (Adapted by Rake et al., 2002) 
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Schematic representation of the 
empiric predictions of the entry 
points of fructose and galactose in 
GSDI hepatic metabolism and the 
subsequent activation of metabolic 
pathways. 
(Rake et al.,2002; Heller et al., 
2008; Bhattaacharya, 2011) 
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IV) Treatment strategies for GSDI patients 
IV.1) Nutritional treatment  
Currently, a curative treatment is still not available for GSDI patients. 
Nevertheless, nutritional management guidelines have been proposed in the early 
1980s. This nutritional treatment for GSDI patients was designed in order to avoid 
hypoglycemia? and suppress increased lactate production, but also to limit excessive 
accumulation of glycogen and lipids in the liver and kidneys. A breakthrough in the 
treatment was the introduction of continuous nocturnal gastric drip-feeding (CNGDF), 
providing a continuous dietary supply of glucose. This treatment allowed a substantial 
increase in life expectancy in GSDI patients. 
The dietary guidelines depend on the age of the patient (Figure 44). In infants, 
the primary source of concern is the management of hypoglycemic episodes. 
Nevertheless, children are not only in need of constant glucose levels, but also sufficient 
protein intake, as well as balanced vitamin and mineral intake, in order to grow and 
develop normally. To prevent hypoglycemia in infancy, soy-based, sugar-free formula, 
or formula free of sucrose, lactose and fructose is given on demand every 2-3h. 
Fructose, lactose and sucrose are avoided, since they are considered as ?fast sugars? 
which can easily be converted into G6P and thus further stimulate lipid and glycogen 
accumulation (Figure 45). However, there has never been a study confirming these 
??????????????????????????????????????????????????????????????????????????????????????
empirical conclusions? from metabolic pathway knowledge (Froissart et al., 2011; Rake 
et al., 2002a, 2002b). 
Once the child sleeps more than 3-4h, it has to be either woken up to eat, or 
CNGDF needs to be employed. Continuous glucose infusion is performed either by 
intragastric feeding by inserting a nasogastric tube, or by a total parenteral nutrition, 
requiring a surgically inserted G-tube, through which a specially designed formula drips 
(Figure 46). Although gastric feeding seems as a good way to prevent hypoglycemia, it 
comes with risks, such as failure to deliver the formula due to occlusions or spilling, as 
well as recurrent infections due to the G-tube, especially in GSDIb patients. Thus the 
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For temporary access, tubes can be placed through the nose and mouth. For permanent tubes, several 
options in the stomach and intestine are available. 
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pros and cons of using this option need to be evaluated regarding the patient 
concerned. 
Solid food is introduced at around 4-6 months. Blood glucose is maintained by 
frequent meals and uncooked cornstarch (UCS), which is introduced between 6 months 
and 1 year. UCS is digested slowly, providing a steady release of glucose, which allows 
more stable glucose levels over a long period of time, as compared with other sources 
of carbohydrates. In addition, sweet products, fruit and dairy product consumption is 
restricted or avoided, since these contain galactose and fructose. This results in a 
decrease in vitamin and mineral intake, which need to be given as supplements. As the 
child grows, small frequent meals rich in UCS supplemented with fibers are usually 
recommended.  
Most adult GSDI patients maintain their glycaemia by consuming UCS at a dose 
of 1.7-2.5g UCS/kg, every 4h-5h (sometimes 6h). Some adults may eventually require 
only one dose of UCS at bedtime (Rake et al., 2002a, 2002b). Less than 2 years ago, a 
modified UCS, Glycosade (Vitaflo), became available in Europe and the United States, 
allowing an increase in fasting periods, compared with Maizena in France.  
Many beneficial effects of this dietary approach have been observed in GSDI 
patients.  Mortality rates were decreased with this nutritional management, as reported 
in the European study of GSDI, mainly due to a decrease in fatal hypoglycemia 
incidence (Chen et al., 1993; Rake et al., 2002a; Wolfsdorf et al., 1990). Plasmatic 
parameters are improved, but not entirely corrected with the dietary therapy, since some 
patients respond better than others (Rake et al., 2002a). Severe hypercholesterolemia 
has been observed in 12% of treated GSDIa patients and in 5% of the treated GSDIb 
patients. Furthermore, severe hypertriglyceridemia was observed in 73% of GSDIa and 
46% of GSDIb treated patients. Thus hyperlipidemia was found to be more present and 
more severe in GSDIa patients, even under dietary regimen (Greene et al., 1991; Levy 
et al., 1988; Rake et al., 2002a). Therapeutic agents such as clofibrate, lovastatin, and 
niacin, intended to decrease lipids and cholesterol, have been used in these patients 
(Geberhiwot et al., 2007; Greene et al., 1991), to counterbalance the dietary treatment. 
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(a) CT image of the liver demonstrates two lesions in the liver representing HCAs (black and white 
arrows). (b) CT image of the same patient 18 months later demonstrates decrease in size of the HCA 
(black arrow). The lesion in the right hepatic lobe, white arrow in (a), has completely resolved. (c) MR 
image of the liver in the same patient 8 years later demonstrates continued decrease in size of the HCA 
(black arrow). Patients analyzed in this study followed strictly the guidelines for GSDI nutritional therapy 
and had optimal metabolic control.  
(Beegle et al., 2014) 
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Finally, it has been reported that growth was improved in GSDI patients who received 
standard nutritional therapy, in comparison with that in a control group who did not 
receive this dietary therapy (Mundy et al., 2003). 
Even though this diet has extremely improved life expectancy in GSDI patients, it 
is unable to prevent entirely all of the symptoms and long-term complications of GSDI, 
including HCA and HCC development. Increased life expectancy leaves more time for 
hepatocellular tumors to develop. On the other hand, regression of HCA right after the 
implementation of the dietary regimen has been observed as early as 1981 (Parker et 
al., 1981). This study including 3 treated and 2 non-treated patients reported that 2 of 
the patients who started dietary intervention presented a disappearance of the hepatic 
lesions, and a marked reduction in size of the adenoma occurred in the third patient. 
The hepatic lesions remained present in the 2 untreated patients. The same results 
were confirmed recently (Beegle et al., 2014), and it was concluded that when HCAs 
are documented in a patient with suboptimal metabolic control, intensive medical 
therapy may be an alternative to surgical intervention in some individuals (Figure 47). 
Optimal metabolic control in this study was defined as: triglycerides less than 2 g/L, 
lactate less than 2.2 mmol/L, and serum glucose greater than 75 mg/dL. 
Diet improved not only hepatic parameters, but it also had a positive effect on the 
renal tubular dysfunction in GSDI patients (Chen et al., 1990). Indeed, even though the 
histological aspects of the kidneys were not analyzed in this study, the tubular function 
in patients with GSDI was assessed by measuring urinary excretion of amino acids, 
??????????? ???? ??-microglobulin (a sensitive indicator of tubulo-interstitial lesions). 
These parameters of kidney injury were different in patients that followed or not the 
recommended dietary therapy, highlighting once again the importance of this regimen 
and its beneficial effects. Similar results were observed in another study, demonstrating 
that in patients with optimal metabolic control due to strict diet, microalbuminuria and 
proteinuria incidence was decreased (Martens et al., 2009). 
In conclusion, even though dietary therapy is not 100% effective in the prevention 
of GSDI complications, it has a striking effect on life expectancy, metabolic control, 
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AT1R and AT2R ? Angiotensin II receptors 
 
 
 
 
 
 
 
???
?
glycaemia maintenance and even long-term complications. Thus it is imperative that the 
patients follow the nutritional guidelines. 
IV.2) Pharmacological therapy 
Angiotensin converting enzyme (ACE) inhibitors, such as benazepril or enalapril, 
have been used for many years in GSDI patients?exhibiting kidney dysfunction, in order 
to block the RAS / TGF-??? ?????????? axis and subsequently inhibit kidney fibrosis 
development (Figure 48). This strategy has been developed mainly for diabetic patients, 
since they present the same molecular mechanisms leading to nephropathy. Several 
studies have reported that this therapeutic strategy can normalize GFR for a limited time 
span and can improve glomerular hyperfiltration in GSDI patients (Martens et al., 2009; 
Melis et al., 2005). Angiotensin receptor blockers (ARBs), which are angiotensin II 
receptor antagonists, such as losartan or irbesartan (Figure 48), are also used by GSDI 
patients, sometimes combined with ACE inhibitors (Gjorgjieva et al., 2016a; Kishnani et 
al., 2014).  
Allopurinol, a xanthine oxidase (XO) inhibitor, is used by many patients in order 
to prevent hyperuricemia (Figure 31). In a cohort of 32 patients followed by Prof. 
Philippe Labrune in Paris, 84% of the patients declared using this treatment (Gjorgjieva 
et al., 2016a), whereas the European study of GSDI has reported only 57% (Rake et al., 
2002a). Nevertheless, in 29% of the patients using Allopurinol or other XO inhibitors, 
serum uric acid levels were still elevated, raising the question of the efficiency of this 
treatment in GSDI patients. 
 Lipid lowering strategies are also commonly used in GSDI patients with 
hyperlipidemia and hypercholesterolemia. Fibrates and other lipid lowering drugs are 
administered, generally in extreme hyperlipidemic conditions, when patients present 
more than 10 g/L of triglycerides in blood plasma. For example, 34% of the patients 
followed by Prof. Philippe Labrune in Paris reported the use of lipid-lowering treatments 
(Gjorgjieva et al., 2016a).  
???
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IV.3) Hepatic and / or renal transplantation in GSDI patients 
 Dietary treatment has an important beneficial effect on GSDI long-term outcome, 
but it is not entirely effective in the inhibition of tumor development and the progression 
of CKD. These complications can still occur in GSDI patients and the last resort when 
the pathologies are highly advanced is hepatic and / or renal transplantation. 
 Liver replacement is the ultimate therapy for hepatic metabolic disease. It is 
recommended in GSDI patients with multifocal, growing lesions that do not regress with 
improved dietary regimens, with bleeding tumors and tumors that do not have evidence 
of distant metastatic disease (Kishnani et al., 2014; Rake et al., 2002b).?The first liver 
transplantation in a GSDI patient was performed in 1983, and after that, hundreds of 
patients have undergone this procedure (Kishnani et al., 2014; Malatack et al., 1983). 
After liver transplantation, all GSDI patients achieve resolution of their metabolic 
derangement, including correction of hypoglycemia, lactic acidosis, hyperuricemia, and 
hyperlipidemia ??????????????????????. Nevertheless, hepatic transplantation comes with 
important risk factors, such as transplant rejection and kidney failure, which were 
observed frequently in GSDI patients (Boers et al., 2014). Indeed, liver transplantation 
does not improve renal complications, which suggested that the hepatic and renal 
pathologies in GSDI are completely independent (Rake et al., 2002a). This finding was 
further confirmed by the development of two mouse models with organ-specific deletion 
of G6pc in the liver or kidneys, which developed the hepatic or renal GSDI pathology, 
respectively (Clar et al., 2014; Mutel et al., 2011a). Therefore, mice which present 
normal expression of G6pc in the kidneys and G6pc deletion in the liver still develop the 
hepatic GSDI pathology and inversely, mice with G6pc deletion in the kidneys develop 
GSDI nephropathy, even with normal G6pc expression in the liver. Finally, liver 
transplantations are associated to mortality rates that need to be taken into 
consideration (Reddy et al., 2009). Indeed, GSDI patients that had undergone liver 
transplantation in North America exhibited a 1-, 5-, and 10-year survival rate of 82%, 
76%, and 64%, respectively (Maheshwari et al., 2012). 
 Renal transplantation has also been performed in GSDI patients when patients 
exhibit renal failure (Rake et al., 2002a). Nevertheless, kidney transplants do not allow a 
???
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normalization of glycaemia (Labrune, 2002). Several studies indicate the beneficial 
effects of combined liver-kidney transplantation in the case of GSDI even in the 
absence of serious liver lesions, with the aim of improving the quality of life of these 
patients (Belingheri et al., 2007; Labrune, 2002; Panaro et al., 2004). 
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Weight gain of G6pc+/+ and G6pc+/- mice (blue), compared to G6pc-/- mice (black), during the first 38 
days after birth. 
(Lei et al., 1996) 
 
 
 
 
 
 
 
???
?
V) Contribution of animal models of GSDI in the comprehension of the 
pathology and first gene therapy studies 
Many aspects of GSDI are still unclear at a molecular level. A better 
understanding of the molecular pathways involved in long-term pathologies associated 
with GSDI will allow us to find new pharmacological targets. One of the reasons why so 
many questions are left unanswered is the limited number of patients, but also the 
evident risk of testing potential treatment strategies in patients, especially since a major 
part of these patients are children. This is why the need of animal models of GSDI is 
essential in order to decipher the mechanisms of this disease. 
V.1) Animal models of GSDI 
Total Knock-out G6pc mouse model 
The first mouse model of GSDIa was developed in 1996, by the team of Janice 
Chou. These mice exhibit a total knock-out of G6pc obtained by transgenesis by the 
deletion of G6pc exon 3 (G6pc-/- mice) (Lei et al., 1996). G6pc-/- mice present low birth 
weight, growth retardation (Figure 49), severe hypoglycemia and significant increase in 
serum cholesterol and triglyceride levels. Moreover, only 60% of mice treated with 
glucose injections, glucose-fortified water and food supplementation survive through 
weaning and have a life expectancy of about 6 months (Lei et al., 1996). As observed in 
GSDI patients, G6pc-/- mice exhibit hepatomegaly and nephromegaly. Interestingly, the 
size, agility, serum lipids and glycemic control were shown improve dramatically in adult 
G6pc-/- mice that have survived the frail weaning period, reaching levels approaching 
their wild-type (WT) littermates (Salganik et al., 2009). In addition, adult G6pc-/- mice 
were shown to be able to mate and produce viable offspring. However, liver histology 
and glycogen accumulation do not improve with age (Salganik et al., 2009). Hepatic 
tumorigenesis was not described in this study. Furthermore, these mice exhibit the renal 
complications associated with GSDI.  
While total knock-out mice represent a great tool to investigate deregulated 
metabolism pathways in GSDIa, long-term complications such as HCA / HCC could not 
be observed in these mice because they do not survive long enough to develop them. 
 ????????????????????????????????????????????????????????????????????????? ????
?????????????????????????????????????????????????????????by Kim et al. 2008; Lei et al. 1996. The data of 
????????????????????????described in Mutel et al. 2011???????????????????????????????????????described 
in Clar et al. 2014. BW: body weight.  
(Rajas et al., 2015) 
 
 
??????????? ????????????????????????????????????????? ????????????????????????????????????
MR images showing the evolution of liver lesions at 12 months (A) and 18 months (B and C) after G6pc 
deletion. Liver resection after 18 months in control mice (D) or in L.G6pc-/- mice (E and F) with multiple 
tumour nodules. 
 (Mutel et al., 2011) 
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These mice exhibit hypoglycemic episodes, which are severe and need constant 
treatment with glucose. This generates difficulties in the manipulation of the mice and in 
the organization of the study protocols.  
To gain further insights into the long-term mechanisms of the disease and to 
evaluate potential treatment strategies, an animal model with sufficient life expectancy 
was required. By disrupting G6Pase activity specifically in the liver (L.G6pc-/- mice), 
kidneys (K.G6pc-/- mice) or intestine (I.G6pc-/- mice), using a tamoxifen-inducible 
CreERT2-lox system (conditional), our laboratory obtained viable mouse models of GSDIa 
(Figure 50) (Rajas et al., 2015).  
Liver-specific G6pc knock-out mouse model (L.G6pc-/- mice) 
 To obtain a liver-specific invalidation of G6pc, the exon 3 of G6pc was deleted in 
the liver of L.G6pc-/- mice?by crossing B6.G6pcex3lox/ex3lox mice with B6.SACreERT2/+ mice 
(SA= serum albumin) (Mutel et al., 2011a). Thus L.G6pc-/- mice exhibit normal glycemia 
during fed state and have normal life expectancy. Glucose production is still assured by 
the kidneys and intestine in these mice, and they develop only moderate hypoglycemia 
(40-60 mg/dL) in post-absorptive periods (6h-fast), since they cannot mobilize their 
glycogen storages. During long fasting periods, the induction of renal and intestinal 
glucose production allows L.G6pc-/- mice to maintain blood glucose in a range similar to 
wild-type mice, around 90 mg/dL (Mutel et al., 2011a, 2011b). Furthermore, hepatic 
G6Pase deficiency translated to hepatic glycogen and G6P accumulation, as well as 
steatosis. Hypertriglyceridemia, hypercholesterolemia, hyperuricemia and lactic acidosis 
are observed in L.G6pc-/- mice as early as 10 days after G6pc deletion, but 
interestingly, these parameters have a tendency to normalize with age, with the 
exception of cholesterol (Mutel et al., 2011a). 
L.G6pc-/- mice develop hepatocellular tumors, similar to those observed in GSDI 
patients (Figure 51). In around 15% of L.G6pc-/- livers, small lesions can be detected as 
early as 9 months of G6pc deletion. At 18 months, all L.G6pc-/- mice have liver nodules 
between 1 and 10 mm in diameter, histologically classified mainly as HCA. However, at 
this stage, 5-10% of the mice develop HCC, as observed in GSDI patients. 
 ??????????? ??????????????? ????????? ????
Increase in kidney size in K.G6pc-/- mice (right) compared to WT mice (left) at 6 months of G6pc deletion.  
(Clar et al., 2014) 
 
 
??????????? ???????????????????????????? ?????????????????????? ????????????????????????
Histological analyses of hematoxylin-eosin staining from WT (a, c) and K.G6pc-/- kidneys (b, d).  
(c, d) correspond to a higher magnification of the kidney cortex observed in a and b, respectively. These 
analyses clearly show tubular dilatation and clarification in K.G6pc-/- kidneys. 
 
(Clar et al., 2014) 
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This mouse model allowed the confirmation of the importance of the dietary 
regimen given to GSDI patients. Indeed, tumor incidence and the transformation rates 
of HCA to HCC were increased in L.G6pc-/- mice?fed a high fat / high sucrose (HF/HS) 
diet (Rajas et al., 2015). Finally, this mouse model could allow an evaluation of the 
effects of various diets, such as galactose-enriched or fructose-enriched diet, in order to 
see whether these sugars actually have a negative impact on the long-term 
complications in GSDI. Furthermore, it can also be used to test pharmaceutical 
therapies, such as lipid-lowering drugs (see results), in order to analyze their effect on 
GSDI livers. 
Kidney-specific G6pc knock-out mouse model (K.G6pc-/- mice) 
K.G6pc-/- mice present a targeted deletion of G6pc specifically in the kidneys; 
they were obtained by crossing B6.G6pcex3lox/ex3lox mice with B6.KapCreERT2/+ mice (Kap= 
kidney androgen protein) (Clar et al., 2014; Rajas et al., 2015). Even though G6pc 
deletion is only partial (50% decrease in G6Pase activity), these mice present all of the 
hallmarks of GSDI nephropathy, yet have normal life expectancy. Indeed, they exhibit 
glycogen and lipid accumulation in the kidney cortex, resulting in nephromegaly (Figure 
52). Blood glucose levels are normal in K.G6pc-/- mice, compared to WT mice, since 
they produce glucose by the liver and intestine, and partially by the kidneys (Clar et al., 
2014). On a histology level, as early as 6 months after G6pc deletion, tubular 
clarification and dilatation can be observed in the kidneys (Figure 53), but at this stage, 
it is not associated to interstitial fibrosis (Clar et al., 2014). Renal lipid accumulation is 
due to an activation of de novo lipogenesis and is responsible for the activation of the 
profibrotic pathway RAS and subsequently TGF-?? and EMT (Clar et al., 2014; Rajas et 
al., 2015).  
As L.G6pc-/- mice, K.G6pc-/- mice could be used to evaluate the effect of diet on 
the development of CKD, thus improving the dietary guidelines for the patients. 
Furthermore, the effects of renoprotective drugs used to treat diabetic CKD could be 
analyzed by treating K.G6pc-/- mice with ACE inhibitors and ARB inhibitors, in order to 
understand better if these drugs should be prescribed in human patients. 
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(Chen et al., 2003) 
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Intestine-specific G6pc knock out mouse model (I.G6pc-/- mice) 
I.G6pc-/- mice present a targeted deletion of G6pc specifically in the intestine; 
they were obtained by crossing B6.G6pcex3lox/ex3lox mice with B6.VillCreERT2/+ mice (Vill= 
villin) (Penhoat et al., 2011). Indeed, these mice present a deficiency in G6Pase in the 
intestine, making them incapable to produce glucose in this organ. During the first year 
after G6pc gene deletion, I.G6pc????????? ???????? ?? ??????? ????? ?? ????? ??? ????? ??????
mice. Meanwhile, no diarrhea or abnormal consistency of the stools has been observed 
??? ?????????? ?????? while these symptoms are often experienced in GSDI patients. 
However, the quality of diet could influence intestine metabolism in the patients. 
Furthermore, h????????? ????????? ??? ?????????? ?????????? ???? ???? ????? ????????? ??? ??????
accumulation, nor inflammation. Thus I.G6pc-/- mice need to be? thoroughly analyzed 
and characterized in order to see if they can actually be used as a model of intestinal 
GSDI pathology.  
Total G6PT knock-out mouse model of GSDIb 
 A total knock-out of the glucose transporter G6PT was created by the deletion of 
the exon 1 of Slc37a4 (Chen et al., 2003). These G6pt-/- mice exhibit growth retardation 
(Figure 54) and the same metabolic derangements as GSDIb patients, including 
neutrophil alterations. Indeed, increased circulating cholesterol, triglycerides, lactate 
and uric acid are observed in these mice, while blood glucose levels are decreased, 
leading to hypoglycemia. As expected, G6pt-/- mice present hepatomegaly and 
nephromegaly (Figure 55). Differential peripheral blood leukocyte counts reveal lower 
neutrophils and lymphocytes in the G6pt-/- mice, compared with age-matched controls, 
as well as altered hematopoiesis in the bone marrow and spleen. 
 G6pt-/- mice are a good model of GSDIb, due to the fact that not only do they 
present the metabolic GSDI alterations, but also exhibit neutropenia. However, G6pt-/- 
mice exhibit strong hypoglycemia in the absence of treatment, similarly to G6pc-/- mice 
and therefore long-term studies are challenging. Nevertheless, different 
pharmacological treatments could be tested in these mice in order to see if we can 
improve the complications specific for GSDIb. 
  
 
 
 
 
 
 
 
??????????????????????????????? ??????????????????????
An affected GSDIa puppy (left), weighted 380 g, is compared with a normal littermate (right), weighted 
660 g, at 14 days of age. Notice the abdominal distention in the affected puppy. 
(Kishnani et al., 2001) 
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Naturally obtained G6Pase-deficient dogs 
Two Maltese puppies presenting massive hepatomegaly, growth retardation and 
failure to thrive were diagnosed with GSDIa, since they exhibited G6Pase deficiency in 
the liver and kidneys (Kishnani et al., 1997). Indeed, a single mutation in the nucleotide 
position 450 was found in G6pc, leading to a guanine to cytosine (G to C) conversion, 
resulting in substitution of a methionine by isoleucine at codon 121. Later on, in order to 
maintain the colony of these dogs and increase their life expectancy, a cross breed 
between Maltese and Beagle breeds was obtained (Kishnani et al., 2001). Affected 
puppies exhibited tremors, weakness, and neurologic signs when hypoglycemic. They 
had postnatal growth retardation and progressive hepatomegaly (Figure 56). 
Biochemical abnormalities included fasting hypoglycemia, hyperlactacidemia, 
hypercholesterolemia, hypertriglyceridemia, and hyperuricemia. Microscopic 
examination of livers from affected puppies showed diffuse, marked hepatocellular 
vacuolation, with distended clear hepatocytes and central to marginally located rounded 
nuclei. Furthermore, segmental glomerular sclerosis and vacuolation of proximal 
convoluted tubular epithelium was detected in the kidneys.  
 Since canine G6PC sequence shares 90% similarities with human G6PC, G6pc-
/- dogs represent a larger animal model than G6pc-/-mice for testing curative therapies 
applicable to human patients, such as gene therapy. 
V.2) Gene therapy 
Even though dietary and pharmacological treatments have many beneficial 
effects in GSDI patients, these strategies are treating the symptoms of the disease but 
are not curative. The only therapeutic strategy that could have a curative effect in GSDI 
patients is gene therapy. Indeed, replacing the mutated gene (G6PC or SLC37A4) with 
a new copy expressing the protein that was initially deficient would be ideal. 
Nevertheless, developing a vector that delivers this gene precisely in the target cells, 
and by doing so, not inducing inflammatory reactions or additional mutations along the 
ways, is extremely complicated. Assays of gene therapy strategies have started in the 
??????????????????mouse and canine models, using various defective virus vectors. First 
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??????????????????????
Affected mice indicated (*), shown in comparison to unaffected age-matched mice. (a) G6pc-/-  mice were 
2 weeks old (w.o.). (b) G6pc-/- mice were 2 w.o. with coin (U.S. quarter) for comparison of sizes. (c) One-
year-old G6pc-/-  mice following HDAd vector administration. 
(Koeberl et al., 2007) 
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viruses used were adenovirus (Koeberl et al., 2007; Zingone et al., 2000) (Figure 57). 
While the normalization of glucose and other plasmatic parameters has been generally 
observed in treated animals, the efficiency of cell transduction was very low. 
Interestingly, adenovirus-treated mice survived, even though only a small percentage of 
the hepatocytes were transduced. Thus targeting 100% of the hepatocytes and proximal 
tubules, as well as expressing the vector in long-term protocols remain big challenges. 
Fortunately, new viral vectors, less inflammatory than adenovirus, were developed 
these last years. 
Recombinant adeno-associated virus vectors 
Recombinant adeno-associated virus (rAAV) gene therapy has progressed 
rapidly over the past decade, especially due to novel capsid serotype development, 
organ-specific promoters, and an increased understanding of the immune response to 
AAVs. In particular, liver-directed therapy has made remarkable advancements, with a 
number of clinical trials currently planned and ongoing in hemophilia A and B, as well as 
other liver disorders (Ahmed et al., 2013; Kattenhorn et al., 2016). Thus it is not 
surprising that this strategy was considered for GSDI gene therapy strategy. 
In 2002, a sustained hepatic and renal G6Pase expression was reported in 
G6pc-/- mice, using a rAAV vector (AAV2-G6PC), expressing G6pc under the chicken 
?-actin promoter/CMV enhancer, in combination with an adenovirus vector previously 
used (Ad-mG6PC) (Sun et al., 2002). AAV2 vectors ensure a more stable long-term 
expression than adenovirus, even though these vectors are not integrative and stay in 
an episomal form in the cell. The strategy prevented premature deaths and corrected 
metabolic abnormalities in G6pc-/- mice for full 12 months. Unfortunately, injection of 
AAV2-G6PC alone did not have this effect. While this dual vector injection presented 
great results in mice, considering it as a strategy in humans could entail many risk 
factors.  
Targeting both the liver and kidneys is an important criterion for GSDI gene 
therapy. Since kidney transduction is optimal with an AAV serotype 2, while liver 
transduction requires AAV type 8 or 9, combining the ITR sequences of AAV2 and the 
 ?????????????????????????????????????????? ????????????????????????????
Kaplan?Meier analysis for treated, affected mice (affected + AAV), in comparison to untreated, affected 
mice (affected).  
(Koeberl et al., 2006) 
?
??????????? ???????????????????????????????????????????????????????????? ???????? ??????
???????? ????
Freshly sectioned liver specimens were analyzed for G6Pase activity using the method of lead trapping of 
phosphate generated by G6P hydrolysis. Each image represents an individual mouse. Treatments are 
indicated by the following notation: -/- untreated G6pc-/- mice; +/+ WT mice; AAV panels are mice infused 
with various dosages of AAV-GPE. AAV-L (n = 6), AAV-M (n= 9), and AAV-H (n = 5) representing AAV-
GPE?treated G6pc-/- mice expressing 3%-9%, 22%-63%, and 81%-128% normal hepatic G6Pase-a 
activity, respectively. 
(Lee et al., 2012) 
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capsid proteins of AAV8 and AAV9, resulting in AAV2/8 and AAV2/9 serotypes, is an 
interesting strategy to target both organs in GSDI (Wu et al., 2006). Interestingly, the 
use of AAV2/9 was able to restore 40-50% of hepatic and renal G6Pase expression, 
successfully decreasing glycogen stores in both the liver and kidneys. Aside from 
resolving hypoglycemia, AAA2/9 gene therapy impeded nephropathy development in 
G6pc-/- mice for 12 months (Luo et al., 2011). Moreover, AAV2/8 vectors carrying G6pc 
under the G6Pase promoter have been tested in G6pc-/- mice, resulting in a significant 
increase in survival rates (Figure 58) (Koeberl et al., 2006). Unfortunately, important 
hepatic vector loss was detected, along with an inefficiency of kidney targeting by the 
vector. Later on, to improve kidney targeting, another strategy using AAV2/1 and 
AAV2/8 serotypes expressing G6pc under the chicken ?-actin promoter/CMV enhancer 
was tested (Ghosh et al., 2006). Interestingly, only AAV2/1 achieved significant increase 
in G6Pase expression in the liver and the kidneys. More importantly, this study reflected 
the need of re-injection when using AAVs, due to the gradual loss of the vector 
overtime. Indeed, during the neonatal period hepatocytes divide intensively resulting in 
a dilution of the vector, since AAVs are not integrated in the genome. More recent long-
term studies using AAV2/8 with G6pc under the human promoter of G6PC corrected 
glycaemia, glycogen and TG accumulation, normalized G6Pase activity in the liver 
(Figure 59) and prevented tumor development in G6pc-/- mice, even in the presence of 
light hepatomegaly (Lee et al., 2012b, 2013). Nevertheless, renal expression of G6pc 
was not reported.  
Gene therapy with AAV2/8 carrying G6pt expressed under the chicke?? ?-actin 
promoter/CMV enhancer was also tested in the GSDIb mouse model (Yiu et al., 2009). 
While this vector allowed the stabilization of plasmatic parameters in G6pt-/- mice, 
tumor development was still detected. To improve the strategy, a more recent study 
used a new AAV2/8, expressing G6pt under the human G6PC promoter/enhancer 
(GPE). Similar results were observed, since the transduced G6pt-/- mice lived almost a 
year, but all of them expressed only low levels of hepatic G6PT and several developed 
multiple HCAs undergoing malignant transformation (Kwon et al., 2016).  
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Both vector systems are capable of transgene expression and endogenous gene knockdown using siRNA 
technology. Genetic material from Lentivirus is translocated to the nucleus, where it can be integrated in 
?????????????????????? ??????????d. The resulting RNA serves either for protein coding, or as a siRNA 
silencing matrix. AAV vectors release the genetic material in an episomal form in the nucleus (rarely 
integrated) and this DNA is used, as for Lentiviral vectors, for the synthesis of the target RNA. 
(Dissen et al., 2012) 
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In the canine model of GSDIa, recent studies reported normoglycemia 
achievement, glycogen accumulation decrease and growth retardation improvement 
with AAV2/8 and AAV2/9 vectors (Brooks et al., 2013; Koeberl et al., 2008). 
Nevertheless, a dilution of the vector overtime is still observed. Finally, a study in 2012 
clearly showed that re-administration of a new type of AAV is needed nearly every 9 
months (in this study the first administered vector was AAV2/9, then AAV2/7, and finally 
AAV2/8) to sustain normoglycemia in GSDIa dogs (Demaster et al., 2012). 
Unfortunately, no long-term studies in GSDI dogs report an actual effect on tumor 
development, representing one of the major concerns in the development of a gene 
strategy for human patients. 
Lentivirus vectors 
????????????? ???? ?????????? ??? ??????????? ??????, even in cells that are actively 
dividing (Ferry et al., 2011; Zahler et al., 2000) and are not associated with insertional 
mutagenesis in the liver (Ferry et al., 2011; Rittelmeyer et al., 2013; Themis et al., 2005) 
thus assuring a long-term expression of the transgene (Figure 60). The efficiency of 
lentiviral-mediated therapy has been validated in several animal models of inherited 
liver diseases, such as Crigler-Najjar type 1, Wilson disease and haemophilia ((Brown 
et al., 2007; Merle et al., 2006; Schmitt et al., 2010).  
In order to stably transduce hepatocytes, a feline immunodeficiency virus (FIV)-
based lentiviral approach has been considered in G6pc-/- mice (Grinshpun et al., 2010). 
This therapy led to normalized blood glucose levels, extended survival, improved body 
weight, and decreased accumulation of liver glycogen. Nevertheless, targeting of the 
liver and especially the kidneys was suboptimal, resulting in the persistence of 
nephromegaly and hepatomegaly. More recently, our laboratory has also started a 
lentiviral gene therapy assay (human immunodeficiency virus (HIV)-based) in L.G6pc-/- 
mice (Clar et al., 2015). This strategy restored G6Pase activity levels sufficient to 
prevent fasting hypoglycemia for more than 8 months after G6pc deletion (Figure 61). 
Lentivirus-treated L.G6pc-/- mice presented a large decrease in hepatic glycogen and 
triglyceride content and were protected against the development of HCA after 9 months 
of gene therapy (Figure 62). The major advantage of this strategy is the insertion of the 
 ?????????????????????????????????????????????? ???? ????????????????????????
Blood glucose after 6 h of fasting following during 9 months after gene deletion in WT (black squares), 
untreated L.???????????????????????????????-G6PC treated L.????????????????????????????????? 
(Clar et al., 2015) 
 
 
?????????????????????????????????????????? ????
(A and B) Liver resection after 9 months of hepatic G6pc deletion. Arrows point nodules of about 3?4 mm 
of diameter. (C?D) Histological analysis by H&E staining of an HCA (C) and HCC (D) developed in 
untreated L.????????????. 
(Clar et al., 2015) 
???
?
vector in the ho????????????????? ????????????????????????????????? ???????? ??????????? ???
kept in both daughter cells, preventing the dilution of the virus. While this lentiviral 
approach is attractive since it seems to allow a long-term expression of the transgene, 
the use in humans is much more complex. Genotoxicity risk associated with the 
preferential intragenic integration events represents the most obvious concern. 
Fortunately, the substantial flexibility of the lentiviral vector genome offers opportunities 
for redesigning sequences of the backbone as well as the therapeutic cargo to further 
reduce this risk. 
In conclusion, developing an optimal gene strategy for GSDI is a very complex 
task. It is noteworthy that restoring normoglycemia was achieved in numerous gene 
therapy assays, proving that only a small amount of cells need to be targeted (about 5 - 
10%) to normalize this parameter. However, stabilizing glycaemia levels does not 
prevent hepatomegaly, hepatic tumor or CKD development. Thus in contrast to other 
monogenic diseases, such as Crigler-Najjar disease or coagulation defects that require 
the expression of only low levels of the related hepatic protein in the blood stream to 
treat the systemic illness manifestations, gene therapy approach for GSDI has to correct 
a maximum of hepatocytes and proximal tubules. Indeed, the rest of the hepatocytes 
which did not receive the vector still accumulate glycogen and lipids, and can still lead 
to the development of HCA / HCC. However, it has been suggested that a limited 
transfer of G6P might be possible between cells that could allow alleviation of metabolic 
burden of the neighboring cells, but this hypothesis has never been proven. 
Furthermore, finding a vector for gene therapy in GSDI patients requires a meticulous 
selection, since this vector is not supposed to induce immune reactions, and should be 
able to integrate safely in the genome of the patient, in order to assure a long-term 
expression of the transgene. Finally, hepatocytes and proximal tubules have different 
tropisms, which render this task difficult to achieve with one vector. 
Finally, advances in the development of genome editing technologies based on 
programmable nucleases have significantly improved our ability to make precise 
changes in the genome. Nowadays, there are new tools that can be used for gene 
therapy, such as zinc finger nucleases (ZFNs), transcription activator like effector 
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??????????????????????
Zinc finger nucleases (ZFN) have domains that recognize groups of 3bp, transcription activator-like 
effector nucleases (TALEN) have domains that recognize 2bp (NI=A, NG=T, NN=G, HD=C) and 
(CRISPR/Cas9) recognize each bp, thus present high specificity. 
(Lu et al., 2015) 
?
?
?
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nucleases (TALENs) and Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR)-associated nuclease Cas9 (Chou et al., 2012; Cox et al., 2015; Engelholm et 
al., 2017; Gaj et al., 2013). These strategies allow site-specific genome editing and thus 
in GSDI they can be used to insert a novel copy of G6PC or SLC37A4 in order to 
replace the mutated gene.  
A ZFN is composed of a site-specific DNA-binding domain and a Fok1 restriction 
enzyme endonuclease domain (Figures 63 and 64). The zinc finger protein recognizes a 
3-bp sequence of DNA, with its tandem repeats potentially attaching to a stretch of 
nucleotides between 9 and 18 bp. To perform site-specific cleavage of DNA, one 
monomer recognizes the binding site on the forward strand, while the other recognizes 
it on the reverse, so that the pair of Fok1 nuclease domains can cleave the DNA 
generating a DSB (Urnov et al., 2010).  
TALENs are similar to ZFN (Figures 63 and 64) and contain a DNA-binding 
domain and a Fok1 catalytic domain (Joung and Sander, 2013). A DNA-binding domain 
is constructed with an N-terminal segment, a central repeat domain, and a half repeat. 
The central repeat domain is comprised of several monomers that are called 
transcription activator-like effectors (TALEs). TALEs are tandem repeats, containing 
repeat-variable di-residue (RVD) domains, used to determine the specificity of the 
TALEs. There are four RVD domains, NN, NI, HD, and NG, for the recognition of 
guanine, adenine, cytosine, and thymidine, respectively. Fok1 is located in the C-
terminal segment and generates a DSB.  
Finally, the CRISPR-Cas9 technology became wildly popular in the gene editing 
field. The CRISPR-associated protein Cas9, an endonuclease, uses a guide sequence 
within an RNA duplex, tracrRNA/crRNA, to form base pairs with DNA target sequences, 
enabling Cas9 to introduce a site-specific double-strand break in the DNA (Doudna and 
Charpentier, 2014) (Figures 63 and 64). The dual tracrRNA/crRNA was engineered as a 
single guide RNA (sgRNA) that ???????? ????????????? ???????????????????????? ????????????
?????????????????????????????????????????????????????????????????????????????????????????
to Cas9. This finding created a simple system in which changes in the guide sequence 
of the sgRNA program Cas9 to target any DNA sequence of interest. 
??
?
?
?
?
?
???????????????????????????????????????????????????????????????????????????????????????
??????????????
(Lu et al., 2015) 
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ZFN, TALENS and CRISPR-Cas9 nucleases have been demonstrated to 
achieve efficient genome editing in a wide range of model organisms and mammalian 
cells and efforts are made in order to develop these tools as therapeutics (Cox et al., 
2015). 
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Dietary therapy was proven to have highly beneficial effects in the stabilization of 
plasmatic parameters in GSDI patients. Indeed, hypoglycemic episodes seem to occur 
far less in patients with optimal metabolic control. Nevertheless, this treatment strategy 
does not impede completely the long-term pathologies that characterize GSDI. Since 
dietary therapy has allowed a substantial extension of the life span of GSDI patients, 
these complications are observed more often than in the past. Thus the focus invested 
in glycaemia maintenance is nowadays diverted to the understanding of molecular 
phenomena involved in the long-term complications. 
In this work, our goal was to decipher the underlying mechanisms behind 
hepatocarcinogenesis and CKD development in GSDI. To achieve this, we used the 
L.G6pc-/- and K.G6pc-/- mice, which are unique GSDIa viable mouse models that 
develop all hepatic and renal long-term complications of GSDIa.  
The first chapter consists in the results related to hepatocarcinogenesis, 
obtained in L.G6pc-/- mice. Indeed, this project consisted in the analysis of the hepatic 
metabolism in these mice and how ?Warburg-like? metabolic reprograming observed in 
GSDI livers could promote tumor formation, progression and transformation in this 
organ. Furthermore, taking into account many studies which reported involvement of 
autophagy, ER stress and altered oxidative state in tumorigenesis, all of these pathways 
were characterized in the liver and tumors of L.G6pc-/- mice. Since tumorigenesis in 
GSDI is a very characteristic process which occurs in the absence of liver fibrosis / 
cirrhosis, different from what is observed in the general population, EMT, a known 
profibrotic pathway, was assessed in the livers and tumors of L.G6pc-/- mice. Last, 
since bibliography reported a loss of the hepatic tumor suppressor HNF1? in GSDI, we 
analyzed other tumor suppressor candidates that could also be involved in GSDI 
tumorigenesis.  
In the same chapter, we have added a review describing the ?Warburg-like? 
metabolic reprograming already reported in the literature. This review summarized the 
similarities between GSDI hepatocytes and cancer cells. 
???
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The second chapter consists in the description of the long-term renal 
complications in GSDI, since this process remains relatively unclear. Furthermore, 
many renal injury markers used to detect nephropathy symptoms in GSDI patients are 
not sensitive enough to report early stages of the disease.  Thus nephropathy is usually 
detected at a later stage in GSDI, when the damages caused in the kidneys are 
irreversible. Therefore, there is a crucial need for a more sensitive biomarker indicating 
kidney injury in GSDI. In this work, kidneys of K.G6pc-/- mice were analyzed at different 
stages of the disease by characterizing histological damages, metabolism, molecular 
RAS/TGF-?1 pathway and renal function. Furthermore, a new urinary marker, i.e. 
lipocalin 2, was proposed in order to earlier detect nephropathy. In addition, CKD 
progression was studied in human patients, by analyzing biological data and kidney 
images obtained by MRI from a 32 GSDI patient cohort. This data highlighted the 
development of renal cysts in K.G6pc-/- mice and GSDI patients at a late stage of CKD, 
just before the occurrence of renal failure.  
The third chapter of the results summarizes a mechanistic study aiming to 
pinpoint the exact role of lipids in the hepatic and renal GSDI pathologies. Indeed, while 
hepatic and renal glycogen accumulation represents a major hallmark of GSDI, these 
organs also present ectopic and excessive lipid accumulation, possibly inducing 
additional damage, independently from glycogen. In the general population, hepatic lipid 
accumulation is associated to NAFLD / NASH, translated to various metabolic 
complications. In the kidneys, lipids have been shown to induce irreversible damages 
such as kidney fibrosis, especially in obese / diabetic patients. Thus the role of lipids 
needed to be defined in the case of GSDI. Therefore, by exacerbating lipid 
accumulation in the liver and the kidneys of L.G6pc-/- and K.G6pc-/- mice, respectively, 
thanks to a HF/HS diet, we examined the effect of lipids and their influence on the 
progression of the disease, by assessing liver and kidney injury markers, histology and 
metabolism. On the other hand, the same analyses were performed after strongly 
decreasing lipid content in both mouse models, using a lipid-lowering drug in order to 
see whether the hepatic and renal GSDI pathologies will be delayed / prevented. 
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Chapter I ? Metabolic reprogramming leading to hepatic tumorigenesis in 
GSDI 
?
?
?
?
?
?
?
?
?
?
?
?
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While one might say that it is obvious that metabolic reprogramming due to 
G6Pase deficiency is the key initiator of tumorigenesis in GSDI, the actual mechanisms 
involved remain unknown. In the review published in the Journal of Inherited Errors 
of Metabolism and Screening (JIEMS) in 2016 (Gjorgjieva et al., 2016b), we have 
summarized all of the metabolic perturbations in GSDI livers that were already reported 
in the literature, highlighting the presence of a Warburg-like phenotype. These findings 
were compared to what is usually observed in glycolytic cancers. Furthermore, the 
involvement of oxidative stress, autophagy and apoptosis during GSDI tumorigenesis 
was described, highlighting the modulations of these functions induced by the altered 
metabolism. Finally, the last part of the review points out the similarities already 
reported between the metabolism of non-GSDI HCA and GSDI livers. Thus this review 
summarizes the potential mechanisms favorable for tumor formation and progression in 
GSDI livers. 
 In the next paper, in order to shed light on hepatic tumor development, we 
characterized the metabolism and cellular defense mechanisms in GSDIa livers and 
tumors at different stages. The livers of L.G6pc-/- mice were analyzed after 4 months of 
HF/HS diet, ????????? ???????????? ???????? ???? ?????? ?????????? ????????? ????????? ????????
where 90% of the mice bore hepatic tumors. Compared to previous reports by our 
laboratory showing only 20% of L.G6pc-/- developed tumors at this age with a standard 
diet (Mutel et al., 2011a), these data highlighted the importance of dietary treatment in 
GSDI. Furthermore, HCA developed in L.G6pc-/- mice fed a HF/HS diet had a tendency 
to increase Glypican3, a marker known to be specific to HCC, pointing out the major 
capacity of these HCA to transform into HCC. ????????????? ???? ???? ?????????? ??
catenin and Glypican3, often observed in HCC in the general population. 
As in GSDI patients, L.G6pc-/- mice developed HCA and HCC in the absence of 
fibrosis and cirrhosis in the liver. Lack of EMT activation was suggested to be the 
answer to the absence of fibrosis. Indeed, we observed epithelial marker up-regulation, 
concordantly with a normal level of mesenchymal markers in L.G6pc-/- livers, indicating 
an absence of EMT. The incidence of HCC in GSDI in the absence of fibrosis / cirrhosis 
could be explained by the fact that HCC does not occur de novo in GSDI livers, but it 
  
?????????????????????????????????????????????????????????????????????????????????????
???????????????????????????? ??????????
In GSDI hepatocytes, glucose-6 phosphatase (G6Pase) deficiency leads to a marked increase in 
glucose-6 phosphate (G6P). G6P then activates glycolysis and leads to a subsequent increased 
production of lactate, responsible for lactic acidosis in GSDI patients and animal models. Furthermore, 
oxidative phosphorylation (OXPHOS) in the mitochondria is decreased, contributing to a Warburg-like 
phenotype in these cells. Lipid synthesis is also increased, leading to lipid accumulation (hepatic 
steatosis), further accentuated by the inhibition of lipid oxidation. Hyper-glycolysis and lipogenesis are 
known to be favorable for cancer formation and progression. Moreover, autophagy is inhibited, resulting 
in further accumulation of glycogen, lipids and non-functional organelles, contributing to genotoxicity and 
thus tumorigenesis. The endoplasmic reticulum (ER) stress pathways are chronically activated. Finally, 
tumor suppressor (HNF1a, PTEN, p53) expression / activity is decreased, potentiating tumorigenesis in 
GSDI livers.  
(Gjorgjieva et al., submitted) 
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was suggested to always arise from HCA. Furthermore, tumor suppressors, such as 
PTEN (phosphatase and tensin homolog), HNF1? and p53 were down-regulated, not 
only in tumor samples, but also in the liver, rendering it favorable for tumorigenesis.  
As expected, we have observed a strong activation of glycolysis and de novo 
lipogenesis in the livers and tumors, with a concomitant decrease in mitochondrial 
OXPHOS, confirming a Warburg-like effect in the liver, as observed in cancer cells in 
general, suggesting these livers exhibit a neoplastic status.  
Finally, we observed a decrease in autophagosome number and a decrease in 
ATG proteins in L.G6pc-/- livers (at 4 and 9 months), indicating a decrease in 
autophagy. Surprisingly, autophagy was reactivated in all HCA / HCC samples. 
Moreover, antioxidant enzyme expression was decreased at both pretumoral and 
tumoral stages. Finally, BiP (ER stress pathway regulator) expression was markedly 
decreased at pretumoral and tumoral stages, facilitating the activation of ER stress 
pathways, indicating chronic ER stress activation in GSDI. Autophagy down-
regulation in GSDI livers could contribute to genetic instability, and its increase in 
tumors could facilitate tumor progression, by providing recycled metabolites as building 
blocks and energy sources for growth and proliferation. Oxidative damage can further 
promote tumorigenesis by favoring DNA mutations. Finally, the activation of the ER 
stress pathway could make the tumor-adjacent environment hospitable for tumor 
survival and tumor expansion. 
To conclude, we suggest that glycolytic cancer cells and GSDI hepatocytes 
present a similar metabolic reprograming, facilitating the formation and progression of 
tumors in the liver. Furthermore, the metabolic alterations induced by G6Pase 
deficiency have a strong effect on the cellular defense pathways and the expression of 
tumor suppressors, which are then unable to fulfill their duty and protect the liver from 
tumorigenesis (Figure 65). 
?
 
Review
Mechanisms by Which Metabolic
Reprogramming in GSD1 Liver Generates
a Favorable Tumorigenic Environment
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Abstract
Glycogen storage disease type 1 (GSD1) is an inherited disorder caused by impaired glucose 6-phosphatase activity. This
impairment translates into the inhibition of endogenous glucose production and the subsequent accumulation of cellular
glucose 6-phosphate. Excess glucose 6-phosphate enhances glycolysis, increases the production of fatty acids, uric acid, and
lactate, causes hepatomegaly due to glycogen and lipid accumulation, and finally results in liver tumor development. Although
the exact mechanisms of tumorigenesis in patients with GSD1 remain unclear, GSD1 hepatocytes undergo a Warburg-like
metabolic switch. The consequent hyperactivation of specific metabolic pathways renders GSD1 hepatocytes susceptible to
tumor development, presumably by providing the building blocks and energy required for cell proliferation. In addition to this,
enhanced apoptosis in GSD1 may promote mitotic activity and hence result in DNA replication errors, thereby contributing to
tumorigenesis. Increased carbohydrate responsive element-binding protein (ChREBP) and mammalian target of rapamycin (mTOR)
activity and impaired AMP-activated protein kinase (AMPK) function likely play key roles in these pro-oncogenic processes.
Keywords
glycogen storage disease type 1, steatosis, hepatocellular adenomas and carcinomas, carcinogenesis, glucose and lipid metabolism,
autophagy, liver
Introduction
Glycogen storage disease type 1 (GSD1) is a rare genetic dis-
ease, due to an impairment in glucose 6-phosphatase
(G6Pase)1,2 activity. Glucose 6-phosphatase is a key enzyme
for energy and metabolite production that catalyzes the conver-
sion of glucose 6-phosphate (G6P) to free glucose, the final
step in both glycogenolysis and gluconeogenesis.3,4 Therefore,
it is a crucial enzyme in the maintenance of blood glucose
levels in the postabsorptive phase and upon fasting. The
G6Pase complex is composed of 2 subunits, that is, a catalytic
domain (G6PC) and a transport protein (G6PT). G6PT is
expressed ubiquitously, whereas G6PC is exclusively
expressed in the 3 gluconeogenic organs: the liver, kidneys and
intestine.3,4 G6PC mutations lead to GSD type 1a (GSD1a),5-7
whereas GSD type 1b (GSD1b) is caused by mutations in
SLC37A4, the gene encoding G6PT.2 Both GSD1a and GSD1b
are characterized by hepatic, renal, and intestinal pathologies
and exhibit largely the same metabolic symptoms.8,9 Because
G6Pase activity is impaired in patients with GSD1, blood glu-
cose levels are low upon fasting, resulting in hypoglycemic
episodes. On the other hand, cellular G6P storage and utiliza-
tion are strongly increased, thereby activating specific meta-
bolic pathways, including glycolysis, as well as uric acid,
lactate, fatty acid, and cholesterol synthesis. Besides fasting
hypoglycemia, the metabolic symptoms of GSD1 therefore
involve hyperuricemia, lactic acidosis, hypertriglyceridemia,
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and hypercholesterolemia. Glucose 6-phosphatase-deficient
hepatocytes are chronically stressed due to abnormal glycogen
and lipid accumulation, which induce hepatomegaly and liver
steatosis.8,9 Similarly, patients with GSD1 and animal models
exhibit nephromegaly,8-10 leading to tubular injury, glomerulo-
sclerosis, and a progressive loss of renal function, characterizedby
albuminuria, proteinuria, and at the last stage, by renal failure.11,12
Strikingly, almost all patients with GSD1 develop hepatocellular
adenoma (HCA) during adulthood, with a 10% incidence of trans-
formation to hepatocellular carcinoma (HCC).13,14 Liver tumor
formation in GSD1 induces significant morbidity and impairment
of quality of life, and these patients frequently require partial
hepatectomy or liver transplantation.15,16 The European Study
on GSD1 showed that HCA can be observed from 15 years of age
on, andup to 75% of patients bear at least 1HCAat the age of25.14
The molecular mechanisms of tumor development in GSD1 are
unclear. It has been hypothesized that the early switch to a
Warburg-like metabolism in nontumoral G6Pase-deficient hepa-
tocytes promotes oncogenesis by providing substrates for cell
proliferation, such as lipids and nucleotides. It has been proposed
that tumor development in GSD1 may be a rectilinear process,
characterized by the initial appearance of HCAs, which may
subsequently transform into HCC.17 To our knowledge, devel-
opment of HCC in the absence of preexisting/coexisting HCA
has not yet been reported for GSD1.
Because the primary consequence of GSD1 is a metabolic
derangement, it is of interest to understand via what mechan-
isms perturbed intrahepatic metabolism may initiate and/or
drive tumor formation. In this review, we discuss the metabolic
reprogramming, stress-inducing, and cellular death pathways
in G6Pase-deficient hepatocytes that may initiate and/or facil-
itate HCA and HCC development.
Tumor Metabolism
Tumor initiation and progression may be considered as a rather
anarchical process; however, several metabolic pathways are
very frequently hyperactivated in tumors. These pathways pro-
vide tumor cells with energy (ATP), carbon skeletons, lipids,
amino acids, nucleotides, and other metabolites required for
biomass gain, growth, and progression.18,19
The Warburg Effect
In normal quiescent cells, ATP is derived mostly from glyco-
lysis, subsequent Krebs cycle activity, and mitochondrial oxi-
dative phosphorylation (OXPHOS).20 This oxygen-dependent
metabolic profile ensures an efficient ATP production.
On the contrary, in cancer cells or rapidly proliferating cells,
metabolism is orientated toward increased glucose uptake and
aerobic glycolysis, resulting in a high lactate production, inde-
pendent of cellular oxygen availability. This metabolic shift is
known as the Warburg effect. Initially, the Warburg effect was
considered as the driving force for cancer development.21
Nowadays, it is generally believed that this effect is rather the
result of metabolic reprogramming induced by oncogenic
mutations. Otto Warburg’s research and other studies suggest
that cancer cells shut down their mitochondrial activity, hence
decreasing OXPHOS, and concluded that a hypoxic tumor
environment selects cells that are dependent on anaerobic
metabolism. However, it has been confirmed that most cancers
exhibit normal mitochondrial activity and normal rates of
OXPHOS, suggesting that other mechanisms drive metabolic
reprogramming of cancer cells toward aerobic glycolysis.18
Several regulatory proteins, including hypoxia-induced factor
1a (HIF1a),22-24 avian myelocytomatosis viral oncogene
homolog (MYC24,25), and tumor protein p53 (P5325,26), are
known to promote this metabolic switch. Most tumors are not
very well vascularized during initial growth and oxygen supply
is therefore not optimal. However, the Warburg effect has also
been observed in lung tumors27 that have sufficient oxygen
supply, indicating that the Warburg effect is not necessarily
related to impaired oxygen availability. Moreover, in aerobic
tissues, HIF1a is stabilized by high presence of lactate,22 indi-
cating that this pro-oncogenic protein also operates when oxy-
gen supply is not limiting. The energy yield of the glucose
catabolism by aerobic glycolysis is much lower (2 ATP/glu-
cose) compared to mitochondrial OXPHOS (38 ATP/glucose),
yet it can generate ATPs at a higher rate. However, high ATP
synthesis rate associated with aerobic glycolysis may be of
minor relevance to tumor growth, since energy alone is not
enough for proliferation. More importantly, in order to increase
their biomass and growth rate, proliferating cells need carbon
skeletons, amino acids, lipids, and cholesterol to synthesize
biomembranes and nucleotides. This accelerated metabolism
results in increased reactive oxygen species (ROS) production.
Even though ROS can be highly oncogenic and therefore pro-
mote tumor development, they can also render tumor cells
vulnerable to oxidative and energetic stress.28 In order to com-
bat ROS, but also to increase anabolic activity, cancer cells
increase nicotinamide adenine dinucleotide phosphate
(NADPH) production via the pentose phosphate pathway
(PPP), as well as other reducing equivalents. This allows not
only the detoxification of cancer cells but also the synthesis of
macromolecules required for proliferation.29,30 Altogether,
metabolic reprogramming allows the cells to maintain suffi-
cient energy levels, but it also provides them with substrates
for growth. One of the main players providing cancer cells with
these substrates is pyruvate kinase (PK), the enzyme responsi-
ble for the conversion of phosphoenolpyruvate (PEP) to pyru-
vate and ATP, the final step of glycolysis. This enzyme exists
under different isoforms (M1, M2, L, and R) and can form
dimers or tetramers, which makes it the key switch between
OXPHOS and aerobic glycolysis. Because the M2 dimer iso-
form has a low affinity for PEP, glycolytic metabolites
upstream of PEP accumulate when this isoform is predominant
in the cell, and metabolism is redirected to nucleotide, lipid,
and amino acid synthesis.31 This phenomenon is observed in
almost every cancer type.32,33 Many important signaling path-
ways, such as MYC,34 HIF1a,33,35,36 STAT3 (for Signal Trans-
ducer and Activator of Transcription),36 and Epidermal Growth
Factor Receptor (EGFR),37 are responsible for the upregulation
2 Journal of Inborn Errors of Metabolism & Screening
of pyruvate kinase isoform M2 (PKM2) in cancer cells. Inter-
estingly, recent studies indicate that PKM2 is not only involved
in the regulation of glucose metabolism but also plays a role in
cancer metastasis in HCC.38,39
Pro-Oncogenic Changes in Lipid Metabolism
Nonalcoholic fatty liver disease (NAFLD)40 is commonly used
to describe liver pathologies characterized by abnormally high
lipid content in the liver, in the absence of alcohol consump-
tion. It is mostly observed in developed countries and fre-
quently associates with obesity, diabetes, and metabolic
syndrome. Multiple studies have established a link between
NAFLD and increased risk of HCC.41,42 Multiple factors, such
as increased lipogenesis, oxidative stress, cytokine-induced
signaling pathways, and environmental and genetic compo-
nents, have been proposed to contribute to liver tumor forma-
tion in patients with steatosis.43,44 Increased de novo
lipogenesis (DNL) requires high concentrations of NADPH,
rendering NADPH a limiting factor in tumor growth. Never-
theless, as mentioned earlier, an increase in PPP activity is
frequently observed in tumors, thereby facilitating NADPH
production.29 The activity of malic enzyme also generates
NADPH synthesis, and the repression of its expression has
been shown to inhibit tumor progression.45,46 Furthermore,
increased DNL promotes malonyl-CoA production, which in
turn inhibits carnitine palmitoyltransferase 1 (CPT1) activity,
thereby reducing intramitochondrial fatty acid availability for
b-oxidation. Thus, under conditions of increased DNL, the
degradation of fatty acids is reduced, which further enhances
steatosis.43 High lipid concentrations induce the production of
ROS in hepatocytes. Reactive oxygen species subsequently
lead to lipid peroxidation, inflammatory cytokine (interleukin
[IL] 6,47 tumor necrosis factor a48) release, and DNA and
protein damage. For example, the trans-4-hydroxy-2-nonenal,
a product of lipid peroxidation, causes mutations in the tumor
suppressor P53 in HCC.49,50 In addition to this, ROS-induced
DNA damage can also result in oncogene activation and/or
tumor suppressor inactivation, thereby driving carcinogen-
esis.28 Once neoplastic lesions are formed, accumulated lipids
are highly favorable for tumor growth, as they are crucial for
the assembly of biomembranes for new tumor cells. A wide
range of DNL-inhibiting drugs are currently being developed to
decrease hepatic stress and even halt tumor development. Most
of these drugs target the fatty acid synthase (FASN), a key
enzyme in DNL.51,52 As this enzyme is frequently overex-
pressed in cancer cells, its inhibition has been proven success-
ful to attenuate cancer progression and metastasis.51,52
Nucleotide Provisions
Besides synthesizing biomembranes, tumor cells need to pro-
duce nucleotides for DNA replication during cell division. In
order to increase nucleotide synthesis, the high glycolytic flux
associated with the Warburg effect is directed toward PPP.53
PKM2 is mainly responsible for the redirection.32 The PPP
produces ribose 5-phosphate, which serves as a substrate for
de novo nucleotide synthesis.54 Interestingly, yet not surpris-
ingly, HIF1a55 and C-MYC56 also promote nucleotide produc-
tion by increasing the PPP activity, thereby likely potentiating
tumor development and growth.
Metabolic Reprogramming in GSD1
Hepatocytes
Hepatocytes have different physiological roles and converge
many metabolic pathways. They are involved in protein, glu-
cose, and lipid metabolism, and their functioning has systemic
effects. Glycogen storage disease type 1 hepatocytes display an
abnormal metabolic phenotype, primarily caused by G6P accu-
mulation. Metabolic pathways that use G6P as a substrate, such
as glycolysis, DNL, glycogen synthesis, and degradation, are
hyperactivated in GSD1 livers.57,58
Hyperactive Glycolysis and Warburg-Like Metabolism
It has been established that excess G6P forces metabolism
toward glycolysis57-59 in G6Pase-deficient nontumoral hepato-
cytes. Increased glycolysis leads to increased pyruvate levels
and subsequent lactate production. Lactate production due to
enhanced glycolysis explains the lactic acidosis observed in
both GSD1 animal models and in patients with GSD1.60,61 This
metabolic phenotype resembles the Warburg effect in cancer
cells (Figure 1). In normal hepatocytes, lactate can be con-
verted back to glucose in the liver via the Cori cycle, thereby
preventing lactic acidosis. On the contrary, it has been hypothe-
sized that G6Pase-deficient hepatocytes cannot convert lactate
back to glucose, since they cannot dephosphorylate G6P, the
final step of the Cori cycle. An impaired Cori cycle in GSD1
may therefore lead to a further increase in circulating lactate
concentrations. Although the expression of the liver isoform of
PK (PKLR) is markedly increased in GSD1,62,63 an induction
of PKM2 has not yet been reported in G6Pase-deficient hepa-
tocytes. However, from a therapeutic perspective, it would be
interesting to assess its enzymatic activity in GSD1, as many
PKM2-inhibiting drugs are currently being developed. In case
PKM2 is activated in GSD1, such drugs may be effective to
reduce nucleotide, lipid, and amino acid synthesis,31 and hence
perhaps impair tumor development in GSD1.64,65
Increased Hepatic Lipid Synthesis Contributing to Liver
Steatosis
In GSD1, increased pyruvate production via glycolysis due to
excess G6P results in increased production of acetyl-CoA,
which subsequently enters the Krebs cycle. Besides generating
energy via OXPHOS, citrate produced in the Krebs cycle can
be transported to the cytosol, converted back to acetyl-CoA,
and serve as a substrate for the synthesis of fatty acids and
cholesterol. Bandsma et al observed a 40-fold increase in de
novo synthesized palmitate in very low density lipoprotein
(VLDL) from patients with GSD1 (Figure 1), in parallel to a
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7-fold increase in cholesterol synthesis and a slower conversion
of VLDL to low density lipoprotein (LDL).66 An increased
expression of genes involved in mitochondrial citrate export
and DNL, such as ATP citrate lyase (ACLY), acetyl CoA car-
boxylase (ACACA), FASN, sterol CoA desaturase (SCD1),
and fatty acid desaturase 1 and 2 (FADS1 and 2), has already
been confirmed in GSD1 livers.58,59 These enzymes are phy-
siologically induced in the fed state by elevated insulin and
glucose levels. Insulin and glucose act via 2 transcription fac-
tors, that is, sterol regulatory element binding protein 1c
(SREBP1c) and carbohydrate responsive element binding pro-
tein (ChREBP).67 In a mouse model of GSD1b, the induction of
glycolytic and lipogenic genes in the liver was found to be
mediated by ChREBP.62 Increased DNL likely represents an
important pathophysiological process in GSD1 hepatocytes, as
it contributes to the accumulation of lipids and potentially
lipotoxicity in the liver, causing NAFLD-like complications
in both patients with GSD1 and GSD1 animal models.60,68
Several studies suggested that dietary treatment can partially
reduce lipid levels in plasma and liver, although hepatic lipid
accumulation cannot be completely alleviated.68,69 The b-oxi-
dation pathway, responsible for fatty acid degradation, is likely
reduced in GSD1, as it was shown that the expression of per-
oxisome proliferator-activated receptor a is significantly
decreased in hepatocyte-specific G6PC null mice.70 As men-
tioned earlier, excessive malonyl-CoA production caused by
DNL induction may result in the inhibition of CPT1 and a con-
sequent reduction in fatty acid b-oxidation. Finally, a decreased
activity of AMP-activated protein kinase (AMPK) in GSD1 non-
tumoral hepatocytes71 may contribute to impaired fatty acid
oxidation and increased fatty acid and cholesterol synthesis72
(Figure 1). AMP-activated protein kinase regulates these pro-
cesses by decreasing malonyl-CoA production via ACC inhibi-
tion and by controlling SREBP173 and ChREBP74 activities.
As mentioned earlier, ChREBP is the key transcription factor
responsible for the elevated hepatic lipogenic gene expression in
GSD1a and GSD1b mouse models.62,71 Increased levels of
ChREBP have already been shown to promote tumorigen-
esis.75,76 This transcription factor not only promotes lipogenesis
but also increases glucose uptake and glycolysis, cell prolifera-
tion, and glucose-dependent de novo nucleotide synthesis in
hepatocytes.77 Carbohydrate responsive element binding pro-
tein–deficient cells exhibit increased OXPHOS, suggesting that
ChREBP is yet another potential metabolic switch in GSD1,
deviating the metabolism from OXPHOS toward aerobic glyco-
lysis. In the same study, ChREBP deficiency was shown to
activate P53-dependent cell cycle arrest, indicating that this
transcription factor interferes with tumor suppression.
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Figure 1. Metabolic deregulation and pro-tumorigenic pathways in the GSD1 liver. Images were drawn by Sevier Medical Art.
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Altogether, as a result of metabolic reprogramming and
deregulated intracellular signaling, GSD1 livers present the full
spectrum of NAFLD, including increased lipid synthesis, hepa-
tic steatosis, and lipotoxicity, which are associated with
tumorigenesis.
Enhanced Nucleotide Metabolism
Because G6P serves as a substrate for the PPP, it can be
assumed that its accumulation in GSD1 promotes de novo
nucleotide synthesis. Although an actual increase in PPP activ-
ity in GSD1 has not yet been reported, an increased flux
through this pathway potentially provides the nucleotides
required for neoplastic cellular proliferation and reducing
equivalents for DNL. On the other hand, when inorganic phos-
phate is depleted, for example, due to the increased retention of
phosphate in G6P, cells start to degrade nucleotides, resulting
in uric acid production.78 Hyperuricemia is a very well-
documented feature of GSD1 animal models and patients with
GSD1.14,60 Uric acid has pro-inflammatory properties contribut-
ing to tumor development and growth.79 Nevertheless, patients
with GSD1 are frequently treated with drugs to lower circulating
uric acid concentrations, hence protecting against uric acid–
induced inflammation. Because these treatments do not prevent
tumor development in patients with GSD1, it seems unlikely that
hyperuricemia is the sole oncogenic factor in GSD1.
Cellular Defense and Death Mechanisms
in GSD1 Livers
Oxidative Stress
Mitochondrial and peroxisome activities generate ROS that are
degraded by cellular antioxidant enzymes such as catalase,
superoxide dismutase, and glutathione peroxidase. Failure to
neutralize excess ROS results in disturbed redox levels, causing
serious tissue injury. Hepatic steatosis renders the liver more
susceptible to ROS.41 Reactive oxygen species not only dam-
age intracellular molecules but also alter the activities of cel-
lular signaling pathways. It has been reported that markers of
oxidative stress and antioxidant defense systems are both
increased in the plasma of patients with GSD1,80 while no data
are currently available on ROS levels in G6Pase-deficient
livers. Accumulated ROS in G6Pase-deficient hepatocytes can
react with the nucleic acids, proteins, lipids, and other metabo-
lites, thereby impairing organelle functions and inducing mem-
brane damage as well as chromosomal instability and
mutations. All of these processes are favorable to tumor devel-
opment28 (Figure 1).
Autophagy
Reactive oxygen species–induced cellular stress is frequently
accompanied by mitochondrial dysfunction, because these
organelles are not only the generator but also a target of ROS.81
Mitochondrial turnover via autophagy, also referred to as
mitophagy, is tightly linked to oxidative stress.82 Autophagy
enables the elimination of nonfunctional proteins, organelles,
and metabolites, providing the cell with energy and recycled
metabolites for reuse. The autophagic substrates can be, in part,
a consequence of increased ROS concentrations. The
autophagy-related (ATG) proteins initiate the formation of and
serve as building blocks for autophagic vesicles. This initiation
and progression is regulated by an orchestrated network that
includes the AMPK and the AKT/mTOR (for Serine/Threonine
Kinase 1/mammalian target of rapamycin) pathways, which are
both key proteins involved in energy and nutrient sensing.83
Although AMPK activation promotes autophagy, mTOR is
known to suppress it.
Recently, it was reported that autophagy is decreased in
G6Pase-deficient livers.71 This study showed that AMPK
activity was impaired, while mTOR was activated, translating
in decreased autophagy (Figure 1). Furthermore, it was shown
that mTOR inhibition by rapamycin restored autophagy and
reduced hepatic lipid and glycogen content in GSD1 livers.
Autophagy depletion in the early stages of cancer development
is a frequently observed phenomenon that generates a tumori-
genic environment, as free radical accumulation, nonfunctional
proteins, and organelle persistence increase chromosome
instability.84,85 For example, a mouse model of impaired autop-
hagy induced by ATG5 ablation developed HCA, suggesting a
tumor suppressive role for autophagy. The HCAs from these
animals showed damaged mitochondria, oxidative stress, and
genomic damage responses.86 Almost the same phenotype,
including liver tumors, was observed in ATG7-deficient
mice.86 Thus, autophagy appears to have an important anti-
oncogenic role in the liver, and its impairment in a pretumor
stage may facilitate oncogenesis in GSD1 livers as well.
Metformin is a drug that is commonly used to treat dia-
betes.87 This hypoglycemic agent reduces circulating glucose
and lipid levels and induces autophagy by activating AMPK.73
Aside from its antidiabetic properties, metformin was shown to
exert anticancerous actions as well.88 Although it is tempting to
evaluate whether metformin treatment activates autophagy and
subsequently impedes tumorigenesis in the GSD1 liver, a puta-
tive decrease in blood glucose levels upon metformin treatment
in these patients poses a potential risk. However, metformin
acts mainly on the liver and reduces hyperglycemia by inhibit-
ing hepatic glucose production.89 Given that G6Pase-
dependent glucose production is absent in GSD1, the risk for
metformin-induced hypoglycemia in these patients may be
negligible, making this treatment appealing for the preven-
tion/treatment of HCA in patients with GSD1.
Apoptosis
Once autophagy fails to improve the metabolic and energy state
of the cell, molecular mechanisms induce a switch from autop-
hagy to apoptotic or even necrotic cell death.90 G6Pase–
deficient mice display increased apoptosis in the liver57
(Figure 1). Caspase3/7 protein levelswere significantly increased
in the livers of these mice, implying a Fas-mediated apoptosis.
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The authors considered that apoptosis in GSD1a mice was acti-
vated through glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) and further promoted by steatosis-derived inflamma-
tion.57 The expression of GAPDH, an enzyme that is primarily
involved in activated glycolysis, was elevated as well. Interest-
ingly, GAPDH has recently been associatedwith increased apop-
tosis.91,92 Increased apoptosis in G6Pase-deficient cells results in
low viability of isolated primary hepatocytes (A. Gautier-Stein,
PhD, unpublished data 2012). Although apoptosis is commonly
regarded as an anti-oncogenic mechanism, it has been shown that
high apoptotic rates can also promote tumorigenesis.93 To retain
proper functioning of the liver, apoptotic hepatocytes must be
replaced rapidly. Thus, an increase in apoptosis in the G6Pase-
deficient livermay trigger hepatocyte proliferation to compensate
for hepatocytes loss. Rapid and constant cell division and growth
of mitotic G6Pase-deficient hepatocytes may consequently
induce DNA replication errors and tumor formation.
Necrosis
Hepatocellular necrosis has also been observed in G6Pase-
deficient livers.94 Necrotic foci, neutrophil infiltration, and
elevated expression of chemokines were documented, indica-
tive of liver injury in mice and patients bearing HCA but also in
liver material in a pretumor stage. Glycogen95 and lipid accu-
mulation96 are known to induce inflammation. Taken together,
the origin of this inflammatory response needs to be investi-
gated, as it may significantly contribute to the tumor develop-
ment in GSD1.
GSD1 Metabolism Drives Adenoma
Formation: Similarities With
HNF1A-Mutated Tumors
Genome sequencing and subsequent classification of HCAs
from non-GSD1 patients has identified 3 main groups of muta-
tions associated with HCA.97 In HCAs from the first group,
hepatic nuclear factor 1a (HNF1a), a transcription factor
involved in glucose and lipid metabolism, is mutated. Hepatic
nuclear factor 1a is considered as a tumor suppressor and a key
factor that maintains hepatocytes in a differentiated state.98,99
In HNF1A-mutated HCAs, the expression of the fatty acid–
binding protein 1 (FABP1) gene, a direct target of HNF1a, is
downregulated, leading to steatosis and lipotoxicity.100 Tumors
bearing a HNF1A mutation have an increased proliferation rate
due to the subsequent activation of the Phosphoinositide 3-
kinase/AKT pathway.101,102 The second group represents
inflammatory HCAs. These HCAs are characterized by muta-
tions that activate the IL-6 and JAK (Janus kinase)/STAT path-
ways and are the most prevalent HCAs, representing 50% of all
HCAs.103 The third group is b-catenin (CTNNB1)-mutated
HCAs. Hepatocellular adenomas with an activating mutation
of b-catenin represent around 10% to 15% of all HCAs103 and
are associated with poor prognosis, since they represent a great
risk of malignant transformation.104
In order to investigate the origin of tumorigenesis in GSD1,
HCAs from patients with GSD1 were subjected to gene expres-
sion and DNA sequencing analysis. This analysis showed that
52% of the HCAs bared inflammatory mutations, 28% were
CTNNB1 mutated, and 20% were unclassified.59 Intriguingly,
none of the GSD1 HCAs were HNF1A mutated, whereas all of
the GSD1 HCAs, even the ones in the inflammatory and
b-catenin groups, had a decreased expression of FABP1. Since
HNF1a is the main regulator of FABP1 expression, one could
infer that HNF1a could be decreased in all of the GSD1 HCAs.
As HNF1a regulates G6PC and G6PT105-107 expression,
HNF1a and G6Pase-mutated hepatocytes may display a similar
phenotype. Consequently, comparison of GSD1 nontumoral
liver tissue and HNF1A-inactivated HCAs revealed similarities
with regard to the expression of glycolytic, gluconeogenic, and
lipogenic enzymes. In both GSD1 nontumoral tissue and
HNF1A-invalidated HCAs, gluconeogenesis was repressed,
and glycolysis and lipogenesis were induced.100 Decreased
Hnf1a messenger RNA expression was observed in the liver-
specific G6pc knockout mice as compared to their wild-type
littermates (M. Gjorgjieva, PhD student, and F. Rajas, PhD,
unpublished data 2015). To summarize, GSD1 nontumoral
liver displays striking phenotypic similarities with HNF1A-
inactivated HCAs, indicating that even in the pretumor stage,
GSD1 livers exhibit a tumor-like metabolism.
Conclusion
Glycogen storage disease type 1 is a complex metabolic disease
that exhibits all the hallmarks of NAFLD. Liver steatosis and
hepatic glycogen accumulation are already present during
infancy, resulting in hepatomegaly. The hepatic accumulation
of lipids and glycogen induces severe stress and causes chronic
inflammation and ROS production, which potentially contri-
butes to the development of liver tumors. The abnormal intra-
hepatic G6P content activates metabolic pathways that support
tumor growth, such as aerobic glycolysis, lipid synthesis, uric
acid and lactate production, glycogen storage, and nucleotide
synthesis. Moreover, autophagy is impaired, which may further
promote accumulation of nonfunctional proteins and orga-
nelles, and possibly translates into cellular stress and DNA and
protein damage. ChREBP and mTOR activation and AMPK
inhibition likely represent key molecular events that orches-
trate metabolic reprogramming in GSD1. The rates of apoptotic
cell death in advanced GSD1 are elevated, probably due to a
switch from autophagy to apoptosis, as well as increased
GAPDH concentrations. Increased levels of ROS and inflam-
matory cytokines may also contribute to the increase in apop-
tosis. As increased hepatocellular apoptosis may trigger cell
division to repopulate the liver, continuous mitosis in
G6Pase-deficient hepatocytes may lead to DNA replication
errors, hence inducing HCA development. In addition, hepato-
cyte necrosis represents another mechanism activated that
likely contributes to inflammation and cell death in GSD1
livers. Finally, by comparing HNF1a-deficient HCAs and
G6Pase-deficient nontumoral tissue, many similarities were
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found, despite a lack of HNF1A mutations. It was suggested
that both groups exhibited HNF1a deficiency, accompanied by
lipotoxicity, due to the reduced FABP1 expression. HNF1a is
considered as a tumor suppressor, and therefore, its impairment
in G6Pase-deficient hepatocytes could lead to dedifferentiation
and further susceptibility to tumor development.101,108
These data accentuate the need for strict metabolic control
of patients with GSD1 in order to slow down the tumorigenesis
process. The consumption of ‘‘fast sugars’’ such as fructose and
galactose represents an important source of the substrate for the
activation of glycolysis, glycogen synthesis, and DNL, there-
fore potentiating tumor formation. Even though a strict dietary
regimen does not appear to fully prevent HCA/HCC formation,
the European study of GSD1 has clearly shown an increase in
life expectancy in patients who followed the nutritional
guidelines.14
Altogether, different metabolic and cellular adaptations ren-
der GSD1 hepatocytes prone to tumor formation and growth.
Although the exact contribution of these different features
needs to be mechanically elucidated, nontumoral G6Pase-
deficient hepatocytes may be considered as preneoplastic cells
that develop to GSD1 HCA, which in some cases even progress
to HCC.
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ABSTRACT  
Background & aims: Glycogen storage disease type Ia (GSDIa) is a rare genetic disease 
associated with glycogen accumulation in hepatocytes and steatosis. With age, most adult 
GSDIa patients develop hepatocellular adenomas (HCA), which can progress to 
hepatocellular carcinomas (HCC). In this study, we characterized metabolism reprogramming 
and cellular defense alterations during tumorigenesis in the liver of hepatocyte-
specific G6pc deficient (L.G6pc-/-) mice, which develop all hepatic hallmarks of GSDIa. 
Methods: Liver metabolism and cellular defenses were assessed at pretumoral (4 months) and 
tumoral (9 months) stages in L.G6pc-/- mice fed a high fat/high sucrose (HF/HS) diet. 
Results: In response to HF/HS diet, hepatocarcinogenesis was highly accelerated since 90% 
of L.G6pc-/- mice developed multiple hepatic tumors after 9 months, classified for 72% as 
HCA and 28% as HCC. Tumor development was associated with high expression of 
mal?????????????????????????????-????????????????????????????-catenin. In addition, L.G6pc-
/- livers exhibited loss of tumor suppressors. Interestingly, L.G6pc-/- steatosis exhibited a 
low-inflammatory state and was less pronounced than in WT livers. This was associated with 
an absence of epithelial-mesenchymal transition (EMT) and fibrosis, while HCA/HCC 
showed a partial EMT in the absence of TGF-?1 increase. In HCA/HCC, glycolysis was 
characterized by a marked expression of PK-M2, decreased mitochondrial OXPHOS and a 
????????? ??? ????????? ?????? ??? ???? ?????????????? ??????????? ?? ????????-?????? ???????????
These metabolic alterations led to a decrease in antioxidant defenses and autophagy and 
chronic ER-stress in L.G6pc-/- livers and tumors. Interestingly, autophagy was reactivated in 
HCA/HCC. 
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Conclusion: The metabolic remodeling in L.G6pc -/- liver generates a preneoplastic status 
and leads to a loss of cellular defenses and tumor suppressors that facilitates tumor 
development in GSDI. 
LAY SUMMARY 
?
Glycogen storage disease type Ia is a rare metabolic disease characterized by hypoglycemia, 
steatosis, excessive glycogen accumulation and tumor development in the liver. In this study, 
we have observed that GSDIa livers reprogram their metabolism similarly to a cancer cell, 
which facilitates tumor formation and progression, in the absence of hepatic fibrosis. 
Moreover, hepatic burden due to overload of glycogen and lipids in the cells leads to a 
decrease in cellular defenses, such as antioxidant enzymes and autophagy, which could 
further promote tumorigenesis in the case of GSDI. 
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INTRODUCTION 
Hepatocellular carcinoma (HCC) is one of the most common primary malignancies of the 
liver1. Many studies have demonstrated a strong link between hepatic tumorigenesis and non-
alcoholic fatty liver diseases (NAFLDs), including obesity, diabetes and other genetic 
metabolic liver diseases, such as Glycogen storage disease type I (GSDI)2,3,4. NAFLD can go 
from simple steatosis characterized by hepatic fat accumulation, to the more aggressive form 
called non-alcoholic steatohepatitis (NASH), associated with inflammation and fibrosis. 
While it is considered that NASH/NAFLD can lead to liver cirrhosis, predisposing the liver 
to HCC, studies have reported that HCC can also develop in the absence of cirrhosis. 
Moreover, hepatocellular adenomas (HCA), which are rare benign tumors, can later 
transform into HCC in the absence of cirrhosis5,6.  
GSDI is due to a deficiency in glucose-6 phosphatase (G6Pase) activity7,8. The mutations in 
G6PC, encoding the catalytic subunit of G6Pase9,10, are responsible for GSD type Ia 
(GSDIa), while mutations in SLC37A4 encoding the transport subunit of the G6Pase, are 
responsible for GSD type Ib (GSDIb). G6Pase is an enzyme expressed only in the liver, 
kidneys and intestine, converting glucose-6 phosphate (G6P) into glucose, ensuring normal 
glycaemia11,12. G6Pase deficiency results in hypoglycemia, associated with 
hypercholesterolemia, hypertriglyceridemia, lactic acidosis and hyperuricemia in GSDI 
patients and animal models 7,8,13. Furthermore, increased accumulation and intracellular flow 
through G6P lead to glycogen and lipid accumulation in the hepatocytes, resulting in 
hepatomegaly and hepatic steatosis7,8,13. As mentioned above, most adult GSDI patients 
develop HCA, which can transform in HCC, with about 10% incidence of transformation, in 
the absence of liver fibrosis and cirrhosis14,15. In a French cohort of GSDI patients, about 
???? ??? ???? ????? ?????????? ??? ?????????????? ??????? ???? ??? ???? ??????? ?-catenin 
mutations and 20% of HCA were unclassified14. 
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While the molecular mechanisms involved in GSDI tumorigenesis remain unclear, there are 
several pathways suspected to be involved in this process16. Since GSDI can be considered as 
a NAFLD-like condition, lipid-related risks could lead to tumorigenesis. Glycogen and lipid 
storages in massive quantities can induce inflammation, apoptosis and even necrosis17,18,19. 
Impaired metabolism can induce abnormal responses in the hepatocytes, such as autophagy 
dysregulation and activation of endoplasmic reticulum (ER) stress pathways. Indeed, recent 
studies showed a decrease in autophagic flux in GSDI livers20,21. All these mechanisms could 
promote tumorigenesis in the case of GSDI.  
In order to investigate the pathways involved in tumorigenesis, our laboratory has developed 
a GSDIa mouse model, in which G6pc is deleted specifically in the liver. These L.G6pc-/- 
mice exhibit the same hepatic and plasmatic complications observed in GSDIa patients, 
including HCA and HCC development13,22.  
In this study, we analyzed cellular and metabolic stress in L.G6pc-/- livers at a pretumoral 
and at a tumoral stage that leads to the loss of tumor suppressors, such as PTEN and p53. 
Indeed, G6Pase deficiency in the liver translates in a metabolic reprogramming in the 
hepatocytes, characterized as a «Warburg-like» effect that alters many aspects of cell 
homeostasis, thus triggering tumorigenesis. 
MATERIALS AND METHODS?
Generation of liver-specific G6pc knock-out mice (L.G6pc-/-) 
L.G6pc -/- mice were obtained by tamoxifen  treatment of B6.G6pclox/lox.SACreERT2 mice at 
the age of 8 weeks as previously described13. C57Bl6/J mice (Charles Rivers, ?????resle, 
France) were used as control (referred to as wild-type [WT] mice). After tamoxifen 
treatment, male and female L.G6pc-/- and control mice were fed a high fat / high sucrose 
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(HF/HS) diet (35% fat, 20% proteins, 35% carbohydrates including starch and sucrose) 
during 4 months or 9 months. Animals were housed in groups of 4-6 mice, with ?Lignocel? 
bedding (JRS, Rosenberg, Germany) in an enriched environment at 21°C, with a 
light/darkness cycle 12h/12h and free access to water and food. All the procedures were 
performed in accordance with the principles and guidelines established by the European 
Convention for the Protection of Laboratory Animals. The regional animal care committee 
(C2EA-55, Université Lyon 1, Lyon) approved all the experiments. 
 
Histological and immunohistological analysis 
Hematoxylin and eosin (H&E) staining of liver and tumors was done as previously 
described13. Liver sections were stained using PCNA or p53 antibodies (Supplem. Table 1), 
as described in the Cell signaling technology immunohistochemistry protocol. For 
transmission electron microscopy (TEM), ultrathin sections were obtained and observed as 
previously described23. Four to five tissue samples were prepared from each group of mice. 
Ten liver or tumor sections from each mouse were documented and the number of autophagic 
vesicles per field was assessed. 
 
Metabolic studies 
Blood was withdrawn by submandibular bleeding 6h after food removal. Plasmatic and 
hepatic metabolites were determined as previously described13,23. Alpha- fetoprotein (AFP) 
(R&D Systems Inc, Lille, France) and C reactive protein (CRP) (Abcam, Cambridge, UK) 
levels were determined by ELISA. AST/ALT activities were determined with colorimetric 
activity assays (Abcam, Cambridge, UK).  
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Gene and protein expression analysis 
Antibodies for western blot analyses are cited in Supplemental CTAT Table. The 
visualization and quantification of the proteins were performed using the BioRad 
ChemiDocTM Touch Imaging System (Marnes La Coquette, France). 
Total RNAs were isolated according to the Trizol protocol (Invitrogen Life Technologies, 
Thermofisher, France). RT-qPCR were performed as previously described,?expressed in 2-
DDCT value with WT normal liver as normalizator13,23. The mouse ribosomal protein mL19 
(Rpl19) was used as reference. Primer sequences are indicated in Supplemental CTAT Table. 
 
Statistics 
The results are reported as the mean ± s.e.m. At the pretumoral stage, WT and L.G6pc-/- 
groups were compared with a ?????????? ?-test. At the tumoral stage, tissue samples were 
compared with one-way ANOVA. Differences were considered to be statistically significant 
at P-value < 0.05. 
RESULTS?
High fat/high sucrose diet accelerates hepatic carcinogenesis in L.G6pc-/- mice 
Wild-type (WT) and L.G6pc-/- mice were fed a HF/HS diet for 4 months or for 9 months. As 
shown previously24, L.G6pc-/- mice fed a HF/HS diet were resistant to obesity compared to 
WT mice, which became obese (Supplem. Fig.1). No tumors were observed in L.G6pc-/- and 
WT livers at 4 months of HF/HS diet; this stage will be referred to as the pretumoral stage.  
Nevertheless, L.G6pc-/- mice exhibited hepatomegaly associated with hepatic glycogen and 
G6P, which were significantly increased (Table 1). However, triglycerides were decreased in 
comparison to WT mice (Table 1). At plasmatic level, a significant increase in cholesterol, 
triglycerides and lactate was observed in L.G6pc-/- mice, whereas plasmatic and hepatic 
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glucose levels were decreased (Table 1). Plasmatic uric acid and non-esterified fatty acids 
(NEFA) were unchanged. Strikingly, 90% of L.G6pc-/- mice had hepatic nodules after 9 
months on HF/HS diet (Fig.1A). This stage will be referred to as the tumoral stage. Among 
all L.G6pc-/- tumors (n=26), 72% were histologically diagnosed as HCA and 28% were HCC 
(Fig.1B panels c and d, respectively). Mice developed multiple millimetric nodules, 
associated with one or several macroscopic tumors. None of the WT mice developed hepatic 
nodules. At this stage, all plasmatic and hepatic parameters were similar to L.G6pc-/- mice at 
the pretumoral stage, with the exception of hepatic triglycerides, which were further 
decreased, compared to pretumoral L.G6pc-/- livers (Table 1). Liver weight increased 
slightly, compared to the pretumoral stage, due to the weight of the tumors. HCAs were 
mainly steatotic (Fig.1B panel c). In general, HCC cells were smaller than L.G6pc-/- 
hepatocytes, with a denser cytoplasm (Fig.1B panel d). At the pretumoral and tumoral stages 
no difference in proliferating cell nuclear antigen (PCNA) staining was observed between 
WT and L.G6pc-/- livers (Fig.1C, panels a-d). As expected, an increased number of PCNA-
positive cells were observed in HCA and HCC samples (Fig.1C panels e and f), indicating an 
increase in cell proliferation in GSDI tumors. At the tumoral stage, no differences in 
circulating CRP, aspartate transaminase (AST) and alanine transaminase (ALT) levels were 
observed between WT and L.G6pc-/- mice (Fig.1D), probably due to the low grade 
inflammation in WT mice fed a HF/HS diet, since these mice also developed steatosis25. 
Interestingly, the expression of malignancy markers of HCC were increased in L.G6pc-/- 
mice bearing tumors26,27. Indeed, the plasmatic concentration of AFP was significantly 
increased in L.G6pc-/- mice bearing HCA/HCC (Fig.1D). Furthermore, glypican3 (Gpc3) had 
a strong tendency to increase in HCC, but also in some low atypia histologically classified as 
HCA (Fig.1E). Glypican3 expression in some HCA samples could be due to a more advanced 
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stage and a tendency to transform into HCC, implying early acquirement of malignant traits 
in HCA. 
 
L.G6pc-/- mice exhibit hepatic loss of tumor suppressors  
In order to analyze further potential actors involved in tumorigenesis, the expression of 
several tumor suppressors i.e. h??????? ???????? ??????? ?? ?? ?HNF1?), phosphatase and tensin 
homolog (PTEN) and p5328,29,30 was assessed in L.G6pc-/- livers and tumors. Interestingly, 
we observed no change in Hnf1a mRNA expression at the pretumoral stage (Fig.2A). 
Nevertheless, Hnf1a mRNA was significantly decreased in L.G6pc-/- livers and tumors at the 
tumoral stage, compared to WT livers, as previously reported in human GSDI livers and 
tumors14,28 (Fig.2B).  Pten expression was decreased in L.G6pc-/- livers at both pretumoral 
and tumoral stage and in tumors (Fig.2A-B). Interestingly, p53 acetylation at Lys379, which 
activates the accumulation of p53 as a stress response following DNA damage31, was 
increased in L.G6pc-/- livers at the pretumoral stage (Fig.2C). On the contrary, acetylated 
p53 was decreased in L.G6pc-/- livers and in HCA/HCC at the tumoral stage (Fig.2D), thus 
indicating a switch in p53 signaling between the stages. Furthermore, phosphorylation of p53 
at Ser39232, which influences the growth suppressor function, DNA binding, and 
transcriptional activation of p53, was increased in L.G6pc-/- livers at both stages and in 
HCA/HCC. It is noteworthy that immunohistochemistry analysis revealed that p53 was 
translocated in the nuclei of WT and L.G6pc-/- hepatocytes, after 4 and 9 months of HF/HS 
diet (Fig.2E), while we observed the presence of p53-negative nuclei in HCA samples 
(Fig.2E panel e). In HCC samples, most nuclei were p53-negative, while p53 preferentially 
accumulated in the cytoplasm of hepatocytes (Fig.2E panel f).  
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Lack of EMT is responsible for the absence of liver fibrosis in L.G6pc-/- livers 
In the general population, hepatic fibrosis / cirrhosis generally precede the development of 
HCC. As already observed in GSDI patients8, L.G6pc-/- livers did not show signs of fibrosis 
(Fig.1), yet HCC occurred. In order to investigate the lack of fibrosis in L.G6pc-/- livers, 
epithelial-mesenchymal transition (EMT), which is known to lead to hepatic fibrosis33, was 
analyzed. At the tumoral stage, the epithelial marker E-cadherin was up-regulated in  L.G6pc-
/- livers compared to WT, while none of the mesenchymal markers , i.e. vimentin (Vim????-
smooth muscle actin (Acta) and plasminogen activator inhibitor-1 (Pai1), were increased 
(Fig.3A-B). Furthermore, transforming growth factor beta 1 (?????), which can activate EMT 
in the liver34, was unchanged, confirming the absence of EMT and fibrosis induction 
(Fig.3B). Surprisingly, E-cadherin remained increased in hepatic tumors (Fig.3A). In 
????????????????????????????????????????????????-catenin was observed only in HCC, as already 
observed in GSDI patients14 (Fig.3A). Concomitantly, the mesenchymal markers were all 
increased in hepatic tumors (tendency for Pai-1), more substantially in HCC than in HCA 
(Fig.3B). Surprisingly, ??????expression was decreased in HCA and HCC (Fig.3B). These 
results indicate a concomitant up-regulation of epithelial and mesenchymal markers in 
HCA/HCC which was mediated in a TGF-????independent manner.  
????????????????????? ?????????????????? ?????-catenin target genes, i.e. glutamine synthetase 
(Glul) and leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5). Surprisingly, 
the expressions of Glul and Lgr5 were decreased in L.G6pc-/- livers, and further decreased in 
???? ???? ???? ?????????? ??????????? ????? ???? ?-catenin pathway was not activated during 
tumorigenesis. 
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Metabolic reprogramming of L.G6pc-/- hepatocytes makes them favorable to 
tumorigenesis  
Hyperactivation of the glycolysis pathway has already been confirmed in GSDI livers35. 
Interestingly, mRNA expressions of the glucokinase (Gck) and the glucose transporter Glut1 
(Slc2a1), usually increased in glycolytic conditions, were dramatically decreased in L.G6pc-
/- livers at both stages, as well as in HCA and HCC (Fig.4A-B), probably to limit G6P 
accumulation. Concomitantly, a significant increase in plasmatic lactate concentrations was 
observed at both stages (Table 1), confirming increased glycolysis. However, lactate 
dehydrogenase A (LDHA), which catalyzes the conversion of pyruvate to lactate, was 
unchanged in L.G6pc-/- livers (Fig.4C-D). The expression of the M2 isoform of pyruvate 
kinase (PK-M2), which is an alternatively spliced variant expressed in cancer cells36, was 
unchanged in L.G6pc-/- livers at both stages (Fig.4C-D). Interestingly, PK-M2 was 
significantly increased in tumors, conferring a strong glycolytic profile on HCA and HCC 
(Fig.4D). 
OXPHOS analyses revealed a decrease in mitochondrial respiration in L.G6pc-/- livers 
compared to WT livers at both stages, characterized by a decrease in pyruvate oxidation 
(Supplem. Fig.2). The global respiration values were low, consistent with the hepatic 
steatosis observed in both L.G6pc-/- and WT mice, due to the HF/HS diet37.  Pyruvate 
dehydrogenase (PDH), a key factor in pyruvate oxidation, was similar in WT and L.G6pc-/- 
livers and tumors (Fig.4C-D). In addition, pyruvate dehydrogenase kinase 4 (PDK4), an 
inhibitor of PDH, was downregulated in L.G6pc-/- livers at both stages. Interestingly, the 
mitochondrial pyruvate carrier 1 (MPC1) was slightly decreased in L.G6pc-/- livers at the 
pretumoral stage (Fig.4C), further decreased at the tumoral stage, and even more in HCA and 
HCC (Fig.4D).  Thus a decrease in pyruvate transport in the mitochondria could explain, at 
least in part, the decreased pyruvate oxidation.  
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Analysis of the main actors in lipid metabolism at the pretumoral stage revealed an increase 
in de novo lipogenesis in L.G6pc-/- livers,  concomitantly with a decrease in fatty acid 
oxidation (FAO) (Fig.5A), as previously reported13,24. This was linked to an increase in 
carbohydrate-responsive element binding protein (Chrebp), especially Chrebp ??isoform 
mRNA expression at this stage. On the contrary, the expression of sterol regulatory element-
binding protein 1 (Srebp1) was unchanged in L.G6pc-/- livers, compared with WT livers, 
while Srebp2 expression was decreased (Fig.5A). At the tumoral stage, a similar increase in 
lipogenesis gene expression was observed in L.G6pc-/- livers, while this increase was less 
pronounced in HCA and HCC (Fig.5B). In addition, Srebp1 and Pparg expressions were 
significantly decreased in L.G6pc-/- livers and tumors at this stage. Concomitantly, the 
expression of genes involved in FAO was more decreased in tumors than in L.G6pc-/- livers. 
Interestingly, total Chrebp expression decreased in L.G6pc-/- livers and tumors at this stage 
(Fig.5B), contrarily to the pretumoral stage. Nevertheless, Chrebp-?? ???????? ???????????
remained increased in L.G6pc-/- livers and tumors. During malignant transformation, 
increased formation of small lipid droplets is often detected and perilipin is an important 
factor in this process38. Interestingly, perilipin was detected only in HCC samples (Fig.5C). 
As expected, L.G6pc-/- mice exhibited an increase in hepatic lipid synthesis and a decrease in 
FAO in pretumoral and tumoral stage livers. In tumors, FAO was considerably decreased, 
concomitantly with a decrease in lipogenesis. This switch in lipid metabolism is possibly 
related to an intriguing switch in ChREBP expression that could be a potential trigger of 
tumorigenesis. 
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Impairment in cellular defenses in L.G6pc-/- livers 
Altered metabolism and steatosis can lead to an increased production of reactive oxygen 
species (ROS) and cause oxidative stress. In order to maintain homeostasis, hepatocytes 
activate antioxidant enzyme production against ROS-induced damage. However, the 
expression of catalase (Cat) and glutathione peroxidase (Gpx1) was decreased at the 
pretumoral and the tumoral stages (Fig.6A-B). These results indicate an oxidative stress in 
L.G6pc-/- livers and tumors that was confirmed by the presence of donut-shaped 
mitochondria in L.G6pc-/- livers and in HCA/HCC (Fig.6C). In order to analyze the 
importance of antioxidant loss in L.G6pc-/- livers, mice were treated with Tempol, an 
antioxidant agonist for 9 months. Although we observed a significant increase in Cat and 
Gpx1 expressions in L.G6pc-/- mice treated with Tempol (Fig.6D), 9 out of 12 treated 
L.G6pc-/- mice developed hepatic tumors with the same characteristics as non-treated 
L.G6pc-/- mice, proving that an increase in antioxidant defenses is not capable of impeding 
HCA/HCC development. 
Recent studies showed a decreased autophagic flux in GSDI livers20,21 that was confirmed in 
L.G6pc-/- livers at both stages (Supplem. Fig.3). However, HCA and HCC showed a 
reactivation of autophagy since we observed a decrease in p62 accumulation (Supplem. 
Fig.3). This was confirmed by the quantification of autophagic vesicles via TEM. Thus a 5-
fold decrease in autophagic vesicle number in L.G6pc-/- livers was observed at the 
pretumoral and tumoral stages, while the number of autophagic vesicles was only decreased 
by 2-fold in tumors, compared to WT livers (Fig.6E). 
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Endoplasmic reticulum stress - another contributor to tumorigenesis in GSDI livers? 
Disrupted cellular homeostasis can lead to ER stress and thus to malignancy39 and/or altered 
lipid metabolism40.  Interestingly, a marked decrease in BiP protein expression (chaperone 
protein that attenuates hepatic steatosis41) was observed in L.G6pc-/- livers at the pretumoral 
and the tumoral stage, and furthermore in HCA/HCC (Fig.7A). BiP downregulation can lead 
to the activation of the three main axes of ER stress (IRE1??/XBP1, PERK/ATF4 and ATF6). 
IRE???????????????? in L.G6pc-/- livers and tumors at both stages, while the active form of 
its target XBP1-S was decreased at the pretumoral stage and increased at the tumoral stage 
(Fig.7A-B). Analysis of the PERK/ATF4 pathway revealed no change in the phosphorylation 
??? ????? (target of PERK) (Fig.7A-B) and Atf4 mRNA expression (data not shown) in 
L.G6pc-/- livers at both stages. Nevertheless, this pathway was markedly inhibited in 
HCA/HCC, as illustrated by the decrease in eIF2 phosphorylation (Fig.7B). ATF6 was 
increased in pretumoral and tumoral stage L.G6pc-/- livers, and varied in tumors (Fig.7A-B). 
Finally, a decrease in CHOP and cleaved caspase 3 was observed in L.G6pc-/- livers at the 
pretumoral stage, indicating a decrease in ER stress-activated apoptosis (Fig.7A). Contrarily 
to the pretumoral stage, at the tumoral stage CHOP was increased in L.G6pc-/- livers, with a 
concomitant increase in cleaved caspase 3, indicating an increase in ER stress-activated 
apoptosis (Fig.7B). As expected, a strong inhibition of caspase 3 was observed in the 
HCA/HCC (Fig.7B), confirming the blockade of apoptosis in tumors. 
In conclusion, ER stress activation was observed in L.G6pc-/- livers. It was mainly mediated 
via the IRE1/XBP1 and ATF6 pathways, but not through PERK/ATF4. Surprisingly, at the 
pretumoral stage, this activation led to decreased apoptosis, whereas at the tumoral level, 
apoptosis levels were restored.  
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CONCLUSION 
In GSDIa, the loss of G6Pase activity is characterized by G6P accumulation in hepatocytes, 
leading to metabolic reprogramming that promotes tumorigenesis14,16. In this work, we 
investigated how G6Pase deficiency affects the cellular defense mechanisms and triggers 
tumorigenesis in a mouse model of GSDIa. We definitely showed that GSDIa hepatocytes 
exhibited the main characteristics of cancer cell metabolism, i.e. a preferential high rate of 
glycolysis, rather than mitochondrial pyruvate oxidation, leading to an increase in lactate 
production. In addition, the accumulation of hepatic lipids was exacerbated by a concomitant 
increase in de novo lipogenesis and a decrease in FAO. This offers advantages to 
proliferating cells, since increased fatty acids provide substrates for cellular membrane 
biogenesis. Altogether, these metabolic perturbations were associated with the loss of several 
cellular defenses, i.e. autophagy, oxidative stress response, dysregulation of ER stress 
responses and apoptosis, which were characterized in this study at a pretumoral and at a 
tumoral stage in livers of L.G6pc-/- mice.?In addition, L.G6pc-/- livers did not exhibit EMT at 
the tumoral stage and were characterized by a low-grade inflammatory response and the 
absence of fibrosis, concomitantly with the development of HCA/HCC. 
L.G6pc-/- mice represent a unique viable model of GSDIa that reproduces all hepatic 
hallmarks of GSDIa pathology. As shown in our previous study13, about 30-40% of L.G6pc-/- 
mice developed millimetric hepatic lesions after 9 months of G6pc deletion, while all 
L.G6pc-/- mice developed hepatic nodules after 18 months. Most of these tumors were 
histologically classified as HCA. Recently, we estimated a 5-10% incidence of 
transformation to HCC at this age (unpublished data). Interestingly, tumor development was 
highly accelerated in L.G6pc-/- mice fed a HF/HS diet, since nearly all mice developed large 
hepatic nodules after 9 months. Some HCA already presented increased expression of 
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glypican 3, a characteristic marker of HCC, highlighting HCA potential to transform into 
HCC. Furthermore, the transformation ratio of HCA to HCC was increased, since almost 
30% of tumors were diagnosed as HCC in L.G6pc-/- mice fed a HF/HS diet. As already 
published, L.G6pc-/- mice fed a HF/HS diet, unlike WT mice, resist obesity development24. 
In addition, the hepatic accumulation of triglycerides was less pronounced in L.G6pc-/- than 
in WT livers, probably due to a decrease in Pparg expression. Lipotoxicity in NAFLD is 
considered to be primarily due to the harmful effect of free fatty acids and free cholesterol 
rather than triglycerides, which are considered relatively inoffensive, and even possibly 
protective. Since GSDI shares common metabolic dysregulations with NASH/NAFLD, many 
of the complications that lead to HCC in this set of metabolic diseases could be accountable 
for HCC development in GSDI16. NAFLD-associated complications include inflammation, 
necrosis, lipotoxicity, adipokine imbalance and liver injury and remodeling. In spite of 
hepatic tumor development, we showed that these metabolic dysregulations did not lead to 
liver injury in GSDI. Thus ASL/ALT and CRP were slightly above healthy control values25, 
but were similar in L.G6pc-/- mice bearing or not bearing tumors. Thus as in obesity, GSDIa 
is characterized by a low-grade chronic inflammatory response that is associated with 
increased tumor development and L.G6pc-/- mice are a very good model to study this 
pathology. Contrarily to the majority of HCC, which arise in fibrotic/cirrhotic livers, HCC in 
L.G6pc-/- livers develop in non-fibrotic conditions. This lack of fibrosis could be explained, 
at least in part, by the absence of inflammation and low levels of the profibrotic factor TGF-
?142. It is noteworthy that unlike HCC in the general population, HCC in GSDI are developed 
from HCA transformation, while de novo formation of HCC has never been reported14. 
Furthermore, while EMT is known to occur during the progression of HCC34 to facilitate 
tumor dissemination, we observed a paradoxical concomitant up-regulation of epithelial and 
mesenchymal markers in HCA/HCC, in the absence of TGF-?? increase. E-cadherin and 
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vimentin co-expression was already observed in breast cancer, associated with poor 
prognosis43. While the co-expression of epithelial and mesenchymal markers might indicate 
only an intermediate stage of EMT or a reverse mesenchymal to epithelial transition (MET) 
in these tumors44, this can still favor metastasis formation, which has already been reported in 
GSDI patients45. Therefore it is important to pinpoint the exact role of EMT in GSDI 
tumorigenesis. Last, increased inflammation and EMT have been reported to occur in GSDI 
kidneys and contrarily to the liver, here this process leads to renal fibrosis and cyst 
development23, but not cancer. Thus the difference in inflammation status in the liver and the 
kidneys in GSDI leads to different outcomes in these organs, and warrants to be further 
studied. 
In L.G6pc-/- mice, HCA and HCC were characterized by a downregulation of tumor 
????????????????????????????????????????????????s of tumor suppressors was also observed 
in L.G6pc-/- liver, conferring important neoplastic characteristics on the non-transformed 
GSDI hepatocytes. Furthermore, p53 was recently characterized as an important factor in 
lipid metabolism, independently of its role as a tumor suppressor46. Thus its deregulation 
could imply additional lipid metabolism alterations. In addition, AMPK and SIRT1, also 
qualified as tumor suppressors, were already found to be downregulated in GSDI livers21,24. 
Interestingly, the development of HCA to HCC was linked to a significant increase in plasma 
???????????????????????????????-catenin and glypican 3. The presence of glypican 3 in some 
HCA samples, as well as the increase of AFP in mice that bore HCA accentuated the strong 
malignant transformation potential of HCA to HCC. 
Contrarily to cancer cells, glucose phosphorylation is significantly decreased in L.G6pc-/- 
hepatocytes and HCA/HCC, limiting the accumulation of G6P. However, as observed in 
cancer cells, L.G6pc-/- hepatocytes preferentially metabolize glucose into lactate, conferring 
?? ????????-?????? phenotype to GSDIa hepatocytes. Interestingly, PK-M2 isoform was 
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overexpressed only in HCA/HCC. As many strategies are being developed to target this 
protein in order to block tumorigenesis47, it is important to confirm this result in human 
patients, to consider PK-M2 inhibition as an anti-????????????????????????????????????-li????
metabolism could also be promoted by the impairment of mitochondrial pyruvate transport, 
illustrated by a decrease of MPC1 expression in L.G6pc-/- livers and tumors. This deficient 
pyruvate transport may concur to lactic acidosis observed in GSDIa patients, as observed in 
patients with MPC1 deficiency48. A decreased import of pyruvate into mitochondria is in 
accordance with the observed downregulation of mitochondrial OXPHOS activity in L.G6pc-
/- livers. In this work, we did not observe an increase in ROS production (data not shown), 
despite the presence of NAFLD. Interestingly, FAO was strongly decreased as well, 
especially in tumoral samples. Indeed, the liver-specific deletion of G6pc results in 
suppressed expression of PPAR?, a master regulator of FAO. However, lipid oxidation is 
generally increased in cancer cells49. In conclusion, increased glycolysis along with the 
downregulation of mitochondrial respiration represents a marked reprogramming of hepatic 
metabolism favoring tumor development in GSDIa liver.  
As previously mentioned, these metabolic perturbations lead to the impairment of cellular 
defenses, i.e. autophagy, ER stress and antioxidant defenses in L.G6pc-/- livers. First, we 
confirmed the suppression of autophagy previously reported in L.G6pc-/- livers20,21. Indeed, it 
was shown that the downregulation of autophagy in GSDI was mediated via SIRT1 and 
FoxO, and was independent of the canonical autophagy regulator mTOR21. Nevertheless, in 
HCA/HCC we observed a reactivation of autophagy, which could be favorable for tumor 
progression, since it provides building blocks and substrate for tumor proliferation and 
biomass gain. Secondly, we showed a specific ER stress response, induced by a significant 
decrease in BiP, accentuated in HCA/HCC. Variations in ER stress responses led to a 
decrease in apoptosis at the pretumoral and an increase in apoptosis at the tumoral stage. 
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Oxidative stress and autophagy can also induce apoptosis in cases where the cell cannot adapt 
to the overbearing cell damage50. Increased apoptosis rates in hepatocytes have been reported 
in both GSDIa patients and animal models, yet the actual cause of apoptosis induction is still 
to be deciphered35. Autophagy, oxidative stress responses and ER stress responses are finely 
tuned mechanisms that can interact at many levels and the result of these interactions 
conditions cell fate. Failure to activate these responses probably leads to tumorigenesis. 
In conclusion, the various metabolic alterations in L.G6pc-/- livers, along with the decrease in 
several tumor suppressors, as well as cell defense deregulations, predispose GSDI livers to 
HCA/HCC development. Therefore, G6Pase deficiency in the liver initiates a complex 
metabolic reprogramming that affects many aspects of cell homeostasis, thus favoring 
tumorigenesis. The precise description here of the various mechanistic changes initiated by 
G6pc deficiency offers as many possible targets and rationales to envision future 
interventions aimed at moderating the severity (or treat) the disease. 
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Table 1: Plasmatic and hepatic parameters of L.G6pc-/- mice. 
Parameters 
Pretumoral stage Tumoral stage 
WT  
(n=6) 
L.G6pc-/- 
(n=11) 
WT 
(n=10) 
L.G6pc-/- 
(n=27) 
     
Glucose (mg/dL) 181.1 ±3.1 84.7 ±3.6*** 151.3 ±5.4 89.3 ±3.2*** 
     
Cholesterol (g/L) 1.7 ±0.1 2.1 ±0.1** 1.5 ±0.1 2.5 ±0.2*** 
     
Triglycerides (g/L) 0.61 ±0.01 0.79 ±0.05* 0.69 ±0.04 0.85 ±0.03* 
     
NEFA (g/L) 24.4 ±1.0 27.4 ±1.5 22.3 ±0.9 30.3 ±1.3** 
     
Uric acid (mg/L) 9.0 ±0.7 12.9 ±2.4 9.1 ±0.3 12.5 ±0.8 
     
Lactate (mM) 5.6 ±0.4 7.4 ±1.0* 4.2 ±0.2 5.2 ±0.5* 
     
 
    
Liver weight (g) 2.67 ±0.10 3.53 ±0.20* 2.46 ±0.09 4.53 ±0.25***$$ 
 
    
Liver weight (% of 
total body weight) 5.4 ±0.2 9.4 ±0.3*** 4.5 ±0.2 14.5 ±0.7*** $$$ 
 
    
Hepatic glycogen      
(mg/g) 38.3 ±1.7 52.1 ±0.8*** 27.0 ±3.0 52.8 ±1.4*** 
 
    
Hepatic G6P          
(μmol/g) 0.19 ±0.02 2.30 ±0.24*** 0.40 ±0.03 3.08 ±0.25*** $ 
 
    
Hepatic glucose       
(μmol/g) 19.9 ±0.8 5.0 ±1.1*** 22.7 ±1.0 6.1 ±0.6*** 
 
    
Hepatic triglycerides   
(mg/g) 184.0 ±11.7 83.7 ±12.4*** 112.6 ±6.9 65.0 ±3.4*** $  
 
    
 
Data were obtained from WT and L.G6pc-/- mice at 4 months (pretumoral stage) or 9 months 
(tumoral stage) of HF/HS diet, after 6h of fasting. Data are expressed as the mean ± s.e.m. 
Significant differences between WT and L.G6pc-/- are indicated as * p<0.05; ** p<0.01; *** 
p<0.001 and differences between pretumoral and tumoral stage L.G6pc-/- mice are indicated 
as $ p<0.05; $$ p<0.01; $$$ p<0.001. 
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FIGURE LEGENDS 
Fig.1. Hepatic tumor development in L.G6pc-/- mice. 
(A) WT and L.G6pc-/- livers after 9 months of HF/HS diet. (B) Histological analyses by 
H&E staining of a) WT liver, b) L.G6pc-/- liver, c) HCA and d) HCC. HCC was 
characterized by a trabecular pattern with thickened cords of cells. (C) Immunohistochemical 
staining of PCNA in a) WT and b) L.G6pc-/- liver at 4 months of HF/HS diet; c) WT and d) 
L.G6pc-/- liver at 9 months of HF/HS diet; e) HCA and f) HCC. (D) Plasmatic CRP and AFP 
levels and AST and ALT activities from WT, non-tumor bearing and tumor-bearing L.G6pc-
/- mice after 9 months of HF/HS diet. (E) Quantitative analysis of Gpc3 gene expression by 
RT-qPCR in WT livers (n=7), L.G6pc-/- livers (n=8), HCA (n=15) and HCC (n=9) at 9 
months of HF/HS diet. The results are expressed as the mean ± s.e.m. * p<0.05; ** p<0.01; 
*** p<0.001. 
Fig.2. Downregulation of tumor suppressors in L.G6pc-/- livers and tumors. 
Quantitative analyses of Hnf1a and Pten expression by RT-qPCR in (A) WT (n=9) and 
L.G6pc-/- (n=14) livers at 4 months of HF/HS diet and in (B) WT livers (n=7), L.G6pc-/- 
livers (n=8), HCA (n=15) and HCC (n=9) at 9 months of HF/HS diet. Quantitative analyses 
of phospho-Ser392 p53, acetyl-Lys379 p53 and total p53 by Western Blot after 4 months (C) 
or 9 months (D) of HF/HS diet. The results are expressed as the mean ± s.e.m. * p<0.05; ** 
p<0.01; *** p<0.001. (E) Immunohistochemical staining of p53 in a) WT and b) L.G6pc-/- 
liver at 4 months of HF/HS diet; c) WT and d) L.G6pc-/- liver at 9 months of HF/HS diet;  e) 
HCA and f) HCC.  Arrows indicate p53-negative nuclei.  
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Fig.3. Epithelial-mesenchymal transition in L.G6pc-/- livers and tumors. 
(A) Western blot analyses of ?-catenin, E-cadherin and vimentin and quantitative analyses of 
(B) Acta, Pai1, Vim and ????? and (C) Glul and Lgr5 expression by RT-qPCR in WT livers 
(n=7), L.G6pc-/- livers (n=8), HCA (n=15) and HCC (n=9) at 9 months of HF/HS diet. The 
results are expressed as the mean ± s.e.m. * p<0.05; ** p<0.01; *** p<0.001. 
Fig.4. Remodeling of glucose metabolism in L.G6pc-/- livers and tumors. 
Quantitative analyses of Gck and Slc2a1 expression by RT-qPCR in (A) WT (n=9) and 
L.G6pc-/- livers (n=14) at 4 months of HF/HS diet and in (B) in WT livers (n=7), L.G6pc-/- 
livers (n=8), HCA (n=15) and HCC (n=9) at 9 months of HF/HS diet. Quantitative analyses 
of LDHA, PK-M2, phospho-Ser293 PDH, PDK4 and MPC1 by Western Blot after at 4 
months (C) or 9 months (D) of HF/HS diet. The results are expressed as the mean ± s.e.m. * 
p<0.05; ** p<0.01; *** p<0.001. 
Fig.5. Lipid metabolism alterations in L.G6pc-/- livers and tumors. 
Quantitative analyses of lipid metabolism gene expression by RT-qPCR in (A) WT (n=9) and 
L.G6pc-/- livers (n=14) at 4 months of HF/HS diet and in (B) WT livers (n=7), L.G6pc-/- 
livers (n=8), HCA (n=15) and HCC (n=9) at 9 months of HF/HS diet. (C) Quantitative 
??????????????????????????????????? ?????????????????????????????????????? The results are 
expressed as the mean ± s.e.m. * p<0.05; ** p<0.01; *** p<0.001. 
Fig.6. Alterations of antioxidant defenses and autophagy in L.G6pc-/- livers and tumors. 
Quantitative analyses of Cat and Gpx1 expression by RT-qPCR and western blots in (A) WT 
(n=9) and L.G6pc-/- (n=14) livers at 4 months of HF/HS diet and (B) in WT livers (n=7), 
L.G6pc-/- livers (n=8), HCA (n=15) and HCC (n=9) at 9 months of HF/HS diet. (C) TEM 
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images of a) WT liver, b) L.G6pc-/- liver and c) HCC at 9 months of HF/HS diet. Arrows in 
panels b-c indicate donut-shaped mitochondria. Bar represents 0.5 μm. (D) Quantitative 
analyses of Cat and Gpx1 expression by RT-qPCR in L.G6pc-/- livers treated or not with 
Tempol (0.2% in drinking water) for 9 months. (E) TEM images and quantification of 
autophagic vesicles in a) WT liver, b) L.G6pc-/- liver and c) HCC sample. Arrows indicate 
autophagic vesicles. The results are expressed as the mean ± s.e.m. * p<0.05; ** p<0.01; *** 
p<0.001. 
Fig.7. ER stress activation and apoptosis in L.G6pc-/- livers and tumors. 
Quantitative analyses of ER stress and apoptosis pathways by Western Blot after 4 months 
(A) or 9 months (B) of HF/HS diet. The results are expressed as the mean ± s.e.m. * p<0.05; 
** p<0.01; *** p<0.001. 
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CTAT methods 
Tables ???????Complete, Transparent, Accurate and Timely account?????????????????
mandatory for all revised submissions. The aim is to enhance the reproducibility of methods.  
? Only include the parts relevant to your study 
? Refer to the CTAT in the main text ???? ????????????????????????  
? Do not add subheadings 
? Add as many rows as needed to include all information 
? Only include one item per row 
 
If the CTAT form is not relevant to your study, please outline the reasons why: 
 
 
 
1.1 Antibodies 
Name Citation Supplier Cat no. Clone no. 
B-catenin Szlachcic et al., Front. Mol. 
Neurosc., 2017 Cell signaling 8480 D10A8 
E-cadherin Liang et al., Nature Com, 2017 Cell signaling? 3195 24E10 
Vimentin Li et al., Nature Com, 2017 Cell signaling? 5741 D21H3 
PK-M2 Li et al., Oncology Letters, 
2017 Cell signaling? 4053 D78A4 
LDHA Shankar et al., Sci. Reports, 
2017 Cell signaling? 2012 Polyclonal 
MPC1 N/A Cell signaling? 14462 D2L9I 
????? Kodo et al, PLoS One, 2017 Abcam ab8934 Polyclonal 
Perilipin Boutant et al., EMBO, 2017 Cell signaling? 9349 D1D8 
Cleaved Caspase 3 Kim et al., Front. Mol. 
Neurosc., 2017 Cell signaling? 9664 5A1E 
Caspase 3 Kim et al., Front. Mol. 
Neurosc., 2017 Cell signaling? 9665 8G10 
Cleaved Caspase 9 Lee et al., Oncology Letters, 
2017 Cell signaling? 7237 D2D4 
Cleaved PARP Burger et al., J. Cell Biol., 2017 Cell signaling? 5625 D64E10 
PARP Zeng et al., Exp. Therap. Med., 
2017 Cell signaling? 9542 Polyclonal 
ATG3 Kaufman et al., Mol.Biol.Cell, 
2017 Cell signaling? 3415 Polyclonal 
ATG5 Jeong et al., Oncotarget, 2017 Cell signaling? 8540 D1G9 
LC3B Dembitz et al., Cell Death 
Discovery, 2017 Cell signaling? 3868 D11 
PDK4 N/A Abcam ab214938 EPR19727-245 
p62 Madill et al., Mol Brain, 2017 Abcam? ab56416 N/A 
Catalase Kaczor et al., Mol Genet Metab 
Rep, 2017 Abcam? ab16731 polyclonal 
GPx1 Magierowski et al., J Abcam? ab22604 polyclonal 
CTAT table
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Gastroenterol, 2017 
PDH Phospho 
Ser293 Ward et al., PLoS One, 2017 Abcam? ab92696 Polyclonal 
PDH Moretton et al., PLoS One, 
2017 Abcam? ab110334 8D10E6 
p53 Pajk et al., Biogerontology, 
2017 Abcam? ab131442 Polyclonal 
p53 Acetyl Lys379 Shao et al., Antioxidants & 
Redox Signaling, 2017 Cell signaling? 2570 Polyclonal 
p53 Phospho 
Ser392 Ashraf et al., Sci. reports, 2017 Cell signaling? 9281 Polyclonal 
BiP Bedau, T., Schumacher, N., et 
al., Oncotarget, 2017 Cell signaling? 3177 C50B12 
GRP94 Bedau et al., Oncotarget, 2017 Cell signaling? 2104 Polyclonal 
????? Zhang et al., Theranostics, 
2017 Cell signaling? 3294 14C10 
??????????????
Ser51 Wu et al., Oncotarget, 2017 Cell signaling? 9721 Polyclonal 
????? Wu et al., Oncotarget, 2017 Cell signaling? 9722 Polyclonal 
CHOP Asano et al., Sci.Reports, 2017 Cell signaling? 2895 L63F7 
ATF6 Pereira et al., Life Sci, 2015 Novus NBP1-40256 70B1413.1 
XBP1 Aivazidis et al., PLoS One, 
2017 Abcam ab37152 Polyclonal 
GAPDH N/A Millipore ABS16 Polyclonal 
B-actin Park et al., Int. J. Mol. Sci., 
2017 Cell signaling 4970 13E5 
PCNA Wei et al., Oncotarget, 2017 Cell signaling 13110 D3H8P 
Goat Anti-Rabbit 
Antibody 
Conjugated to HRP 
N/A BioRad 170-5046  
 
1.2 Cell lines 
Name Citation Supplier Cat no. Passage no. Authentication 
test method 
NO 
 
1.3 Organisms 
Name Citation Supplier Strain Sex Age Overall 
n 
number 
WT Mutel et 
al., 
2011  
Charles River 
Laboratory 
C57BL6/J Male 
and 
female 
6 and 
11 
months 
36 
L.G6PC-
/- 
Mutel et 
al., 
2011  
Animalerie Lyon 
Est 
Conventionnelle 
B6.G6pclox/lox.SACreERT2 Male 
and 
female 
6 and 
11 
months 
86 
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et SPF 
 
1.4 Sequence based reagents 
 
Name Sequence Supplier 
?????????????????? ???????????????????? ????????????????????? Eurogentec, USA 
?????????????????? ???????????????????? ????????????????????? Eurogentec, USA?
?????????????????????????????????????????? ????????????????????? Eurogentec, USA?
?????????????????????????????????????????? ????????????????????? Eurogentec, USA?
?????????????????????????????????????????????? ????????????????????????? Eurogentec, USA?
?????????????????????????????????????????????? ??????????????????????? Eurogentec, USA?
???????????? ???????????????????????????? ?????????????????????? Eurogentec, USA?
???????????? ???????????????????????????? ?????????????????????? Eurogentec, USA?
??????????????????????????????????????????????? ???????????????????? Eurogentec, USA?
??????????????????????????????????????????????? ??????????????????????? Eurogentec, USA?
?? ????????? ?????????? ???????????????????? Eurogentec, USA?
?? ????????? ?????????? ??????????????????????? Eurogentec, USA?
?????????????????????????????????????????????? ????????????????????????? Eurogentec, USA?
?????????????????????????????????????????????? ????????????????????????? Eurogentec, USA?
????????????????????????? ????????????????????? Eurogentec, USA?
????????????????????????? ????????????????????? Eurogentec, USA?
????????????????????????????????????????????? ????????????????????? Eurogentec, USA?
????????????????????????????????????????????? ????????????????????? Eurogentec, USA?
????????????????????????????????????????????? ?????????????????????? Eurogentec, USA?
????????????????????????????????????????????? ??????????????????????????? Eurogentec, USA?
?????????????????????????????????????????????? ???????????????????? Eurogentec, USA?
?????????????????????????????????????????????? ???????????????????? Eurogentec, USA?
??????????????????????????????????????????????
?????????????????????????? ???????????????????? Eurogentec, USA?
??????????????????????????????????????????????
?????????????????????????? ?????????????????????? Eurogentec, USA?
?????????????????????????????????????????????
???????????????????????? ???????????????????? Eurogentec, USA?
?????????????????????????????????????????????
???????????????????????? ???????????????????????? Eurogentec, USA?
????????????????????????????????????????
???????????????????????????????????????? ????????????????????? Eurogentec, USA?
????????????????????????????????????????
???????????????????????????????????????? ????????????????????? Eurogentec, USA?
????????????????????????????????????????
??????????????????????????????????????? ??????????????????? Eurogentec, USA?
????????????????????????????????????????
??????????????????????????????????????? ???????????????????? Eurogentec, USA?
???????????????????????????????????????? ????????????????????? Eurogentec, USA?
???????????????????????????????????????? ????????????????????? Eurogentec, USA?
????????????????????????????????????????????? ????????????????????? Eurogentec, USA?
???????????????????????????????????????????? ????????????????????? Eurogentec, USA?
??????????????????????????????????????? ????????????????????? Eurogentec, USA?
??????????????????????????????????????? ??????????????????????? Eurogentec, USA?
????????????????????????????????????????? ?????????????????? Eurogentec, USA?
?Updated version August 2017 
????????????????????????????????????????? ?????????????????? Eurogentec, USA?
???????????????????????????????????????????
???????????????????????????? ????????????????????? Eurogentec, USA?
???????????????????????????????????????????
???????????????????????????? ????????????????????? Eurogentec, USA?
??????????????????????????????????????????? ????????????????????? Eurogentec, USA?
??????????????????????????????????????????? ????????????????????? Eurogentec, USA?
?????????????????????????????????????????????????
?????????????????????? ?????????????????????? Eurogentec, USA?
?????????????????????????????????????????????????
?????????????????????? ?????????????????????? Eurogentec, USA?
??????????????????????????????????? ????????????????????? Eurogentec, USA?
??????????????????????????????????? ????????????????????? Eurogentec, USA?
????????????? ?????????????????????????????????? ???????????????????? Eurogentec, USA?
????????????? ?????????????????????????????????? ?????????????????????? Eurogentec, USA?
?????????????????????????????????? ????????????????????? Eurogentec, USA?
?????????????????????????????????? ????????????????????? Eurogentec, USA?
?????????????????????????????????? ????????????????????? Eurogentec, USA?
?????????????????????????????????? ???????????????????????? Eurogentec, USA?
???????????????????????????????????????????
???????? ????????????????????? Eurogentec, USA?
???????????????????????????????????????????
???????? ?????????????????????? Eurogentec, USA?
????????????????????????????????????????????????? ?????????????????????? Eurogentec, USA?
????????????????????????????????????????????????? ?????????????????????? Eurogentec, USA?
??????????????????????? ????????????????????? Eurogentec, USA?
??????????????????????? ?????????????????????????? Eurogentec, USA?
???????????????????????????????????????? ????????????????????? Eurogentec, USA?
???????????????????????????????????????? ????????????????????? Eurogentec, USA?
 
1.5 Biological samples 
Description Source Identifier 
   
 
1.6 Deposited data 
Name of repository Identifier Link 
Raw and analysed data  This paper 
 
 
1.7 Software 
Software name Manufacturer Version 
ChemiDoc Software Biorad Version 1.2.0.12 
Image Lab Biorad Version 5.2.1 ; RRID: 
SCR_014210 
GraphPad Prism 5 ???????????????????????? Version 5.04 ; RRID: 
SCR_002798 
 
1.8 Other (e.g. drugs, proteins, vectors etc.) 
?Updated version August 2017 
NO   
   
 
1.9 Please provide the details of the corresponding methods author for the 
manuscript: 
 
 
 
2.0  Please confirm for randomised controlled trials all versions of the clinical 
protocol are included in the submission. These will be published online as 
supplementary information. 
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Supplementary Figure 1: Growth rates of WT and L.G6pc-/- mice.  
The weight of WT (n=32; black symbols) and L.G6pc-/- mice (n=74; gray symbols) fed HF/HS 
diet was followed once a month, during 9 months.  The values are expressed as the ratio current 
weight / initial weight. 
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Supplementary Figure 2: Mitochondrial oxidative phosphorylation activity in L.G6pc-/- 
livers. 
Oxidative phosphorylation rates in mitochondria isolated form (A) WT (n=5) and L.G6pc-/- 
livers (n=8) at 4 months of HF/HS diet and from (B) WT (n=5) and L.G6pc-/- livers (n=5) at 9 
months of HF/HS diet were analyzed via mitochondrial oximetry analysis. Mitochondrial 
oxidative phosphorylation activity was measured at 37??? ??? ?? ????????????? ????? ?????? ?????? ??
Clark electrode (Rank Brothers Ltd, UK), as previously described (Abdul-Wahed et al., 2014). 
Isolated liver mitochondria were incubated in a respiratory buffer (120 mM KCl, 5 mM KH2PO4, 
1 mM EGTA, 2 mM MgCl2, 3 mM Hepes, 0.3% bovine serum albumin, pH 7.4) with 5 mM 
????????? ???? ??????????????? ????? ?????????? ??? ???? ????????? ??? ?? ??? ?????????? ??? ??? ???
pamitoyl-carnitine and 2.5 mM malate as respiratory substrates. The phosphorylating respiration 
(state 3) was initiated with 1 mM ADP. The basal non-phosphorylating respiration (state 4) was 
????????? ??? ???? ????????? ??? ???????? ??????????? ???? ?????????? ??????? ??????????? ????????????
respiration was obtained with ?? ?? carbonyl-cyanide p-trifluoromethoxyphenylhydrazone 
(FCCP, a mitochondrial uncoupler). The respiratory control ratio (RCR) refers to the ratio of 
ADP-stimulated oxygen consumption (state 3) to that consumed in the presence of oligomycin 
(state 4). 
 Quantitative analyses of Cox4 expression by RT-qPCR in (C) WT (n=9) and L.G6pc-/- (n=14) 
livers at 4 months of HF/HS diet and in (D) WT livers (n=7), L.G6pc-/- livers (n=8), HCA 
?????????????????????????? ?????????????????????????????????????????????????????? ???????????
* p<0.05; ** p<0.01; *** p<0.001. 
 
 
 
 
 
 
 
 
 Supplementary Figure 3: Autophagy in L.G6pc-/- livers and tumors. 
Quantitative analyses of ATG3, ATG5, LC3B and p62 by Western Blot in (A) WT and L.G6pc-
/- mice at 4 months of HF/HS diet and (B) in WT livers, L.G6pc-/- livers, HCA and HCC at 9 
months of HF/HS die?????????????????????????????????????????????????????????????????????????
p<0.001. 
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Chapter II ? Characterization of the long-term renal complications in a 
mouse model of GSDI nephropathy 
?
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description, CKD in GSDI was recognized much later as a major complication. Renal 
failure is one of the main causes of morbidity in patients with aging (Martens et al., 
2009). While it was reported that it is the lipid-induced RAS signalization pathway that is 
responsible for fibrosis in GSDI kidneys (Yiu et al., 2008b), further characterization of 
this process was required.  
 In this study, we have characterized the long-term development of the 
nephropathy, between 9 and 18 months in K.G6pc-/- mice. We have thus reported a 
progressive installation of fibrosis during this period. Overtime, glomerulosclerosis and 
pedicel effacement was detected, concomitantly with a more pronounced EMT. This led 
to the development of fibrosis in accordance with an increase of TGF-???????????????
concomitantly with the development of renal cysts. Thus, at 18 months of G6pc deletion, 
several mice developed macroscopic renal cysts, which were never reported in GSDI. 
Thanks to a collaboration with Prof. Philippe Labrune (referent pediatrician for GSDI 
patients in Paris), we have found that renal cysts are frequently observed in GSDI 
patients, yet this occurrence was not considered as a major complication. Interestingly, 
we have established that in the cohort of 32 patients followed by Prof. Labrune, 7 
patients presented macroscopic renal cysts, which appeared independently from the 
type of GSDI, the sex and the age of the patient. Nevertheless, a correlation between 
aggravated parameters of renal function and cyst development has been established, 
situating cyst occurrence in the later stages of GSDI nephropathy. 
 It is noteworthy that, in this study, we have reported that the biomarker of kidney 
injury, Lipocalin-2, was increased in the urine of K.G6pc-/- mice, in the early stages of 
the nephropathy. Thus we propose that the utility of this biomarker should be evaluated 
in GSDI patients at different stages of the nephropathy.  
 To conclude, while many efforts are made to prevent hypoglycemia in children, 
renal complications should also be closely monitored from the youngest age. Indeed, 
kidney imaging as well as an evaluation of the renal function should be done once a 
year, in young and in older patients, in order to avoid renal cyst development and 
failure. 
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Abstract
Glycogen storage disease type I (GSDI) is a rare metabolic disease due to glucose-6 phosphatase deﬁciency, characterized by
fasting hypoglycemia. Patients also develop chronic kidney disease whose mechanisms are poorly understood. To decipher
the process, we generated mice with a kidney-speciﬁc knockout of glucose-6 phosphatase (K.G6pc-/- mice) that exhibited the
ﬁrst signs of GSDI nephropathy after 6 months of G6pc deletion. We studied the natural course of renal deterioration in
K.G6pc-/- mice for 18 months and observed the progressive deterioration of renal functions characterized by early tubular dys-
function and a later destruction of the glomerular ﬁltration barrier. After 15 months, K.G6pc-/- mice developed tubular-
glomerular ﬁbrosis and podocyte injury, leading to the development of cysts and renal failure. On the basis of these ﬁndings,
we were able to detect the development of cysts in 7 out of 32 GSDI patients, who developed advanced renal impairment. Of
these 7 patients, 3 developed renal failure. In addition, no renal cysts were detected in six patients who showed early renal
impairment. In conclusion, renal pathology in GSDI is characterized by progressive tubular dysfunction and the development
of polycystic kidneys that probably leads to the development of irreversible renal failure in the late stages. Systematic obser-
vations of cyst development by kidney imaging should improve the evaluation of the disease’s progression, independently of
biochemical markers.
Received: April 17, 2016. Revised: June 15, 2016. Accepted: June 15, 2016
VC The Author 2016. Published by Oxford University Press.
All rights reserved. For Permissions, please email: journals.permissions@oup.com
3784
Human Molecular Genetics, 2016, Vol. 25, No. 17 3784–3797
doi: 10.1093/hmg/ddw224
Advance Access Publication Date: 19 July 2016
Original Article
Downloaded from https://academic.oup.com/hmg/article-abstract/25/17/3784/2525836/Progressive-development-of-renal-cysts-in-glycogen
by guest
on 18 September 2017
Introduction
Chronic kidney disease (CKD) is a frequent complication in gly-
cogen storage disease type I (GSDI) and can progress to renal
failure. GSDI is a rare metabolic disease caused by deﬁcient
glucose-6 phosphatase (G6Pase) activity, resulting in the de-
crease in endogenous glucose production (1,2). G6Pase catalytic
subunit (G6PC) deﬁciency results in GSD type Ia and glucose-6
phosphate translocase deﬁciency results in GSD type Ib (3–5).
Patients with GSDIa or GSDIb present a wide spectrum of clini-
cal manifestations, including fasting hypoglycemia, hypertrigly-
ceridemia, hypercholesterolemia, hyperuricemia and lactic
acidosis. Excessive accumulation of glycogen and fat in the liver
and kidneys leads to chronic hepatic and renal complications
(6–8). Patients with GSDIb also suffer from neutropenia associ-
ated with recurrent bacterial infections (6,7). The view on renal
complications in GSDI is merely based on the collaborative
European Study on GSDI (ESGSDI) cohort, which retrospectively
included 231 GSDIa and 57 GSDIb patients. Thus, renal manifes-
tations of GSDI appear in early childhood (8,9). Almost 70% of
young adult patients exhibit hyperﬁltration and microalbumi-
nuria, and 40% develop proteinuria (8,9). Many patients also
have nephrocalcinosis, due to hypercalciuria and hypocitraturia
that enhance the likelihood of urinary calcium precipitation. As
with diabetic nephropathy, this dysfunction remains clinically
silent for a long time (6,10,11). Unfortunately, few data are avail-
able on the evolution of this CKD over time, because of the
small number of patients and a lack of longitudinal clinical
data.
To characterize the evolution of kidney dysfunctions in
GSDIa, we generated a viable mouse model in which G6PC dele-
tion was restricted to the kidneys (K.G6pc-/- mice). Interestingly,
K.G6pc-/- mice developed early-onset nephropathy, including
nephromegaly and microalbuminuria after 6 months of G6pc
deletion (12). However, long-term renal complications, such as
interstitial ﬁbrosis and focal segmental glomerulosclerosis ob-
served in GSDI patients (6), were not observed in mice at this
stage (12). In this study, we show that the development of renal
interstitial ﬁbrosis and glomerular sclerosis induced by long-
term G6pc deletion results in the later development of polycystic
kidneys, and then to the development of renal failure in the ﬁ-
nal stage of the disease. On the basis of our ﬁndings in mice, we
were able to detect the development of cysts in 22% of GSDI pa-
tients (6 patients with GSDIa and 1 patient with GSDIb) in a co-
hort of 32 individuals. Strikingly, renal cysts were never
reported in individuals with GSDI.
Results
Deterioration in tubule function in K.G6pc-/- mice
To characterize the development of nephropathy in GSDIa, we
studied the natural course of deterioration of the renal function
in K.G6pc-/- mice for 18 months. In contrast to total G6pc knock-
out mice (3), K.G6pc-/- mice showed no growth retardation and
had similar weight gain and glycaemia to control (WT) mice.
However, K.G6pc-/- mice exhibited gradual weight loss after 14
months of G6pc deletion (Supplementary Material, Fig. S1). As
previously observed, K.G6pc-/- mice exhibited enlarged and
paler kidneys compared to WT kidneys (Figure 1) . Kidney en-
largement increased with age (Figure 1A and B) and the kidney
weight of K.G6pc-/- mice was about 2.5-fold higher than that of
WT mice at 18 months (Figure 1C). As expected, we observed an
accumulation of excessive glycogen in the proximal tubule cells
in K.G6pc-/- kidneys (Figure 2A). As we had previously observed
deposits of lipids in the K.G6pc-/- kidneys (12), we quantiﬁed the
renal lipid content. The content in triglycerides reached 9.061.
2mg/g of tissue compared to 3.560.7mg/g of tissue in WT mice
after 9 months of G6pc deletion. However, no further increase in
triglyceride accumulation was observed between 9 and
18 months (Figure 2B). Histological observations revealed large
lipid droplets in the tubule cells in K.G6pc-/- kidneys at 9 months
(Figure 2C). Thus, both the accumulation of lipids and excessive
glycogen in the proximal tubules led to the clariﬁcation and
enlargement of tubular cells (Figure 3A). Renal tubules play an
important role in urine formation, and ﬂuid electrolyte and
acid-base homeostasis. Consequently, tubular damage ap-
peared early since K.G6pc-/- mice presented polyuria, urinary
acidiﬁcation and electrolyte imbalance at this stage (12).
However, polyuria gradually worsened with age (Table 1), con-
comitantly with polydipsia (Supplementary Material, Fig. S2),
conﬁrming an inability to concentrate urine. Thus, urine pro-
duction was about 4-fold higher that of WT mice at 18 months
(Table 1). As previously observed at 6 months, the urinary pH of
K.G6pc-/- mice was also more acidic than that of WT mice at
each stage (Table 1). In addition, the excretion of urea and uric
acid increased with age (Table 1). In parallel, biochemical anal-
yses also revealed normal plasma uric acid, cholesterol and
triglyceride levels, indicating normal liver metabolism in
K.G6pc-/- mice (Table 2).
Contrary to most GSDIa patients, no nephrolithiasis was
observed in K.G6pc-/- mice despite hypercalciuria. This can be
explained by the fact that hypocitraturia was not observed
concomitantly with a hypercalciuria. On the contrary,
K.G6pc-/- mice developed hypercitraturia and hypercalciuria
(Supplementary Material, Table S1). We previously suggested
that this could protect mice from calcium stone development
(12). In addition, Kþconcentration was increased in the urine of
K.G6pc-/- mice (Supplementary Material, Table S1). No modiﬁca-
tion in chloride, magnesium, phosphate, sodium and oxalate
excretion was observed in K.G6pc-/-mice (Supplementary
Material, Table S1).
In conclusion, these data show that tubular damage is an
early hallmark of K.G6pc-/- kidneys, and suggest that these de-
fects are probably secondary to the accumulation of glycogen
and lipids.
Development of ﬁltration barrier damage and renal
failure in K.G6pc-/- mice with age
Our previous study showed that the ﬁrst signs of impairment of
the ﬁltration barrier (i.e. microalbuminuria) occurred after 6
months of G6pc deletion (12). However, electron microscopy im-
ages and histological analyses of K.G6pc-/- kidneys showed in-
tact glomerular structures and no ﬁbrosis at this age (12).
Comparable alterations in biochemical urine and plasma pa-
rameters were observed at 9 months (Tables 1 and 2).
Nevertheless, albuminuria increased considerably in K.G6pc-/-
mice at 15 and 18 months, reaching 7766264mg/24h in
K.G6pc-/- mice compared to 97618mg/24h in WT mice at 18
months (Table 1). Interestingly, the accumulation of blood urea
nitrogen (BUN) was observed after only 15 months of G6pc dele-
tion (but not after 12 months, data not shown) (Table 2). These
results suggest the onset of renal failure, potentially responsible
for the weight loss observed at this age (Supplementary
Material, Fig. S1). Interestingly, the level of Lipocalin 2 (LCN2),
recently considered as a promising biomarker of CKD
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progression (13,14), progressively increased in urine in K.G6pc-/-
mice (Table 1) and was signiﬁcantly higher in the plasma in the
renal failure stage (Table 2). This was associated with a marked
increase in Lcn2 mRNA expression in K.G6pc-/- kidneys observed
after only 9 months of G6pc deletion (Supplementary Material,
Fig. S3), conﬁrming that the kidney is the major source of uri-
nary LCN2 (13,15).
These results suggest a gradual degradation of the ﬁltration
barrier with aging in K.G6pc-/-mice, leading to a late-onset of
renal failure after 15 months of G6pc deletion.
Progressive tubular and glomerular ﬁbrosis and
development of renal cysts in K.G6pc-/- mice with age
As the process of excessive ﬁbrosis is a major cause of CKDs, we
analyzed the progression of ﬁbrosis in K.G6pc-/- kidneys. It is
noteworthy that the kidneys were macroscopically sclerotic af-
ter 15 months of G6pc deletion and cystic after 18 months
(Figure 1A). As observed after 6 months, neither renal ﬁbrosis
nor glomerular injury were observed after 9 months of G6pc de-
letion (Figures 3 and 4, Supplementary Material, Fig. S4). After
15 months, early cell degeneration and necrosis were observed
in tubules with condensed nuclei. In addition, inﬂammatory
(lymphoid and plasma cells) areas and ﬁbrosis were observed in
the interstitium of the cortex (Figure 3A and B). At 18 months, tu-
bular dilation, inﬂammation and ﬁbrosis were more signiﬁcant
and numerous microscopic and macroscopic cysts up to 3–4mm
were observed (Figure 3). This was consistent with the
progressive increase in mRNA expression of the proinﬂamma-
tory cytokine TNF-a (Figure 3C). In addition to large areas of
interstitial ﬁbrosis, glomerular scarring was observed (Figure
3B). As observed in diabetes, the glomeruli showed mesangial
hypertrophy and expansion at 15 and 18 months, leading to an
increase of glomerular size (Supplementary Material, Fig. S4).
No tubular dysplasia or preneoplastic lesion was observed in K.
G6pc-/-kidneys. In agreement with histological observations,
the thickness of the glomerular basement membrane was more
prominent in K.G6pc-/- mice after 15 and 18 months compared
to WT mice (Figure 4A and B). In addition, foot process efface-
ment was observed at both ages (Figure 4A) and conﬁrmed the
substantial podocyte injury. Furthermore, Western Blot analy-
ses showed that the amount of structural proteins of the ﬁltra-
tion barrier (podocin and nephrin) had already slightly
decreased at 9 months and was markedly reduced at 18 months
(Figure 4C).
Thus, these results show that the development of interstitial
and glomerular ﬁbrosis results in the later development of poly-
cystic kidneys in GSDIa mice. This is associated with a marked
destruction of the ﬁltration barrier that ﬁnally leads to renal
failure.
Molecular mechanisms involved in renal
ﬁbrosis in K.G6pc-/- mice
One widely recognized pro-ﬁbrotic factor orchestrating renal ﬁ-
brosis is the TGF-b1 cytokine (16,17), which was already
1
5
 m
o
n
th
s
1
8
 m
o
n
th
s
9
 m
o
n
th
s
WT K.G6pc
-/-
0
0.8
0.4
0.2
0.6
1.0
k
id
n
e
y
 w
e
ig
h
t 
(g
)
*
**
***
$
0
2
1
3
*
**
***
$$
ki
d
n
e
y 
w
e
ig
h
t 
(%
 o
f 
b
o
d
y)
9 M 15 M 18 M
A
B
C
9 M 15 M 18 M
WT
KG6pc
-/-
Figure 1. Kidney phenotype of K.G6pc-/- mice. (A) Representative images of WT and K.G6pc-/- kidneys at 9, 15 and 18 months after tamoxifen treatment. Scale
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overexpressed in K.G6pc-/- kidneys at 6 months. In line with the
development of ﬁbrosis, the expression of Tgfb1 mRNA progres-
sively increased with age in K.G6pc-/- kidneys (Figure 5B). As
previously shown, the activation of the RAS (illustrated here by
the increase in renal angiotensinogen expression) could ac-
count for the increase in TGF-b1 expression (Figure 5A).
Concomitantly with the increase in TGF-b1, epithelial-to-
mesenchymal transition (EMT) and/or endothelial-to-
mesenchymal transition (EndoMT) were progressively observed
in K.G6pc-/- kidneys over time. The progression of CKD was as-
sociated with a 2-fold decrease in the expression of epithelial
markers, such as E-Cadherin (Cdh1) and b-catenin (Ctnnb1)
(Figure 5C). Concomitantly, we observed a progressive increase
in the expression of mesenchymal markers, such as vimentin
(Vim), ﬁbronectin (Fn1), and collagen type I (Col1a1) (Figure 5D).
After 18 months, a 10-fold induction of plasminogen activator
inhibitor-1 (Pai1) expression was observed in K.G6pc-/- mice
compared to WT mice and was signiﬁcantly higher than after 9
and 15 months of G6pc deletion (Figure 5D). In addition to the
changes in the EMT markers, we observed a decrease in the
amount of two main antioxidant enzymes, catalase and gluta-
thione peroxidase (GPX) after 18 months (Supplementary
Material, Fig. S5), probably leading to an increase in reactive ox-
ygen species (ROS) accumulation and oxidative stress (18).
Cystic renal disease and kidney failure in
GSD1a patients
Renal status was studied in 32 patients with GSDI (27 with type
Ia and 5 with type Ib), in order to detect renal cysts and/or kid-
ney dysfunction (Tables 3 and 4). Renal failure was deﬁned on
the basis of the estimated glomerular ﬁltration rate
(eGFR)<60ml/min/1.73 m2 for more than 3 months. Patients in
the cohort were born between 1962 and 2014. The median age of
the cohort when the data was collected was 26 years (ranging
Figure 2. Glycogen and lipid accumulation in K.G6pc-/- kidneys. (A) PAS-stained kidneys fromWT (a, c, e) and K.G6pc-/- mice (b, d, f) at 9, 15 and 18 months after tamoxi-
fen treatment. The same magniﬁcation was used for each panel. Scale bar¼200 mm. (B) Triglyceride content of kidneys fromWT (white bars) and K.G6pc-/- mice (black
bars) after 9, 15 and 18 months of tamoxifen treatment. Data are expressed as the mean6 s.e.m. Signiﬁcant differences between WT mice and K.G6pc-/- mice are indi-
cated as *, P<0.05; **, P<0.01, respectively. (C) Histological analysis of Sudan red staining fromWT (a, d) and K.G6pc-/- mice (b–c, e–f). Scale bars¼50 mm.
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from 1 to 53 years). The median age of GSDI patients with renal
dysfunction was higher than in patients without renal dysfunc-
tion (33 and 34 years for groups 2 and 3, respectively versus 22
years for group 1; Table 3). Our data suggest that early renal im-
pairment was detected in the young adult GSDI patients (20–30
year-old) (Supplementary Material, Fig. S6). The overall preva-
lence of patients with urinary albumin/creatinine ratio> 20 or
of patients treated with renoprotective drugs was 37.5% (13 pa-
tients) but only three patients developed renal failure (about
10% of GSDI patients) (Tables 3 and 4). Out of the three patients
with renal failure, Patient 1 was waiting for renal transplanta-
tion and Patient 2 underwent kidney transplantation in 2014.
Seven patients (6 with GSDIa and 1 with GSDIb) presented renal
cysts, representing 22% of GSDI patients in this cohort (Table 5)
and 54% of GSDI patients with renal dysfunction. Interestingly,
cysts appeared in GSDI patients at later stages of CKD,
characterized by a high albumin/creatinine ratio and a signiﬁ-
cant decrease of eGFR (Group 3, Table 3). Furthermore, all three
patients with renal failure (Patients 1 to 3) have developed cysts
(Table 4; Figure 6). Among these 7 patients, one or multiple cysts
were detected in both kidneys, mainly in the cortical area (Table
5). The size and number of cysts increased over a 6–8-year
follow-up period (Table 5 and Figure 6). Most of them were small
(size<10mm) but some were supracentimetric (Table 5). One
cyst in Patient 5 was classiﬁed as Bosniak II. These results sug-
gest that the development of renal cysts probably appears be-
fore kidney failure in patients with GSDI. Despite intensive
dietary treatment, hyperlipidaemia was observed in all patients
with GSDI, even when patients were treated with lipid-lowering
drugs. Indeed, mild and severe (TG> 10g/l) hypertriglyceridemia
were observed in GSDI patients with cysts while hypertriglyceri-
demia was more moderated in GSDI patients without cysts
Figure 3. Histological alterations in K.G6pc-/- kidneys. (A) Hematoxylin-eosin staining of WT (a, c, e,) and K.G6pc-/- mice (b, d, f) at 9, 15 and 18 months after tamoxifen
treatment. Scale bars¼50 mm (B)Masson’s trichrome staining of WT (a, c, e) and K.G6pc-/- mice (b, d, f). Scale bars¼50 mm. Arrows show inﬂammation areas. Asterisks
localize cysts. (C) Relative Tnfa mRNA expression. Signiﬁcant differences between WT mice and K.G6pc-/- mice are indicated as *P< 0.05. (D) Scans of the kidney slides
observed on panel A.
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(Table 3). Uric acid levels were similar in all GSDI patients but a
majority of them, if not all, were treated with xanthine oxidase
inhibitors (Table 3). However, metabolic parameters could not
be associated with the compliance with dietary treatment in
this cohort.
Discussion
Until recently, liver damage in GSDI was considered of greater
concern than nephropathy. To date, owing to improved nutri-
tional and medical management, GSDI patients have a consid-
erably longer life expectancy and develop renal complications
that were not frequently observed before. In this study, a longi-
tudinal study of the progression of CKD in mice with kidney-
speciﬁc knockout of G6Pase (K.G6pc-/- mice) allowed us to detect
renal cysts before the development of renal failure.
Retrospective analyses of the renal status of 32 patients with
GSDI showed that renal cysts were detected in seven patients
who developed advanced kidney dysfunction.
First, we analyzed the progression of CKD in K.G6pc-/- mice
that reproduce early-onset GSDIa nephropathy observed in hu-
mans (19). In a previous study, we showed that K.G6pc-/- mice ac-
cumulated glycogen in proximal tubules leading to tubular
clariﬁcation and nephromegaly as well as microalbuminuria after
6 months of G6pc deletion (12). At this early stage, the ﬁrst signs
of EMT were observed but no ﬁbrosis was detected in the kidneys
(12). Interestingly, we observed almost the same symptoms at 9
months, with increased in albuminuria and polyuria. This indi-
cated the worsening of the nephropathy stage, with considerable
tubular dysfunction since the kidneys could no longer concen-
trate urine successfully. Nevertheless, the glomerular ﬁltration
barrier was not damaged at this stage. Between 9 and 18 months,
albuminuria increased progressively and the ﬁrst signs of kidney
failure were observed after 15 months of disease. Interestingly,
this age corresponded to signiﬁcant destruction of the glomerular
ﬁltration barrier, podocyte depletion, mesangial expansion, tubu-
lar ﬁbrosis and inﬂammation, glomerular sclerosis and to the
early development of microscopic cysts. The symptoms wors-
ened at 18 months, with the development of macroscopic cysts.
These results suggest that tubular dysfunction leads to the de-
struction of glomeruli and the ﬁltration barrier, as previously sug-
gested by Lee et al. (20).
The extent to which EMT contributes to renal ﬁbrosis
in vivo remains a matter of intense debate (21,22). In the con-
text of GSDIa, we observed progressive but partial EMT lead-
ing to the development of ﬁbrosis. At the early stages of the
nephropathy, we observed a decrease in the expression of
epithelial markers. Mesenchymal markers appeared progres-
sively, after 15 months of G6pc deletion. This intermediate
stage corresponds with the initiation of chronic inﬂamma-
tion. In addition, glomerular podocytes also undergo trans-
formation after injury, which can lead to podocyte depletion
and to defective glomerular ﬁltration and glomerulosclerosis
(23,24). This process is often accompanied with the fusion of
the remaining pedicels in order to decrease ﬁltration dam-
age. In K.G6pc-/- kidneys, podocyte injury and the thickening
of the glomerular basement membrane were observed after
15 months, corresponding to kidney failure. Finally, elevated
expression of PAI-1 was observed after 15 months, leading to
high accumulation of collagen and the development of se-
vere interstitial and glomerular ﬁbrosis (25). The major driv-
ing factors behind EMT during the ﬁbrogenic phase of renal
Table 1. Urinary parameters of wild-type and K-G6pc-/- mice after 9, 15 and 18 months of G6pc deletion.
9 months 15 months 18 months
WT K.G6pc-/- WT K.G6pc-/- WT K.G6pc-/-
pH 6.460.4 6.060.1* 6.260.1 5.860.1** ND ND
volume (ml/24h) 1.160.1 2.160.2* 0.960.1 2.860.4** 0.960.1 3.860.9**
creatinine (mmol/24h) 23.462.3 26.262.1 18.161.5 20.760.9 9.561.0 11.561.6
albumin (mg/24h) 3664 6464* 72615 255640***,$ 97618 7766264***,$$
uric acid (mg/24h) 0.1160.01 0.1860.04 0.2860.01 0.5960.07** 0.2560.03 0.6860.15**
urea (mmol/24h) 1.560.2 2.660.1 2.360.4 3.160.4* 1.760.2 3.760.5**
lipocalin 2 (ng/24h) 27.264.2 148.5633.8* 30.469.4 247.641.5** 58.1623.4 319.8668.9**
Data were obtained from mouse urine samples collected during 24h using a metabolic cage and are expressed as the mean6 s.e.m (n¼7–8 mice in each group).
Signiﬁcant differences between WT and K-G6pc-/- mice are indicated as *P<0.05; **P<0.01 and ***P<0.001. Signiﬁcant differences between K-G6pc-/- mice over age are
indicated as $P<0.05 and $$P<0.01. ND: not determined.
Table 2. Plasmatic parameters of wild-type and K-G6pc-/- mice.
9 months 15 months 18 months
WT K.G6pc-/- WT K.G6pc-/- WT K.G6pc-/-
uric acid (mg/l) 6.261.3 8.860.6 6.260.7 8.361.1 7.960.9 7.561.6
cholesterol (g/l) 0.9560.02 0.9160.04 1.0760.02 1.2860.06* 0.9960.03 1.1260.03
triglycerides (g/l) 0.5460.02 0.5360.02 0.5160.04 0.5060.03 0.5260.03 0.4760.04
BUN (mg/dl) 23.860.9 21.760.7 31.960.6 44.165.2** 27.163.6 53.963.6**
lipocalin 2 (mg/dl) 127.7630.3 138.7617.5 103.463.5 187.7634.3 135.8643.7 305.7668.2*
Data were obtained from mice after 6h of fasting and are expressed as the mean6 s.e.m. Signiﬁcant differences between WT and K-G6pc-/- mice are indicated
(*P<0.05*, **P<0.01, ***P<0.001); n¼7–8 mice in each group.
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Figure 4. Glomerular alterations in K.G6pc-/- kidneys. (A) Electron microscopy analyses of glomeruli of WT (a, c, e) and K.G6pc-/- mice (b, d, f) at 9, 15 and 18 months after
tamoxifen treatment. Double white arrows delimit the basement membrane. Black arrowheads show pedicels. Scale bar¼500nm (B) Thickness of the basement
membrane of WT (white bars) and K.G6pc-/- glomeruli (black bars). Signiﬁcant differences between WT mice and K.G6pc-/- mice are indicated as ***P<0.001. (C)
Representative Western Blot of Nephrin, Podocin and Histone H3 (control) proteins in the kidneys of WT and K.G6pc-/- mice. At 9 months, quantiﬁcation analyses per-
formed by densitometry (student’s t test) showed a 1.4-fold (ns, n¼4) decrease in the quantity of Nephrin and Podocin in K.G6pc-/- compared to WT mice. After 18
months of G6pc deletion, the quantity of Nephrin decreased 1.9-fold (P¼ 0.03, n¼4) and the quantity of Podocin decreased 2.3-fold (P¼0.003, n¼4).
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ﬁbrosis appear to be various proﬁbrotic growth factors, espe-
cially TGF-b1 (17). The latter was progressively increased dur-
ing CKD development in K.G6pc-/- mice. We previously
suggested that the persistent activation of the RAS is mainly
responsible for the induction of TGF-b1 (12). Nevertheless,
there are other mechanisms that might contribute to this
proﬁbrotic stimulus, such as activation of the endoplasmic
reticulum stress (ER stress) and the subsequent Unfolded
Protein Response (UPR), which were shown to activate TGF-
b1 and promote ﬁbrosis in the kidney (26,27). ER stress can be
easily triggered by glucose concentration imbalance, as well
as metabolite accumulation, both of which being observed in
GSD1. Furthermore, apoptosis induced by ER stress alone is
sufﬁcient to induce ﬁbrosis. In addition, inﬂammatory cells
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and cytokines certainly play a vital role in the process of ﬁ-
broblast activation, as has been demonstrated for diabetic
nephropathy (28). Taken together, these results suggest that
EMT and/or EndoMT occur in GSDIa kidneys and play a vital
role in the progression of CKD. Finally, the decrease in
antioxidant defenses, which is also observed in diabetic kid-
neys (29), could participate to the progression of nephropa-
thy in GSDI (30). Indeed, the production of ROS and oxidative
stress are interlinked with TGF-b1 production and thus are
key factors in ﬁbrosis (31).
2007 2015
A B
C D
Figure 6. Axial T2-weighted MRI images from patient 3 with GSDIa. Two different sections are shown in 2007 (panels A–C) and in 2015 (panels B–D). Arrows indicate re-
nal cysts.
Table 3. Clinical and biochemical parameters of the 32 GSDI patients.
Characteristics Group 1 Group 2 Group 3 All GSDI patients
No cysts - No renal
impairment
No cysts - Early renal
impairment
Cysts and renal
impairment
number of patients 19 6 7 32
GSDIa/GSDIb 16/3 5/1 6/1 27/5
Male/Female 7/12 5/1 4/3 16/16
Median Age 22 years 34 years 33 years 26 years
(range) (1–44) (26–48) (23–53) (1–53)
Creat (mmol/l) 49.362.4 66.066.7 125.9626.2*** 69.267.9
(range) (27–64) (52–88) (69–228) (27-228)
Alb/Creat (mg/mmol) 0.760.3 15.765.7 150.8660.8*** 28.3614.0
(range) (0–4.8) (0–37.9) (26.5–375) (0-375)
eGFR (min/min/1.73m2) 126.067.6 117.5610.1 75.7615.4 113.466.8
(range) (63–200) (95–152) (23–119) (23-200)
TG (g/l) 3.860.5 5.961.9 7.761.8* 5.160.6
(range) (1.5–11.5) (2.1–14.7) (2–16.8) (1.7-16.8)
Uric acid (mmol/l) 379.8624.4 401.8674.8 383.0630.4 384.6620.3
(range) (179–577) (177–705) (258–486) (177-705)
Lipid lowering therapies (% of patients) 15.8% 50% 71.4% 34.4%
Treatments for hyperuricemia (% of patients) 73.7% 100% 100% 84.3%
Renoprotective treatments (% of patients) 0% 83.3% 100% 37.5%
Group 1 corresponds to GSDI patients without renal dysfunction and cysts. Group 2 corresponds to GSDI patients without cyst but with microalbuminuria and/or
treated with ACE inhibitors. Group 3 corresponds to GSDI patients with advanced renal impairment and renal cysts. All data were collected in 2015. Creat: creatinine;
Alb: albumin, a: data available from only 4 GSDI patients. Data are expressed as mean6 s.e.m. Signiﬁcant differences with Group 1 are indicated as *P<0.05;
***P<0.001.
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In clinical practice, the most commonly used markers of the
progression of renal disease are urinary albumin/creatinine ex-
cretion, measurement of serum electrolytes, blood urea and se-
rum creatinine with calculation of eGFR. Unfortunately, not all of
them are sufﬁciently sensitive to detect the early stages of the
disease. Urinary LCN2 was recently considered as a promising
biomarker of CKD progression, mainly reﬂecting early defective
tubular function (13–15). This protein is released from the kidneys
in the case of acute kidney injury, long before a decrease in the
glomerular rate can be detected (32). Elevated levels of urinary
LCN2 and their inverse correlation with eGFR have also been
shown in CKD patients with autosomal dominant polycystic kid-
ney disease (PKD) (33). In the context of diabetes, conﬂicting re-
sults have failed to conﬁrm urinary LCN2 as a reliable biomarker
of CKD progression (32). Here, the progressive increase in urinary
LCN2 levels during the development of kidney disease in
K.G6pc-/- mice probably reﬂects the deterioration of tubular
function. Thus LCN2 could be proposed as a speciﬁc biomarker of
CKD progression in GSDIa patients. It is noteworthy that recent
work has suggested that LCN2 might participate in the pathogen-
esis of cysts and CKD, by inducing EGFR (Epithelial Growth Factor
Receptor) signalling (13). Interestingly, it might also activate cell
proliferation of renal tubules and cysts in other pathological con-
texts (34). Consequently, the overexpression of LCN2 in K.G6pc-/-
kidneys could be involved in the progression of the CKD in GSDIa.
Finally, GSDIa nephropathy is associated with the activation of
a variety of pathways, in particular glycolysis, de novo lipogenesis,
and the RAS that leads to the progression of kidney disease
(Figure 7). The accumulation of glycogen and lipids in the kidneys
probably leads to the activation of cell defenses involved in the
maintenance of cell homeostasis. Impaired autophagic activity, ER
stress and ROS production are involved in the development of
CKD (35). In GSDI, oxidative stress was already shown to mediate
nephropathy (30). Interestingly, recent publications have proposed
Table 4. Clinical and biochemical parameters of GSDI patients who developed renal cysts.
Patients Gender Age
(years)
GSDI
Type
G6PC
mutations
Creat
(mmol/l)
Alb/creat
(mg/mmol)
Prot/creat
(g/mmol)
eGFR (ml/min
per 1.73m2)
TG
(g/l)
Uric acid
(mmol/L)
Renoprotective treatment
1 M 24 Ia c.1039C>T 215 375 0.55 36 6.6 304 Ibersatan (since 2008)
Waiting for a transplant
2 F 37 Ia c.328G>A
c.1039C>T
228 nd 0.34 23 6.8 258 Ramipril/ Hydrochlorothiazide
(since 2003)
Transplanted in 2014
3 F 44 Ib c.82C>T
c.1015G>T
137 160 0.17 40 2 402 Ibersatan/Ramipril
(since 2004)
4 F 23 Ia c.247C>T
c.734_735insG
71 nd 0.06 103 16.8 486 Enalapril (since 2006)
5 M 25 Ia c.209G>A
c.323C>T
86 nd <0.01 107 4.5 450 Ramipril (since 2005)
6 M 27 Ia c.809G>T 75 26.5 0.15 119 >10 363 Ramipril/ Hydrochlorothiazide
(since 2006)
7 M 43 Ia c.793DelC
c.1039C>T
69 41.8 0.06 102 7.6 417 Enalapril
(since 2005)
Data were collected in 2015. Creat: creatinine; Alb: albumin; Prot: Protein. Nd: not determined. The date of the beginning of treatment is indicated in brackets.
Table 5. Cyst development in GSDI patients.
Renal MRI at T1 Renal MRI at T2
Patients Date cysts<10mm cysts > 10mm Date cysts<10mm cysts > 10mm
1 2007 1/1 cortical 0 2015 0/2 cortical
2/1 medullar
0
2 2007 2/2cortical
0/2 medullar
1/0 cortical 2013 4/2 cortical
0/1 medullar
1/1 cortical (10 to 19mm)
3 2007 3/4 cortical
1/1 medullar
1/0 cortical (16mm) 2015 9/6 cortical
3/2 medullar
3/1 cortical (10 to 33mm)
0/3 medullar (11 to 16mm)
4 2008 0/2cortical
2/10 medullar
2/1 cortical (12 to 16mm)
2/4 medullar (10 to 18mm)
2014 6/3 cortical
3/8 medullar
2/2 cortical (10 to 13mm)
1/2 medullar (11 to 13mm)
5 2008 2/3 cortical
2/1 medullar
1/1 cortical (10 to12mm) 2013 4/3 cortical
4/0 medullar
3/4 cortical (11 to 21mm)
6 2008 1/3 cortical
1/0 medullar
1/0 cortical (12mm) 2015 3/7 cortical
5/4 medullar
0
7 2007 23/27 cortical 3/4 cortical (11 to 19mm)
1/0 medullar (17mm)
2015 25/30 cortical 4/11 cortical (10 to 17mm)
1/0 medullar (18mm)
The number, size and localization of cysts were analyzed by MRI by two radiologists. A ﬁrst set of data was obtained at T1 (in 2007–2008) and a second set was obtained
6 to 8 years later at T2 (in 2013–2015). Number of cysts on the right kidney/number of cysts on the left kidney observed in the cortical or medulla area are indicated. The
size of supracentimetric cysts was indicated in brackets.
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pharmacological modulation of ER stress for preserving renal
function and morphology (15,36). In addition, better control of
metabolism could be crucial for preventing the progression of re-
nal damage. As suggested for diabetic nephropathy, fat accumula-
tion in K.G6pc-/- kidneys probably causes renal damage due to
lipotoxicity and oxidative stress (37,38). Moreover, the progression
of renal damage has been recently associated with dyslipidemia
(39). In this cohort, hyperlipidaemia tended to be higher in the
groups of patients with renal dysfunction (Table 3, Groups 2 and
3), while more than 50% of these patients were treated with lipid-
lowering drugs. The synergistic effects of lipid-lowering drugs and
blockers of the RAS system in renal protection have been docu-
mented in diabetic patients (40). In addition, the overproduction of
uric acid by GSDIa kidneys (due to PPP activation) possibly contrib-
utes to the development of CKD. Indeed, uric acid exerts a deleteri-
ous effect on renal tubular cells by inducing EMT (41). The
treatment of hyperuricemia with allopurinol was reported to pre-
serve kidney function (7). Thus, a combined therapy including al-
lopurinol, ACE-inhibitors and lipid-lowering drugs has been
proposed to slow down CKD in patients with cysts. Despite this
combined treatment, three GSDI patients developed renal failure.
As CKD appears in young GSDI adults or earlier (8,9), a combined
therapy from the youngest age could be more efﬁcient, in order to
obtain preventive effects rather than curative results. This sug-
gests that care management of GSDI patients should be coordi-
nated by a paediatrician and a nephrologist from the youngest
age. It is noteworthy that the ACE-inhibitors signiﬁcantly delayed
the progression of renal damage only in the cases where the ther-
apy was given right when glomerular hyperﬁltration was de-
tected (39,42). Nephrology recommendations were reported in the
clinical practice guidelines of the American College of Medical
Genetics and Genomics (6). In addition to these recommenda-
tions, systematic observations of cyst development by kidney
imaging should provide a better estimation of the progression of
the disease, independently of biochemical markers. Indeed, until
recently, abdominal real-time ultrasonography was performed
occasionally in order to estimate the enlargement of the kidneys
and detect nephrolithiasis or nephrocalcinosis. The quality of the
images was not sufﬁcient to precisely detect cysts. More recently,
the detection of renal cysts has been facilitated by improved ab-
dominal imaging techniques (higher resolution), such as MRI.
Interestingly, imaging of the kidneys has been systematically pro-
posed once a year in patients with GSDI. This allowed us to detect
cysts in patients with advanced stage of CKD, before the develop-
ment of renal failure. Thus renal imaging by MRI should be per-
formed once a year to increase the likelihood of detecting renal
cysts in GSDI patients. It is noteworthy that cysts were detected
in young adult GSDI patients, as well as in older patients, who all
developed severe impairment of kidney function. No cysts were
observed in patients with early kidney impairment. Thus, our re-
sults suggest that the appearance of cysts is strongly linked to
the progression of CKD in GSDI.
In conclusion, the renal pathology of GSDI is characterized
by the progressive development of polycystic kidneys, leading
to the development of irreversible renal failure in a late stage of
the disease. Interestingly, K.G6pc-/-mice developed all of the
hallmarks of the nephropathy observed in GSDIa patients. Thus
they can be a useful tool in future studies relating to the phar-
macological treatment of CKD.
Materials and Methods
Patients
A cohort of 32 patients with GSDI was reviewed retrospectively.
All cases of GSDI with mutations were identiﬁed at Antoine
Figure 7. Proposed model for the progression of CKD in GSDI. The accumulation of G6P in tubules induces the activation of metabolic pathways, such as glycogen syn-
thesis, de novo lipogenesis (DNL), and the pentose phosphate pathway. These dysregulations lead to the accumulation of glycogen and lipids and to inﬂammation. This
is associated with the activation of the renin-angiotensin system, which could account for the increased expression of the pro-ﬁbrotic factor TGF-b1. Ultimately, the
progression of tubular and interstitial ﬁbrosis and glomerular sclerosis leads to the development of polycystic kidneys. Blue cells around glomeruli represent the
mesangial expansion.
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Beclere Hospital (Clamart), which is the reference centre for rare
diseases of hepatic metabolism. Seven patients of this cohort (i.e.
22%) developed renal cysts, which were detected by abdominal
real-time ultrasonography and MRI. These examinations are sys-
tematically proposed once a year. For this study, the images were
retrospectively reviewed on the Picture Archiving and
Communication System (PACS), the radiology software, since
2007–2008. To count the number of cysts, two radiologists re-
corded any cyst detected by axial T2-weighted images (Table 5).
The clinical and biochemical parameters of these patients, shown
in Tables 3 and 4, were collected in 2015. Urine was collected over
24h. Urinary albumin and protein excretion are expressed as a ra-
tio to creatinine to account for differences in urinary dilution.
The eGFR was calculated using the CKI-EPI formula (43).
Generation of kidney-speciﬁc G6pc knock-out mice
Deﬁciency in renal G6Pase was obtained by speciﬁc deletion of
G6pc exon 3 in the kidney as previously described (12). Adult
male (6–8 weeks old) B6.G6pclox/lox.KapcreERT2/w and C57Bl/6J
mice (Charles Rivers Laboratories, L’Arbresle, France) were in-
traperitoneally injected daily with 1mg of tamoxifen on ﬁve
consecutive days to obtain K-G6pc-/- and wild-type (WT) mice,
respectively (12). Mice were housed in the animal facility of
Lyon 1 University under temperature controlled (22 C) condi-
tions and with a 12h/12h light/dark cycle. Mice had free access
to water and standard chow (A04 Safe, Augy, France). They were
studied from 9 to 18 months after tamoxifen treatment. After
6h of fasting (with continuous access to water), mice were killed
by cervical dislocation. A piece of fresh kidney was ﬁxed in
formaldehyde (for histology) or glutaraldehyde (for transmis-
sion electron microscopy - TEM). The rest of the kidney was fro-
zen by freeze-clamping in liquid nitrogen, and then stored at
80 C. All the procedures were performed in accordance with
the principles and guidelines established by the European
Convention for the Protection of Laboratory Animals. The re-
gional animal care committee (C2EA-55, Universite´ Lyon 1,
Lyon) approved all the experiments.
Histological analysis
Formalin-ﬁxed and parafﬁn-embedded kidneys were cut in 4
mm thick sections and stained with hematoxylin and eosin
(H&E), or periodic acid Schiff (PAS) staining, or Masson’s tri-
chrome staining. Cross-sections (10 mm thick) were obtained
from frozen, OCT-embedded tissues and stained with Sudan
red. The slides were examined under a Coolscope microscope
(Nikon). Section preparations and staining were performed by
the “Centre d’histopathologie du petit animal” (Anipath) -
University Lyon 1 Laennec, Lyon.
Transmission electron microscopy
A piece of kidney cortex was cut into smaller pieces (1mm3) and
ﬁxed in 2% glutaraldehyde at 4 C. Ultrathin sections (approxi-
mately 70nm thick) were cut on a Reichert ultracut E (Leica) ul-
tramicrotome, mounted on 200 mesh copper grids coated with
1:1,000 polylysine, stabilized for 1day at room temperature (RT)
and contrasted with uranyl acetate and lead citrate by the
CIQLE platform (Lyon, Laennec). Sections were examined with a
Jeol 1400JEM (Tokyo, Japan) transmission electron microscope
equipped with an Orius 1000 camera and Digital Micrograph.
Four kidney samples were prepared from each group of mice.
Ten glomerular sections from each mouse were documented
and the thickness of the basal membrane was measured and
noted at 5 random spots.
Plasma parameters
Blood was withdrawn by submandibular bleeding using a lancet
after 6h of fasting and collected in EDTA (0.5M, pH8.0). Plasma
triglyceride, cholesterol and uric acid concentrations were de-
termined with Biome´rieux colorimetric kits (Marcy l’Etoile,
France). Blood urea nitrogen concentration was measured using
a BioAssay Systems colorimetric kit (Hayward, CA, USA).
Urine parameters
Mice were housed in individual metabolic cages (UgoBasile,
Comerio, Italy) for 24h for acclimation before the experiment.
Urine was collected for 24h. Urine urea, creatinine and electro-
lytes were measured in an automatic analyzer (Konelab, Thermo,
France). Albuminuria was assessed using a mouse albumin Elisa
kit (Neobiotech) and the uric acid concentration was determined
using a colorimetric kit (Biome´rieux, Marcy l’Etoile, France). LCN2
levels were assessed using a mouse Lipocalin-2/NGAL Elisa kit
(R&D Systems, Abingdon, UK). Urine pH was determined using
strips with DpH¼ 0.2. Oxalate was measured using gas chroma-
tography mass spectrometry with stable isotope dilution. Citrates
were assessed by an enzymatic method using a commercial set
(R-Biopharm AG, Darmstadt, Germany).
Gene expression analysis
Western blot analyses were carried out using rabbit polyclonal
antibodies against Podocin (Abcam, 1:5,000), Nephrin (Abcam,
1:5,000), E-cadherin (Cell Signalling, 1:1,000), b-catenin (Cell
Signalling, 1:1,000), Vimentin (Cell Signalling, 1:1,000), GPX
(Abcam, 1:1,000), Catalase (Abcam, 1:2,000), and Histone H3 (Cell
Signalling, 1:2,000). Total RNA was isolated according to the
Trizol protocol (Invitrogen Life Technologies, Saint Aubin,
France). Reverse transcription was done using the Qiagen
Quantitec Reverse Transcription kit. Real-time PCRs were per-
formed using sequence-speciﬁc primers with SsoAdvancedTM
Universal SYBRVR Green Supermix in a CFX ConnectTM Real-
Time System (Bio-Rad). The mouse ribosomal protein ml 19
transcript (Rpl19) was used as reference. Primer sequences are
indicated in Supplementary Material, Table S2.
Statistics
The results are reported as the mean6 s.e.m. Groups were com-
pared using two-way ANOVA followed by Tukey’s post hoc test
(against all groups), except for the quantiﬁcation analyses by
Western Blot. An unpaired two-tailed a Student’s t test was per-
formed for Western Blot analyses. Differences were considered
to be statistically signiﬁcant at P-value < 0.05.
Study approval
The regional animal care committee (C2EA-55, Universite´ Lyon 1,
Lyon) approved all the experiments. Written informed consent
was obtained from participants prior to inclusion in the study.
Supplementary Material
Supplementary Material is available at HMG Online.
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Supplemental Figure 1: 
Figure S1: Relative weight gain of wild-type mice (white square) and K.G6pc-/- mice 
(black square) after the tamoxifen treatment (T=0). Data are expressed as the mean 
± s.e.m. Significant differences between WT and K.G6pc-/- mice are indicated as **, 
p<0.01. Significant differences between the weight of 14 month-aged K.G6pc-/-  mice 
and older K.G6pc-/- mice are indicated as $$, p<0.01 and $$$, p<0.001.  
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Supplemental Figure 2: 
 
 
 
Figure S2: Water intake (A) and food intake (B) of WT (white bars) and K.G6pc-/- 
(black bars) mice at 9, 15 and 18 months after tamoxifen treatment.  Parameters 
were measured on individual mice during 24h. n=5-7 mice. Significant differences 
between WT and K.G6pc-/- mice are indicated as *, p<0.05. Groups were compared 
using two-way ANOVA followed by Tukey’s post hoc test.  
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Figure S3: Lipocalin 2 expression in the kidneys of WT (black circle) and K.G6pc-/- 
(white circle) mice at 9, 15 and 18 months after tamoxifen treatment.  The expression 
of Lcn 2 mRNA in K.G6pc-/- mice was expressed relatively to WT mice. N=5-8. Data 
are expressed as the mean ± s.e.m. Significant differences between WT and K.G6pc-
/- mice are indicated as *, p<0.05 and **, p<0.01. Groups were compared using two-
way ANOVA followed by Tukey’s post hoc test.  
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Supplemental Figure 4: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4: Structure of glomeruli of WT and K.G6pc-/- kidneys. PAS-stained 
kidneys from WT (a, c, e) and K.G6pc-/- (b, d, f) mice at 9, 15 and 18 months 
after tamoxifen treatment. Scale bars = 20 µm.  
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Figure S5: Decrease in the quantity of antioxidant enzymes in the kidneys of WT and 
K.G6pc-/- mice at 9, 15 and 18 months after tamoxifen treatment. Representative 
western blot of GPx, Catalase and Histone H3 (referent protein) were shown on the 
left. Quantification analyses of western blot, shown on the right, were performed by 
densitometry (t-student test). Data are expressed as the mean ± s.e.m. Significant 
differences between WT mice and K.G6pc-/- mice are indicated as **, p<0.01. 
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Figure S6: Prevalence of renal dysfunction and cyst development in GSDI patients 
at different ages.  
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Supplemental Table 1: Urinary parameters of wild-type and K-G6pc-/- mice after 9, 
15 and 18 months of G6pc deletion? 
?
?
?
?
Data were obtained from mouse urine samples collected during 24h using a 
metabolic cage and are expressed as the mean ± SEM (n = 7-8 mice in each group). 
Significant differences between WT and K-G6pc-/- mice are indicated (p<0.05*, p < 
0.01**, p<0.001***). ND: not determined. Groups were compared using two-way 
ANOVA followed by Tukey’s post hoc test.  
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Chapter III ? The role of lipids in hepatic and renal complications in GSDI 
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?
 GSDI is a disease whose most characteristic feature is excessive glycogen 
accumulation. Nevertheless, it is also characterized by hepatic steatosis, due to strong 
activation of lipid synthesis and a decrease in lipid oxidation (Bandsma et al., 2008, 
2014; Derks and van Rijn, 2015; Mutel et al., 2011a). Strong lipid accumulation is 
known to induce hepatic injury and even tumor development, as observed in diabetic 
and obese patients (Alkhouri et al., 2009; Baffy, 2013; Baffy et al., 2012; El-Serag et al., 
2006). Similarly, GSDI kidneys present strong lipid accumulation also due to increased 
lipid synthesis?and decreased lipid oxidation (Clar et al., 2014; Rajas et al., 2015). Thus 
lipids were suggested to play an important role in GSDI hepatic and renal pathologies, 
yet this role was never fully dissociated from the negative effects of excessive glycogen.  
 To highlight the role of lipids in GSDI hepatic and renal complications, L.G6pc-/- 
and K.G6pc-/- mice were submitted to a HF/HS diet, in order to exacerbate lipid 
accumulation in the liver and the kidneys, respectively. Interestingly, increased lipid 
content led to further injury in both organs, even though glycogen levels remained 
unchanged in the liver and even decreased in the kidneys. 
On the other hand, we studied liver and kidney injury in L.G6pc-/- and K.G6pc-/- 
mice treated with a lipid-lowering drug, fenofibrate. Fenofibrate is a pharmacological 
???????? ??? ??????????h is the main activator of lipid oxidation (Balfour et al., 1990; 
Montagner et al., 2016). As expected, we observed an increase in lipid oxidation in 
L.G6pc-/- livers and K.G6pc-/- kidneys, ???????????? ??? ??????????? ????????? ??? ????? 
and its target genes. Furthermore, PPAR? activation by fenofibrate led to an increase in 
lipid synthesis. This indicated an increase in lipid turnover in both the liver and the 
kidneys, resulting in normalization of hepatic and renal lipid content. Interestingly, since 
lipid turnover was increased, G6P accumulated in the cell was diverted from glycogen 
metabolism to the lipid metabolism, resulting in a decrease in glycogen synthesis. 
Therefore, glycogen levels were normalized in L.G6pc-/- livers of mice treated with 
fenofibrate, and were drastically decreased in the kidneys of K.G6pc-/- mice treated with 
fenofibrate.  
Finally, a decrease in lipids accumulated in the liver of L.G6pc-/- mice led to the 
decrease of hepatic injury markers, normalization of the histology of the liver and a 
 ???????????????????????????????????????????? ?????????? ??????? ???????????????????
??????????????????????????
In non-treated GSDI hepatocytes and renal tubular cells the loss of glucose-6 phosphatase (G6Pase) 
stimulates glucose-6 phosphate (G6P) accumulation leading to a subsequent activation of glycogen and 
lipid synthesis. These result in strong glycogen and lipid accumulation, respectively, and lipid 
accumulation is further promoted by lipid oxidation inhibition. Thus lipid accumulation results in liver / 
kidney injury, liver tumor suppressor loss and kidney fibrosis. Fenofibrate-induced lipid oxidation 
increases the turnover of lipids in the cell and results in decreased lipid accumulation, as well as 
subsequent decrease in liver and kidney injury. Furthermore, excessive G6P is diverted from glycogen 
synthesis toward lipid metabolism, resulting in a decrease of glycogen synthesis and accumulation. 
(Monteillet*, Gjorgjieva* et al., submitted; *co-authors) 
 
 
???
?
restoration of tumor suppressor gene expression. Moreover, decreased renal lipid 
content led to a normalization of renal function parameters, an inhibition of the pro-
fibrotic RAS / TGF-?1 pathway and a subsequent prevention of fibrosis development in 
K.G6pc-/- mice. 
In conclusion, while we cannot exclude glycogen and other hepatic and renal 
alterations as potential triggers in organ injury, lipids seem to have a key role in the 
development of these pathologies. Thus maintaining quasi-normal lipid levels in GSDI 
through dietary therapy management and / or with lipid-lowering drugs is a crucial 
strategy to avoid premature development of GSDI long-term complications (Figure 66). 
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SUMMARY 
Glycogen storage disease type I (GSDI) is a genetic disease, characterized by 
excessive glycogen and lipid accumulation in the liver and kidneys. These metabolic 
perturbations lead to long-term complications, i.e. non-alcoholic fatty liver disease 
(NAFLD) and chronic kidney disease (CKD). Here, we show the central role of ectopic 
lipids in the development of liver injury and CKD. Exacerbated lipid accumulation upon 
high-calorie diet strongly accelerated hepatic and renal pathologies in mouse models of 
GSDI, while glycogen contents remained unchanged in the liver or even decreased in 
the kidneys. Interestingly, the activation of lipid oxidation by a PPAR?-agonist led to 
decreased lipid accumulation and prevented the development of NAFLD and CKD. In 
addition, inducing lipid turnover redirected glucose metabolism, resulting in decreased 
glycogen synthesis. To conclude, our study highlights the crucial role that lipids play in 
hepatic and renal GSDI pathologies, demonstrating the importance of lipid-lowering 
treatments in GSDI. 
 
Key words: metabolic disease, steatosis, non-alcoholic fatty liver disease, chronic 
kidney disease, glycogen, glucose and lipid metabolism, fenofibrate, PPAR???fibrosis. 
  
? ??
INTRODUCTION 
Lipid accumulation in non-adipose tissues can induce organ damage and dysfunction 
(Schaffer, 2003).  Abnormal lipid content observed in many metabolic diseases, such as 
non-alcoholic fatty liver disease (NAFLD), diabetes and obesity, is responsible for cell 
injury, inflammation, necrosis and activation of pathological pathways, due to lipotoxicity 
(Asrih and Jornayvaz, 2013; Park et al., 2010; Streba et al., 2015).  
The ectopic accumulation of lipid droplets in the liver and kidneys is an important 
feature of a rare disease named Glycogen Storage Disease type I (GSDI) (Gjorgjieva et 
al., 2016a; Mutel et al., 2011). GSDI is due to glucose-6 phosphatase (G6Pase) 
deficiency, leading to severe hypoglycemia during short fasts (Chou, 2001; Froissart et 
al., 2011; Kishnani et al., 2014). G6Pase operates the hydrolysis of glucose-6 
phosphate (G6P) in glucose, and it allows the liver and kidneys, the main organs 
responsible for endogenous glucose production, to release glucose in the blood and 
regulate plasma glucose concentration (Soty et al., 2017), Mutations in the gene 
encoding the catalytic subunit of G6Pase (G6PC) are responsible for GSD type Ia and 
mutations in SLC37A4, encoding the glucose-6 phosphate translocase (G6PT), result in 
GSD type Ib (Bruni et al., 1999; Lei et al., 1995). The lack of G6Pase induces G6P 
accumulation in the liver and kidneys, leading to metabolic reprogramming in these 
organs (Gjorgjieva et al., 2016b). The first consequence of G6P increase is abnormal 
accumulation of glycogen in both organs (Clar et al., 2014; Kishnani et al., 2014; Mutel 
et al., 2011; Rake et al., 2002), which gives its name to the disease. However, the 
hepatic and renal lipid metabolism is also altered, characterized by an increase in de 
novo lipogenesis and fatty acid chain elongation, associated with a decrease in fatty 
? ??
acid oxidation (Bandsma et al., 2008; Clar et al., 2014; Gjorgjieva et al., 2016a; Mutel et 
al., 2011; Rajas et al., 2013). Furthermore, a delay in the export of very low density 
lipoproteins (VLDL) has been reported in GSDI patients (Bandsma et al., 2008).  
All of these phenomena lead to hepatic steatosis, characterized by a low-inflammatory 
state but no fibrosis in patients (Bandsma et al., 2014; Derks and van Rijn, 2015), as 
well as excessive lipid deposition in the kidney cortex (Clar et al., 2014). Interestingly, 
even in the absence of liver fibrosis, most adult patients with GSDI develop 
hepatocellular adenomas (HCA), which can later transform in hepatocellular carcinomas 
(HCC) (Calderaro et al., 2013; Labrune et al., 1997). Moreover, lipid deposition in the 
kidneys could play a major role in the development of a chronic kidney disease (CKD) in 
GSDI, as observed in diabetic CKD (Clar et al., 2014). Indeed, in both diabetes and 
GSDI, lipids are responsible for the induction of pro-fibrotic pathways, entailing renal 
fibrosis and in some cases renal failure (Gjorgjieva et al., 2016a; Rajas et al., 2013; Yiu 
et al., 2008). Thus almost 70% of young adult GSDI patients show first signs of CKD, 
i.e. microalbuminuria and glomerular hyperfiltration, which can progress to kidney failure 
with age (Froissart et al., 2011; Gjorgjieva et al., 2016a; Kishnani et al., 2014). 
Importantly, the extent to which glycogen and lipid accumulations are involved in the 
long-term GSDI complications remains unclear. Thereby, modulating the lipid content in 
both the liver and kidneys could reveal the degree of implication of lipids in the 
development of the hepatic and renal GSDI pathologies. Fenofibrate is a lipid-lowering 
drug, acting as an agonist of the Peroxisome Proliferator Activat??? ????????? ??
???????????????????????????????????????????????(Duval et al., 2007)????????????????????????
catabolism by stimulating fatty acid transport, as well as lipid oxidation (Kersten, 2014; 
? ??
Montagner et al., 2016; Pawlak et al., 2015). In mouse models of NAFLD, fenofibrate 
reduces hepatic steatosis and inflammation (Kostapanos et al., 2013a; Pawlak et al., 
2015; van der Veen et al., 2017). Human data from large clinical trials on NAFLD are 
lacking. However, several studies reported that fenofibrate treatment leads to weight 
loss and improves vascular circulation in obese and/or diabetic patients (Kostapanos et 
al., 2013a; Najib, 2002). Interestingly, some studies in obese and/or diabetic patients 
have suggested renoprotective effects of fenofibrate, as illustrated by the prevention of 
nephropathy (Kostapanos et al., 2013b). Renal benefits of fenofibrate have also been 
suggested in db/db mice (Hong et al., 2014; Park et al., 2006) and high-fat diet induced 
obese mice (Sohn et al., 2017; Tanaka et al., 2011). Therefore, lowering ectopically 
accumulated lipids could be beneficial in a variety of metabolic diseases. 
In order to elucidate the role of lipids in the development of hepatic and renal 
complications in GSDIa, we first investigated whether an exacerbation of lipid 
accumulation could accelerate liver and kidney injury in mouse models of GSDIa. 
Secondly, in the same mouse models, we examined whether lipid-lowering via 
fenofibrate could prevent or delay NAFLD and CKD. Previously, we developed two 
mouse models of GSDIa.  L.G6pc-/- mice, in which G6pc was deleted specifically in the 
liver, develop all hallmarks of GSDIa hepatic NAFLD-like complications (Mutel et al., 
2011). K.G6pc-/-mice, in which G6pc was deleted specifically in the kidneys, developed 
first signs of CKD after 6 months of G6pc deletion (Clar et al., 2014). Thus these two 
mouse models are ideally suited for unraveling the molecular mechanisms underlying 
hepatic and renal complications in GSDIa.  
? ??
RESULTS 
High fat / high sucrose diet aggravates ectopic lipid accumulation and 
exacerbates hepatic and renal complications in GSDIa mice 
To elucidate the role of lipids in GSDIa hepatic and renal pathologies, we decided to 
exacerbate lipid accumulation in both the liver and kidneys of L.G6pc-/- and K.G6pc-/- 
mice with a high fat / high sucrose (HF/HS) diet. The progression of the hepatic and 
renal pathologies with the HF/HS diet was compared with L.G6pc-/- and K.G6pc-/- mice 
fed a standard diet. As previously observed, L.G6pc-/- mice fed a standard diet 
developed marked steatosis as indicated by elevated triglyceride (TG) content in the 
liver, while K.G6pc-/- mice exhibited a discrete TG accumulation in the kidneys (Fig.1A). 
As expected, hepatic and renal lipid accumulation was increased when L.G6pc-/- and 
K.G6pc-/- mice were fed a HF/HS diet, as illustrated by the significant increase in 
hepatic and renal TG contents (Fig.1A). Strikingly, HF/HS diet exacerbated liver injury 
and CKD that were characteristic of L.G6pc-/- and K.G6pc-/- mice, respectively (Fig.1B-
D). Accordingly, assessment of liver injury markers showed a significant increase in 
plasmatic aspartate transaminase (AST) and alanine transaminase (ALT) activities in 
L.G6pc-/- mice fed a HF/HS diet, compared to a standard diet (Fig.1B). Nephropathy 
was also worsened by the HF/HS diet, since urinary excretion of albumin and lipocalin 
2, two markers of renal injury, was higher than that observed in K.G6pc-/- fed a 
standard diet (Fig.1C). In accordance with the loss of renal function, marked fibrosis 
was observed in the kidneys of HF/HS-fed K.G6pc-/- mice, while fibrosis was more 
discrete in the kidneys of standard-fed K.G6pc-/- mice (Fig.1D). Interestingly, the 
worsening of hepatic injury and CKD was independent of glycogen content. Indeed, the 
hepatic glycogen content in L.G6pc-/-mice fed a HF/HS diet, although high compared to 
? ??
WT mice, was similar to that observed in L.G6pc-/- mice fed a standard diet (Fig.1E). 
Moreover, renal glycogen content was drastically decreased in K.G6pc-/- mice fed a 
HF/HS diet, compared to K.G6pc-/- mice fed a standard diet (Fig.1E). These results 
suggest a critical role of ectopic lipid accumulation in the development of hepatic and 
renal pathologies in GSDIa, independently of glycogen storage.  
 
Fenofibrate exerts a blood lipid-lowering effect in both L.G6pc-/- and K.G6pc-/- 
mice. 
?
To further assess the role of lipids, L.G6pc-/- and K.G6pc-/- mice fed a standard diet 
were treated with a lipid-lowering drug fenofibrate. This treatment was initiated at 6 
months after G6pc deletion, the starting point of the first signs of long-term hepatic (i.e. 
NAFLD) and renal (i.e. microalbuminuria) pathologies (Clar et al., 2014; Mutel et al., 
2011), and was continued during 3 months.  
The lipid-lowering effect of fenofibrate was confirmed by the assessment of several 
plasmatic parameters in L.G6pc-/- and K.G6pc-/- mice, compared to WT mice fed a 
standard diet. While hypertriglyceridemia was observed right after G6pc deletion in 
L.G6pc-/- mice (Mutel et al., 2011), plasmatic TG levels in L.G6pc-/- mice and K.G6pc-/- 
mice were similar to those in WT mice after 9 months of G6pc deletion (Table 1), as 
previously shown (Gjorgjieva et al., 2016a; Mutel et al., 2011). Nevertheless, the levels 
of plasmatic TG and non-esterified fatty acids (NEFA) were strongly reduced by 
fenofibrate (Table 1). Moreover, L.G6pc-/- and K.G6pc-/- mice showed a 20% decrease 
in body weight during fenofibrate treatment, compared to untreated mice (Table 1). 
? ??
Taken together, these results confirmed the lipid-lowering effect of fenofibrate. 
Interestingly, cholesterol level in L.G6pc-/- mice was slightly increased under 
fenofibrate;?this could be explained by the fact that fenofibrate is known to increase the 
synthesis of the HDL cholesterol (van der Hoogt et al., 2007). Furthermore, as 
expected, L.G6pc-/- mice exhibited hypoglycemia in the post-prandial state (6h-food 
deprivation), since they are unable to mobilize their glycogen stores (Mutel et al., 2011), 
and fenofibrate was not capable of normalizing this parameter (Table 1). K.G6pc-/- mice 
showed similar blood glucose as WT mice in the absence or presence of fenofibrate. 
Concomitantly, L.G6pc-/- and K.G6pc-/- mice had increased plasma ketone body 
concentration, which was further increased with fenofibrate. Finally, plasmatic uric acid 
concentration, which was slightly increased in K.G6pc-/- mice compared to WT, was 
further increased with fenofibrate and had a tendency to increase in fenofibrate-treated 
L.G6pc-/- mice (Table 1). 
 
Fenofibrate normalizes hepatic and renal triglycerides in L.G6pc-/- and K.G6pc-/- 
mice 
Next, lipid metabolism in GSDIa liver and GSDIa kidneys was analyzed to 
characterize the lipid-lowering effect of fenofibrate in these organs. As expected, lipid 
catabolism was strongly induced in both L.G6pc-/- livers and K.G6pc-/- kidneys after the 
treatment with fenofibrate, compared to untreated L.G6pc-/- and K.G6pc-/- mice, 
respectively. Indeed????????????????????????????? ????????? ??? ???? ???????????????-/- 
mice treated with fenofibrate (Fig.2A), associated with a restoration of Ppara gene 
expression (Fig.2B). Concomitantly, a strong increase in the expression of several 
? ???
genes implicated in lipid catabolism, such as carnitine palmitoyltransferase 1a (Cpt1a), 
fatty acid binding protein 1 (Fabp1), acyl-CoA oxidase 1 (Acox1), acyl-CoA 
dehydrogenase long-chain (Acadl), cytochrome P450 4A10 (Cyp4a10) and cytochrome 
P450 4A14 (Cyp4a14) was observed in the fenofibrate-treated L.G6pc-/- livers (Fig.2B). 
In addition, the expression of Fgf21, a well-known hepatokine up-regulated by 
PPAR??(Badman et al., 2007), was highly increased by fenofibrate, confirming, once 
again, the efficiency of the treatment. Furthermore, in the kidneys of K.G6pc-/- mice 
treated with fenofibrate, we observed a normalization ?????????????????????????the latter 
being decreased in untreated K.G6pc-/- mice (Fig.2C). Thereby, ???????ncrease was 
accompanied with a rise in the expression of Fabp1, Cyp4a10 and Cyp4a14 (Fig.2D), 
resulting in a marked activation of renal lipid catabolism.  
 Since pharmacological activation of PPAR? has also been shown to promote the 
expression of lipogenic genes (Montagner et al., 2016; Oosterveer et al., 2009), we 
analyzed the expression of the key enzymes of de novo lipogenesis. In the liver of 
L.G6pc-/- mice and in the kidneys of K.G6pc-/- mice treated with fenofibrate, we 
observed a high increase in fatty acid synthase (Fasn) and fatty acid elongase 6 
(Elovl6), while both enzymes were already up-regulated in untreated KO-mice, 
compared to WT mice (Fig.3A and B). The expression of stearoyl-CoA desaturase-1 
(Scd1) was also increased after fenofibrate treatment (Fig.3A and B). Concomitantly, an 
increase in the expression of 3-Hydroxy-3-Methylglutaryl-CoA Synthase 2 (Hmgcs2), a 
key enzyme in ketogenesis, was observed with the fenofibrate treatment in both 
L.G6pc-/- and K.G6pc-/- mice (Fig.3A and B), in accordance with the increased 
plasmatic ketone body levels (Table 1). The rise in the expression of genes involved in 
? ???
de novo fatty acid synthesis in L.G6pc-/- fenofibrate-treated livers might be mediated via 
the Carbohydrate-responsive element-binding protein (ChREBP). Indeed, the 
expression of its total and ?? ?????????????was increased in L.G6pc-/- livers treated 
with fenofibrate, compared to untreated L.G6pc-/- liver, while sterol regulatory element-
binding protein 1c (Srebp1c) and Srebp2 expression remained unchanged (Fig.2A). On 
the other hand, lipid synthesis in K.G6pc-/- fenofibrate-treated kidneys might be 
mediated via SREBP1c, since fenofibrate significantly decreased the expression of the 
total Chrebp and Chrebpb mRNA in K.G6pc-/- kidneys, whereas it slightly increased 
Srebp1 expression, and normalized Srebp2 expression (Fig.3B). 
Interestingly, this increase in lipid anabolism did not induce further hepatic and 
renal lipid accumulation. Indeed, we observed a normalization of TG content in the liver 
of L.G6pc-/- mice treated with fenofibrate, compared to untreated L.G6pc-/- mice, which 
exhibited severe hepatic steatosis (Fig.3C). In the kidneys, TG content had a tendency 
to decrease in K.G6pc-/- fenofibrate-treated mice and was similar to that of WT mice 
(Fig.3D). 
In conclusion, these data suggest a stimulation of lipid turnover by fenofibrate, 
resulting in a normalization of lipid content in both the liver and kidneys of GSDIa mice.  
 
? ???
Fenofibrate decreases glycogen synthesis and prevents hepatic and renal 
glycogen accumulation 
 As the modifications of lipid metabolism could have an impact on the whole cell 
energy homeostasis, we next assessed glycogen metabolism in GSDIa liver and 
kidneys. Interestingly, L.G6pc-/- mice presented excessive glycogen accumulation in 
the liver, while fenofibrate-treated L.G6pc-/- mice exhibited normalized hepatic glycogen 
content (Fig.4A). In accordance, L.G6pc-/- mice treated with fenofibrate showed a 
decrease in serine 9 phosphorylation of ???????????????????????????????????, which is 
known to decrease glycogen synthase activity, thereby decreasing glycogen synthesis 
(Fig.4B). In addition, glycogen debranching enzyme (AGL), which was increased in 
untreated L.G6pc-/- mice, was normalized with fenofibrate, suggesting a decrease in 
glycogen degradation (Fig.4B). These results indicated that the decrease in glycogen 
content in fenofibrate-treated L.G6pc-/- livers was probably due to a decrease in 
glycogen synthesis, rather than an increase in degradation. Moreover, hepatic glucose 
content, which was already decreased in L.G6pc-/- mice compared to WT, was further 
decreased in fenofibrate-treated L.G6pc-/- mice (Fig.4C). Glucose transporter 1 
(Slc2a1) expression was decreased in L.G6pc-/- mice treated with fenofibrate, 
compared to untreated L.G6pc-/- mice, while glucose transporter 2 (Slc2a2) expression 
remained unchanged (Fig.4D). As previously observed, glucokinase (Gck) expression 
was decreased in L.G6pc-/- mice (Hijmans et al., 2017). Interestingly, Gck expression 
was further decreased with fenofibrate (Fig.4D). Thus these results suggest a decrease 
in hepatic glucose uptake and phosphorylation, in accordance with the decrease in 
hepatic glucose levels and in glycogen synthesis. Finally, hepatomegaly, which was 
? ???
observed in L.G6pc-/- mice, was further aggravated with fenofibrate (Fig.4E), probably 
due to the proliferation of peroxisomes (observed by transmission electronic microscopy 
in Fig.6B, panel c) ???????? ??? ????? activation in rodents (Balfour et al., 1990; 
Oosterveer et al., 2009) (Fig.3E). 
 As observed in L.G6pc-/- livers, K.G6pc-/- kidneys presented excessive glycogen 
content, which was drastically decreased after fenofibrate treatment (Fig.4F). This was 
associated with a decrease in both glycogen synthesis and degradation, as illustrated 
by the decrease in phospho-??????at Ser9 and AGL levels (Fig.4G). Renal glucose 
content was lower in K.G6pc-/- mice than in WT mice and was further decreased after 
fenofibrate treatment (Fig.4H). This was consistent with concomitant decrease in 
glucose uptake and phosphorylation, highlighted via the decreased expression in 
glucose transporters Slc2a1 and Slc2a2a and in hexokinase enzyme (HK) (Fig.4I). As 
observed in the liver, these data suggest that the decrease in uptake and 
phosphorylation of glucose results in a decrease in glycogen synthesis. Interestingly, 
the decrease in glycogen accumulation in the fenofibrate-treated kidneys was 
associated with a decrease in nephromegaly, which is a hallmark of GSDIa (Fig.4J).  
Fenofibrate treatment prevents nephropathy development in K.G6pc-/- mice 
 In order to investigate whether the decrease in renal lipid content had an effect 
on the nephropathy development, renal structure and function were assessed. As 
mentioned before, K.G6pc-/- mice developed first signs of CKD, i.e. microalbuminuria, 
associated with an increase in urine excretion and renal expression of lipocalin 2 
(Fig.5A and B). In addition, urea and uric acid excretions were slightly increased in 
? ???
K.G6pc-/- mice. Interestingly, renal function was normalized after fenofibrate treatment 
in K.G6pc-/- mice, since we observed a concomitant decrease in albumin, lipocalin 2, 
urea and uric acid excretion (Fig.5A and B). This was in accordance with histological 
observations of the kidneys. Indeed, H&E staining of K.G6pc-/- kidneys showed a 
strong tubular clarification due to lipid and glycogen accumulation in the proximal 
tubules (Fig.5C panel b). Furthermore, strong collagen accumulation was observed 
owing to ??????????????????? ????????? confirming the development of fibrosis (Fig.5C 
panel e). On the contrary, histology features of fenofibrate-treated K.G6pc-/- kidneys 
(Fig.5C panel c) were similar to those in WT mice (Fig.5C panel a). In addition, fibrosis 
was significantly decreased and even nearly absent in the presence of fenofibrate 
(Fig.5C, panel f). 
 As CKD was prevented in K.G6pc-/- mice treated with fenofibrate, we analyzed 
molecular mechanisms behind GSDIa nephropathy, which were characterized in 
previous studies (Clar et al., 2014; Gjorgjieva et al., 2016a). In K.G6pc-/- mice, the 
Renin-Angiotensin system (RAS) was induced, which in turn increased Tgf-?? 
expression, responsible for the activation of the epithelial-mesenchymal transition 
(EMT) and subsequent fibrosis development. Here, renal angiotensinogen (Agt) 
expression was significantly decreased in fenofibrate-treated K.G6pc-/- mice, compared 
to untreated K.G6pc-/- mice (Fig.5D). Consequently, Tgf-?? expression was normalized 
with fenofibrate, indicating a decrease in RAS/TGF-??? ??????????? ????? ??????? was 
confirmed with the decrease in EMT. Indeed, the expression of the epithelial markers E-
????????? ???? ??catenin, which was decreased in untreated K.G6pc-/- kidneys, was 
restored with fenofibrate (Fig.5D). Furthermore, the expression of the mesenchymal 
? ???
markers vimentin (Vim), fibronectin (Fn1), ?-smooth muscle actin 2 (Acta2) and 
plasminogen activator inhibitor 1 (Pai1), which was increased in K.G6pc-/- kidneys, was 
significantly reduced with the fenofibrate treatment (Fig.5D). 
 In conclusion, these results strongly suggest that fenofibrate down-regulated the 
RAS/TGF-???pathway of signalization, subsequently inhibiting the EMT process. This 
inhibition markedly prevents renal fibrosis and thereby maintains the integrity of renal 
function. 
Liver injury is prevented by fenofibrate in L.G6pc-/- mice 
As hepatic steatosis was markedly decreased by fenofibrate in L.G6pc-/- livers, 
liver structure and function were further characterized. Histological analyses confirmed 
a marked accumulation of lipid droplets and glycogen in L.G6pc-/- livers (Fig.6A and B; 
panels b and e), which was strongly reduced with the fenofibrate treatment (Fig.6A and 
B; panels c and f). Furthermore, TEM revealed a large reduction in the size of the lipid 
vesicles in the livers of fenofibrate-treated L.G6pc-/- mice (Fig.6B panel c), compared to 
untreated L.G6pc-/- mice (Fig.6B panel b). This observation was in accordance with the 
increase in Perilipin 2 (Plin2), an important factor in small lipid droplet formation, in the 
livers of L.G6pc-/- mice treated with fenofibrate (Fig.6C). Interestingly, we observed 
donut-shaped mitochondria (indicator of cellular stress) in the livers of L.G6pc-/- mice 
(Fig.6B panel e) that were observed neither in WT (Fig. 6B panel d), nor in fenofibrate-
treated L.G6pc-/- livers (Fig. 6B panel f).  
Finally, fenofibrate treatment allowed the normalization of liver injury markers, i.e. 
AST and ALT activities, compared to untreated L.G6pc-/- mice (Fig. 6D). Furthermore, 
? ???
previous studies showed that the metabolic reprogramming occurring in GSDIa livers, 
as a consequence of the excessive G6P levels, promotes hepatic tumorigenesis 
(Calderaro et al., 2013; Gjorgjieva et al., 2016b). Recent data have shown a decrease in 
tumor suppressors in L.G6pc-/- livers (unpublished data), in accordance with the pre-
neoplastic status of G6pc-/- hepatocytes (Gjorgjieva et al., 2016b). Interestingly, several 
tumor suppressors, such as AMP-activated protein kinase (AMPK) and phosphatase 
and tensin homolog (PTEN) were down-regulated in L.G6pc-/- livers, while fenofibrate 
restored the their expression to the level observed in WT mice (Fig.6E).   
To conclude, these data suggest that the normalization in hepatic lipid content in 
L.G6pc-/- mice results in the restoration of liver function and rescue of tumor suppressor 
expression. 
DISCUSSION 
GSDI is a pathology characterized by abnormal lipid and glycogen accumulation, 
specifically in the liver and kidneys, leading to hepatic tumor development and CKD with 
age. The deficiency in G6Pase and the subsequent G6P accumulation in hepatocytes 
and renal proximal tubules is at the origin of an important metabolic remodeling 
(Calderaro et al., 2013; Gjorgjieva et al., 2016b; Rajas et al., 2007). Indeed, the 
accumulation of G6P, a common substrate for both lipid and glycogen synthesis, 
markedly induces these anabolic pathways in GSDI. Interestingly, in GSDIa mouse 
models and patients, excessive lipid accumulation is caused by an increase in de novo 
lipogenesis and an impairment of fatty acid oxidation, which is characterized by a 
significant decrease in PPAR? in both the liver and kidneys (Abdul-Wahed et al., 2014; 
? ???
Bandsma et al., 2008; Clar et al., 2014; Mutel et al., 2011). Until now, the degree of 
contribution of lipids in GSDIa pathology was a subject of speculation. In this study, we 
demonstrate that excessive ectopic lipid accumulation in the liver and kidneys is a major 
contributor in the development of long-term complications, i.e. NAFLD and CKD, 
independently of glycogen content. Furthermore, our results indicate an important 
induction in lipid turnover by chronic activation of PPAR??via fenofibrate. This leads to a 
normalization of glycogen stores by remodeling the carbohydrate metabolism through 
the availability of the intermediary substrate G6P. Thus increasing lipid oxidation and 
consequently lipid turnover appears to be an original option to prevent both the hepatic 
and renal GSDIa complications.  
Submitting L.G6pc-/- mice and K.G6pc-/- mice to a HF/HS diet exacerbated the 
hepatic and renal lipid accumulations, whereas glycogen content was not increased in 
the liver and even decreased in the kidneys. Nevertheless, both chronic hepatic and 
renal pathologies were strongly aggravated, suggesting an important role of lipids in the 
induction of GSDIa long-term complications, independently of glycogen content.  
The central role of lipids was confirmed by decreasing ectopic lipid accumulation 
using fenofibrate. Indeed, enhanced PPAR? activity strongly stimulated? the expression 
of genes involved in lipid catabolism in L.G6pc-/- livers and K.G6pc-/- kidneys, that 
entailed a decrease in hepatic and renal TG content and prevention of NAFLD and 
CKD. In the K.G6pc-/- kidneys, this beneficial effect of lipid-lowering was associated 
with the inhibition of RAS and TGF-??? ????????, preventing EMT and thereby, 
tubulointerstitial fibrosis and glomerulosclerosis. These results are in accordance with 
? ???
previous data reporting that fenofibrate prevented the induction of RAS/TGF-?? 
pathway and fibrosis in diabetic and/or obese mice by decreasing lipids (Cheng et al., 
2016; Hong et al., 2014; Li et al., 2010; Park et al., 2006; Tanaka et al., 2011). At the 
molecular level, it was proposed that lipid derivates, such as diacylglycerol and 
ceramides, are potent activators of protein kinase C, leading to the activation of Agt 
expression in the kidneys (Bobulescu, 2010; Koya and King, 1998). In the L.G6pc-/- 
liver, the decrease in steatosis by fenofibrate treatment lowered the risks associated 
with NAFLD, since L.G6pc-/- mice exhibited a decrease in liver injury markers, 
concomitantly with a rescue of hepatocyte histology features. Even though fenofibrate 
seems to prevent the loss of tumor suppressors in L.G6pc-/- livers, a limitation of this 
study is that we did not examine the effect of fenofibrate on the long-term development 
of hepatic tumors. Indeed, fenofibrate has been suggested to play a role in hepatic 
tumorigenesis in rodents (Nesfield et al., 2005; Nishimura et al., 2007), which was 
fortunately not observed in humans (Bonovas et al., 2012; Pawlak et al., 2015). Thus, 
as many studies have demonstrated a strong link between hepatic tumorigenesis and 
NAFLD, like in the case of obesity / diabetes (Baffy, 2013; Streba et al., 2015), we could 
expect to limit HCA /HCC incidence by decreasing lipid accumulation in GSDIa. The 
adverse effects of lipids have also been confirmed in a previous study, since HF/HS diet 
accelerated hepatocarcinogenesis in L.G6pc-/- mice (Rajas et al., 2015). Taking into 
account our results obtained with the HF/HS diet and fenofibrate, these data highlight 
that lipid accumulation is the main contributor to liver injury and CKD in GSDIa, 
independently of excessive glycogen content. Therefore, lipid lowering is a novel 
unconventional strategy that should be particularly considered in GSDIa to prevent, not 
? ???
only hypertriglyceridemia, but also hepatic and renal long-term complications. Currently, 
fenofibrate treatment was only recommended in GSDIa patients who present severe 
hypertriglyceridemia (generally over 10 g/L), in order to lower plasmatic TGs (Froissart 
et al., 2011). Unfortunately, there is no data addressing effects of fibrates on the onset 
of CKD, as well as on hepatic complications in patients with GSDIa. Indeed, most 
patients presenting the first signs of CKD are also generally treated with an inhibitor of 
ACE or an angiotensin receptor analogue (Gjorgjieva et al., 2016a). Therefore, the use 
and the effects of fenofibrate alone in GSDIa patients should be further examined, 
independently of other treatments. 
This study also provides evidence that fenofibrate treatment induced lipid 
turnover since the expression of several genes involved in de novo lipogenesis was 
enhanced concomitantly with increased lipid catabolism in L.G6pc-/- and K.G6pc-/- 
mice. This may protect the liver and kidneys against the putative toxic effects of excess 
intracellular NEFA and their oxidation products (Oosterveer et al., 2009). Moreover, lipid 
turnover induction, by a PPAR? agonist, radically changed glycogen metabolism in 
GSDIa. It is noteworthy that an additional and unexpected benefit of fenofibrate is that 
the treatment markedly decreased hepatic and renal glycogen accumulation observed 
in L.G6pc-/- and K.G6pc-/- mice, respectively. This decrease was not due to an 
increase in glycogen degradation but rather to an inhibition of glycogen synthesis. 
Thereby, we suggest that the glycogen metabolism remodeling by fenofibrate derives 
from the diversion of G6P from glycogen synthesis towards lipid anabolism and thus 
results in a decrease in glycogen synthesis. The decrease in glucose uptake by glucose 
transporters and glucose phosphorylation should also participate to the decrease in 
? ???
G6P availability for glycogen synthesis. These processes may play a key role in the 
correction of nephromegaly observed after treatment.  
In conclusion, this study shows for the first time that the mechanisms involved in 
the development of hepatic and renal long-term complications of GSDIa are mainly 
induced by lipid accumulation, independently of excessive glycogen contents in these 
??????????????????????????????????????????????????????????????????????????????????????
be a therapeutically suitable strategy to prevent the development of GSDIa hepatic and 
renal complications. Therefore, lipid-lowering is a novel unconventional strategy that 
should be particularly considered in GSDIa treatment and that could considerably 
improve life quality and expectancy of GSDIa patients. In addition, a recent overview of 
PPAR? agonist action in human highlighted the potential efficacy of these drugs to treat 
NAFLD (Kersten and Stienstra, 2017). Finally, our results suggest that promoting lipid 
turnover via PPAR? agonists may represent a potential therapeutic target to prevent 
NAFLD and CKD development in GSDIa and other metabolic diseases, such as obesity 
and diabetes.   
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FIGURE LEGENDS 
Figure 1: High fat/high sucrose diet exacerbates hepatic and renal complications 
in GSDIa mice. 
(A) TG content in the livers and kidneys, (B) Plasmatic AST and ALT activities (C) 
Urinary parameters obtained from mouse urine samples collected during 24h (n=5-11 
mice/group). Data were obtained from WT mice fed a standard (STD) diet, and L.G6pc-
/- or K.G6pc-/- mice fed a STD or high fat / high sucrose (HF/HS) diet (n=5-10 
mice/group). (D) Histo???????? ????????? ???????????? ?richrome staining of the kidneys 
from WT and K.G6pc-/- mice fed a STD diet, and K.G6pc-/- mice fed a HF/HS diet (E) 
Glycogen content of livers and kidneys of WT mice fed a STD diet, and L.G6pc-/- or 
? ???
K.G6pc-/- mice fed a STD or HF/HS diet (n=5-8 mice/group). ND= not detected. Data 
???????????????????????????????? Significant differences are indicated as * p<0.05; ** 
p<0.01; *** p<0.001. 
Figure 2: Fenofibrate induces strong lipid catabolism in L.G6pc-/- and K.G6pc-/- 
mice. ?
(A,C) ????????????????????????????????????????????????????????????western Blot (n=4-5 
mice/group). (B,D) Quantitative analyses of hepatic (B) and renal (D) lipid catabolism by 
RT-qPCR. The expression of target mRNA of L.G6pc-/- (B) or K.G6pc-/- (D) mice 
treated or not with fenofibrate is expressed relatively to the WT mice (n=7-8 
mice/group). ????? ???? ?????????? ??? ???? ????? ?? ????? Significant differences are 
indicated as * p<0.05; ** p<0.01; *** p<0.001.  
 
Figure 3: Fenofibrate entails an induction of lipid anabolism in L.G6pc-/- and 
K.G6pc-/- mice.  
(A-B) Quantitative analyses of hepatic lipid (A) and renal (B) anabolism by RT-qPCR. 
The expression of target mRNA of L.G6pc-/- (A) or K.G6pc-/- (B) mice treated or not 
with fenofibrate is expressed relatively to the WT mice (n=7-8 mice/group).  (C-D) 
Triglycerides (TG) content in the livers (C) and kidneys (D) from WT and L.G6pc-/- (C) 
or K.G6pc-/- (D) mice treated or not with fenofibrate (n=5-7 mice/group). Data are 
?????????? ??? ???? ????? ?? ???? Significant differences are indicated as * p<0.05; ** 
p<0.01; *** p<0.001.  
 
? ???
Figure 4: Fenofibrate decreases glycogen synthesis and prevents hepatic and 
renal glycogen accumulation. ?
(A,F) Glycogen content of L.G6pc-/- livers (A) and K.G6pc-/- kidneys (F) treated or not 
with fenofibrate, compared to WT liver / kidney (n=5-7 mice/group). (B-G) Quantitative 
??????????????????????????????????????????????????????????????????????? ????????????
(n=4-5 mice/group). (C,H) Glucose content of L.G6pc-/- livers (C) and K.G6pc-/- kidneys 
(H) treated or not with fenofibrate, compared to WT liver / kidney. (n=5-7 mice/group). 
(D,I) Quantitative analyses of hepatic (D) and renal (I) glucose utilization by RT-qPCR. 
The expression of target mRNA in the L.G6pc-/- livers (D) and K.G6pc-/- kidneys 
treated or not with fenofibrate is expressed relatively to WT liver / kidney (n=7-8 
mice/group). (E,J) Weight of L.G6pc-/- liver (E) and K.G6pc-/- kidney (J) treated or not 
with fenofibrate, compared to WT liver / kidney (n=7-8 mice/group). Data are expressed 
??? ????????? ?? ?????Significant differences are indicated as * p<0.05; ** p<0.01; *** 
p<0.001.  
 
Figure 5: Prevention of nephropathy development by fenofibrate treatment in 
K.G6pc-/- mice. ?
(A) Urinary parameters of WT mice and K.G6pc-/- mice treated or not with fenofibrate. 
Data were obtained from mouse urine samples collected during 24h (n=5-11 
mice/group). (B) Relative lipocalin-2 gene expression in the kidneys of K.G6pc-/- mice 
treated or not with fenofibrate, expressed relatively to WT mice. (C) Histological 
analyses of H&E-staining (panels a-c) and Masso????Trichrome staining (panels d-f) of 
the kidneys from (a,d) WT, (b,e) K.G6pc-/- and (c,f) fenofibrate-treated K.G6pc-/- mice. 
? ???
(D) Quantitative analyses of renal pro-fibrotic pathways by RT-qPCR (n=7-8 
mice/group) and western Blot (n=4-5 mice/group). The expression of target mRNA of 
K.G6pc-/- mice treated or not with fenofibrate is expressed relative to the WT mice. 
????? ???? ?????????? ??? ???? ????? ?? ????? Significant differences are indicated as * 
p<0.05; ** p<0.01; *** p<0.001.  
 
Figure 6: Liver injury is prevented by fenofibrate in L.G6pc-/- mice. 
(A) Histological analysis of H&E-staining of the livers and (B) Transmission electron 
microscopy analysis of hepatocytes from WT (a,d), L.G6pc-/- (b,e) and fenofibrate-
treated L.G6pc-/- (c,f) mice. Arrows show donut-shaped mitochondria. (C) Quantitative 
analysis of Plin2 gene expression by RT-qPCR; (D) Plasmatic AST and ALT activities; 
(E) Quantitative analysis of AMPK phosphorylation (Thr172) by western Blot (n=4-5 
mice/group) and (F) Quantitative analyses of Pten gene expression by RT-qPCR from 
WT and L.G6pc-/- treated or not with fenofibrate. The expression of target mRNA in the 
livers is expressed relative to WT livers (n=7-8 mice/group). Data are expressed as the 
????????????Significant differences are indicated as * p<0.05; ** p<0.01; *** p<0.001.  
 
 
  
? ???
Table 1: Body weight and plasmatic parameters of WT, L.G6pc-/- and K.G6pc-/- mice 
treated or not with fenofibrate. 
  
WT L.G6pc
-/-
 
   L.G6pc
-/- 
+ fenofibrate 
 WT K.G6pc
-/-
 
   K.G6pc
-/-
 
+ fenofibrate 
TG (g/L) 
 
??????????? 
 
??????????? 
 
??????????? 
*** ## 
  
??????????? 
 
??????????? 
 
??????????????
*** # 
NEFA (mg/dL) 
 
?????????? 
 
?????????? 
 
?????????? 
* ## 
  
???????? 
 
?????????? 
 
?????????? 
*** ### 
Cholesterol (g/L) 
 
??????0.2 
 
????????? 
 
????????? 
## 
  
????????? 
 
????????? 
 
????????? 
Glucose (mg/dL) 
 
??????? 
 
?????? 
*** 
 
?????? 
*** 
  
??????? 
 
??????? 
 
??????? 
Ketone bodies 
(nmol/L) 
 
??????????? 
 
??????????? 
* 
 
??????????? 
** 
  
??????????? 
 
????????????
** 
 
????????????
*** ## 
Uric acid (mg/L) 
 
????????? 
 
????????? 
 
?????????? 
  
????????? 
 
?????????? 
* 
 
?????????? 
*** ### 
Body weight (g) 
 
38.7 ????? 
 
36.1
 
????? 
 
 
29.1
 
????? 
*** ### 
  
?????????? 
 
?????????? 
 
 
?????????? 
*** ### 
 
Data were obtained from mice after 6h of ???????? ???? ???? ?????????? ??? ????????? ??
S.E.M. (n=5-14). Significant differences between WT and L.G6pc-/- and between WT 
and K.G6pc-/- are indicated as * p<0.05; ** p<0.01; *** p<0.001. Significant differences 
between L.G6pc-/- and fenofibrate-treated L.G6pc-/- and between K.G6pc-/- and 
fenofibrate-treated K.G6pc-/- are indicated as # p<0.05; # # p<0.01; # # # p<0.001. 
  
? ???
Highlights  
? Exacerbating lipid accumulation aggravated liver / kidney injury in GSDI. 
? Fenofibrate-mediated PPAR? activation induced hepatic and renal lipid turnover. 
? Increased lipid turnover inhibited glycogen synthesis and accumulation. 
? PPAR??mediated metabolic reprograming prevented hepatic and renal GSDI 
complications. 
eTOC Blurb 
In this article, the authors showed a clear aggravation of renal and hepatic GSDI 
pathologies by lipid accumulation exacerbation. On the contrary, a decrease in lipids, 
mediated via a PPAR?-agonist fenofibrate, prevented these complications, highlighting 
the crucial role of lipids in GSDI, independently from glycogen.    
?
?
  
? ???
STAR METHODS 
Experimental model and subject details 
L.G6pc-/- mice and K.G6pc-/- mice were obtained by specific deletion of exon 3 of the 
G6pc in the livers or kidneys, respectively, thanks to an inducible CRE-lox strategy, as 
previously described (Clar et al., 2014; Mutel et al., 2011). Briefly, B6.G6pcex3lox/lox mice 
were crossed with transgenic mice expressing the inducible CREERT2 recombinase 
under the control of the serum albumin promoter (B6.SAcreERT2/w) or under the control of 
the kidney androgen-regulated protein promoter (B6.KapcreERT2/w) to generate L.G6pc-/-
and K.G6pc-/- mice, respectively. CREERT2 recombinase was activated by daily 
intraperitoneal injections of tamoxifen on five consecutive days in 6-8 weeks old male 
B6.G6pclox/lox.SAcreERT2/w and B6.G6pclox/lox.KapcreERT2/w mice, in order to obtain L.G6pc-/- 
and K.G6pc-/- mice, respectively. Male C57Bl/6J mice (Charles Rivers Laboratories) 
were also treated with tamoxifen (here referred to as WT mice). Female mice were not 
used because Kap promoter is under androgenic control. 
Mice were housed in the animal facility of Lyon 1 University (ALECS) under temperature 
?????????????????????????????????with a 12/12h light/dark cycle, in enriched environment 
in groups of 4 to 6 mice. All mouse linage was C57Bl/6J backcrossed (two generations 
per year). Mice were fed a standard (STD) chow diet (A04 diet, Safe, Augy, France). 
After tamoxifen treatment, mice were fed either a STD diet or a HF/HS diet (consisting 
of 36.1% fat, 35% carbohydrates composed by maltodextrine (50%, wt/wt) and sucrose 
(50%, wt/wt), ?????? ?????????? ????????? ??? ???? ??????? ??? ?????????on des Aliments 
?????? ????????? UE0300 INRA, Jouy-en-Josas, France) for 9 months. Fenofibrate-
treated mice were first fed a STD chow diet for 6 months and then a STD diet 
? ???
supplemented with 0.2% fenofibrate (Sigma, wt/wt) (Safe, Augy, France) for additional 3 
months. All mice were killed 9 months after tamoxifen treatment by cervical dislocation 
at 6 h of fasting (with continuous access to water). Tissue was frozen by freeze-
clamping in liquid nitrogen, and then stored at -????????????????????????????????????????
in accordance with the principles and guidelines established by the European 
Convention for the Protection of Laboratory Animals. The regional animal care 
committee (C2EA-???????????????????????????? approved all the experiments.  
Method details 
Histological analysis 
A piece of fresh liver and kidney was fixed in formaldehyde and embedded in paraffin. 
????????-thick sections were stained with hematoxyl????????????? ??????????????????
Trichrome staining. The slides were examined under a Coolscope microscope (Nikon).  
Transmission electron microscopy 
Small pieces of the liver (1mm3??????? ? ?????????? ?????? ?????????????????????????????
The sample was dehydrated in a grade series of ethanol and embedded in an epoxy 
resin. Tissue was surveyed with a series of 70 nm sections and observed with a Jeol 
1400JEM (Tokyo, Japan) transmission electron microscope equipped with a Orius 100 
camera and digital micrograph.  
Urine parameters  
K.G6pc-/- mice were housed in individual metabolic cages (Ugo Basile) for a 24h-
acclimation period before urine collection. Urine production and food intake were 
measured for another 24h period. Urine was collected and stored at -?????? ?????
? ???
concentration was assessed using a BioAssay Systems colorimetric kit (Hayward, CA, 
USA). Uric acid concentration was measured with a colorimetric kit (DiaSys, Holzheim, 
Germany). Albuminuria and lipocalin 2 levels were assessed using a mouse albumin 
ELISA kit (Neobiotech, Clinisciences, Nanterre, France) and a mouse Lipocalin-2/NGAL 
ELISA kit (R&D Systems, Lille, France), respectively.  
Plasma parameters  
Blood was withdrawn by submandibular bleeding using a lancet after 6h of fasting and 
collected into EDTA (0.5M, pH8.0). Blood glucose was measured with an Accu-Check 
Go glucometer (Roche Diagnostic, Meylan, France). Plasma TG, cholesterol, NEFAs, 
and uric acid concentrations were determined with colorimetric kits (DiaSys, Holzheim, 
?????????? ?-hydroxybutyrate concentration, AST and ALT activities were assessed 
with colorimetric kits (Abcam, Cambridge, UK). 
Glycogen assay 
A piece of 100 mg of frozen tissue was added to 8 volumes of perchloric acid 6% and 
crushed with the Fast Prep? system (MP Biomedicals). After a centrifugation at 10,000g 
???? ??????? ??? ????? ???? ???????????????? ????????????????? ????????2CO3 and pH was 
adjusted between 6.5 and 8.5. The solution was then centrifuged at 10,000g for 5 min at 
???????????????????????????????????????????????????mined on the supernatant, by using 
the Keppler and Decker method as previously described (Mithieux et al., 2002) 
Glycogen was partially hydrolyzed with by boiling for 20min in NaOH 0.15M and then 
????????? ????? ???????? ??? ?-????????????????? ???? ??? ??? ?????? ???????? ????????? ????
measured after the addition of 0.7U of hexokinase and glucose-6-phosphate 
deshydrogenase in the presence of NADP+. NADPH production was detected at 340nm.  
? ???
Triglyceride assay 
Hepatic and renal TG were extracted by ?????Folch? procedure. Briefly, a piece of 100 
mg of frozen tissue was added to chloroform/methanol 2/1 solution (1.7mL for 100mg of 
tissue) and crushed with the Fast Prep? system. The solution was centrifuged twice at 
?????????????????????????????????????????????????????????????????????????????????????
were created. The inferior organic phase, which contains TG, was kept. After chloroform 
evaporation, TG ???????????????????????????????????????????????????????????? ??????????
(DiaSys, Holzheim, Germany).    
Western blots 
Western blot analysis were carried out using the whole cell extracts from 50mg of 
tissues lysed in lysis buffer (50 mM Tris pH 7.5, 5 mM MgCl2, 100 mM KCl, 1 mM 
EDTA, 10% glycerol, 1 mM DTT, 1% NP40, protease and phosphatase inhibitors) and 
homogenized thanks to the FastPrep? ???????????????????????????????????????????????????
???????????????????????? Assay Kit???????????????????????????????????????????????????
??????? ???????????? ?-mercaptoethanol and SDS), were separated by 9 or 12%-SDS 
polyacrylamide gel electrophoresis and transferred to PVDF Immobilon membranes 
(Millipore). After 1h-saturation in TBS/0.2% Tween/5% BSA at room temperature, the 
??????????????????????????????????????????????????????????lonal antibodies (see Table-
template 1) diluted in TBS/0.2% Tween/5% BSA. After washing with TBST/Tween 0.2%, 
membranes were incubated (1h at room temperature) with goat anti-rabbit IgG antibody 
linked to peroxidase diluted in TBS/Tween 0,2%/BSA 5%. Membranes were rinsed 
again and exposed to ClarityTM Western ECL Substrate. The visualization and 
? ???
quantification of proteins were performed using the BioRad ChemiDocTM Touch Imaging 
system (Marnes La Coquette, France).  
Gene expression analyses  
A piece of 50 mg of frozen tissue was homogenised thanks to Fast Prep? system and 
total RNAs were isolated according to the Trizol protocol (Invitrogen Life Technologies, 
?????? ??????? ????????? ???????? ?????????????? ???? ????? ??? ???? ??? ????? ?????? ????
Qiagen QuantiTect Reverse Transcription kit. Real-time qPCRs were performed using 
sequence-specific primers with SsoAdvancedTM ????????????????????????????????????
CFX ConnectTM Real-Time System (Bio-Rad, Marnes La Coquette, France). Primer 
sequences are indicated in Table-template 1. 
 
Quantification and statistical analyses  
Western blot quantification 
The spots intensity was determined by densitometry with ChemiDoc Software (Biorad) 
and analysed using the Image LabTM software (Biorad). 
RT-qPCR quantification 
The expression of mRNA was normalized to the mouse ribosomal protein mL19 
transcript (Rpl19) expression thanks to the 2-???????????? The expression of target 
mRNA in the L.G6pc-/- livers and K.G6pc-/- kidneys was expressed relatively to WT 
liver / kidney.  
? ???
Statistical analysis 
???? ???????? ???? ????????? ??? ????????? ?? ????? (standard error of the mean). Groups 
were compared using one-?????????? ????????????????????post hoc test (against all 
groups), except for western Blot analyses. An unpaired two-????????????????????????????
performed for western Blot analyses. Differences were considered to be statistically 
significant at P-value < 0.05. 
Study approval 
The regional animal care committee (C2EA-??????????????????????????????????????????
the experiments performed on lived mice.  
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?KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rabbit monoclonal anti-??????????????
(Thr172) (40H9) 
Cell Signaling 
technology ?????????????? 
Rabbit monoclonal anti- ???????????? Cell Signaling technology ?????????????? 
Rabbit monoclonal anti-????? Abcam ????????Ab8934 RRID:AB_306869 
Rabbit monoclonal anti-AGL Abcam ????????Ab133720 
Rabbit monoclonal anti-phospho-??????(Ser9) 
(D3A4) 
Cell Signaling 
technology ????????#9322 
Rabbit monoclonal anti-????? (27C10) Cell Signaling technology ????????#9315 
Rabbit monoclonal anti-E-cadherin (24E10) Cell Signaling technology ????????#3195 
Rabbit monoclonal anti-?-catenin (D10A8) Cell Signaling technology ?????????8480 
Rabbit monoclonal anti-GAPDH (D16H11) Cell Signaling technology ????????#5174 
Goat secondary anti-rabbit IgG linked to 
peroxidase Biorad ???????????-5046 
Mouse Lipocalin-2/NGA ELISA kit R&D Systems ?????????????? 
Mouse Albumin ELISA kit NeoBiotech Cat ??????-06-0062 
Bacterial and Virus Strains 
   
   
   
   
   
Biological Samples 
   
   
   
   
   
Chemicals, Peptides, and Recombinant Proteins 
   
   
   
   
   
?Critical Commercial Assays 
????????????????????????????? Thermo Scientifique Cat ????????? 
ClarityTM Western ECL Substrate Biorad ???????????-5061 
Trizol Life technologies ???????????????? 
QuantiTect??Reverse Transcription Quiagen ?????????????? 
NEFA FS* DiaSys ?????????????????????930 
Uric acid FS* DiaSys ?????????????????????021 
Cholesterol FS* DiaSys ?????????????????????021 
Triglycerides FS* DiaSys ?????????????????????026 
QuantiChromTMUrea Assay Kit (DIUR-500) BioAssay Systems ????????????-500 
Alanine Transaminase Activity Assay Kit 
(Colorimetric/ Fluorometric) Abcam Cat ???????????? 
Aspartate Aminotransferase Activity Assay Kit Abcam ???????????????? 
Beta Hydroxybutyrate (betaHB) Assay Kit 
(Colorimetric) Abcam ??????????????? 
Deposited Data 
   
   
   
   
   
Experimental Models: Cell Lines 
   
   
   
   
   
Experimental Models: Organisms/Strains 
Mouse : L.G6pc -/-   
Mouse : K.G6pc-/-   
Mouse : WT : C57BL6/J Charles River Laboratory JAX : 000664 
Oligonucleotides 
????-Smooth muscle actin (Acta2) Fw : GTCCCAGACATCAGGGAGTAA Rev : TCGGATACTTCAGCGTCAGGA Eurogentech  
?3-hydro-3-methylglutaryl-
CoenzymeA synthase 2 
Fw : AGCTTTGTGCGTTCCATCAG 
Rev : CCGTATGGGCTTCTGTTCAG Eurogentech  
Acyl-CoenzymeA deshydrogenase 
long chain (Acadl) 
Fw : AGAAGTTCATCCCCCAGATGAC 
Rev : GGCGTTCGTTCTTACTCCTTGT Eurogentech  
Acyl-CoA Oxidase 1 (Acox1) Fw : TGCCAAATTCCCTCATCTTC Rev : CTTGGATGGTAGTCCGGAGA Eurogentech  
Angiotensinogen (Agt) Fw : TTCACTGCTCCAGGCTTTCGTCTA Rev : TTCTCAGTGGCAAGAACTGGGTCA Eurogentech  
Carbohydrate-responsive element-
binding protein - ???????????
(Chrebp - ?? 
Fw : TCTGCAGATCGCGTGGAG 
Rev : CTTGTCCCGGCATAGCAAC Eurogentech  
Carbohydrate-responsive element-
binding protein, CHREBP 
(Chrebp), total 
Fw : GAAGCCACCCTATAGCTCCC 
Rev : CTGGGGACCTAAACAGGAGC Eurogentech  
Carnitine palmitoyltransferase1 
(Cpt1a) 
Fw : ACCTCCATGGCTCAGACAG 
Rev : AGCAGAGGCTCAAGCTGTTCA Eurogentech  
Cytochrome P450 (Cyp4a10) Fw : TCCAGCAGTTCCCATCACCT Rev : TTGCTTCCCCAGAACCATCT Eurogentech  
Cytochrome P450 (Cyp4a14) Fw : TCAGTCTATTTCTGCTGTTC Rev : GAGCTCCTTGTCCTTCAGATGGT Eurogentech  
Fatty acid binding protein (Fabp1) Fw : GTCTCCAGTTCGCACTCCTC Rev :  GCAGAGCCAGGAGAACTTTG Eurogentech  
Fatty acid elongase 6 (Elovl6) Fw : ACAATGGACCTGTCAGCAAA Rev : GTACCAGTGCAGGAAGATCAGT Eurogentech  
Fatty acid synthase, FAS (Fasn) Fw : TTCCAAGACGAAAATGATGC Rev : AATTGTGGGATCAGGAGAGC Eurogentech  
Fibronectin (Fn1) Fw : TGGCTGCCTTCAACTTCTCCT Rev : TGTTTGATCTGGACTGGCAGTTT Eurogentech  
Glucokinase(Gck) Fw : CCCTGAGTGGCTTACAGTTC Rev : :ACGGATGTGAGTGTTGAAGC Eurogentech  
Glucose transporter1, Glut1 
(Slc2a1) 
Fw : GCTGTGCTTATGGGCTTCTC 
Rev : CACATACATGGGCACAAAGC Eurogentech  
?Glucose transporter2, Glut2 
(Slc2a2) 
Fw : TGTACGCAAAACCCGAAGTCT 
Rev : 
CACATTCAAACTGACTTTCTGTTACC 
Eurogentech  
????????????????????????????????? Fw : GAGGACACTGTGGGACTGGT Rev : TCACAGACACCAACCTCAGC Eurogentech  
Perilipin 2 (Plin2) Fw : GACCTTGTGTCCTCCGCTTAT Rev : CAACCGCAATTTGTGGCTC Eurogentech  
Peroxisome proliferator-activated 
???????????????????????????? 
Fw : AGTTCACGCATGTGAAGGCTG 
Rev : TTCCGGTTCTTCTTCTGAATC Eurogentech  
Phosphatase and tensin homolog 
(Pten) 
Fw : TGGGTTGGGAATGGAGGGAATGCT 
Rev : GGACAGCAGCCAATCTCTCGGA Eurogentech  
Plasminogen activator inhibitor 
(Pai1) 
Fw : TTCAGCCCTTGCTTGCCTC 
Rev : ACACTTTTACTCCGAAGTCGGT Eurogentech  
Ribosomal protein mL19 (Rpl19) 
Fw :GGTGACCTGGATGAGAAGGA 
Rev: TTCAGCTTGTGGATGTGCTC 
 
Eurogentech  
Stearoyl-CoA desaturase 1 (Scd1) Fw : TGGGTTGGCTGCTTGTG Rev : GCGTGGGCAGGATGAAG Eurogentech  
Sterol regularory element binding 
protein 1c, SREBP1C (Srebp1c) 
Fw : GCAGCCACCATCTAGCCTG 
Rev : CAGCAGTGAGTCTGCCTTGAT Eurogentech  
Sterol regularory element binding 
protein 2, SREBP2 (Srebp2) 
Fw : GCAGCAACGGGACCATTCT 
Rev : CCCCATGACTAAGTCCTTCAACT Eurogentech  
??????????????????????????????
??????? 
Fw : CAACAATTCCTGGCGTTACCTTGG 
Rev : GAAAGCCCTGTATTCCGTCTCCTT Eurogentech  
Vimentin (Vim) Fw : CGGCTGCGAGAGAAATTGC Rev : CCACTTTCCGTTCAAGGTCAAG Eurogentech  
Recombinant DNA 
   
   
   
   
   
Software and Algorithms 
ChemiDoc Software Biorad Version 1.2.0.12 
?Image Lab Biorad Version 5.2.1 ; RRID: SCR_014210 
ImageJ http://imagej.nih.gov/ij Version 1.47 ; RRID: SCR_003070 
GraphPad Prism 5 http://www.graphpad.co
m/ 
Version 5.04 ; RRID: 
SCR_002798 
Other 
Standard diet SAFE Laboratory A04 
Fenofibrate-enriched diet INRA N/A 
High-Fat/High Sucrose diet INRA N/A 
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 Over the last decades, several advancements in the knowledge and 
management of GSDI have been achieved. Indeed, dietary treatment has greatly 
improved life expectancy of GSDI patients. Hypoglycemic episodes are rarer with this 
treatment and an effect on the long-term complications has also been reported 
(Kishnani et al., 2014; Okechuku et al., 2017; Rake et al., 2002a, 2002b). Nevertheless, 
while some patients respond very well, this regimen is not completely effective in 
abolishing all of the complications of GSDI. Furthermore, by expanding the life span of 
GSDI patients, hepatic complications become more frequent and new types of 
complications arise, such as renal cysts, which were not observed previously. Thus in 
order to treat GSDI and to propose a curative strategy, we need to unravel all of the 
underlying molecular mechanisms leading to hepatic and renal complications. Since 
GSDI is a rare disease, the number of patients is restrained and does not allow us to 
study important cohort studies. Furthermore, tissue biopsy needed for research 
purposes is not largely available due to these reasons, but also due to the risks 
associated with the sampling. Thus animal models of GSDI represent a valuable tool to 
study this pathology and to test different treatment strategies.  
 Total G6pc knock-out mice exhibit the hepatic and renal complications observed 
in GSDI patients, but do not allow long-term studies on hepatic tumor development or 
CKD, due to severe hypoglycemia in the absence of treatments. This is why our 
laboratory has developed organ-specific G6pc knock-out mouse models. Indeed, 
L.G6pc-/- mice, which have a liver-specific deletion of G6pc, have previously allowed us 
to understand the hepatic, but also the peripheral metabolism alterations induced by the 
absence of hepatic G6Pase activity (Abdul-Wahed et al., 2014; Mutel et al., 2011a, 
2011b). This mouse model has also enabled our laboratory to test a lentiviral approach 
for GSDI gene therapy (Clar et al., 2015). In this work, L.G6pc-/- mice were used to 
decipher the altered molecular pathways and cellular defenses of the liver in two 
different conditions (at a pretumoral and tumoral stage) as well as in the tumors, in 
order to understand the possible mechanisms triggering tumorigenesis. Interestingly, 
this study revealed a metabolic ?Warburg-like? reprogramming favoring 
tumorigenesis, associated with a decrease in tumor suppressors and down-
???
?
regulated cellular defenses in GSDI livers (Gjorgjieva et al., 2016a, Gjorgjieva et al. 
submitted).  A decrease in mitochondrial respiration and activation of de novo 
lipogenesis was also confirmed, contributing to the ?Warburg-like? phenotype. This 
reprogramming is favorable for tumor formation and progression. Furthermore, this 
study showed that while glycolysis is elevated in both GSDI liver and tumors, PK-M2 is 
overexpressed only in tumor samples. It would be interesting to confirm this result in 
tumor samples from GSDI patients, in order to possibly propose this enzyme as a target 
for a treatment strategy. In parallel, L.G6pc-/- mice were used to test the effect of lipid-
lowering drugs, in order to understand the impact that lipids have on the progression of 
GSDI hepatic complications. We demonstrated that a decrease in hepatic lipid 
accumulation led to a net blunting in liver injury and a restoration of tumor 
suppressors in GSDI livers (Monteillet*, Gjorgjieva* et al., submitted; *co-authors). 
Interestingly, this treatment led to a decrease in glycogen levels, possibly by diverting 
G6P flux from glycogen synthesis to lipogenesis, thus preventing glycogen 
accumulation. 
 Another mouse model with a kidney-specific G6pc deletion (K.G6pc-/- mice) was 
developed in our laboratory. This mouse model was previously described as an 
excellent model of GSDI nephropathy (Clar et al., 2014) yet the long-term development 
of the nephropathy was not characterized. In this work, we have described the 
development of CKD in K.G6pc-/- mice and in a collaboration with Prof. Philippe 
Labrune (General pediatrics, Hospital Antoine-???????, Paris) we have reported for the 
first time the development of renal cysts in both K.G6pc-/- mice and in GSDI patients 
at a late stage of the nephropathy (Gjorgjieva et al., 2016a). Thus the development of 
renal cysts needs to be taken seriously into account during the annual medical follow-up 
of the patients. K.G6pc-/- mice, like L.G6pc-/- mice, were also used to test the effect of 
lipid-lowering on the development of GSDI nephropathy. Interestingly, similarly to 
hepatic complications, CKD was strongly delayed in fenofibrate-treated K.G6pc-/- 
mice, thanks to the prevention of lipid accumulation, highlighting the important role 
of lipids in GSDI long-term complications. 
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Hepatic fibrosis is the wound-healing response of the liver to many causes of chronic injury, of which viral 
infection, alcohol and non-alcoholic steatohepatitis (NASH) are the most common. Regardless of the 
underlying cause, injury causes inflammatory damage, matrix deposition, parenchymal cell death and 
angiogenesis leading to progressive fibrosis. The scar matrix typically accumulates very slowly, but once 
cirrhosis is established the potential for reversing this process is decreased and complications develop. 
Genetic polymorphisms, epigenetic marks and cofactors (such as obesity and alcohol) can modulate the 
risk of fibrosis progression. If the cause of fibrosis is eliminated, resolution (that is, complete reversal to 
near-normal liver architecture) of early hepatic fibrosis can occur. In cirrhosis, although resolution is not 
possible, regression of fibrosis improves clinical outcomes. Anti-fibrotic therapies are emerging that can 
slow, halt or reverse fibrosis progression. Currently, liver transplantation is the only available treatment for 
liver failure or for some cases of primary liver cancer. Hepatocellular carcinoma is rising in incidence 
worldwide and is a major cause of liver-related death in patients with cirrhosis. 
(Pellicoro et al., 2014) 
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Hepatocellular carcinoma development ? is fibrosis a must? 
While many aspects of GSDI are being deciphered, the tumorigenesis process 
observed is not completely understood. In the general population, the major triggers of 
hepatic carcinogenesis include hepatic viral infection, alcohol overconsumption and 
metabolic syndrome (Cha and DeMatteo, 2005; Ingle et al., 2016). In most cases, these 
chronic liver injury factors induce chronic inflammation, tissue damage, regeneration 
and remodeling, leading to a multistage process including fibrosis, cirrhosis and finally 
carcinogenesis (Figure 67).  While fibrogenesis is a process meant to repair liver injury 
and prevent further damage, chronic exposure to hepatic stress results in an imbalance 
between the production and dissolution of the extracellular matrix, thus leading to 
fibrosis development (Elpek, 2014; Pellicoro et al., 2014) (Figure 67). Induction of 
fibrosis is mainly mediated by inflammation. Many pathways were reported to contribute 
to this process, such as NF-?B, TGF-?1, TNF-1?, JAK/STAT, IL-1? etc (Elpek, 2014; 
Seki and Schwabe, 2015). If left untreated, fibrosis can progress to liver cirrhosis, 
ultimately leading to organ failure and death. Cirrhosis is the histological development of 
regenerative nodules surrounded by fibrous bands in response to chronic liver injury, 
that leads to portal hypertension and end stage liver disease (Schuppan and Afdhal, 
2008). Finally, this condition leads to HCC development.  
 Interestingly, hepatic carcinogenesis is very different in GSDI. Indeed, de novo 
HCC development has never been reported in patients and animal models. Instead, in 
GSDI livers, which resemble a NAFLD condition, HCA formation is firstly observed, and 
these benign tumors can later undergo malignant transformation in HCC. This malignant 
transformation is observed in about 10% of the cases, which is an incidence of 
transformation significantly higher than in non-GSDI HCA transformation cases (4.2%) 
(Kishnani et al., 2014; Stoot et al., 2010). Furthermore, carcinogenesis occurs in the 
absence of fibrosis and cirrhosis in GSDI. This absence of fibrosis could be due to the 
low-grade inflammation in GSDI livers. Indeed, in our work, we did neither observe 
TGF-?1 overexpression, nor a subsequent EMT needed for the activation of profibrotic 
pathways in the livers (Gjorgjieva et al., submitted). Besides TGF-?????????????????????
growth factor (PDGF), hepatocyte growth factor (HGF), connective tissue growth factor 
  
 
 
 
??????????? ????????????????????????????????????????????????????????????????????????????
NAFLD is closely linked to obesity and related adverse health effects such as the metabolic syndrome 
and type 2 diabetes. NAFLD manifests primarily as steatosis and can further progress into steatohepatitis 
associated to fibrosis or cirrhosis due to obesity-associated metabolic derangements. HCC may 
complicate any stage of NAFLD, yet the mechanisms leading to HCC in non ? fibrotic conditions are still 
relatively unknown. 
Arrows illustrate relative probabilities of disease transitions based on current evidence. 
(Baffy et al., 2012) 
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(CTGF), tumor necrosis factor-??????-?????????????????????????????????????????????????
can also induce fibrosis (Elpek, 2014). While the activation of these pathways was not 
previously assessed in GSDI literature, VEGF and TNF-?? ???? also found to be 
unchanged in L.G6pc-/- livers (Gjorgjieva, unpublished data). Furthermore, liver injury 
markers such as AST/ ALT are relatively normal in GSDI patients, especially with 
dietary treatment. All these data highlight that the canonical pathways involved in 
fibrosis / cirrhosis development are inactive in GSDI. 
 Hepatocarcinogenesis is also observed in non-fibrotic, non-cirrhotic NAFLD 
livers, but this event remains relatively rare (Baffy, 2013; Baffy et al., 2012; Calzadilla 
Bertot and Adams, 2016; Inayat et al.). An uncertain fraction of tumors in non-fibrotic 
livers likely arise through transformation of HCA, just like in GSDI, yet the etiology of 
these tumors is hard to pinpoint (Baffy et al., 2012; Stoot et al., 2010) (Figure 68). In the 
last decades, metabolic syndrome has become more and more prevalent, and has been 
associated with HCC development (Paradis et al., 2009). The definition of metabolic 
syndrome is based on the presence of several clinical and biological parameters 
reflecting dyslipidemia, insulin resistance, hypertension, and obesity (Eckel et al., 2005). 
Interestingly, HCC development in metabolic syndrome was shown to occur mainly in 
the absence of liver fibrosis and cirrhosis, but in the presence of hepatic steatosis. This 
incidence of HCC in non-fibrotic / cirrhotic livers is statistically different from what is 
observed in the general population in HCC induced by viral infections, alcoholic liver 
diseases etc. (Paradis et al., 2009). Paradis and coll. reported that HCA-to-HCC 
transformation was observed only in metabolic syndrome livers in the absence of 
fibrosis and this transformation sequence was not observed in HCC developed in 
fibrotic livers. These HCC were described as well-differentiated and larger than tumors 
which are developed in fibrotic/cirrhotic livers, which is not surprising, since it has been 
reported that liver fibrosis limits tumor growth (Osada et al., 2008). Interestingly, 
metabolic syndrome and GSDI are both characterized by a rare carcinogenesis 
process, in which the striking reprograming of the metabolism probably leads to benign 
lesion formations that have the capacity to acquire malignant traits. Thus the L.G6pc-/- 
mouse model can be exploited to study this specific tumorigenesis process in order to 
understand not only GSDI, but also other metabolism-related tumorigenic events. Since 
 ??????????? ????????????????????????????????????????????????????????????????????????????????
??????????????????????????
Excessive G6P in GSDI activates lipid synthesis via ChREBP. Lipid synthesis leads to lipid accumulation, 
further promoted by a decrease in lipid oxidation, characterized by PPAR? down-regulation. SIRT1, a 
target of PPAR?, is therefore down-regulated, entailing a decrease in autophagy levels. This leads to 
further metabolite, cell debris and lipid accumulations, which can lead to DNA damage, cell injury and 
finally, it can potentiate tumorigenesis. Furthermore, lipids activate ER stress pathways such as 
IRE1/XBP1 and ATF6, which can then activate lipogenesis on their own. Moreovere, ER stress can 
contribute to genotoxicity, cell injury and eventually tumorigenesis. 
ER ? endoplasmic reticulum; ChREBP???carbohydrate responsive element binding protein; SIRT1- sirtuin 
1; IRE1 - inositol-requiring enzyme 1; XBP1 - X-box binding protein 1; ATF6 - activating transcription 
factor 6; ??????- peroxisome proliferator-????????????????????. 
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the lowering of lipid accumulation in GSDI produced promising results, we might be 
soon able to propose a comparable strategy of prevention in NAFLD patients. 
Metabolic reprograming in GSDI leads to deregulated cell defense mechanisms 
and tumor suppressors 
 The comparison of the HCC occurrence in NAFLD and GSDI livers, in addition to 
the beneficial effect of fenofibrate, argue for a dominant role of metabolic 
reprogramming in the molecular induction of tumor development. We indeed showed 
that hepatic metabolism reprograming leads to a decrease in cellular defenses, as a 
consequence of the accumulation of glycogen and lipids in L.G6pc-/- livers. 
Interestingly, as observed in GSDI, a decrease in autophagy levels has also been 
reported in other NAFLD (Koga et al., 2010; Mao et al., 2016; Yang et al., 2010).?Long-
term lipid load changes membrane lipid composition and reduces autophagosome / 
lysosome fusion both in vitro and in vivo, which partly explains why excessive lipid 
content reduces autophagy and accelerates lipid accumulation (Koga et al., 2010). 
Furthermore, lipid accumulation and defective autophagy induce ER stress in NAFLD 
conditions (Yang et al., 2010). Interestingly, chronic ER stress is also a potential 
contributor to hepatic steatosis, since the main actors of the unfolded protein response 
pathway (UPR) could activate de novo lipogenesis and decrease FAO by decreasing 
???????(Basseri and Austin, 2011; Han and Kaufman, 2016). Thus chronic ER stress 
induced by steatosis could further contribute to lipid accumulation (Figure 69). As in 
NAFLD, chronic ER stress activation was observed in the liver of L.G6pc-/- mice 
(Gjorgjieva et al., submitted). Moreover, a recent study demonstrated that activating 
autophagy pathways in GSDI mice reduces lipid content (Farah et al., 2016), suggesting 
that inhibition of autophagy by lipids in NAFLD and GSDI livers closes a vicious circle 
that promotes steatosis. 
The canonical autophagy-regulation pathway involves the mammalian target of 
rapamycin (mTOR), but SIRT1 can also regulate this degradation process, in relation to 
the nutrient status of the cell. SIRT1 is known to induce autophagy via deacetylation of 
ATG proteins and FoxO family of transcriptional factors, which transactivate autophagy 
genes. Moreover, SIRT1 is regulated by AMPK and vice versa, enclosing a positive 
  
??????????????????????????????????????????????????????????????????
Under conditions of limited energy supply the ratio of ATP/ADP drops, switching the balance towards 
phosphorylation (p) and activation of AMPK, predominantly catalysed by LKB1, and away from 
dephosphorylation and inactivation by protein phosphatases (PPase). Activation of AMPK can lead to a 
reduction in cell growth through a number of different pathways: 1) phosphorylation and activation of 
TSC2 prevents activation of mTORC1 by inhibiting the GTPase activity of RHEB; 2) direct 
phosphorylation of mTOR by AMPK antagonizes phosphorylation and activation by Akt; 3) 
phosphorylation of RAPTOR increases 14-3-3 binding causing inhibition of mTORC1 activity; 4) 
phosphorylation of ACC1 decrease de novo fatty-acid synthesis; 5) suppression of SREBP1c expression 
leads to down-regulation of FAS gene expression resulting in a reduction in fatty acid synthesis. 
Activatory phosphorylation sites are depicted in green and inhibitory phosphorylation sites are shown in 
red.  
(Carling et al., 2012) 
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feedback loop (Ruderman et al., 2010). Interestingly, autophagy is regulated by SIRT1 
in GSDI livers (Figures 69 and 29), rather than mTOR. Concordantly, SIRT1 restoration 
resulted in reactivation of autophagy (Cho et al., 2017). Indeed, liver-specific knockout 
of G6pc leads to the downregulation of Sirt1 and AMPK (Cho et al., 2017, Monteillet, 
Gjorgjieva et al., submitted) in accordance with the decreased autophagy levels. Since 
glucose production is virtually absent and G6P is accumulated in GSDI, it is not 
surprising that AMPK is inhibited, as a consequence of elevated energy stores 
(increased G6P). Interestingly, besides their role in autophagy regulation, SIRT1 and 
AMPK have many other roles in the cell. Both SIRT1 and AMPK were shown to have 
properties of a tumor suppressor or tumor promoter, depending on the context, their 
targets in specific signaling pathways or in specific cancers (Lin and Fang, 2013; Luo et 
al., 2010; Zadra et al., 2015). 
 This ambiguity relating to SIRT1 is due to its connection to many crucial 
pathways, such as its interaction with p53, NF-kB, TGF-??, etc (Lin and Fang, 2013). 
For example, SIRT1-mediated deacetylation suppresses the function of p53, a well-
known tumor suppressor, suggesting a pro-oncogenic role of SIRT1 (Herbert et al., 
2014; Lee and Gu, 2013; Lin and Fang, 2013).? In contrast, SIRT1 may have a 
suppressive activity in tumor cell growth by suppressing NF-???? ?? ?????????????? ???????
playing a central role in carcinogenesis and malignancy (Kauppinen et al., 2013; Yeung 
et al., 2004). Therefore, besides its role on autophagy in GSDI, SIRT1 down-regulation 
could be highly involved in tumorigenesis.  
On the other hand, AMPK is known to regulate many pathways involved in 
energy homeostasis, including the increase in FAO and inhibition of hepatic glucose 
production (Luo et al., 2010; Zadra et al., 2015), but also cell cycle arrest, cell polarity, 
senescence, autophagy and apoptosis (Jansen et al., 2009; Shackelford and Shaw, 
2009). All these findings lead to the conclusion that AMPK is a tumor suppressor (Luo et 
al., 2010). Interestingly, AMPK is a downstream effector of LKB1 (a recognized tumor 
suppressor) and carries out many of the key functions of LKB1, such as mTOR 
inhibition (Faubert et al., 2015; Gwinn et al., 2008; Inoki et al., 2003) (Figure 70). 
However, these two can act independently as well. Indeed, recent studies have 
  
 
 
 
 
 
 
???????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????
Down-regulation of PTEN, mediated by fatty acids, cytokines, adipokines, miRNAs and hepatic viral 
infections as well as mutations / deletions, lead to steatosis and fibrosis development. Furthermore, these 
events can potentiate HCA, CC and HCC development, due to the loss of the tumor suppressor functions 
of PTEN. On the other hand, upregulated expression of PTEN results in increased apoptosis levels.  
 
HBV: Hepatitis B virus; HCV: Hepatitis C virus; HCA: Hepatocellular adenomas; CC: Cholangiocellular 
carcinomas; HCC: Hepatocellular carcinomas; HCA: hepatocellular carcinoma; PTEN: Phosphatase and 
tensin homolog. 
(Adapted from Peyrou et al., 2010) 
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identified ROS as an upstream activator of AMPK, and this appears to be LKB1-
independent (Emerling et al., 2009). Loss of LKB1 due to somatic mutations, leading to 
failure of AMPK activation is frequently observed in cancer and was estimated to occur 
in approximately 30% of non-small cell lung cancers, 20% of cervical cancers, and 10% 
of cutaneous melanomas (Liu et al., 2012; Sanchez-Cespedes et al., 2002; Wingo et al., 
2009). More importantly, under-expression of AMPK is frequently observed in HCC, and 
inactivation of AMPK was shown to promote hepatocarcinogenesis by destabilizing p53 
in a SIRT1-dependent manner (Lee et al., 2012a). Thus the down-regulation of AMPK 
observed in GSDI livers, accompanied with a decrease of SIRT1, could play a major 
role in GSDI hepatic tumorigenesis. 
In our study, other tumor suppressors were reported to be down-regulated, not 
only in tumor samples, but also in the liver of L.G6pc-/- mice. These include PTEN, 
????????? p53. PTEN is one of the most commonly lost tumor suppressors in human 
cancer, and its loss is also observed in NAFLD livers (Figure 71) (Leslie and Downes, 
2004; Peyrou et al., 2010; Sanchez-Pareja et al., 2016). Moreover, even a haplo-
insufficiency of PTEN and a subsequent reduction in protein levels was observed to be 
responsible for some human inherited conditions and cancer development (Cook and 
McCaw, 2000; Kwabi-Addo et al., 2001; Leslie and Foti, 2011; Peyrou et al., 2010). 
Interestingly, PTEN could also contribute to liver steatosis in GSDI, since de novo fatty 
acids synthesis was shown to be enhanced in liver-specific Pten-/- mice (Horie et al., 
2004). Indeed, L.Pten-/- mice revealed ballooning hepatocytes, lobular inflammatory cell 
infiltration, and fibrosis that are characteristic of NASH (Watanabe et al., 2005). 
Furthermore, at a later stage L.Pten-/- mice presented HCA and HCC development, 
confirming the tumor suppressor role of this phosphatase in the liver. The tumor 
suppressor activities of PTEN include maintenance of genomic integrity (Puc et al., 
2005), inhibition of cell migration (Liliental et al., 2000) and cellular senescence and 
interactions with p53 (Chen et al., 2005; Stambolic et al., 2001). 
For the first time, we have shown a deregulation of another well-known tumor 
suppressor in L.G6pc-/- livers, which is p53. While we did not observe a complete loss 
????????????????????????????????????????????????????????????????????????????????????????
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pretumoral stage in L.G6pc-/- livers and a decrease in livers and tumors at the tumoral 
stage. This acetylation is observed following DNA damage to enhance p53-DNA binding 
and promote the expression of p53 target genes (Sakaguchi et al., 1998). The switch 
observed between the two stages might indicate a lesser response to DNA damage, 
facilitating tumor development and progression in L.G6pc-/- mice. Furthermore, we 
observed an increase in phosphorylation of p53 at Ser392 not only in L.G6pc-/- livers at 
both pretumoral and tumoral stages, but also in tumors (Cox and Meek, 2010; Lu et al., 
1997). This phosphorylation was reported to be increased in human tumors (Ullrich et 
al., 1993). Confirming this result in GSDI patients is an urgent matter, seen as p53 is the 
most commonly lost tumor suppressor in human cancers (Kruiswijk et al., 2015; Rivlin et 
al., 2011).  
Taken together, G6Pase deficiency leads to a profound reprogramming of the 
metabolism, but also of the cellular defense mechanisms and tumor suppressors. The 
exact contribution to tumorigenesis by each of these processes remains unclear, but for 
now we can only speculate if restoring one of these mechanisms or tumor suppressors 
could impede GSDI pathology. Thus further studies need to be conducted in order to 
evaluate if one of these pathways represents a suitable therapy target for GSDI 
patients. 
Glycogen storage disease type III ? similar name but different carcinogenic 
pathways? 
 Interestingly, GSDI is not the only glycogen storage disease characterized with 
HCC development. Indeed, HCC development has also been reported in GSDIII, 
GSDIV and GSDVI, whereas the underlying mechanisms were found to be very 
different. For example, GSDIII is characterized by hepatic fibrosis development, 
followed by cirrhosis, eventually leading to HCC formation (Demo et al., 2007; Haagsma 
et al., 1997; Kishnani et al., 2010). During adulthood, around 15% of patients with 
GSDIII present cirrhosis and are at risk of developing HCC. Interestingly, GSDIII 
hepatocytes exhibit excessive glycogen accumulation, but unlike GSDI, glycogen 
presents a modified structure, due to the lack of GDE activity (Kishnani et al., 2010). 
Indeed, the degradation of glycogen in GSDIII is only partial, leading to the 
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In GSDI, steatosis is exhibited due to an increase in lipid synthesis and impairment in lipid oxidation. 
Nevertheless, ROS produced in the liver of these patients is neutralized by the increase in antioxidants 
reported in GSDI patients. This inhibition of ROS prevents the activation of proinflammatory / 
profibrogenic pathways and thus prevents fibrosis in GSDI. Finally, while glycogen is stored in excessive 
amounts, the structure of glycogen is intact, thus limiting the negative effects of this event. 
On the other hand, GSDIII patients exhibit a strong activation in lipid oxidation, leading to an important 
production in ROS which are not neutralized. These ROS therefore activate proinflammatory / 
profibrogenic pathways, as well as hepatic stem cells (HSCs). Furthermore, ROS can induce cellular 
damage and subsequently lead to fibrosis, cirrhosis and HCC development. Furthermore, abnormal 
glycogen structure can further activate inflammatory pathways and contribute to this process. 
(Herrema., 2007) 
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accumulation of short-branched glycogen, called limit dextrin. Contrarily to GSDI, G6P 
levels are decreased, due to reduced glycogenolysis, leading to a decrease in glucose 
production and associated hypoglycemia. Secondary to abnormalities in glycogen 
metabolism, lipid metabolism is severely affected. Contrary to GSDI, lipids are not 
accumulated in GSDIII liver, since G6P levels are very low and lipid oxidation is highly 
enhanced. This difference between GSDI and GSDIII lipid metabolisms was suggested 
to be the key player responsible for the different outcomes in these two pathologies 
(Herrema et al., 2007). Indeed, increased fatty acid oxidation (FAO) in GSDIII leads to 
an increase in production of ketone body and fatty acid metabolites, as well as reactive 
oxygen species (ROS).? Continuous ROS production could therefore induce 
profibrogenic and proinflammatory pathways, entailing de novo carcinogenesis in 
GSDIII (Figure 72).  
Finally, the modified structure of glycogen in GSDIII is not to be neglected, since 
it was also suggested to be an important factor contributing to carcinogenesis (Demo et 
al., 2007; Kishnani and Chen, 2007). The importance of this limit dextrin has been 
confirmed by studying another GSD where glycogen structure is altered ? GSDIV. In 
GSDIV, there is an accumulation of amylopectin (long unbranched polymers of glucose) 
with poor solubility (Li et al., 2010). That the abnormally structured glycogen causes 
liver damage is supported by the marked elevation of transaminases in both GSDIII and 
GSDIV. Concordantly, HCC development has also been reported in GSDIV, 
accentuating the negative impact of abnormal glycogen, that can lead to fibrosis, 
cirrhosis and eventually HCC development (de Moor et al., 2000). 
The characterizations of hepatic metabolism in different GSDs corroborate that 
different carcinogenesis processes take place. Indeed, in GSDI, increased ROS 
production was never reported, in concordance with the absence of fibrosis / cirrhosis 
and ultimately de novo carcinogenesis. Glycogen has a normal structure and therefore 
its role in GSDI pathology could be less important than in other GSDs. Finally, optimal 
metabolic control in GSDI patients under dietary therapy can lead to a decrease in 
glycogen deposits, and thus a decrease in liver injury markers, such as AST / ALT, 
???
?
while this decrease in not observed in GSDIII patients under metabolic control (Kishnani 
et al., 2010). 
Much can be learned by comparing the complex molecular mechanisms leading 
to HCC in both GSDI and GSDIII. Interestingly, this comparison could contribute not 
only to the understanding of tumorigenesis in GSDs, but also to the deciphering of 
different types of hepatic tumorigenesis in general. This could be achieved in mouse 
models such as L.G6pc-/- and Agl-/- mice (Pagliarani et al., 2014) (Vidal et al., In 
revision, Annex I). Indeed, Agl-/- mice exhibit all hallmarks of GSDIII, including 
hepatomegaly (due to glycogen accumulation), intolerance to exercise, muscular 
alteration and even tumor development (Vidal et al., unpublished data). With this 
objective, our laboratory has established a collaborative project with Genethon, aiming 
to link hepatic metabolism and carcinogenesis in L.G6pc-/- mice in comparison to Agl-/- 
mice and to decipher the underlying mechanisms behind GSDI and GSDIII hepatic 
carcinogenesis. This should allow us to identify potential therapeutic targets and more 
specific biochemical markers for HCC, since currently used markers, such as AFP, are 
not suitable. Furthermore, the development of hepatic tumors will be carefully analyzed 
in GSDI and GSDIII cohorts of French patients by liver imaging and analysis of 
biochemical parameters and tumor markers, under the care and supervision of Prof. 
Labrune. 
Down-regulation of HNF1 in GSDI liver and kidneys: A common factor in the 
development of GSDI hepatic and renal complications? 
HNF1 in GSDI livers 
HNF1 belongs to the homeobox protein family and is an essential transcription 
factor for many hepatic genes involved in detoxification, homeostasis and metabolism of 
glucose, lipid, and amino acids (Shih et al., 2001). There are two isotypes of this 
protein, which are HNF1A and HNF1B (Harries et al., 2009). These two isoforms are 
responsible for maturity-onset diabetes of the young (MODY), which is a monogenic 
form of diabetes mellitus characterized by autosomal dominant inheritance, early age of 
onset (<25 years) and pancreatic ??cell dysfunction (Gardner and Tai, 2012). Indeed, 
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Two steatotic nodules (limited by arrows) are separated by a thin band of nontumoral liver (NTL) 
(Hematoxylin & eosin stain, big panel).  
This thin band normally expresses liver fatty acid binding protein (FABP1 ? target of HNF1A), contrasting 
with negative H-HCA (small panel).  
(Bioulac-Sage et al., 2011) 
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HNF1A mutations lead to MODY3 and HNF1B to MODY5 (Ellard, 2000). In MODY3, 
besides metabolic alterations, HNF1A inactivation has been shown to lead to liver 
adenomatosis (presence of < 10 HCA) (Reznik et al., 2004). HNF1A-mutated HCA (H-
HCA) in the general population (Figure 73) and in MODY3 exhibit steatosis and present 
a particular metabolism, characterized by activation of glycolysis and fatty acid 
synthesis, along with an inactivation of GNG (Calderaro et al., 2013; Nault and Zucman 
Rossi, 2013). Furthermore, the targets of HNF1A, i.e. FABP1 and UGT2B7, are down-
regulated in these tumors (Figure 73). These studies led to the classification of HNF1A 
as a tumor suppressor (Luo et al., 2015; Pelletier et al., 2010). 
As observed in H-HCA, steatosis, increased glycolysis and repressed GNG are 
also features of GSDI HCA. Concordantly, in our study, HNF1A was found to be down-
regulated in tumors and L.G6pc-/- livers at the tumoral stage, explaining in part the 
histological and metabolic similarities between H-HCA and GSDI HCA. Interestingly, 
another study in GSDI human patients reported HNF1A down-regulation, not only in 
HCA, but also in the liver samples, in accordance with our observations (Calderaro et 
al., 2013). It was further shown that this down-regulation of HNF1A in GSDI HCA was 
not due to a mutation, like in H-HCA in the general population, but rather due to a 
metabolic repression of HNF1A.   
To conclude, further mechanistic studies are required in order to see the extent 
to which HNF1A down-regulation is responsible for adenoma formation, but also for 
other metabolic perturbations in GSDI. In the meantime, one could learn a lot by 
extrapolating the knowledge on HNF1A mutations and their effects on metabolism and 
tumorigenesis in GSDI. 
HNF1 in GSDI kidneys 
 As mentioned, HNF1B mutations have been associated with MODY5. These 
patients present renal cysts and renal function decline that precedes diabetes, hence 
MODY was initially referred to as renal cysts and diabetic syndrome (Faguer et al., 
2011; Verhave et al., 2016). It is noteworthy that the predominant site of HNF1B 
expression is the kidney, while the predominant site of HNF1A expression is the 
  
 
 
????????????????????????????????? ??????????????? ?????????????????????????????????????
??????????????????????????????????????????? ?????????
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organelle that has an important role in controlling the proliferation of tubular cells, it provides the 
background to explain the large spectrum of different macroscopic and microscopic overt renal diseases, 
including single kidney, hypoplastic kidney, microcystic hypoplastic kidney, horse-shoe kidney, multicystic 
kidney, glomerulomegalia, glomerulocystic kidney, or kidney with small tubular cysts, that have been 
described in patients with alterations in the HNF-???????? 
(Stratta et al.,2010) 
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pancreas and liver (Owen et al., 2014). HNF1B is expressed very early in kidney 
development. Indeed, it has been shown that HNF1B mutations can lead to abnormal 
???????? ????????????? ????? ??? ????????? ????????? ???????? ???? ?????? ????????
dysgenesis (Massa et al., 2013) (Figure 74). Furthermore, HNF1B has been shown to 
affect genes that are known to be involved in renal cyst formation, such as polycystic 
kidney disease 2 (PKD2) and polycystic kidney and hepatic disease 1 (PKHD1) 
(Hiesberger et al., 2005; Igarashi et al., 2005). Therefore, HNF1B plays a central role in 
renal cyst development in various diseases and is potentially responsible for the similar 
phenotype in many polycystic kidneys diseases (Faguer et al., 2011). 
 While the expression of HNF1B has never been assessed in GSDI kidneys in 
published bibliography, we observed a down-regulation of this gene at the kidney failure 
and cyst development stage in K.G6pc-/- mice, but not earlier (Gjorgjieva et al., 
unpublished data). This down-regulation is not surprising, since increased glycolysis 
and lipogenesis, associated with a decrease in GNG, is observed in GSDI kidneys, due 
to the excessive amounts of G6P in the tubular cells of the kidneys (Clar et al., 2014; 
Gjorgjieva et al., 2016a). Thus GSDI kidneys present a highly similar metabolic profile 
with GSDI livers, with a concomitant down-regulation of HNF1B. Moreover, these data 
suggest that development of a polycystic kidney disease-like syndrome, characteristic 
for both MODY and GSDI, could be due to HNF1B down-regulation in both cases. 
 To conclude, a down-regulation of HNF1A in the liver and HNF1B in the kidneys 
due to metabolic repression exerted by G6Pase deficiency could be a common 
underlying cause of hepatic and renal pathology in GSDI.  
Cyst development in end-stage kidneys in GSDI: a risk of renal neoplasia? 
 Renal fibrosis is an important part of CKD progression in GSDI (Gjorgjieva et al., 
2016a; Kishnani et al., 2014). In our study we have reported that profibrotic TGF-?1 and 
subsequent EMT induced by RAS pathway were activated in GSDI kidneys, leading to 
gradual progression of renal fibrosis (Gjorgjieva et al., 2016a). Renal fibrosis led to the 
formation of cysts in the kidneys of K.G6pc-/- mice, as observed in GSDI patients, in the 
later stages of CKD. Cysts seemed to have both tubular and glomerular origin, and 
  
 
 
 
 
 
 
????????????????????????????????????????????????????
 
 
 
 
 
 
 
 
 
 
???
?
were observed in a great number and size variety, conferring polycystic kidney disease-
like features to GSDI nephropathy.  
Cystic kidney diseases can vary in origin and outcome and can have an 
increased prevalence in renal cancer development (Bonsib, 2009). Indeed, polycystic 
kidney diseases were associated with a higher incidence of cancer, not only in the 
kidneys, but also in the liver and colon (Yu et al., 2016). Renal cancer has never been 
reported in GSDI, yet one can argue if cysts developed in GSDI kidney present pre-
neoplastic features and could potentially evolve in renal cell carcinoma. In our study, we 
have reported one patient with Bosniak II grade cyst. The Bosniak grading system for 
renal cysts is used to predict the outcome for the patient and is described in Figure 75. 
While it is argued whether Bosniak II cysts present malignant potential, a meta-analysis 
of 6 studies estimated 15.6% possibility of malignancy for this group (Graumann et al., 
2011). Therefore, we can suggest that GSDI patients could be at risk of renal cancer. 
Furthermore, it has been pointed out that clear cell cysts in acquired cystic diseases are 
a precursor for renal cell carcinoma, since both present very similar immunological and 
metabolic features (Hosseini et al., 2014).  Thus the morphological, histological, 
immunological and metabolic aspect of GSDI cysts needs to be determined precisely in 
order to evaluate the malignant risks associated with this long-term complication. 
While GSDI renal metabolism remains in part unknown, G6P levels are 
increased, leading to glycolysis, lipid synthesis enhancement and lipid oxidation 
decrease (Clar et al., 2014; Gjorgjieva et al., 2016a), similar to the ?Warburg-like? 
phenomenon observed in the liver. Therefore, we can suggest a pre-neoplastic status 
not only to GSDI livers, but also to the kidneys. This metabolic reprogramming could 
thus be responsible for renal cyst development.? In accordance with a common 
mechanism between both tissues, reducing lipid metabolism has the same beneficial 
effect in the kidney and liver in GSDI. 
With the increase in life span in GSDI patients thanks to the dietary therapy, 
renal complications in older patients are just starting to arise and are observed for the 
first time. However, cysts were detected only right before the renal failure stage 
???
?
occurred. Unfortunately, late malignant transformation of cysts could be a possibility in 
GSDI patients. Therefore, frequent follow up in kidney imaging and renal function 
should be highly recommended, once a year, as soon as the first symptoms of 
nephropathy appear. 
Treatment strategies for GSDI 
While GSDI is a monogenic disease, many metabolic fluxes are altered, resulting 
in a redirection of G6P toward other pathways, especially glycogen synthesis, 
glycolysis, de novo lipogenesis and nucleotide synthesis. Thus the treatment of GSDI 
should include increased glucose supply to maintain glycaemia, but it should also avoid 
glycogen and lipid accumulation in the liver and kidneys. As tumorigenesis can be 
initiated from any small population of damaged hepatocytes that are actively 
proliferating, GSDI therapy should target a maximum of hepatocytes in order to prevent 
disease progression. The same problem should be taken into account for the treatment 
of CKD. 
A strategy aiming to inhibit lipid synthesis in order to prevent deleterious effects 
of this pathway in GSDI patients might therefore sound like a suitable alternative to 
prevent both liver and kidney injury. Furthermore, glycolysis and cholesterol synthesis 
inhibition could also be a solution to GSDI. Indeed, HMG-CoA reductase inhibitor, FAS 
inhibitors, SCD1 inhibitors have already been used in various pathologies, as lipid 
lowering strategies in order to decrease lipid injury, but also as anti-cancer strategies, 
since these pathways are crucial for tumor development and progression (Alkhouri et 
al., 2009; Smith et al., 2009; Zaytseva et al., 2012). Nevertheless, inhibiting one of the 
pathways activated in GSDI might not result in a normalization of the parameters, since 
G6P utilization should be redirected toward the rest of the metabolic fluxes. The 
successful results obtained in our work by treating GSDIa mice with the lipid-lowering 
drug fenofibrate relied on the fact that G6P was up-taken by the lipid synthesis pathway 
and was subsequently metabolized via lipid oxidation, avoiding the redirection of G6P 
towards glycogen and lipid accumulation. Unfortunately, while the lipid-lowering effects 
of fenofibrate were highly beneficial in both the liver and kidneys of GSDI mice, this 
strategy did not insure normal glycaemia. 
???
?
Contrarily to these promising data, the inhibition of glycogen synthesis did not 
allow the total prevention of hepatic complications in L.G6pc-/- mice. This study was 
performed in collaboration with Dicerna pharmaceuticals, USA (Annex II) who provided 
an RNA interference vector (RNAi), specifically inhibiting glycogen synthase II (Gys2) 
gene expression in the liver. The delivery of the RNAi in the liver was performed by 
targeting the asialoglycoprotein receptors thanks to a modified RNA and GalNAc 
conjugation of a tetraloop hairpin (Thapar et al., 2014). This RNAi efficiently inhibited 
Gys2 in the liver of L.G6pc-/- mice. Subsequently, this resulted in about 20% decrease 
in hepatic glycogen and G6P contents that was sufficient to improve liver histology 
(Annex II). Moreover, lipid synthesis and accumulation was also slightly inhibited, due to 
reduced G6P availability. Unfortunately, this approach did not increase glucose levels in 
L.G6pc-/- mice, nor it normalized plasmatic cholesterol and TG. The short duration (5 
weeks) of the study did not permit the assessment of the effect of Gys2 RNAi on tumor 
development. Thus the inhibition of glycogen synthesis did not allow us to prevent 
hepatomegaly in L.G6pc-/- mice. Interestingly, Gys2 inhibition by RNA interference was 
performed for a longer time to treat Agl-/- mice, which represent a GSDIII mouse model 
(Annex II). Agl-/- mice were injected weekly or monthly for 36 weeks to 12 months with 
RNAi targeting Gys2. Long-term Gys2 inhibition prevented glycogen accumulation, 
hepatomegaly, liver injury, fibrosis and nodule development (Annex II). However, Gys2 
RNAi failed to correct glycaemia in Agl-/- mice, as observed in L.G6pc-/- mice. It is 
noteworthy that this approach has several advantages compared to viral vectors. 
Indeed, the development of a gene therapy approach for GSDs is practically limited by 
transduction efficiency, expression transience, and viral genome size restriction. In 
contrast to gene therapy, RNAi-mediated inhibition of glycogen synthesis has the 
advantage of reaching and correcting nearly all of the hepatocytes, thus preventing 
glycogen accumulation evenly throughout the liver. Indeed, gene therapy essays 
allowed only mosaic glycogen alleviation. Although Gys2 inhibition had no effect on 
hypoglycemia, it has the potential to complement a gene therapy approach by 
correcting liver abnormalities in GSDs and provides therapeutic options to GSD patients 
with hepatic injury who currently have no therapeutic options. The difference in the 
success rates obtained in GSDI and GSDIII models could be due to the length of the 
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AAV-ZFN vectors are used in a dual vector strategy. The first vector containing the zinc finger nuclease 
(ZFN) is designed to cut DNA in a specific site called Rosa26, which is a safe harbor locus. The specificity 
of the ZFN to Rosa26 comes from the homology of this nuclease with the Rosa26 locus. Once Rosa26 is 
cut, the second vector provides a new copy of G6pc. The insertion of the new gene is assured by the 
??????????????????d at each extremity of the gene. These so-called sticky ends share perfect homology 
with the cut Rosa26 locus, facilitating the insertion of the gene and a subsequent homologous 
recombination, repairing the missing nucleotide bases around the sticky ends and the extremities of the 
cut DNA.   
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treatment. Indeed, treating L.G6pc-/- mice for a longer period could result in a 
prevention of hepatomegaly and liver injury as in Agl-/- mice, but this hypothesis needs 
to be confirmed. Last, while both GSDI and GSDIII are both characterized by glycogen 
accumulation and hypoglycemia, they present marked differences in other metabolic 
pathways, such as lipid metabolism, possibly playing a role in the different outcomes of 
the RNAi treatment. 
 Finally, the best curative option for GSDI would be gene therapy, allowing a 
replacement of the mutated sequence of G6PC or SLC37A4 in the liver and the 
kidneys. Nevertheless, designing a vector that can transduce a maximum of 
hepatocytes and renal tubular cells, that does not induce any inflammatory responses 
nor non-target insertions, and that is not lost overtime, is an extremely delicate task. 
 Nevertheless, nowadays many advanced gene therapy tools are being 
developed, opening a new horizon for GSDI gene therapy assays. Indeed, our 
laboratory, in collaboration with Dr Dwight Koeberl from Duke University, USA, tested 
an innovative AAV gene therapy strategy, employing ZFN. This approach combines the 
inoffensive AAV vectors with the ability of ZFN to insert a copy of G6pc in harbor loci, 
allowing a safe integration of the target gene (Figure 76). After 12 months of AAV-ZFN 
injection, L.G6pc-/- mice exhibited normal glycaemia and a normalization of TG, uric 
acid and BUN levels, due to a two-fold increase in G6Pase activity (unpublished data). 
Furthermore, hepatic glycogen content was significantly decreased, while hepatic TG 
had only a tendency to decrease. Nevertheless, this therapy did not change hepatic 
tumor incidence in L.G6pc-/- mice treated with AAV-ZFN (unpublished data). 
Interestingly, all of the tumors exhibited an absence of AAV-ZFN or gene insertion, 
confirming: 1) that these tumors were not a result of an oncogenic insertion of our target 
gene; 2) the efficiency of the therapeutic vector to protect against tumorigenesis. Finally, 
an optimization of the vector could allow a more important transduction in the liver, 
eventually resulting in a larger inhibition of tumor formation, besides normalization of the 
plasmatic parameters. 
???
?
 At the last International glycogen storage disease conference (IGSD2017) that 
took place in Groningen, Netherlands, the pediatric endocrinologist Dr. David Weinstein 
(USA) announced the beginning of the first gene therapy assay in patients with GSDI. 
This treatment will involve an AAV vector, which was tested in GSDI mouse and dog 
models. While this announcement is extremely exciting and promising, clinical trials 
such as these take time to be properly evaluated, validated and optimized. This is why it 
is crucial to keep deciphering the underlying mechanisms of hepatic and renal GSDI 
pathologies, in order to get the most out of the gene therapy strategies, or to find other 
back-up treatment targets. 
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Abstract (200 max) 
Glycogen storage disease type III (GSDIII) is an autosomal recessive disorder caused by a 
deficiency of glycogen debranching enzyme (GDE), which results in profound liver metabolism 
impairment and muscle weakness. To date, no cure is available for GSDIII and current 
treatments are mostly based on diet. Here we describe the development of a mouse model of 
GSDIII, which faithfully recapitulates the main features of the human condition. We used this 
model to develop and test novel therapies based on adeno-associated virus (AAV) vector-
mediated gene transfer. First, we showed that overexpression of the lysosomal enzyme alpha-
acid glucosidase (GAA) with an AAV vector led to a decrease in liver glycogen content but 
failed to reverse the disease phenotype. Using dual overlapping AAV vectors expressing the 
GDE transgene in muscle, we showed functional rescue with no impact on glucose metabolism. 
Liver expression of GDE, conversely, had a direct impact on blood glucose levels. These results 
provide proof-of-concept of correction of GSDIII with AAV vectors, and indicate that 
restoration of the enzyme deficiency in muscle and liver is necessary to address both the 
metabolic and neuromuscular manifestations of the disease.  
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Introduction 
Glycogen storage disease type III (GSDIII) is a rare (incidence of 1 in 100,000 at birth)1 
autosomal recessive disorder caused by mutations in the AGL gene encoding for the glycogen 
debranching enzyme (GDE or amylo-alpha-1,6-glucosidase, EC no. 3.2.1.33, UniProt P35573). 
GDE is an enzyme with two catalytic sites involved in the conversion of cytosolic glycogen to 
glucose2. 
The clinical manifestations of GSDIII are characterized by two phases, during childhood, the 
disease has mainly the features of a metabolic disorder with hepatomegaly and severe fasting 
hypoglycemia, hyperlipidemia, and hyperketonemia; during adolescence and adulthood, a 
progressive debilitating myopathy, with a heterogeneous involvement of different muscle groups 
and exercise intolerance appear, rendering the metabolic impairment less prominent2. GSDIII 
disease burden is important especially in patients that suffer from severe skeletal muscle 
weakness and exercise intolerance1, 2. Histological analysis of muscle biopsies from GSDIII 
patients confirms the muscle involvement, and shows accumulation of glycogen in large 
vacuoles that disrupt the myofibrils architecture3. Additionally, most of GSDIII patients have a 
cardiac involvement, although only a small percentage (15%) of them develops 
cardiomyopathy2. Additionally, liver complications such as cirrhosis, development of 
hepatocellular adenomas (HCA) and hepatocellular carcinomas (HCC) has been described in a 
significant proportion of GSDIII patients2.  
To date, the only therapeutic approach currently available for GSDIII is symptomatic2, 4. During 
childhood, to avoid recurrent hypoglycemia, patients follow a strict diet regimen with frequent 
meals rich in complex carbohydrates, typically uncooked cornstarch5. High-protein high-fat diet 
has been proposed for adults GSDIII patients, and a strict ketogenic regimen has been reported to 
??
?
be efficacious in preventing hypertrophic cardiomyopathy6, 7. At present, no therapy has been 
proposed to address the muscle impairment observed in GSDIII, thus the disease remains an 
unmet medical need.  
 
The monogenic nature of GSDIII, and the fact that it is caused by a well-defined enzyme 
deficiency, make the disease a possible target for gene replacement therapies. To this aim, 
adeno-associated virus (AAV) vectors represent the platform of choice for in vivo gene transfer8. 
Data obtained in the context of clinical trials for hemophilia9, congenital blindness10, and spinal 
muscular atrophy11 demonstrate the safety and therapeutic potential of the AAV vector gene 
transfer platform. Furthermore, the experience accumulated in large animal models of 
neuromuscular disorders indicates that systemic administration of AAV vectors results in 
efficient targeting of muscle12, 13.  While promising, one of the most important restrictions in the 
use of AAV vectors is the size of the transgene expression cassette, which is limited to ~5 Kb. 
Consequently, due to the large size of the GDE cDNA, ~4.6 Kb, the development of AAV 
vector-based GDE gene transfer strategies is challenging.  
Here we describe a new murine model of GSDIII, which faithfully recapitulates the human 
condition, including body-wide glycogen accumulation, low blood glucose levels, and muscle 
weakness. Using this model, we tested different gene therapy-based approaches aimed at 
correcting the disease. Specifically, we showed that overexpression of the lysosomal enzyme 
alpha-acid glucosidase (GAA) with AAV vectors was not sufficient to fully rescue the GSDIII 
phenotype in vivo. Conversely, using dual overlapping AAV vectors14-16, for the first time we 
showed restoration of the GDE enzyme in both liver and muscle thus demonstrating that the 
expression of the endogenous enzyme in those tissues  is required for clearance of cytosolic 
??
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glycogen, rescue of muscle strength, and amelioration of blood glucose levels in treated animals. 
The work presented here provides the framework for the future development of gene therapy 
approaches to GSDIII.  
 
  
??
?
Results 
 
Development of a murine model of GSDIII which fully recapitulates the human condition 
A mouse model of GSDIII (Agltm1b(EUCOMM)Wtsi) was acquired through the International Mouse 
Phenotyping Consortium (http://www.mousephenotype.org/about-ikmc/eucomm).  
Three-month-old GDE knock-out (Agl-/-) mice completely lacked GDE expression in liver and 
skeletal muscle as determined by Western blot (Figure 1A) and GDE activity measurement in 
liver (Figure 1B). As expected, the lack of the enzyme was associated with the accumulation of 
glycogen in liver, heart, different skeletal muscle groups, and brain (Figure 1C). Additionally, 
the block of glycogen degradation in the liver led to a dramatic decrease of glucose-6-phosphate 
levels in Agl-/- animals (Figure 1D).  
Detailed histological analysis confirmed the accumulation of glycogen in muscle (Figure S1). 
Interestingly, the accumulation of glycogen was not homogenous in all fibers, as some showed 
comparable glycogen content to that observed in muscle from wild-type littermates (Agl+/+ mice, 
Figure S2). Hematoxylin-eosin (HE) revealed the presence of large vacuoles in muscle fibers 
that appear to contain periodic acid-Schiff (PAS) ?positive material (Figures 1E,F and S1). The 
presence of vacuoles filled with glycogen strongly resembles the pattern of glycogen 
accumulation encountered in muscle biopsies from GSDIII patients3. Electron microscopy 
studies on quadriceps from Agl-/- animals disclosed the presence of large glycogen pools 
disrupting the myofibrillar structure both in transversal and longitudinal ultrathin sections 
(Figure 1G and H). Higher magnification of transversal section revealed the presence of small 
areas containing apparently normally structured glycogen granules that misplaced the 
myofibrils(Figure 1I), leading to progressive sarcomeric degeneration. 
??
?
Perhaps one of the most evident phenotype in young GSDIII patients is the relatively severe and 
persistent hypoglycemia1, 4. Accordingly, 6-month-old Agl-/- mice showed a significant reduction 
in blood glucose levels (Figure 2A) accompanied by a ~three-fold increase in the liver/body 
weight ratio (Figure 2B), consistent with hepatomegaly and similar to what described in GSDIII 
patients1, 2. We then evaluated muscle function in affected animals at 3, 6, and 9 months of age. 
No differences were observed in total distance traveled and rotarod performance (Figure 2C,D 
and Table S1), indicating that glycogen accumulation in muscle and hypoglycemia did not affect 
general locomotion in Agl-/- mice. Interestingly, when the same mice were tested for muscle 
strength, we observed a significant (p=0.006) ~20% reduction in grip strength and a profound 
impairment (p=2.2x10-7) in the wire-hang test performance (Figure 2E and 2F, respectively). 
Functional testing repeated in 6- and 9- month-old animals showed similar results (Table S1).  
These results confirm that the model used in this study recapitulate faithfully the human 
phenotype and therefore is suitable to test novel therapeutic strategies to treat GSDIII.  
 
High levels of GAA secreted in the bloodstream decreases glycogen accumulation in liver but not 
in muscle 
Previous results obtained in vitro suggest that supraphysiological levels of GAA activity can 
clear glycogen from primary human GSDIII myoblasts17. To test whether GAA overexpression 
has the potential to rescue glycogen accumulation in GSDIII mice, we took advantage of a 
recently developed AAV vector expressing a secreted form of GAA (AAV-GAA)18. Three-
month-old GSDIII mice were treated with an AAV-GAA vector at 1x1011 or 1x1012 vector 
genomes (vg)/mouse and followed-up for three months (Figure 3A). As expected, the injection 
of the AAV-GAA vector resulted in a dose-dependent increase of GAA activity in the 
??
?
bloodstream (Figure 3B), and in supraphysiological levels of GAA enzyme activity in all tissues 
(Figure 3C, measured at sacrifice).  
Interestingly, the administration of the AAV-GAA vector significantly decreased glycogen 
accumulation in the liver of Agl-/- mice, both at the 1x1011 and 1x1012 vg/mouse dose level (p = 
0.00025 and 2.7x10-6 vs. Agl-/- animals, respectively), to levels comparable to those observed in 
wild-type littermates (p=0.092 and 0.639 vs. Agl+/+, for the low and high vector dose, 
respectively, Figure 3D). However, this did not lead to a significant improvement in the 
metabolic phenotype of Agl-/- mice, as the treatment did not improve blood glucose or 
hepatomegaly (Figure S3). Treatment with AAV-GAA had no effect on glycogen accumulation 
in Agl-/- muscle (Figure 3D). Accordingly, grip strength and wire hang performance measured 3 
months post gene transfer were not rescued in mice treated with AAV-GAA (Figure 3E and 
Table S2). Interestingly, one month after treatment we observed a transient significant reduction 
in the number of fall per minute in the wire hang test in animal treated with the AAV-GAA 
vector at the highest dose (p=0.008 vs. untreated Agl-/-). No improvement in grip strength was 
observed at any time point (Table S2).    
Together these results indicate that although high levels of GAA enzyme activity result in a 
decreased glycogen accumulation in the liver, they fail to rescue glycemia and muscle function 
in GSDIII mice.  
 
Dual overlapping vectors expressing GDE efficiently rescue glycogen accumulation in muscle of 
GSDIII mice  
Dual overlapping AAV vectors have been used to express genes larger than 5Kb in muscle13, 14, 
19
. We therefore developed a dual AAV vector expressing the GDE transgene in which ???????
??
?
portion (nucleotides 1 to 2688) of the human GDE (hGDE) cDNA was fused with the CMV 
promoter and second intron of human beta globin (HBB2)20 (GDE-HEAD, Figure 4A). ???????
portion (nucleotides 1693 to 4599) of the hGDE coding sequence was fused with a 
polyadenylation signal derived from HBB2 (GDE-TAIL, Figure 4A). A region of overlap of 996 
nucleotides (nucleotides 1693 to 2688 of the GDE cDNA) was used to mediate the homologous 
recombination of GDE-HEAD and GDE-TAIL vectors. The two overlapping cassettes were 
pseudotyped21 into an AAV9 vector and co-injected in Agl-/- mice at a dose of 1x1012 vg per 
mouse each (Figure 4B). Three months after vector injection, most of the vector genomes were 
found in liver and heart, whereas quadriceps and triceps had the lowest vector genome copy 
number (Figure S4). However, while Western blot analysis revealed GDE protein expression in 
heart and skeletal muscles, no protein was detectable in liver (Figure 4C). Similarly, hGDE 
transgene mRNA expression levels, normalized for vector genome copy number, were 50 to 800-
fold lower in the liver compared to muscle (Figure 4D), suggesting that CMV promoter 
inactivation in the liver occurred22. Accordingly, the absence of expression of the GDE transgene 
in the liver was associated with lack of correction of the glycemia or hepatomegaly (Figure 
S5A,B). 
 
AAV vector treatment resulted in a significant decrease in glycogen accumulation in several 
muscle groups but not in the liver (Figure 4E). In heart and quadriceps, we observed an inverse 
correlation (R2 = 0.9 and 0.97, respectively) between the quantity of GDE protein expressed and 
the glycogen accumulated in the tissue (Figure 4 F,G). Accordingly, the levels of expression of 
GDE necessary to clear 80% of glycogen could be estimated to be 8% in heart and 2% in 
quadriceps. 
???
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PAS staining confirmed the robust reduction in glycogen accumulation in all muscle groups 
analyzed, accompanied by a general rescue of the fiber structure as highlighted by HE staining 
(Figure 5). Muscle function was also evaluated by monthly measurement of wire-hang 
performance and grip strength. In agreement with the biochemical and histological data, the 
administration of the dual AAV vector expressing GDE significantly rescued wire hang 
performance to levels undistinguishable to those measured in wild-type animals (p=0.934 and 
0.836 vs. Agl+/+ at 2 and 3 months post treatment, respectively, Figure 6A and Table S3). 
Additionally, a significant increase in the grip strength was observed in Agl-/- mice treated with 
overlapping vectors three months after the injection (p=0.026 vs. Agl-/-, Figure 6B and Table 
S3).  
These results indicate that CMV-driven GDE transgene expression mediated by overlapping 
AAV vectors can rescue the muscle phenotype in GSDIII mice. However, the approach has no 
effect on the liver manifestations of the disease.   
 
Hepatocyte-restricted GDE expression improves glycemia in GSDIII mice 
We then tested the dual vector approach by expressing GDE under the transcriptional control of 
a potent liver-specific promoter23. For this experiment, vectors were pseudotyped into AAV8, a 
capsid that efficiently targets the liver in mice24. The injection of Agl-/- mice with 1x1012 
vg/mouse of the combination of the overlapping vectors (GDE-HEAD with the liver-specific 
promoter and GDE-TAIL), resulted in detectable expression of GDE protein in liver of 5/8 
AAV-treated mice, measured by Western blot (Figure 7A). Glycogen accumulation in the liver 
of Agl-/- animals treated with the dual AAV vector was undistinguishable from that measured in 
wild-type Agl+/+ animals (p=0.409, Figure 7B). Accordingly, we observed a significant 
???
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improvement of the blood glucose in treated Agl-/- mice at all time points tested (p=0.0008 vs. 
untreated Agl-/-, two-way ANOVA time x treatment, Figure 7C). Despite the positive impact on 
glycogen accumulation and glycemia, AAV gene transfer was not able to correct hepatomegaly 
(Figure S6).  
These results demonstrate that liver expression of GDE can rescue glycemia and decrease 
glycogen accumulation but has no effect on hepatomegaly. 
 
Impact of gene transfer on liver metabolism in GSDIII mice 
Based on results obtained with gene transfer in vivo, we sought to compare the effect of GAA 
and GDE gene transfer on liver metabolic pathways. To this aim, we analyzed the levels of 
expression of a panel of genes involved in different pathways of the mouse glucose and glycogen 
metabolism (Figure 8A). The level of expression of 70 genes expressed in the mouse liver was 
analyzed. When we compared the profile of expression in wild-type Agl+/+ animals, untreated 
Agl-/- mice showed, with some exception, a generalized down-regulation of all the pathways 
investigated (Figure 8B). 43 genes significantly changed in at least one of the three groups 
analyzed (untreated Agl-/-, AAV-GAA, and AAV-GDE overlapping treated Agl-/-, p<0.05 by 
ANOVA). Of these 43 genes, only 19 showed an n-fold > ±1.75 (Table S4), and 11 genes were 
changed in untreated Agl-/- mice. 4/11 genes were rescued in animals treated with AAV-GAA 
vector whereas the treatment with overlapping AAV vectors expressing GDE rescued 8/11 genes 
(Table S4). A general tendency to the normalization of all the genes modified in Agl-/- animals 
could be observed after treatment with GDE-expressing vectors but not in AAV-GAA treated 
animals vectors as showed by heat map analysis (Figure 8C,D).  
???
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These results suggest that GDE expression in the liver mediates a better control of glucose 
metabolism in the liver.  
  
???
?
Discussion 
GSDIII is a debilitating neuromuscular and metabolic disease with no curative therapeutic 
options. This exposes young patients to persistent alterations of glycemia, which become less 
severe in adulthood when a more pronounced debilitating muscle phenotype appears. The major 
impact of the disease on the quality of life of patients, and the lack of effective treatments 
besides dietary management, prompted us to develop new gene therapy approaches to GSDIII. 
Here we describe the development and characterization of a mouse model that faithfully 
recapitulates the disease phenotype in humans, including low blood glucose, hepatomegaly, 
whole-body accumulation of glycogen, and muscle weakness. With this model, we tested 
different treatment modalities based on AAV vector gene transfer.  
Based on the observation that there is a small percentage of glycogen continuously trafficking 
from the cytosol to the lysosome25, we tested whether the overexpression of the lysosomal 
enzyme GAA could rescue the phenotype of GSDIII. To this aim, we used a highly efficient 
AAV vector expressing GAA, which was recently demonstrated to mediate whole-body 
treatment of Pompe disease18. Despite achieving supraphysiological levels of GAA activity in 
most tissues, in GSDIII mice this approach had only a limited and transient effect on muscle 
performance. A significant reduction of glycogen accumulation was only observed in liver, 
although no effect on glycemia or hepatomegaly was observed. These results are consistent with 
data obtained in vitro with GSDIII myoblasts treated with recombinant GAA enzyme, in which a 
partial rescue of glycogen accumulation was observed17. Why the effect of GAA on muscle 
function in GSDIII mice is only transient remains to be assessed. One hypothesis is that, due to 
the low rate of cytosolic glycogen trafficking to lysosomes in muscle, its pathological 
accumulation is not fully cleared by GAA overexpression. Based on this, adjuvant therapies 
???
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aimed at enhancing autophagy, e.g. by using rapamycin26, or combination with diet27-29, may 
improve the efficacy of this approach in GSDIII. The mechanism(s) underlying the difference in 
glycogen clearance mediated by GAA in muscle vs. liver is also unclear. However, similar 
observations have been reported after the treatment of GSDIV mice with GAA that resulted in 
the clearance of liver but not muscle glycogen30. 
Based on the observation that overexpression of GAA alone does not fully correct GSDIII, we 
sought to address the enzymatic deficiency, hallmark of the disease, by directly restoring the 
GDE enzyme activity with AAV vectors. The fact that GDE is a large cytosolic protein of 170 
kDa with two different enzymatic domains31, complicates the design of AAV vectors expressing 
the enzyme and does not allow for the development of gene therapy strategies based on cross-
correction18, 32, 33.  
To overcome the limitation of the size of the GDE transgene, we developed a dual AAV vector 
strategy13, 14, 19, 34 to express GDE transgene in liver and muscle. CMV promoter-driven GDE 
transgene expression mediated the complete rescue of muscle function and glycogen 
accumulation in different muscle groups, including heart35. Biochemical parameters correlated 
with muscle histology and PAS staining, which showed good correction of the disease 
phenotype. Conversely, due to the silencing of the CMV promoter in liver22, no liver GDE 
expression was detected and no correction of glycogen accumulation, hepatomegaly, or glycemia 
were observed, indicating that targeting muscle alone would not rescue the metabolic impairment 
hallmark of GSDIII.  
To address this limitation and to better explore the role of liver pathology in GSDIII, we 
designed a dual AAV vector expressing the GDE transgene under the control of a liver-specific 
???
?
promoter24. With this strategy, treated animals showed improved glycemia and clearance of liver 
glycogen. No effect of gene transfer on hepatomegaly was observed, perhaps indicating that 
higher expression levels are needed to fully correct the hepatic phenotype in our model.  
 
Gene expression analysis allowed us to compare the impact of GAA vs. GDE gene transfer on 
glucose metabolism in the liver. In untreated knock-out animals vs. wild-type controls, the 
pathways that appeared mostly affected were the regulation of glucose metabolism and the 
tricarboxylic acid (TCA) cycle. A general normalization of all pathways studied was observed 
following hepatic GDE gene transfer, while GAA gene transfer mediated the rescue of only a 
limited subset of genes, further supporting the need for correction of the underlying enzyme 
defect in GSDIII.  
To our knowledge, this is the first proof-of-concept study showing correction of GSDIII in vivo. 
Data presented here also provide insights into the disease and its treatment, in particular on the 
importance of mobilizing cytosolic glycogen in both liver and muscle to mediate full rescue of 
the phenotype. Moreover, as metabolic impairment in adults with GSDIII, although less severe 
than in children, is associated with the development of HCA and HCC36, the development of 
effective treatments targeting the liver, in addition to muscle, is highly needed. Thus, future work 
will be focused on the development of expression cassettes to drive efficient GDE expression in 
both tissues. 
The approach presented here has some limitations associated with the use of dual AAV vectors, 
specifically i) the low efficiency of reconstitution of the full-length transgene cDNA mediated by 
the overlapping complementary sequence 15; and ii) the fact that the homologous recombination 
???
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machinery is not equally efficient in all tissues15. Alternative strategies could be utilized to 
enhance the efficiency of homologous recombination to reconstitute the full-length transgene 
expression cassette. These may include the use of dual hybrid AAV carrying transgene-
independent highly recombinogenic DNA sequences15, 16.  Additionally, small enhancer 
elements37 and synthetic promoters38 combined with AAV serotypes that efficiently target the 
muscle39, could increase expression of the GDE transgene.  
Finally, data obtained here provide some estimate on the threshold of GDE transgene expression 
required to obtain therapeutic efficacy. A nearly full rescue of muscle function was observed in 
GSDIII mice treated with the dual AAV vector expressing the GDE transgene, despite partial 
restoration of the enzyme expression. This indicates that only a small increment in enzyme 
activity is sufficient to dramatically improve the muscle phenotype in GSDIII, in line with the 
concept that the therapeutic threshold, in terms of vector dose, for muscle enzyme deficiencies is 
lower than that of muscular dystrophies, in which muscle structural proteins are defective40.  
Future efforts will have to focus on improving efficiency of GDE expression in muscle but also 
in liver, to mediate correction of both the muscle and the metabolic impairment hallmarks of 
GSDIII. As more information about efficiency of transduction of dual AAV vectors in muscle14, 
16, 19, 41-44
 and in other tissues15, 34 will emerge from preclinical and clinical studies, critical 
parameters for the successful translation of dual AAV vectors to the clinic will become evident. 
Specific safety parameters of dual AAV vectors will also have to be carefully defined, such as 
expression of truncated sequences from the single non-annealed AAV carrying the GDE 
transgene and transgene immunogenicity.  
 
???
?
In conclusion, the work presented here provides the first demonstration of correction of GSDIII 
in both liver and muscle in vivo with dual AAV vectors. Results obtained help defining the levels 
of GDE protein expression needed to rescue the disease phenotype both at the functional and 
biochemical level, and lay the fundaments for future translational efforts towards the 
development of a curative treatment for the disease.  
  
???
?
 
Materials and methods 
In vivo studies 
The Agl knock-out (Agl-/-) mice were developed in the frame of the International Mouse 
Phenotyping Consortium (IMPC). Mice were generated in a pure C57Bl6/J background by 
replacing exons 6 to 10 of the Agl gene with a neomycin expressing cassette. Mice were bred 
into a mixed BALB/c background for the purpose of this study. 
All mouse studies were performed according to the French and European legislation on animal 
care and experimentation (2010/63/EU) and approved by the local institutional ethical committee 
(protocol no. 2016-002). AAV vectors were administered intravenously via the tail vein to 3-
month-old male Agl-/- mice and wild-type littermates (Agl+/+).  
 
Western blot analysis 
Mouse tissues were homogeneized in DNAse/RNAse free water and protein concentration 
determined using the BCA Protein Assay (Thermo Fisher Scientific, Waltham, MA). SDS-PAGE 
electrophoresis was performed in a 4-15% gradient polyacrylamide gel. After transfer, the 
membrane was blocked with Odyssey buffer (Li-Cor Biosciences, Lincoln, NE) and incubated 
with an anti-GDE antibody (Rabbit polyclonal  
AS09-454, Agrisera), and an anti-actin antibody (Rabbit monoclonal, sc-8432, SantaCruz 
Biotechnology). The membrane was washed and incubated with the appropriate secondary 
antibody (Li-Cor Biosciences), and visualized by Odyssey imaging system (Li-Cor Biosciences).  
 
Enzyme activity measurements 
???
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GAA activity was measured as previously described18. The protein concentration of the samples 
prior to GAA activity measurement was quantified by BCA (Thermo Fisher Scientific, Waltham, 
MA). GAA activity was reported as nmol/hour/mg protein when measured in tissue and as 
nmol/hour/μL when measured in plasma. 
GDE activity was measured as previously described45. Briefly, 50mg of tissue were 
homogeneized in 50μL of DNAse/RNAse free water. The lysate was incubated at 37°C with 
limit dextrin in 4.5 mM EDTA and 0.16 M of phosphate buffer (pH=7). The reaction was then 
centrifuged. Supernatants were used to measure the glucose produced using a glucose assay kit 
(Sigma Aldrich, Saint Louis, MO) and by measuring resulting absorbance on an EnSpire alpha 
plate reader (Perkin-Elmer, Waltham, MA) at 540 nm. 
 
Measurement of glycogen content  
Glycogen content was measured indirectly in tissue homogenates as the glucose released after 
total digestion with Aspergillus Niger amyloglucosidase (Sigma Aldrich, Saint Louis, MO). 
Samples were incubated for 5 min at 95°C and then cooled at 4°C; 25 μl of amyloglucosidase 
diluted 1:50 in 0.1M potassium acetate pH5.5 were then added to each sample. A control 
reaction without amyloglucosidase was prepared for each sample. Both sample and control 
reactions were incubated at 37°C for 90 minutes. The reaction was stopped by incubating 
samples for 5 min at 95°C. The glucose released was determined as described above.  
 
Histology and electron microscopy 
For muscle histology, heart, diaphragm, triceps brachii, quadriceps femoris, tibialis anterior and 
posterior, gluteus maximus and psoas were snap-frozen in isopentane previously chilled in liquid 
???
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nitrogen. Serial 8 μm cross-sections were cut in a Leica CM3050 S cryostat (Leica Biosystems, 
Nussloch, Germany).  To minimize sampling error, 3 sections of each specimen were obtained 
and stained with HE and PAS according to standard procedures.  
Electron microscopic analysis was performed in quadriceps muscles from wild-type and Agl-/- 
????????? ?????????? ????? ????? ????? ??????????????? ??????? ??? ?????? ????????? ????? ???????
tetroxide (2%), dehydrated, and embedded in resin (EMBed-812; Electron Microscopy Sciences, 
???????????????????????????????????????????????????????????????????????tate and lead citrate. The 
grids were observed using an electron microscope (80 kV; Model CM120; Philips Electronics 
NV, Eindhoven, The Netherlands) and photographed (Morada Soft Imaging System; Olympus 
France). 
 
Glycemia measurement 
Glycemia was measured using sera collected from mice normally fed. A glucose assay kit 
(Sigma Aldrich, Saint Louis, MO) was used and the resulting absorbance was acquired on an 
EnSpire alpha plate reader (Perkin-Elmer, Waltham, MA) at a wavelength of 540 nm.  
 
Muscle function tests 
Forelimbs wire-hanging test was performed as already reported18, 46. A 4 mm-thick wire was 
used to record the number of fall over a period of 3 minutes. The average number of falls per 
minute was reported for each animal.  
Grip strength was measured as already reported 18, 46. Using a grip strength meter, (Columbus 
instruments, San Diego, CA) three independent measurements of the four limbs strength were 
recorded at each time point. Max values of the weight-normalized grip strength were reported.   
???
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Rotarod testing was performed as already reported18, 47 using a LE8200 apparatus (Harvard 
Apparatus, Holliston, MA). An accelerating protocol 4-40 rpm in 5 minutes was used. The test 
was repeated three times and the best performance of each animal was reported.  
 
Production of AAV vectors 
All AAV vectors used in this study were produced using an adenovirus-free transient 
transfection method48 and purified as described earlier49. Titers of the AAV vector stocks were 
determined using a quantitative real-time PCR (qPCR) and confirmed by SDS-PAGE followed 
by SYPRO Ruby protein gel stain and band densitometry.  
 
Vector genome copy number determination 
 Vector genome copy number was determined using a qPCR assay as previously described20. The 
PCR primers used in the reaction were located in the overlapping region of human GDE 
transgene, forwar?? ??????? ??-GTCTTGATAACTGCCACTCA-???? ???????? ??????? ??-
AAAGTAACATGGGATAAGGT-???? ???? ???? ???????? ???? ???? ????????? ???????? ?????? ?????? ????
?????????? ??? ???? ???????? ???? ???????? ???????? ????? ??-AAAACGAGCAGTGACGTGAGC-???
??????-TTCAGTCATGCTGCTAGCGC-?????????????ely.  
In some experiments, a nested PCR was used to amplify of the overlapping region prior to qPCR. 
Genomic DNA was extracted from 20mg of tissue on a MagNAPure instrument following the 
manufacturer instructions (MagNAPure 96 system, Roche, Basel, Switzerland). PCR primers 
used were localized in the regions flanking the overlapping region of human GDE transgene, 
???????? ??-GTCTTGATAACTGCCACTCA-??? ???? ???????? ??-
AAAGTAACATGGGATAAGGT-????????-amplification genome copy number was determined 
???
?
by qPCR using a LightCycler 480 (Roche, Basel, Switzerland) as previously described20. 
Oligonucleotides used for qPCR were located in the overlapping region (see Figure S3A) 
???????? ??-CTGGAGTTGCCACAAAAGGG-??? ???? ???????? ??-
AGTGAGGACTGAATTGTGTC-???? 
 
Gene Expression analysis  
For GDE transgene expression, total RNA was extracted from cell lysates using Trizol (Thermo 
Fisher Scientific, Waltham, MA). DNA contaminants were removed using the Free DNA kit 
(Thermo Fisher Scientific, Waltham, MA). Total RNA was reverse-transcribed using random 
hexamers and the RevertAid H minus first strand cDNA synthesis kit (Thermo Fisher Scientific, 
Waltham, MA). qPCR was performed with oligonucleotides specific for the GDE transgene 
???????????-CTGGAGTTGCCACAAAAGGG-??? ??????????-AGTGAGGACTGAATTGTGTC-
??? and normalized by the l?????? ??? ??????????? ??? ?????? ????????? ??-
GTTGTCTCCTGCGACTTCA-??, ??????????-GGTGGTCCAGGGTTTCTTA-??). 
For the gene expression analysis with RT² Profiler PCR Array, a Mouse Glucose Metabolism 
RT² Profiler PCR Array (Qiagen, Hilden, Germany) was used followin?? ???? ???????????????
directions. The array included 89 genes, 5 of which were housekeeping genes used for 
normalization. 14 genes were removed because not expressed in mouse liver. The level of 
expression of the remaining 70 genes was used for the heat map analysis. Six genes, as indicated 
by the manufacturer, were assigned to two different functional classes.  Genes were sorted based 
on their role in specific glucose metabolism pathways.  
 
Statistical analysis 
???
?
All the data showed in the present manuscript are reported as mean ± standard deviation. The 
StatistiXL software (StatistiXL, Broadway, Australia) was used for statistical analysis. p values 
<0.05 were considered significant. For all the data sets, data were analyzed by parametric tests, 
alpha = 0.05, (one-way and two-???????????????????????????-hoc correction). The statistical 
analysis performed for each data set is indicated in each figure legend.  
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????
?
?????????????????? 
??? ???????????? ??? ????? I (Glycogen storage disease type I - GSDI) est une 
???????????????????? ?????? ????????????? ????????????????????????????????????????????
???? ???????????????????????????? ????????????????????????????????????????????????????
de traitement (Froissart et al., 2011; Kishnani et al., 2014; Rake et al., 2002a, 2002b). 
?????? ???????? ?????????? ??? ???? ?? ??? ???????? ??? ???????? glucose-6 phosphatase 
(G6Pas?????????????????????????????????????????-??????????????????????????????????? 
pour la GSD de type Ia et des mutations au niveau de la sous-??????????????????????? 
p????????????????????????????????????????????? ??????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????, les 
?????????????????????????????????????????????????????????????????? ???????, entrainant 
????????????????????????????????????? ????????????? En effet, le ?????????? G6Pase ?????te 
en une forte accumulation en glucose-?? ??????????? ???? ??? ???????? ??? ????? ???? ?????
converti en  glucose libre, menant ????????????????????????????????? ? ?????????.  En 
????? ???? ??????????????? ???? ????????? ??????????? ???? ?????????????????????? ????
hypercho??????????????une acidose lactique et une hyperuric?mie. 
??????? ???? ??????????? ????????????? ????? ???????????? ?????????????????????? ?????
???????? ??? ???????????? ???????? ??? ?????? ??? ???? ?? ??????? ??????????? ????????????????? ?????
????????????? ?????Ces mesures d?????????????????? ???????? ?????? ??????????? ?????????
une nutrition nocturne, ???????????????????? ????????????????????? ?????????? ?????????????
????????????? ??? ??????? ??????? ??? ???????????? ??? ??????? ??? ????? ????? ????????????
??????? ???? ??????????? ?????? ??? ???????? ??? ??????? ???????????? ????? ??? ?????????? ????
??????????????????????????????????????????????????????????????????????????????????????
????????? ???? ????????? ???????????? ???? ?????????????? ?? ????? ??????? ??????? ???? ????
???????? ???????????? une ???????? ?????????? ??????? ??? ???? ???????????????? ??????? 
(Kishnani et al., 2014)???????????? ?????????????????????????????????????? ?? ?????????
???????????????????????????? ?????????????????????????????????????????????????????????
sous-jacents restent mal connus (Rake et al., 2002). ???????????? ?????????????????????
????????????????????????????????????????????????????????????????????????? ?????????????
????
?
??? ?????????????? ???? ?????????????? ??????????? ??? ???????? ??? ???????? ?? nouvelles 
cibles de traitements ?????????????????????????????? ??????????? ?????????????????????? 
 ??????????????????? ??? ??????? ??????????????? ??????? ??? ?????????? ??? ?????vent 
???? ?????? ??? ???????? ??? ???????? ????? ??????? ??? ???????? ?????-constant. Pour cette 
???????? ?????? ???????????? ?? ?????????? ?????????? ???? ???????? ??? ??????? ????? ????
???????????????????????????????????????????????????????-???????????????????????? (souris 
L.G6pc-/-), les reins (souris K.G6pc-/-) ??? ?????????? (souris I.G6pc-/-). Ces souris sont 
?????????????????????????????????????????????????????????la production de glucose par les 
??????? ???????? ?????????????????? ??????? ???? ??????? L.G6pc-/- ??????????? ????
????????????? ????? ??? ??????? ??????, car elles sont incapables de mobiliser leur 
?????????? ??????????? ??? ????? ????? ?????? ????? ?????? ??? ????????? ?? ces souris est 
?????????????????????????????????????????????????????????????????????????(Abdul-Wahed 
et al., 2014; Mutel et al., 2011a). 
??????????? ??? ??? ???????? ?????? ??? ?????? ????????????? ??? ?????????????? des 
???????????????????????????? ?????????? ????-?????????????????? ?????????Effectivement, 
????? ??????????????? ??? ??? ????????? ???????????????? ???????????? ??? ???? ???? ????????? ??
augmen??????????????????????????????????????????????????? ??????????????????????????
???????????? ????????? ??????????? ??????? ???? ????????????? ????? ???????????? ????
???????????????????????? ? ???????????????????????????????????????????????????????
????????????????????cruciale pour une meilleure prise en charge des ???????????????????
???????????????????????????? ?????????????????????????????????????????????????????
?????? ?????????? ???????? ???????? ??? ????? ????? ? ????? ?????? ??? ????????????? dans une 
????????? ??????? ???? ?????? ?????? ???????????? ??? ?????????????? ???????? chez les 
souris L.G6pc-/-, puis identifier ??????????????????????????????? ??????????? ???????
????s ???????????????????????????????????????????????????????????????????????????? le 
????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????? ??? ????????????????
??????????? ????????????????? ???????????? ??? ????????, ou au moins de ralentir 
????????????????????????????????????????????ients atteints de GSDI.  
 
????
?
Dans ?????????????????? de ce travail, les souris L.G6pc-/- ???????????????????????
?????????????????????????????????????????????e??????????????????????????????????????
?????? ??? ?????? ?????????????? ???? ??????? ??????-/- ???????????? l?????????? ????
?????????? ????????????????? ?? ??? ??????????? ?????????? ?????????? ????? les patients 
????????? ??? ?????? ???????? ?? ???? ?????????????? ????????????? ?????? ???? ????????
?????????? ???? ??????????????? ???? ????????????????????? ??? ???? ??????????????????????
??????????? ?????? ??????????????? ??? ????? G6pc?? ???? ??????? ???????????? ????
??????????????????????????????????????????????????????????????????????????????????????
???? ????????? ????????????????? (AHC), pouvant se transformer en carcinomes 
????????????????? (CHC) (Mutel et al., 2011a) (cf paragraphe V.1 de la partie Literature 
data). En effet, dans le cas de la GSDI, ??? ?????????????? ???? ??? ?????????? ??????????
c?????????? ???????? ??? ??????????????????? ???? ??? ????????????? ???? ??? ?????? ????????
????? ????????????? ??? ???? de novo ???? ??????? ???? ?????????? Les souris L.G6pc-/- 
????????????????AHC ?????????????????????????????????????G6pc chez 20% des souris 
???????????????? ???????????????????????????????????????????????????????????????????
???????????????????????????????CHC ont?????????? ???????????????????????????????????
L.G6pc-/- ????? ?????? ??? ??????? ??? ????????????? ??????? ???? ??????? ???????? ????
??????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????
??????? ???? ???????????? ???????????????????????????????????????? ?????????????????????????
????????????????????? ???????????????????????????????????????????????????????????????
?????? ?????? ??????? ????? ??? ?????????????? ??? ???????? ces liens ????? ???? ?????? ????????
??????Journal of Inherited Errors of Metabolism and Screening????????? (Gjorgjieva et 
al., 2016b). 
Au niveau des foies des souris L.G6pc-/-?? ???? ????????????? ??? ???
???????????????? ???????????? ?????????? ???? ??? ??????????? ??? ????? ??????? ? 
???????????????????????????? ? ?????????????????????????? ?????????????????????????? au 
cours du processus ?????????????????????????????????????????????????????? ???????????
gras et en sucre (high fat / high sucrose ? HF/HS) ??????????????????????????????????????
????????????? ???? ??? ???? ?? ??????????? ?????????? ??? ?????????????? ???????? ?????
????????????? ??? ??? ???????? (Rajas et al., 2015)?? ?????????????????? ???? ????nses 
????
?
???????????? ???? ???? ????????? ?? ????? ??????? ???????????? ??????????? ?????? ?????? ???-
??????????? ??????????? ??????????????????????????????????? ??? 
En analysant les souris au stade tumoral, nous avons ????????????? ????????????
tumorale ????? fortement au???????? ????? ??? ???? ?? hypercalorique?? ???????? ????? ???
???? ???? ??????? ????????????? ???? ???????? ???????????????? ????? ???? ???? ????
?????????????? ?????? ???? ????? ??? ?????? ???? ??????? ???? ?????????? ???? CHC en 
?????????????????????????????????????????????????????????????????????????????????????
le cas ?????????????????????????????. En effet, dans le foie, la carcinoge??????????????
???????? ????????? ???? ??????????????? ?????? ????????????? ?????????? ????????? ???
?????????????? ?????? ???????? ??????????? ???????? ???????? ??? ??rrhose (Cha and 
DeMatteo, 2005). En analysant l??? ?????? ??????? ?? ??? ????????? ?????? ??? ???????????
??????lio-m?senchymateuse (TEM), aucune activation des voies pro-?????????????????? 
???? ????????????????????? ????????????? ????????????? ???? ???????????????????????-/- au 
stade tumoral. En effet, la voie TGF-??? ???? ??????? ??? ??????est pas induite dans les 
foies et les tumeurs des souris L.G6pc-/-?? ??? ?????? ????????????? ???? ??????????
m?????????????? ????? ?????????????? ????????? ???? ??????????? ????? ???????????? ???
????????????? ???? ?????????? ????????????? ??????????? ???? ??? ?????????? ???? ???? ????
???????????????????? ???? ????????? ???? ??????s des souris L.G6pc-/- ???????ent une perte 
??? ??????????????? c?????????????????????????????? ???????? ????? ???????????????
??????????????????????????????????????????????????????????????? ???????????????????????? 
??? ????? ????? ???? ??????????????? ??? ???????????? ???? ???????????? ??????-/- se 
????????????????????????????????tion de la glycolyse, ???????????????????????????????-6 
phosphate intracellulaire, ????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????
phosphorylation par la g??????????? ????? ?? ?????? ???? ????? ???????? ?????? ????? ???
plupart des cancers????????????????????????????????????????????????????????????????????
????? ???? ???? ??? ????? ??? ??????????? ???????????? ??????????????? ??? ????????? ????
???????????? ?????????????????? ??????????????????????????????????????????????????????
lipidique ????????????de novo) ???????????????????????????????Fasn, Acaca, Elovl6 et 
Scd1?? ??? ???????????? ?????????? ???? ?? ?????? ?????????????? ???????????? ??? Ppara, Cpt1, 
????
?
Cyp4a10 et Cyp4a14). Dans les tumeurs, les voies de la ??????????? de novo et de 
???????????? ???? ???????? ????????? ?? ??????? ???? ???????? ??? ?????? ????????????
???????????? ??? ?????????? ????????? ????????????????-?? ?????????-?? ??????? ???????????
??????????????????????????????????al.  
?????????????????????????????????????????????????????????????????????????????
????????????? ??? ??? ??????????? ??? ??? ??????????? ??? ???? ?? ???????? ??? ??? ????????????
??????????????? ??????? ?? ?????????????????????-??????? ????? ???????? ????????????? ????
cancers ??????????????????????????????????????????????????????????????????? la formation 
et la progression des tumeurs, car elle ????????? ???? ?????????????? ???????? ??????? ???
????????????????????????????????? ??????????????????-???????????? 
???????????? ??????????????? ???????????????????? ??????? dans le cas de la GSDI 
entraine une perturbation ???? ?????? ??? ???????? ???????????? ?????? ?????????????? ?es 
??????????????????????????????????????????????????????????????? stress oxydatif. Tous 
???? ?????????? ???? ????? ???? ??? ?????????? ?????????????? ??????????? ??? ?????
dysfonctionnement peut favoriser le ?????????????? ???????? Une forte diminution de 
????????????????de ??????????????????????????????????????????????????????????e foie des 
souris L.G6pc-/- ???? ??? ?????? ???????????? ??? ?????? ?????????????? ???? ???????????
??????????????????????????????????????????????????????????????? ???????????????????????
??????????? ????? ???????? ??????????????? ????? ??????? ?????????? ??? ??? ??? ?????? ?? la 
???????????? dans les foies des souris L.G6pc-/-?? ?????? ?????? ??????????????
?????????????????????????????????????????????????????????????????????probablement leur 
?????????????????????????????????????? ????????????????????????????????????????????????? 
?????????????????????????????????????? au niveau du foie ????????????????????
????????????? ??? ???????????? et d??? ????????? ????????????? ??????????? ?? une cellule 
?????????? ??????????? ??? ?????? ?????????? ??? ?????????????? ???????? ????????? ????? ???
plupart des patients GSDI. En effet, la plupart des patients atteints de GSDI 
???????????? ???? ???????? ?????????? ?? ?????? ???????? ????? ???? ?????? ?????????? ???
transformation en CHC (Calderaro et al., 2013; Franco et al., 2005; Kishnani et al., 
2014). L??? ??????? ????? ???? ??????? ??????-/- ????? ???? ??????? ??? ???????? ????
modifications ????????????? ??????????? ??? ????????????? ?????????? ??? ????????? ???? ???
????
?
???????????????????????????????????????????????????????????????????????????????????-
???? ??? ?????????????? ????????? ??? ??? ??????????????? ?????????? ????? ??? ????????? ????
meilleure prise en charge des patients atteints de GSDI. ????????????????????????????????
???????????????????????????? 
Dans ????????????partie????????????????????????? ?????????????????????????????
?????????? ??????? ?????? ????? ??? ??????? ??? ??????? ??????????? ????? ??? ????? ???????
(souris K.G6pc-/-??? ???? ??????? ???????????? ???? ????????????? ????? ????????????? ??????
???????????????????????????????????????ion (Clar et al., 2014) (cf paragraphe V.1 de la 
partie Literature data??? ??? ?????? ?????? ??????????? ???? ?????????????? ???? ? une forte 
?????????????????????????????de lipides au niveau ???????????????????????????????????????
???? ???? ?????????????? ?????????? ??? ???? ?????? ???????????? ???? ?????????? ?? ??????????? ???
????????????????????????????????????????????? ????????????????? ???????????????? ????????
??????-????????????? ?????? ????? ?? ???? ????????????? ??? ????????????? ??? ???-????
facteur pro-fibrotique. Cet axe de signalisation RAS/TGF-??????????????????????????????
????????????????????????????????????? ???????????? ?????????????du ??????????? ?????? 
(Ribeiro-Oliveira et al., 2008)??????????????????????????????????????????on, aucun signe de 
??????????????????? ????????au ???????????????????? ????????????????????????????-/- . 
A?????????????????????????????????u cours du temps, nous avons pu observer une 
?????? ??? ??? ????????? ??? ??????????? ???? ??????? ???????????? ???? ??? ?????????????? ???
???????? ????????????? ???????????? ???? ??????? ????????????? ???? ????????????? ??????? ?? ???
????? ???????????????? ????????????? ???? ???? ???????????? ??? ??????????????? ??? ????????
???????????? ????????????????????????????????????????????-????? ????-?????????????????
???????????????? ????????????????????????????????? ???????? ????????????? ????????????????
??????? ???????? ????? ????????????? ???? ??????? ??? ?????????? ???? ???? ????????? ?????
????????? ??????????????????????????? ????????????????? ??????????????????????????au niveau des 
glom???????????????????????????????????????????????????????????????????????????????????
??????????????? ??????????????????????? ??? ???????????????????? ???????????????????????
??????????????????????????????????????????? ???????????????????????????????????????????
????? ??? ??????? ?? ????? ?? ?????????? ?????? ???????? ???? ????????? ????????? ??? ??? ??????
????????? ?????? ??? ????????? ??? ??????? ????? ????????? ??? ???????? ??? ?2 patients 
????
?
????????? ???? ??????? ?? ??????? ???? le Prof Philippe Labrune, et comporte des patients 
ayant de ??? 53 ans, dont 27 sont atteints de GSDIa et 5 de GSDIb. Ces patients ont 
???????????????????????????????????????????????????????????????????????????????????????
?? ?? ????????? ????? ???? ????????? ?????????? ?????? ????????????? ?????????????????? ???
hyperfiltration ?????????????? ? ??? ??????? ?? ?? ????????? ????? ???? ????????????? ???????? 
Seuls l??? ????????? ??? ??????? ?? ????????????? ???? ??????? ???????? ????? ????????????? ??
patients parmi les 32 ??????????nt ???????????????????????????????????????????????????
ce qui nous a perm???????????????????????????????????????????????????????????????????????
??????? ????? ??? ???? ??? ??? ?????? ??? ?????? ?? ?????? ???? ?? ????????? ???? ???????? ??? ??????
??????????????????????????????????????????????????????????????????????????????????????
???????????????hropathi?????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????
???? ???? ?????????????? ??????????? ??? ????? ???? ???? ??????? ?????????????? ?? ????-terme 
dans le cadre de la GSDI. ????????????????????????????????Human Molecular Genetics? 
(Hum. Mol. Gen.)  en 2016 (Gjorgjieva et al., 2016a). 
Dans ??????????????????? ??????????????????????????????????????????????????????????
??? ?????????????? ??? ??? ??????????? ?????????? ??? ???????? ??? ?????? ?????????????? ???
?????????????????????????????????? ??????????????????????????????????????ues dans le 
????????????????????????????????????????????????????????????????????????????????????????
???????????????????????? ?????????????????????????????????????????????????? dans le foie 
et les reins, les lipides semblent avoir un effet propre sur la progression de la 
????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????-fibrotique TGF-???????????????????????
dans la n???????????????????? ?????????????? ??????? (Clar et al., 2014; Cooper, 2004; 
Ribeiro-Oliveira et al., 2008; Yiu et al., 2008a). Au nivea?? ??????????? ??? ?????????
????????????????????????????????????????????????????????????????????, ???????????????
dans les patholog???? ??????????? ????? ??? ???? ??? ?non-alcoholic fatty liver disease??
(NAFLD), (Alkhouri et al., 2009; Jung and Choi, 2014).  
????? ?????? ??????? ????? ?????? ??????? ???? ???? souris L.G6pc-/- et K.G6pc-/- 
nourries en ???? ?? ????????????????? ?ucre (HF/HS??? ??????????????? ?????? ?????????????
????
?
???? ?????????????? ?????????? ??? ????????? ????????????s par une augmentation des 
?????????? ??? ???????? ?????????? ??? ???? ?????? ????? ??????? ?? la ????????? ????????
respectivement. ???????????????????? ????????????????????????????????????????????
de lipides plus importante dans le foie des souris L.G6pc-/- et dans les reins des souris 
K.G6pc-/-, bien que le taux de ?????????? ???? ?????? ????????? ????? ??? ????? ??? ??????
?? ????? ????? ???? ??????? ??????????????? ???? ?????????????? ?? ????-?????? ?????? ??
??????????????? ??? ??????????????? ?????????? ???????? ???? ??? ???? ?? ?????? ???????
??????????? ??? ????? ???????? ???? ???????? ????? ??? ?????? ?????????????? des taux de 
??????????? ??? ?????? ?????????????? ??????????????? ??? ???????? ???? ?????????? ???? ????
?????????????? ??? ???????????de novo, mais aussi par une forte inhibit??????? ????????????
des lipides (Abdul-Wahed et al., 2014; Clar et al., 2014; Mutel et al., 2011a).  
Dans le but ??? ?? ????? ??????????????? ???? ????????? ????? ?????? ??????? ???? ???????
L.G6pc-/- et K.G6pc-/- ?????????????????????????, ?????????????????????????????????????
???????????????????????????????????????? ??????????????????????????????????????????????
les patients o??????????????????????????????????????????????????????????????????????????
??? ?????? ??? ??????????? ?? ???? ???????? ?? ??? ?????? ??? ?????????????? ???????? des 
???????????????????????????????, ?????????????????????????????????????????????????G6pc.  
?????? ?? ????? ??? traitement, le f??????????? ?? ????????????? ???????? ??? ?????????
????????? chez les souris L.G6pc-/-???????????????????????????????????????????????????????
??? ?????? ??? ???? ?????? ??????? ?Cpt1, Acadl, Fabp1, Cyp4a10, Acox1). De plus, la 
????????? ?????????? a ?????????? ???? ??????????? ????????e ???? ??????????????? ???
????????????????????????????????????????de novo (Fasn, Acaca, Scd1, Elovl6), indiquant 
un turn-over ???? ???????? ????? ? ?????????????????? ?????????????? ??? ????????????????????
???????????????????????????????????????????????????????????????????????????? du glucose-
?? ?????????? ??? ??? ????? ??? ??? ????????? ??? ?????????? ????? ??? ????-over lipidique. La 
?? ???????? ???? ???????? ?? ????? ????? ?? ???? ?????????????? ???? ?????????? ???
dysfonctionnement ?????????, comme les transaminases (AST et ALT), ?????????? une 
??????????? ?????????? ????????? ???????????? ??? ??????????? ?? ??????? ??augmentation de 
????????????? ???? ?????? ????????????? ??? ??????? ?????? PTEN ??? ?????? ???? ????????
????? ??? chez les souris non-?????????? ?????????? ??? ????????? ?????? ?????????? ????? ???
?????????????????????????????????????????????????????? 
????
?
 ??????????????? ??? ????????? ?????????? ??????? ?? ??? ?????????????? ??? ????? ???
???????????? de ??????????????????????????????????????????????????s souris K.G6pc-/- 
????????? ??? ????????????? ????? ?? ????? ?? ??? ?????????????? ???? ?????????? ?????????? 
?????????????????????????????? ?????????????-??????????? ????????????????????????? ????????
???? ???????? ??????? ?? ???? ??? ??????????? ?????-totale de la fibrose r??????? ???????? ???
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